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EXECUTIVE SUMMARY OF THE GUIDELINE
Philosophy of the guideline
▸ Oxygen is a treatment for hypoxaemia, not
breathlessness. Oxygen has not been proven to
have any consistent effect on the sensation of
breathlessness in non-hypoxaemic patients.
▸ The essence of this guideline can be summarised
simply as a requirement for oxygen to be prescribed
according to a target saturation range and for those
who administer oxygen therapy to monitor the
patient and keep within the target saturation range.
▸ The guideline recommends aiming to achieve
normal or near-normal oxygen saturation for all
acutely ill patients apart from those at risk of
hypercapnic respiratory failure or those receiv-
ing terminal palliative care.
1 Assessing patients
▸ For critically ill patients, high-concentration
oxygen should be administered immediately
(table 1 and ﬁgure 1 (chart 1)) and this should
be recorded afterwards in the patient’s health
record.
▸ Clinicians must bear in mind that supplemental
oxygen is given to improve oxygenation but it
does not treat the underlying causes of hypox-
aemia which must be diagnosed and treated as a
matter of urgency.
▸ The oxygen saturation should be checked by
pulse oximetry in all breathless and acutely ill
patients, ‘the ﬁfth vital sign’ (supplemented by
blood gases when necessary) and the inspired
oxygen concentration should be recorded on the
observation chart with the oximetry result. (The
other vital signs are pulse rate, blood pressure,
temperature and respiratory rate).
▸ Pulse oximetry must be available in all locations
where emergency oxygen is used. Clinical assess-
ment is recommended if the saturation falls by
≥3% or below the target range for the patient.
▸ All critically ill patients outside of a critical care
area (eg, intensive care unit (ICU), high depend-
ency unit (HDU), respiratory HDU) should be
assessed and monitored using a recognised
physiological track and trigger system such as
the National Early Warning Score (NEWS).
2 Target oxygen prescription
▸ Oxygen should be prescribed to achieve a target
saturation of 94–98% for most acutely ill
patients or 88–92% or patient-speciﬁc target
range for those at risk of hypercapnic respira-
tory failure (tables 1–4).
▸ Best practice is to prescribe a target range for all
hospital patients at the time of admission so that
appropriate oxygen therapy can be started in the
event of unexpected clinical deterioration with
hypoxaemia and also to ensure that the oxim-
etry section of the early warning score (EWS)
can be scored appropriately.
▸ The target saturation should be written (or
ringed) on the drug chart or entered in an elec-
tronic prescribing system (guidance on ﬁgure 1
(chart 1)).
3 Oxygen administration
▸ Oxygen should be administered by staff who are
trained in oxygen administration.
▸ These staff should use appropriate devices and
ﬂow rates in order to achieve the target saturation
range (ﬁgure 2 (chart 2)).
▸ Staff should be trained in the use of a range of
different oxygen delivery devices to ensure
oxygen is delivered safely.
4 Monitoring and maintenance of target
saturation
▸ Oxygen saturation and delivery system (includ-
ing ﬂow rate) should be recorded on the
patient’s monitoring chart.
▸ Oxygen delivery devices and ﬂow rates should
be adjusted to keep the oxygen saturation in the
target range. Prompt clinical assessment is
required if oxygen therapy needs to be initiated
or increased due to a falling saturation level.
▸ Oxygen should be prescribed and a signature
should be entered on the drug chart on each
drug round.
5 Weaning and discontinuation of oxygen
therapy
▸ Oxygen should be reduced in stable patients
with satisfactory oxygen saturation.
▸ Oxygen should be discontinued once the patient
can maintain saturation within or above the
target range breathing air but the prescription
for a target range should be left in place in case
of future deterioration and to guide EWS/
NEWS.
3 SUMMARY OF GUIDELINE
RECOMMENDATIONS AND GOOD PRACTICE
POINTS
A Achieving desirable oxygen saturation ranges
in acute illness (see sections 6 and 8 and
ﬁgures 1–2)
A1: This guideline recommends aiming to achieve a
normal or near-normal oxygen saturation for all
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acutely ill patients apart from those at risk of hypercapnic
respiratory failure (grade D).
A2: The recommended target saturation range for acutely ill
patients not at risk of hypercapnic respiratory failure is 94–98%
(grade D).
A3: For most patients with known chronic obstructive pul-
monary disease (COPD) or other known risk factors for hyper-
capnic respiratory failure (eg, morbid obesity, cystic ﬁbrosis
(CF), chest wall deformities or neuromuscular disorders or ﬁxed
airﬂow obstruction associated with bronchiectasis), a target sat-
uration range of 88–92% is suggested pending the availability of
blood gas results (grade A for COPD, grade D for other
conditions).
A4: Most non-hypoxaemic breathless patients do not beneﬁt
from oxygen therapy, but a sudden reduction of ≥3% in a
patient’s oxygen saturation within the target saturation range
should prompt fuller assessment of the patient (and the oxim-
eter signal) because this may be the ﬁrst evidence of an acute
illness (grade D).
A5: Since oxygenation is reduced in the supine position, fully
conscious hypoxaemic patients should ideally be allowed to
maintain the most upright posture possible (or the most com-
fortable posture for the patient) unless there are good reasons to
immobilise the patient (eg, skeletal or spinal trauma) (grade D).
B Clinical and laboratory assessment of hypoxaemia and
hypercapnia
B1: Fully trained clinicians should assess all acutely ill patients
by measuring respiratory rate, pulse rate, blood pressure and
temperature and assessing circulating blood volume and
anaemia (see section 7). Expert assistance from specialists in
intensive care or from other disciplines should be sought at an
early stage if patients are thought to have major life-threatening
illnesses and clinicians should be prepared to call for assistance
when necessary including a call for a 999 ambulance in prehos-
pital care or a call for the resuscitation team or ICU outreach
team in hospital care (grade D).
B2: Oxygen saturation, ‘the ﬁfth vital sign’, should be
checked by trained staff using pulse oximetry in all breathless
and acutely ill patients (supplemented by blood gases when
necessary) and the inspired oxygen device and ﬂow rate should
be recorded on the observation chart with the oximetry result
(grade D).
B3: Initial clinical assessment and subsequent monitoring of
acutely unwell patients should include the use of a recognised
physiological ‘track and trigger’ system, such as the NEWS
which may trigger clinical review due to hypoxaemia, need for
supplementary oxygen or for other reasons (grade D).
B4: For patients who are at risk of hypercapnic respiratory
failure, it is recommended that the relevant section of the 2017
NEWS chart should be used. Points are awarded if the oxygen
saturation is below or above the target range (grade D).
Good practice points for clinical assessment of patients with sus-
pected hypoxaemia
✓ The medical history should be taken when possible in an
acutely breathless patient and may point to the diagnosis of a
particular acute illness such as pneumonia or pulmonary
embolism or an exacerbation of a chronic condition such as
COPD, asthma or heart failure.
✓ Never discontinue oxygen therapy to obtain an oximetry
measurement on room air in patients who clearly require
oxygen therapy.
✓ Physical examination should be undertaken urgently.
This may provide evidence of a speciﬁc diagnosis such as
heart failure or a large pleural effusion, but it is
common for the cause of breathlessness to remain
undiagnosed until the results of tests such as chest radio-
graphs are available.
✓ Record arterial oxygen saturation measured by pulse oxim-
etry (SpO2) and consider blood gas assessment in patients
with unexplained confusion and agitation as this may be pre-
senting feature of hypoxaemia and/or hypercapnia (cyanosis
is a difﬁcult physical sign to record conﬁdently, especially in
poor light or with an anaemic or plethoric patient).
Table 1 Critical illness requiring high levels of supplemental oxygen
Section 8.10
The initial oxygen therapy is a reservoir mask at 15 L/min pending the availability of reliable oximetry readings.
For patients with spontaneous circulation and a reliable oximetry reading, it may quickly become possible to reduce the oxygen dose while maintaining a target saturation
range of 94–98%.
If oximetry is unavailable, continue to use a reservoir mask until definitive treatment is available.
Patients with COPD and other risk factors for hypercapnia who develop critical illness should have the same initial target saturations as other critically ill patients pending
the results of blood gas results after which these patients may need controlled oxygen therapy with target range 88–92% or supported ventilation if there is severe
hypoxaemia and/or hypercapnia with respiratory acidosis.
Additional comments Recommendations
Cardiac arrest or resuscitation Refer to resuscitation guidelines for choice of delivery device during active resuscitation.
Give highest possible inspired oxygen concentration during CPR until spontaneous
circulation has been restored.
Recommendation E1
Shock, sepsis, major trauma, drowning, anaphylaxis,
major pulmonary haemorrhage, status epilepticus
Also give specific treatment for the underlying condition Recommendations
E2–E4
Major head injury Early tracheal intubation and ventilation if comatose Recommendation E5
Carbon monoxide poisoning Give as much oxygen as possible using a bag-valve mask or reservoir mask. Check
carboxyhaemoglobin levels.
A normal or high oximetry reading should be disregarded because saturation monitors
cannot differentiate between carboxyhaemoglobin and oxyhaemoglobin, owing to their
similar absorbances.
The blood gas PO2 will also be normal in these cases (despite the presence of tissue
hypoxia).
Recommendation E6
COPD, chronic obstructive pulmonary disease; CPR, cardiopulmonary resuscitation; PO2, oxygen tension arterial or arterialised blood gases.
i2 O’Driscoll BR, et al. Thorax 2017;72:i1–i90. doi:10.1136/thoraxjnl-2016-209729
BTS guideline
group.bmj.com on April 7, 2018 - Published by http://thorax.bmj.com/Downloaded from 
✓ Carefully measure respiratory rate and heart rate because
tachypnoea and tachycardia are more common than a phys-
ical ﬁnding of cyanosis in hypoxaemic patients.
✓ Appropriate changes should be made to any ‘track and trigger’
system used to allow for a lower target range in patients at risk
of hypercapnic respiratory failure. These patients should score
no EWS points for saturation if within their target range and
they should score points if the oxygen saturation falls below
the target range or if the saturation rises above the target
range while breathing oxygen. The 2017 update of the NEWS
chart has a special section for oximetry measurements for use
with patients who have target range 88–92% and it is recom-
mended that the 2017 NEWS chart should be used in all hos-
pitals (see recommendation B4).
Figure 1 Chart 1 - Oxygen prescription for acutely hypoxaemic patients in hospital. Any increase in FIO2 must be followed by repeat blood gases
in 1 hour (or sooner if conscious level deteriorates). *If pH is < 7.35 ([H+] > 45 nmol/L) with normal or low PaCO2, investigate and treat for
metabolic acidosis and keep SpO2 94–98%. ABG, arterial blood gas; COPD, chronic obstructive pulmonary disease; FiO2, fraction of inspired oxygen;
ICU, intensive care unit; NIV, non-invasive ventilation; PaCO2, arterial carbon dioxide tension; PCO2, carbon dioxide tension; PO2, oxygen tension;
SpO2, arterial oxygen saturation measured by pulse oximetry.
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Table 2 Serious illnesses requiring moderate levels of supplemental oxygen if the patient is hypoxaemic
Section 8.11
The initial oxygen therapy is nasal cannulae at 2–6 L/min (preferably) or simple face mask at 5–10 L/min unless stated otherwise.
For patients not at risk of hypercapnic respiratory failure who have saturation below 85%, treatment should be started with a reservoir mask at 15 L/min and the
recommended initial oxygen saturation target range is 94–98%. If oximetry is not available, give oxygen as above until oximetry or blood gas results are available. Change
to reservoir mask if the desired saturation range cannot be maintained with nasal cannulae or simple face mask (and ensure that the patient is assessed by senior medical
staff ). If these patients have coexisting COPD or other risk factors for hypercapnic respiratory failure, aim at a saturation of 88–92% pending blood gas results but adjust to
94–98% if the PCO2 is normal (unless there is a history of previous hypercapnic respiratory failure requiring NIV or IMV) and recheck blood gases after 30–60 min, see table 4.
Additional comments Recommendations
Acute hypoxaemia (cause not yet
diagnosed)
Reservoir mask at 15 L/min if initial SpO2 below 85%, otherwise nasal cannulae or simple face
mask
Patients requiring reservoir mask therapy need urgent clinical assessment by senior staff.
Recommendations D1–D3
Acute asthma pneumonia lung cancer Recommendations F1–F3
Deterioration of lung fibrosis or other
interstitial lung disease
Reservoir mask at 15 L/min if initial SpO2 below 85%, otherwise nasal cannulae or simple face
mask
Recommendation F4
Pneumothorax Needs aspiration or drainage if the patient is hypoxaemic. Most patients with pneumothorax are
not hypoxaemic and do not require oxygen therapy.
Use a reservoir mask at 15 L/min if admitted for observation. Aim at 100% saturation. (Oxygen
accelerates clearance of pneumothorax if drainage is not required.)
Recommendations F5–F6
Pleural effusions Most patients with pleural effusions are not hypoxaemic. If hypoxaemic, treat by draining the
effusion as well as giving oxygen therapy.
Recommendation F7
Pulmonary embolism Most patients with minor pulmonary embolism are not hypoxaemic and do not require oxygen
therapy.
Recommendation F8
Acute heart failure Consider CPAP or NIV in cases of pulmonary oedema. Recommendations F9–F10
Severe anaemia The main issue is to correct the anaemia. Most anaemic patients do not require oxygen therapy. Recommendations F11–12
Postoperative breathlessness Management depends on underlying cause. Recommendation J1
COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; IMV, invasive mechanical ventilation; NIV, non-invasive ventilation; PCO2, arterial or
arterialised carbon dioxide tension; SpO2, arterial oxygen saturation measured by pulse oximetry.
Table 3 Conditions for which patients should be monitored closely but oxygen therapy is not required unless the patient is hypoxaemic
Section 8.13
If hypoxaemic, the initial oxygen therapy is nasal cannulae at 2–6 L/min or simple face mask at 5–10 L/min unless saturation is below 85% (use reservoir mask) or if at risk
from hypercapnia (see below).
The recommended initial target saturation range, unless stated otherwise, is 94–98%.
If oximetry is not available, give oxygen as above until oximetry or blood gas results are available.
If patients have COPD or other risk factors for hypercapnic respiratory failure, aim at a saturation of 88–92% pending blood gas results but adjust to 94–98% if the PCO2 is
normal (unless there is a history of respiratory failure requiring NIV or IMV) and recheck blood gases after 30–60 min, see table 4.
Additional comments Recommendations
Myocardial infarction and acute coronary
syndromes
Most patients with acute coronary artery syndromes are not hypoxaemic and the benefits/
harms of oxygen therapy are unknown in such cases. Unnecessary use of high concentration
oxygen may increase infarct size.
Recommendation F13
Stroke Most patients with stroke are not hypoxaemic. Oxygen therapy may be harmful for
non-hypoxaemic patients with mild–moderate strokes.
Recommendation F14
Hyperventilation or dysfunctional breathing Exclude organic illness. Patients with pure hyperventilation due to anxiety or panic attacks
are unlikely to require oxygen therapy.
Rebreathing from a paper bag may cause hypoxaemia and is not recommended.
See section 8.13.3
Most poisonings and drug overdoses (see table 1
for carbon monoxide poisoning)
Hypoxaemia is more likely with respiratory depressant drugs, give antidote if available, for
example, naloxone for opiate poisoning.
Check blood gases to exclude hypercapnia if a respiratory depressant drug has been taken.
Avoid high blood oxygen levels in cases of acid aspiration as there is theoretical evidence that
oxygen may be harmful in this condition.
Monitor all potentially serious cases of poisoning in a level 2 or 3 environment (high
dependency unit or intensive care unit).
Recommendation F15
Poisoning with paraquat or bleomycin Patients with paraquat poisoning or bleomycin lung injury may be harmed by supplemental
oxygen.
Avoid oxygen unless the patient is hypoxaemic.
Target saturation is 85–88%.
Recommendation F16
Metabolic and renal disorders Most do not need oxygen (tachypnoea may be due to acidosis in these patients) Recommendation F17
Acute and subacute neurological and muscular
conditions producing muscle weakness
These patients may require ventilatory support and they need careful monitoring which
includes spirometry. If the patient’s oxygen level falls below the target saturation, they need
urgent blood gas measurements and are likely to need ventilatory support.
Recommendation G4
Pregnancy and obstetric emergencies Oxygen therapy may be harmful to the fetus if the mother is not hypoxaemic. Recommendations
H1–H4
COPD, chronic obstructive pulmonary disease; IMV, invasive mechanical ventilation; NIV, non-invasive ventilation; PCO2, arterial or arterialised carbon dioxide tension.
i4 O’Driscoll BR, et al. Thorax 2017;72:i1–i90. doi:10.1136/thoraxjnl-2016-209729
BTS guideline
group.bmj.com on April 7, 2018 - Published by http://thorax.bmj.com/Downloaded from 
✓ The presence of a normal SpO2 does not negate the need for
blood gas measurements especially if the patient is on supple-
mental oxygen therapy. Pulse oximetry will be normal in a
patient with normal oxygen tension (PO2) but abnormal blood
pH or carbon dioxide tension (PCO2) or with a low blood
oxygen content due to anaemia. For this reason, blood gases and
full blood count tests are required as early as possible in all situa-
tions where these measurements may affect patient outcomes.
✓ All clinical staff who use oximeters must be trained in their
use and made aware of the limitations of oximetry.
(Oximetry is a valuable clinical tool but subject to artefact
and errors of interpretation).
C Arterial and capillary blood gases
C1: For critically ill patients or those with shock or hypotension
(systolic blood pressure <90 mm Hg), the initial blood gas
measurement should be obtained from an arterial sample (see
sections 7.1.3 and 8.4 and 8.5). For most patients who require
blood gas sampling, either arterial blood gases (ABGs) or arter-
ialised earlobe blood gases may be used to obtain an accurate
measure of pH and PCO2. However, the PO2 is less accurate in
earlobe blood gas samples (it underestimates the PO2 by 0.5–
1 kPa) so oximetry should be monitored carefully if earlobe
blood gas specimens are used and a repeat arterial specimen
should be taken if there is any concern about the accuracy of a
capillary sample (grade D).
C2: Local anaesthesia should be used for all ABG specimens
except in emergencies (grade A).
C3: Blood gases should be checked in the following
situations:
• All critically ill patients (grade D).
• Unexpected or inappropriate fall in SpO2 below 94% in
patients breathing air or oxygen or any patient requiring
oxygen to achieve the above target range. (Allowance should
be made for transient dips in saturation to 90% or less in
normal participants during sleep) (grade D).
• Deteriorating oxygen saturation (fall of ≥3%) or increasing
breathlessness in a patient with previously stable chronic hyp-
oxaemia (eg, severe COPD) (grade D).
• Most previously stable patients who deteriorate clinically and
require increased fraction of inspired oxygen (FiO2) to main-
tain a constant oxygen saturation (grade D).
• Any patient with risk factors for hypercapnic respiratory
failure who develops acute breathlessness, deteriorating
oxygen saturation, drowsiness or other features of carbon
dioxide retention (grade D).
• Patients with breathlessness who are thought to be at risk of
metabolic conditions such as diabetic ketoacidosis or meta-
bolic acidosis due to renal failure (grade D).
• Any other evidence from the patient’s medical condition that
would indicate that blood gas results would be useful in the
patient’s management (eg, an unexpected change in ‘track
and trigger’ systems such as a sudden rise of several units in
the NEWS or an unexpected fall in oxygen saturation of 3%
or more, even if within the target range) (grade D).
Good practice point: patients requiring increased concentration
of oxygen
✓ The requirement for an increased concentration of oxygen is
an indication for urgent clinical reassessment of the patient
(and repeat blood gas measurements in most instances, see
recommendations W13 and W18 for exceptions).
D Initial oxygen therapy; initial choice of equipment for
patients who do not have critical illness
Initial oxygen therapy in critical illness is covered in the next
section.
D1: For acutely breathless patients not at risk of hypercapnic
respiratory failure who have saturations below 85%, treatment
should be started with a reservoir mask at 15 L/min in the ﬁrst
instance (see ﬁgures 1–2 (charts 1–2) and table 2 and sections
8.9 and 10).* The oxygen concentration can be adjusted down-
wards (using nasal cannulae at 1–6 L/min or a simple face mask
at 5–10 L/min) to maintain a target saturation of 94–98% once
the patient has stabilised (grade D).
D2: In other cases of acute hypoxaemia without critical
illness or risk factors for hypercapnic respiratory failure, treat-
ment should be started with nasal cannulae (or a simple face
mask if cannulae are not tolerated or not effective) with the
ﬂow rate adjusted to achieve a saturation of 94–98% (grade D).
D3: If medium-concentration therapy with nasal cannulae or
a simple face mask does not achieve the desired saturation,
change to a reservoir mask and seek senior or specialist advice
(grade D).
Table 4 COPD and other conditions requiring controlled or low-dose oxygen therapy
Section 8.12
Prior to availability of blood gases, use a 24% Venturi mask at 2–3 L/min or 28% Venturi mask at 4 L/min or nasal cannulae at 1–2 L/min and aim for an oxygen saturation
of 88–92% for patients with risk factors for hypercapnia but no prior history of respiratory acidosis. Adjust target range to 94–98% if the PCO2 is normal (unless there is a
history of previous NIV or IMV) and recheck blood gases after 30–60 min.
Additional comments Recommendations
COPD and other conditions causing fixed
airflow obstruction (eg, bronchiectasis)
May need lower range if acidotic or if known to be very sensitive to oxygen therapy.
Ideally use ‘alert cards’ to guide therapy based on previous blood gas results. Increase
Venturi mask flow by up to 50% if respiratory rate is above 30 breaths/min.
Recommendations G1–G2 and
section 8.12.1
Exacerbation of CF Admit to regional CF centre if possible, if not discuss with regional centre or manage
according to protocol agreed with regional CF centre. Ideally use ‘alert cards’ to guide
therapy. Increase Venturi mask flow by up to 50% if respiratory rate is above 30 breaths/
min.
Recommendations G1, G3, G6
Neuromuscular disease, neurological condition
and chest wall deformity
May require ventilatory support. Recommendations G1, G4, G6
Risk of hypercapnic respiratory failure
Morbid obesity Recommendations G1,G5, G6
CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; IMV, invasive mechanical ventilation; NIV, non-invasive ventilation; PCO2, arterial or arterialised carbon dioxide tension.
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Good practice point
✓ High-ﬂow nasal oxygen using specialised equipment should
be considered as an alternative to reservoir mask treatment
in patients with acute respiratory failure without
hypercapnia.
*For initial management of patients at risk of hypercapnic
respiratory failure, see recommendations G1 and G2.
E Oxygen therapy in critical illness
E1: Use the highest feasible inspired oxygen for ventilation
during cardiopulmonary resuscitation (CPR; see table 1 and
section 8.10). Once spontaneous circulation has returned and
arterial blood oxygen saturation can be monitored reliably, aim
for a target saturation range of 94–98% and take an ABG
sample to guide ongoing oxygen therapy. If the blood gas shows
hypercapnic respiratory failure, reset the target range to
88–92% or consider mechanical ventilation (grade D).
E2: In critical illness, including major trauma, sepsis, shock
and anaphylaxis, initiate treatment with a reservoir mask at
15 L/min and aim at a saturation range of 94–98%. This advice
also applies to patients with critical illness who have risk factors
for hypercapnia pending the results of blood gas measurements
and expert assessment. In patients with spontaneous circulation
and a reliable oximetry reading it may be possible to maintain a
saturation of 94–98% using lower concentrations of oxygen
(grade D)
Figure 2 Chart 2 - Flow chart for oxygen administration on general wards in hospitals. *For Venturi masks, the higher ﬂow rate is required if the
respiratory rate is >30. ABG, arterial blood gas; COPD, chronic obstructive pulmonary disease; EPR, electronic patient record; EWS, early warning
score; NEWS, National Early Warning Score; SpO2, arterial oxygen saturation measured by pulse oximetry.
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E3: In cases of drowning, aim at an oxygen saturation of 94–
98% once spontaneous circulation is restored (grade D).
E4: In patients with acute seizures due to epilepsy or other
causes, high-concentration oxygen should be administered until
a satisfactory oximetry measurement can be obtained and clini-
cians should then aim for an oxygen saturation of 94–98% or
88–92% if the patient is at risk of hypercapnic respiratory
failure (grade D).
E5: In cases of major head injury, aim at an oxygen saturation
of 94–98%. Initial treatment should involve high-concentration
oxygen from a reservoir mask at 15 L/min pending availability
of satisfactory blood gas measurements or until the airway is
secured by intubation (grade D).
E6: In cases of carbon monoxide poisoning, an apparently
‘normal’ oximetry reading may be produced by carboxyhaemo-
globin, so aim at an oxygen saturation of 100% and use a reser-
voir mask at 15 L/min irrespective of the oximeter reading and
arterial oxygen tension (PaO2) (grade D).
F Oxygen therapy for speciﬁc conditions that frequently
require oxygen therapy
Respiratory conditions with low risk of hypercapnic respiratory
failure
F1: In acute asthma, aim at an oxygen saturation of 94–98%
(see tables 2 and 3 and sections 8.11 and 8.13) (grade D).
F2: In cases of pneumonia who are not at risk of hypercapnic
respiratory failure, aim at an oxygen saturation of 94–98%
(grade D).
F3: In acute breathlessness due to lung cancer, aim at an
oxygen saturation of 94–98% unless there is coexisting COPD.
See also ‘Oxygen use in palliative care’ section 8.17 (grade D).
F4: In acute deterioration of pulmonary ﬁbrosis or other
interstitial lung diseases, aim at an oxygen saturation of 94–
98% or the highest possible if these targets cannot be achieved
(grade D).
F5: In most cases of pneumothorax, aim at an oxygen satur-
ation of 94–98% if the patient is not at risk of hypercapnic
respiratory failure (grade D).
F6: In patients with pneumothorax having hospital observation
without drainage, the use of high-concentration oxygen (15 L/
min ﬂow rate via reservoir mask) is recommended unless the
patient is at risk of hypercapnic respiratory failure (grade D).
F7: In pleural effusion, aim at an oxygen saturation of 94–
98% (or 88–92% if the patient is at risk of hypercapnic respira-
tory failure) (grade D).
F8: In pulmonary embolism, aim at an oxygen saturation of
94–98% (or 88–92% if the patient is at risk of hypercapnic
respiratory failure) (grade D).
Non-respiratory conditions
F9: In acute heart failure, aim at an oxygen saturation of 94–
98% (or 88–92% if the patient is at risk of hypercapnic respira-
tory failure) (grade D).
F10: Continuous positive airway pressure (CPAP) with
entrained oxygen or high-ﬂow humidiﬁed nasal oxygen to main-
tain saturation 94–98% (or 88–92% if at risk of hypercapnia)
should be considered as an adjunctive treatment to improve gas
exchange in patients with cardiogenic pulmonary oedema who
are not responding to standard treatment (or non-invasive
ventilation (NIV) if there is coexistent hypercapnia and
acidosis) (grade B).
F11: In anaemia, aim at an oxygen saturation of 94–98% or
88–92% if the patient is at risk of hypercapnic respiratory
failure (grade D).
Good practice point
✓ Correction of anaemia by blood transfusion should be based
on national guidelines.
F12: In sickle cell crisis and acute chest syndrome, aim for an
oxygen saturation of 94–98% or aim at the saturation level that
is usual for the individual patient (grade D).
Good practice point regarding sickle cell crisis
Arterial or arterialised capillary blood gases should be
sampled if there is any doubt about the reliability of oximetry
during a sickle cell crisis.
F13: In myocardial infarction and acute coronary syndromes,
aim at an oxygen saturation of 94–98% or 88–92% if the
patient is at risk of hypercapnic respiratory failure (grade D).
F14: High concentrations of oxygen should be avoided in
patients with stroke, unless required to maintain normal oxygen
saturation. Aim at an oxygen saturation of 94–98% or 88–92% if
the patient is at risk of hypercapnic respiratory failure (grade D).
Good practice points regarding stroke management
✓ Oxygen saturation should be monitored at least every
4 hours throughout the day and night in patients with acute
stroke and all episodes of hypoxaemia treated.
✓ Patients with hypoxaemia post-stroke require medical review
to establish and treat the cause.
✓ Oxygen should only be given once the airway has been
cleared and at the lowest concentration necessary to achieve
an oxygen saturation of 94–98% or 88–92% if the patient is
at risk of hypercapnic respiratory failure.
✓ Oxygen should be given via nasal cannulae, unless there are
clear indications for a different oxygen delivery system.
✓ Patients with stroke and cardiorespiratory comorbidities
should be positioned as upright as possible, in a chair if pos-
sible (see recommendation A5).
✓ Patients with a reduced level of consciousness after stroke
should be nursed in the recovery position with the paralysed
side lowest.
Suspected hyperventilation
Good practice points regarding patients with suspected
hyperventilation
✓ Organic illness must be excluded before making a diagnosis
of hyperventilation.
✓ Patients with a deﬁnite diagnosis of hyperventilation should
have their oxygen saturation monitored. Those with normal
or high SpO2 do not require oxygen therapy.
✓ Rebreathing from a paper bag can be dangerous and is NOT
advised as a treatment for hyperventilation.
F15: In most poisonings, aim at an oxygen saturation of 94–
98% unless the patient is at risk of hypercapnic respiratory
failure (grade D).
F16: In poisoning by paraquat and poisoning by bleomycin,
give oxygen only if the saturation falls below 85% and reduce or
stop oxygen therapy if the saturation rises above 88% (grade D).
F17: In most metabolic and renal disorders, aim at an oxygen
saturation of 94–98% unless the patient is at risk of hypercapnic
respiratory failure (grade D).
F18: For patients with cluster headaches, oxygen should be
administered using a ﬂow of at least 12 L/min from a reservoir
mask and home oxygen should be provided (grade D).
G Patients at risk of hypercapnic respiratory failure (See
table 4 and section 8.12)
G1 (also A3): For most patients with known COPD or other
known risk factors for hypercapnic respiratory failure (eg,
morbid obesity, CF, chest wall deformities or neuromuscular
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disorders or ﬁxed airﬂow obstruction associated with bronchiec-
tasis), a target saturation range of 88–92% is suggested pending
the availability of blood gas results (grade A for COPD, grade D
for other conditions).
G2: Some patients with COPD and other conditions are vul-
nerable to repeated episodes of hypercapnic respiratory failure.
In these cases it is recommended that treatment should be based
on the results of previous blood gas estimations during acute
exacerbations. For patients with prior hypercapnic failure
(requiring NIVor intermittent positive pressure ventilation) who
do not have an alert card, it is recommended that low-
concentration oxygen treatment should be started using a 24%
Venturi mask at 2–3 L/min (or a 28% Venturi mask at 4 L/min
or nasal cannulae at 1–2 L/min if a 24% mask is not available)
with an initial target saturation of 88–92% pending urgent
blood gas results. These patients should be treated as a high pri-
ority by emergency services and the oxygen concentration
should be reduced if the saturation exceeds 92% but increased if
it falls below 88% (grade D).
Good practice points for COPD and other conditions that may
cause hypercapnic respiratory failure
Diagnosis of COPD or suspected exacerbation of COPD
✓ If the diagnosis is unknown, patients over 50 years of age
who are long-term smokers with a history of chronic breath-
lessness on minor exertion such as walking on level ground
and no other known cause of breathlessness should be treated
as having suspected COPD for the purposes of this guideline.
✓ Spirometry should be measured at least once during hospital
admissions for suspected COPD (as per National Institute of
Health and Care Excellence (NICE) COPD guideline1).
Measurement of spirometry may conﬁrm (or exclude) a diag-
nosis of airﬂow obstruction and the forced expiratory
volume in 1 s (FEV1) level is a useful indicator of disease
severity in COPD.
Immediate management of patients with known or suspected
COPD
✓ If the saturation remains below 88% in prehospital care
despite a 28% Venturi mask, change to nasal cannulae at 2–
6 L/min or a simple face mask at 5 L/min with target satur-
ation of 88–92% and alert the accident and emergency
(A&E) department that the patient is to be treated as a high
priority.
✓ Patients with a respiratory rate >30 breaths/min should have
the ﬂow rate from Venturi masks set above the minimum ﬂow
rate speciﬁed for the Venturi mask packaging to compensate
for the patient’s increased inspiratory ﬂow (see ﬁgure 11B).
Increasing the oxygen ﬂow rate into a Venturi mask does not
increase the concentration of oxygen which is delivered.
✓ Patients with a signiﬁcant likelihood of severe COPD or
other illness that may cause hypercapnic respiratory failure
should be triaged as very urgent on arrival in hospital emer-
gency departments and blood gases should be measured on
arrival in hospital.
✓ Prior to availability of blood gas measurements, use a 24%
Venturi mask at 2–3 L/min or nasal cannulae at 1–2 L/min or
28% Venturi mask at 4 L/min and aim for an oxygen satur-
ation of 88–92%.
Initial hospital management of patients with exacerbation of
COPD
✓ Patients with exacerbations of COPD need careful moni-
toring for hypercapnic respiratory failure with respira-
tory acidosis which may develop in the course of a
hospital admission even if the initial blood gases were
satisfactory.
✓ Avoid excessive oxygen use in patients with COPD. The risk
of respiratory acidosis in patients with hypercapnic respira-
tory failure is increased if the PaO2 is above 10.0 kPa due to
previous excessive oxygen use.
✓ If following blood gas measurements the pH and PCO2 are
normal, aim for an oxygen saturation of 94–98% unless
there is a history of previous hypercapnic respiratory failure
requiring NIV or intermittent positive pressure ventilation or
if the patient’s usual oxygen saturation when clinically stable
is below 94% (these patients should have a target range of
88–92%). Blood gases should be repeated at 30–60 min to
check for rising PCO2 or falling pH.
✓ Recheck blood gases after 30–60 min (or if there is evidence
of clinical deterioration) for all patients with COPD or other
risk factors for hypercapnic respiratory failure even if the
initial PCO2 measurement was normal.
✓ If the PCO2 is raised but pH is ≥7.35 (H+]≤45 nmol/L) and/
or a high bicarbonate level (>28 mmol/L), the patient has
probably got long-standing hypercapnia; maintain target
range of 88–92% for these patients. Blood gases should be
repeated at 30–60 min to check for rising PCO2 or falling
pH.
✓ If the patient is hypercapnic (PCO2>6 kPa or 45 mm Hg)
and acidotic (pH<7.35 or [H+]>45 nmol/L), start NIV with
targeted oxygen therapy if respiratory acidosis persists for
more than 30 min after initiation of standard medical
management.
✓ For patients using Venturi masks, consider changing from
Venturi mask to nasal cannulae once the patient has
stabilised.
✓ For patients who use long-term home oxygen (LTOT) for
severe COPD, a senior clinician should consider setting a
patient-speciﬁc target range if the standard range of 88–92%
would require inappropriate adjustment of the patient’s
usual oxygen therapy while the patient is in hospital.
Good practice points
Management of hypercapnia or respiratory acidosis due to
excessive oxygen therapy (avoidance of life-threatening rebound
hypoxaemia)
✓ If a patient is suspected to have hypercapnic respiratory
failure due to excessive oxygen therapy, the oxygen therapy
must be stepped down to the lowest level required to main-
tain a saturation range of 88–92%. This may be achieved
using 28% or 24% oxygen from a Venturi mask or 1–2 L/
min via nasal cannulae depending on oxygen saturation and
subsequent blood gas measurements.
✓ Sudden cessation of supplementary oxygen therapy can
cause life-threatening rebound hypoxaemia with a rapid fall
in oxygen saturations below the starting oxygen saturation
prior to the start of supplementary oxygen therapy.
G3: Initial oxygen treatment of CF exacerbations should be
similar to the initial oxygen treatment of COPD exacerbations
with target saturation 88–92% (see sections 8.12.1–8.12.2;
grade D).
G4: In the initial management of musculoskeletal and neuro-
logical disorders with acute respiratory failure or
acute-on-chronic respiratory failure, aim at an oxygen saturation
of 88–92% and measure blood gases to determine if NIV will
be required (grade D).
Good practice point regarding patients with neurological
disorders
✓ Patients with respiratory failure due to neurological disorders
or muscle disease are at high risk of dying and require urgent
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assessment to determine if they are likely to require non-
invasive or invasive ventilator support rather than oxygen
therapy. Monitor these patients with blood gases and regular
spirometry (forced vital capacity). Patient’s wishes regarding
this form of treatment should be established as early as pos-
sible in the course of the illness, ideally before an acute
episode has developed.
G5: Morbidly obese patients (body mass index (BMI)>40 kg/
m2), even without evidence of coexistent obstructive sleep
apnoea (OSA) are at risk of hypoventilation and should be given
titrated oxygen to maintain a target saturation of 88–92%
(grade D).
G6: NIV should be considered for hypercapnic patients with
COPD, CF, neuromuscular disorders or morbid obesity who are
at risk of hypercapnic respiratory failure if the pH is <7.35 or
[H+]>45 nmol/L (grade D). See BTS/ICS Guideline for the
ventilatory management of acute hypercapnic respiratory failure
(ref 299).
H Oxygen use during pregnancy (See section 8.14)
H1: Women who suffer from major trauma, sepsis or acute
illness during pregnancy should receive the same oxygen
therapy as any other seriously ill patients, with a target oxygen
saturation of 94–98%. The same target range should be applied
to women with hypoxaemia due to acute complications of preg-
nancy (eg, collapse related to amniotic ﬂuid embolus, eclampsia
or antepartum or postpartum haemorrhage) (grade D).
H2: Women with underlying hypoxaemic conditions (eg,
heart failure) should be given supplemental oxygen during
labour to achieve an oxygen saturation of 94–98% unless they
are at risk of hypercapnic respiratory failure (target range 88–
92%) (grade D).
H3: Pregnant women who are fully conscious with no car-
diovascular compromise may be managed in the sitting pos-
ition or if lying down should use the full left lateral position
(grade D).
H4: Pregnant women above 20 weeks gestation (uterine
fundus at or above the level of the umbilicus) who are at risk of
developing associated cardiovascular compromise (eg, trauma,
vaginal bleeding, etc) should be positioned to avoid aortocaval
compression by using left lateral tilt, manual uterine displace-
ment or by placing them in a full left lateral position (grade D).
H5: Women who are more than 20 weeks pregnant with evi-
dence of hypoxaemia associated with reduced consciousness or
those requiring respiratory or cardiovascular support or CPR
should be managed with left lateral tilt or manual uterine dis-
placement (ideally to the left) to improve cardiac output and
oxygen delivery (grade D).
H6: The use of oxygen supplementation during intrauterine
fetal resuscitation during labour was widespread in the past but
there is no evidence of beneﬁt. There is weak evidence of harm
to the fetus if supplemental oxygen is given for long periods
during uncomplicated labour. Overall, the use of oxygen during
labour is only required when there is evidence of maternal hyp-
oxaemia (oxygen saturation <94%) (grade D).
J Oxygen use in perioperative care and during procedures
requiring conscious sedation (see sections 8.15 – 8.16 and
10.11)
J1: Hyperoxaemia is not recommended routinely in the peri-
operative and postoperative period to reduce the incidence of
postoperative nausea and vomiting (grade D).
J2: All procedures involving conscious sedation warrant
routine continuous monitoring of oxygen saturation via pulse
oximetry prior to and during the procedure, and in the recovery
period, particularly ﬁbre optic bronchoscopy and upper gastro-
intestinal (GI) endoscopy where a reduction in arterial oxygen
saturation (SaO2) is common, particularly with concurrent use
of sedation (grade C).
J3: Signiﬁcant arterial oxygen desaturation (SpO2<90% or
fall of 4% or more that is prolonged (>1 min during endoscopy
procedures)) should be corrected by supplemental oxygen with
the aim of achieving target oxygen saturations of 94–98%, or
88–92% in those at risk of hypercapnic respiratory failure
(grade D).
J4: Complicated upper GI endoscopy or procedures in
patients with cardiorespiratory comorbidity are especially likely
to lead to hypoxaemia and may also lead to hypercapnia, espe-
cially if the patient is heavily sedated. It is recommended that
blood gases should be measured if such patients should require
prolonged oxygen administration. The routine administration of
oxygen is not recommended as it may delay the recognition of
respiratory failure (grade D).
J5: Constant clinical assessment of the patient is crucial at
all stages of conscious sedation procedures and monitoring of
capnography or transcutaneous carbon dioxide levels may be
a useful adjunct to identify early respiratory depression
(grade D).
J6: During the recovery period after procedures requiring
conscious sedation, supplemental oxygen should be titrated to
achieve target saturations of 94–98% in most patients and 88–
92% in those at risk of hypercapnic respiratory failure (see
10.5.1) (grade D).
Good practice points related to oxygen use in perioperative care
✓ A target saturation of 94–98% is recommended for most
surgical patients except those at risk of hypercapnic
respiratory failure when a range of 88–92% should be
achieved.
✓ Pulse oximetry monitoring is recommended for post-
operative patients despite the lack of evidence from rando-
mised studies.
✓ Patients using patient controlled analgesia (PCA) should have
two-hourly oximetry observations because of the risk of hyp-
oxaemia. Oxygen should be administered to keep patients
within the appropriate target saturation range.
✓ A target saturation of 94–98% is advised in most patients
having PCA except those at risk of hypercapnic respiratory
failure when a range of 88–92% should be achieved.
✓ There is conﬂicting evidence concerning the balance of
potential beneﬁts and risks of perioperative hyperoxaemia to
reduce the risk of surgical site infection in elective surgery
and there is no evidence for this practice in patients having
emergency surgical procedures. More trials are required for
speciﬁc procedures and more information is required con-
cerning long-term mortality risks to patients with cancer. In
the meantime, oxygen should not be used for this indication
outside of clinical trials.
K Oxygen use in palliative care (see section 8.17)
K1: Oxygen use in palliative care patients should be restricted to
patients with SpO2 consistently <90% or patients who report
signiﬁcant relief of breathlessness from oxygen. In non-
hypoxaemic patients, opioids and non-pharmacological measures
should be tried before oxygen (grade B).
K2: In general, there is no role for the monitoring of oxygen
saturation or PaO2 in comfort-focused care in the last few days
of life. If the patient appears comfortable, oxygen levels are
irrelevant and should not inﬂuence care (grade D).
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Good practice points related to oxygen use in palliative care
Oxygen therapy for the symptomatic relief of breathlessness
in palliative care patients is more complex than the simple cor-
rection of hypoxaemia. Consider the following issues:
✓ Consider early involvement of palliative care specialists and
physiotherapists;
✓ As breathlessness is a multifactorial sensation—a comprehen-
sive assessment of contributing factors (such as anxiety)
should be carried out.
✓ Low-dose opioids should be considered because they are
effective for the relief of breathlessness in palliative care
patients.
✓ A trial of a hand held fan to help relieve breathlessness is
recommended prior to trial of oxygen.
✓ Oxygen use has to be tailored to the individual and a formal
assessment made of its efﬁcacy for reducing breathlessness
and improving quality of life for that person.
✓ Oxygen therapy should not be continued in the absence of
patient beneﬁt or where its disadvantages (eg, discomfort of
masks or nasal cannulae, drying of mucous membranes) out-
weigh any likely symptomatic beneﬁt.
L Mixtures of oxygen with other gases (Heliox and Entonox)
Use of helium–oxygen mixtures (Heliox) see section 8.18
L1: There is insufﬁcient evidence to support the use of
Heliox either as an inhaled gas or as the driving gas for nebu-
liser therapy in adult patients with acute exacerbations of
asthma or acute exacerbations of COPD (AECOPD) except as
part of randomised clinical trials or in exceptional circumstances
(grade D).
L2: A therapeutic trial of Heliox is reasonable in patients
with mechanical upper airway obstruction or postoperative
stridor (grade D).
L3: Heliox use for patients with asthma or COPD should be
considered only in clinical trials or in specialist hands for severe
exacerbations that are not responding to standard treatment
(and in patients with COPD where there are contraindications
to intubation) (grade D)
M Use of nitrous oxide/oxygen mixtures (Entonox) for
analgesia (see section 9.11)
M1: The use of Entonox gas mixture for analgesia should be
avoided if possible in patients at risk of hypercapnic respiratory
failure (grade D).
N CPAP and humidiﬁed high-ﬂow nasal oxygen
Use of CPAP in the perioperative period and for pulmonary
oedema (see section 8.19)
N1: Patients with diagnosed sleep-disordered breathing estab-
lished on CPAP undergoing surgery should bring their machines
with them and use them in the preoperative and postoperative
period. If adequate saturations are not achieved despite CPAP
therapy then assess for worsening ventilation with blood gases
and oxygen should be entrained to achieve a saturation of
88–92% (grade D).
N2: CPAP with entrained oxygen to maintain saturation
94–98% should be considered as an adjunctive treatment to
improve gas exchange in patients with cardiogenic pulmonary
oedema who are not responding to standard treatment in hos-
pital care or in prehospital care (grade B).
Good practice point, high-ﬂow humidiﬁed nasal oxygen via
nasal cannulae
✓ High-ﬂow humidiﬁed nasal oxygen should be considered as
a potentially superior alternative to reservoir mask treatment
in patients with acute respiratory failure without
hypercapnia.
The preﬁx O is not in use for recommendations.
P Patients with tracheostomy or laryngectomy (see section
10.3)
P1: When oxygen is required by patients with prior tracheos-
tomy or laryngectomy, a tracheostomy mask (varying the ﬂow as
necessary) should achieve the desired oxygen saturation
(tables 1–4). An alternative delivery device, usually a T-piece
device ﬁtted directly to the tracheostomy tube, may be necessary
if the patient deteriorates (grade D).
Q Humidiﬁcation of oxygen (see section 10.2)
Q1: Humidiﬁcation is not required for the delivery of low-ﬂow
oxygen (mask or nasal cannulae) or for the short-term use of
high-ﬂow oxygen. It is not therefore required in prehospital
care. Pending the results of clinical trials, it is reasonable to use
humidiﬁed oxygen for patients who require high-ﬂow oxygen
systems for more than 24 hours or who report upper airway dis-
comfort due to dryness (grade D).
Q2: In the emergency situation, humidiﬁed oxygen use can
be conﬁned to patients with tracheostomy or an artiﬁcial
airway although these patients can be managed without
humidiﬁcation for short periods of time (eg, ambulance jour-
neys) (grade D).
Q3: Humidiﬁcation may also be of beneﬁt to patients
with viscous secretions causing difﬁculty with expectoration.
This beneﬁt can be achieved using nebulised normal saline
(grade D).
Q4: Bubble bottles which allow a stream of oxygen to bubble
through a container of water should not be used because there
is no evidence of a clinically signiﬁcant beneﬁt but there is a risk
of infection (grade D).
Good practice points related to humidiﬁed oxygen therapy
✓ Consider use of a large volume oxygen humidiﬁer device for
patients requiring high-ﬂow rates or longer term oxygen,
especially if sputum retention is a clinical problem.
✓ In the absence of an artiﬁcial airway the decision to humidify
supplemental oxygen needs to be made on an individual
basis but this practice is not evidence-based.
R Driving gas for nebulised treatments (see section 10.4)
R1: For patients with asthma, nebulisers should be driven by
piped oxygen or from an oxygen cylinder ﬁtted with a high-
ﬂow regulator capable of delivering a ﬂow rate of >6 L/min.
The patient should be changed back to his/her usual oxygen
mask or cannulae when nebuliser therapy is complete. If the
cylinder does not produce this ﬂow rate, an air-driven nebuliser
(with electrical compressor) should be used with supplemental
oxygen by nasal cannulae at 2–6 L/min to maintain an appropri-
ate oxygen saturation level (grade D).
R2: When nebulised bronchodilators are given to patients
with hypercapnic acidosis, they should be given using an ultra-
sonic nebuliser or else a jet nebuliser driven by compressed air
and, if necessary, supplementary oxygen should be given concur-
rently by nasal cannulae to maintain an oxygen saturation of
88–92%. The same precautions should be applied to patients
who are at risk of hypercapnic respiratory failure prior to the
availability of blood gas results and the oxygen saturation
should be monitored continuously during treatment. Once the
nebulised treatment is completed for patients at risk of hyper-
capnic respiratory failure, their previous targeted oxygen
therapy should be reinstituted (grade D).
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Good practice points
Do not allow hypoxaemia to occur while administering nebu-
lised treatments:
✓ For hypoxaemic patients, oxygen therapy should continue
during nebulised treatments.
Driving gas for nebulised treatment in ambulances
✓ During treatment by ambulance staff oxygen-driven nebuli-
sers should be used for patients with asthma and may be
used for patients with COPD in the absence of an air-driven
compressor system. If oxygen is used for patients with
known COPD, its use should be limited to 6 min. This will
deliver most of the nebulised drug dose but limit the risk of
hypercapnic respiratory failure (section 10.4). Ambulance
services are encouraged to explore the feasibility of introdu-
cing battery-powered, air-driven nebulisers or portable ultra-
sonic nebulisers.
S Prescribing oxygen therapy (see section 11)
S1: Every healthcare facility should have a standard oxygen pre-
scription document or, preferably, a designated oxygen section
on all drug-prescribing cards or guided prescription of oxygen
in electronic prescribing systems (grade D).
S2: A prescription for oxygen should always be provided,
except in sudden illness when it must be started immediately
and documented retrospectively (grade D).
S3: Doctors and other prescribers should prescribe oxygen
using a target saturation range (sections 8, 9 and 11) and sign
the drug chart or electronic prescribing order (grade D).
S4: An oxygen target saturation range should be prescribed
for all patients who are admitted to hospital. This will ensure
that every patient will receive appropriate oxygen therapy if it
should be required. It will also ensure that all clinicians are
aware of the appropriate oxygen target range for every patient
under their care (grade D).
Good practice points related to prescribing and administering
oxygen therapy to patients
✓ Oxygen should be prescribed on the drug chart or electronic
prescribing system using a target saturation range.
✓ Oxygen should be prescribed to a target saturation range
rather than prescribing a ﬁxed concentration of oxygen or
FiO2 (see recommendations A1, A2, A4 and A5)
✓ In most emergency situations, oxygen is given to patients
immediately without a formal prescription. The lack of a
prescription should never preclude oxygen being given when
needed in an emergency situation. However, a subsequent
written record must be made of what oxygen therapy has
been given to every patient in a similar manner to the
recording of all other emergency treatment.
✓ If a patient has an oxygen alert card, initial oxygen therapy
should be based on the guidance on the card until the results
of blood gases are available.
T Monitoring and adjusting oxygen therapy (see sections 9–11)
T1: Pulse oximetry must be available in all locations where emer-
gency oxygen is being used by healthcare professionals (see also
the limitations of using pulse oximetry section 7.1.2) (grade D).
T2: All documents which record oximetry measurements or
blood gas results should state whether the patient is breathing
air or a speciﬁed oxygen delivery device and ﬂow rate using the
abbreviations shown in table 5 (grade D).
T3: In all situations where repeated blood gas measurements
are required, they should be measured as soon as possible,
usually within 30 min of any treatment change, to determine if
the proposed target saturations are appropriate. Consider the
use of an indwelling arterial catheter if multiple samples are
likely to be required (grade D).
T4: Adjustments should only be made by registered staff who
have been trained to administer oxygen. If the oxygen saturation
falls below the prespeciﬁed range, the concentration of oxygen
should be increased; if the saturation rises above this range, the
oxygen concentration should be reduced. If the monitoring of
oxygen saturation is performed by unregistered staff (eg, health-
care assistants), there must be a clear protocol in place which
requires that they should inform staff who are trained to admin-
ister oxygen if the oxygen saturation is above or below the
target saturation (grade D).
Good practice points related to administration of oxygen therapy
✓ For hypoxaemic patients, oxygen therapy should continue
during other treatments such as nebulised therapy. Clinicians
should assess the clinical status of the patient prior to pre-
scribing oxygen and the patient’s condition should be reas-
sessed frequently during oxygen use (see recommendations
B1-B3).
✓ The administering healthcare professional should note the
oxygen saturation before starting oxygen therapy whenever
possible but never discontinue or delay oxygen therapy for
seriously ill patients (see recommendation B2).
✓ The healthcare professional should start oxygen therapy
using an appropriate delivery system and ﬂow rate as speci-
ﬁed in sections 8 –10 of this guideline. The target oxygen
saturation should be documented on the respiratory section
of the observation chart.
Table 5 Abbreviations for oxygen devices for use on bedside charts
Add flow in L=min eg N 2 L=min ¼ nasal oxygen at 2 L=min
V28 4 L=min ¼ 28% Venturi mask at 4 L=min
RM 15 L=min ¼reservoir mask at 15 L=min
A, air
N, nasal cannulae HFN, high-flow humidified oxygen via nasal cannulae
V24, Venturi mask 24% V28, Venturi mask 28% V35, Venturi mask 35%
V40, Venturi mask 40% V60, Venturi mask 60%
H28, humidified O2 28% H40, humidified O2 40% H60, humidified O2 60%
RM, reservoir mask SM, simple face mask TM, tracheostomy mask
CPAP, continuous positive airway pressure NIV, non-invasive ventilation
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✓ Whenever possible, patients should be given an oxygen
information sheet (example in web appendix 6 of this guide-
line on the BTS website).
✓ Staff should check the oxygen supply and connections on a
regular basis because there have been serious incidents due
to disconnection or misconnection of oxygen supplies.
✓ Staff must ensure that adequate oxygen is provided during
transfers and while patients are in diagnostic departments.
Additionally, oxygen saturation should be monitored con-
tinuously for seriously ill patients who require escorted
transfers. This is because there have been serious incidents
involving accidental discontinuation of oxygen or cylinders
running out during interward transfers or transfers to other
departments such as for x-rays.
U Weaning and discontinuation of oxygen therapy
U1: Lower the oxygen concentration if the patient is clinically
stable and the oxygen saturation is above the target range or if it
has been in the upper zone of the target range for some time
(usually 4–8 hours) (grade D).
U2: If the target saturation is maintained, the new delivery
system and ﬂow should be continued. Repeat blood gas mea-
surements are not required. If the patient is stable the process
can be repeated and the patient can eventually be weaned off
oxygen (see section 12) (grade D).
U3: Most stable convalescent patients will eventually be
stepped down to 2 L/min via nasal cannulae prior to cessation
of oxygen therapy. Patients at risk of hypercapnic respiratory
failure may be stepped down to 1 L/min (or occasionally 0.5 L/
min) via nasal cannulae or a 24% Venturi mask at 2 L/min as
the lowest oxygen concentration prior to cessation of oxygen
therapy (grade D).
U4: Oxygen therapy should be stopped once a patient is clin-
ically stable on low-concentration oxygen and the oxygen satur-
ation is within the desired range on two consecutive
observations (but the prescription for a target saturation range
should remain active in case of future deterioration). It may be
appropriate to alter the target range following senior review in
patients with chronic cardiopulmonary disease who either have
saturations <94% when stable or in whom it is deemed sensible
to discharge from hospital with saturations <94% pending an
outpatient oxygen assessment. Oxygen should also be stopped if
the patient has come to the end of a written protocol of timed
oxygen (eg, postoperatively) (grade D).
U5: Oxygen saturation on air should be monitored for 5 min
after stopping oxygen therapy. If it remains in the desired range
it should be rechecked at 1 hour (grade D).
U6: If the oxygen saturation and physiological ‘track and
trigger’ score (eg, NEWS) is satisfactory at 1 hour, the patient
has safely discontinued oxygen therapy. However, saturation
and physiology should continue to be monitored on a regular
basis according to the patient’s underlying clinical condition
(grade D).
U7: If the saturation falls below the patient’s target range on
stopping oxygen therapy, restart the lowest concentration that
maintained the patient in the target range and monitor for
5 min. If this restores the saturation into the target range, con-
tinue oxygen therapy at this level and attempt discontinuation
of oxygen therapy again at a later date provided the patient
remains clinically stable (grade D).
U8: If a patient requires oxygen therapy to be restarted at a
higher concentration than before to maintain the same target
saturation range, the patient should have a clinical review to
establish the cause for this deterioration (grade D).
U9: Some patients may have episodic hypoxaemia (eg, after
minor exertion or due to mucus plugging) after they have safely
discontinued oxygen therapy. An ongoing prescription for a
target saturation range will allow these patients to receive
oxygen as the need arises but transient asymptomatic desatur-
ation does not require correction (grade D).
V Practical aspects of oxygen use in prehospital and
hospital care and use of oxygen alert cards (see sections 9–11)
V1: Emergency oxygen should be available in primary care
medical centres, preferably using oxygen cylinders with integral
high-ﬂow regulators. Alternatively, oxygen cylinders ﬁtted with
high-ﬂow regulators (delivering up to 15 L/min) must be used to
allow use with reservoir masks (grade D).
V2: Healthcare organisations should take measures to elimin-
ate the risk of oxygen tubing being connected to the incorrect
wall oxygen outlet or to outlets that deliver compressed air or
other gases instead of oxygen. Air ﬂow meters should be
removed from the wall sockets or covered with a designated air
outlet cover when not in use. Special care should be taken if
twin oxygen outlets are in use (grade D).
Good practice points related to practical aspects of oxygen
therapy
Assessment and immediate oxygen therapy
✓ Chronically hypoxaemic patients with a clinical exacerbation
associated with a 3% or greater fall in oxygen saturation on
their usual oxygen therapy should usually be assessed in hos-
pital with blood gas estimations. PaO2 of <7 kPa equates to
SpO2 below ∼85%.
✓ The initial oxygen therapy to be used in the various clinical
situations is given in tables 1–4.
✓ If there is a clear history of asthma or heart failure or other
treatable illness, appropriate treatment should be instituted
in accordance with guidelines or standard management plans
for each disease.
✓ The oxygen saturation should be monitored continuously
until the patient is stable or arrives at hospital for a full
assessment. The oxygen concentration should be adjusted
upwards or downwards to maintain the target saturation
range.
✓ In most emergency situations oxygen is given to patients
immediately without a formal prescription or drug order.
The lack of a prescription should never preclude oxygen
being given when needed in an emergency situation.
However, a subsequent written record must be made of what
oxygen therapy has been given to every patient (in a similar
manner to the recording of all other emergency treatment).
✓ General practitioners (GPs) or ﬁrst responders visiting a
patient’s home should carry a portable pulse oximeter to
assess hypoxaemia and guide use of oxygen if available and
should call emergency services if hypoxaemia or other
serious illness is suspected.
✓ Those attending patients as an emergency in rural or remote
areas should consider carrying a portable oxygen cylinder as
part of their emergency equipment.
Oxygen alert cards for patients with hypercapnic respiratory
failure
✓ Patients with COPD (and other at-risk conditions) who have
had an episode of hypercapnic respiratory failure should be
issued with an oxygen alert card and with a 24% or 28%
Venturi mask. They should be instructed to show the card to
the ambulance crew and emergency department staff in the
event of an exacerbation.
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✓ Oxygen alert cards with agreed content can be obtained via
the BTS website.
✓ The content of the alert card should be speciﬁed by the
physician in charge of the patient’s care, based on previous
blood gas results.
✓ The primary care team and ambulance service should also
be informed by the hospital COPD team that the patient
has had an episode of hypercapnic respiratory failure and
carries an oxygen alert card. The home address and ideal
oxygen concentration or target saturation ranges of these
patients can be ﬂagged in the ambulance control systems
and information disseminated to ambulance crews when
required.
✓ When possible, out-of-hours services providing emergency
primary care services should be informed by the hospital
COPD team or by the primary care team that the patient
has had an episode of hypercapnic respiratory failure and
carries an oxygen alert card. Use of oxygen in these
patients will be guided by the instructions on the alert card
or by a patient-speciﬁc protocol which can be shared by
hospital teams, the ambulance service and the primary care
team.
W Practical aspects of oxygen dispensing, documentation
and monitoring
W1: Registered nurses and others who dispense drugs in hospi-
tals should sign the drug chart or electronic prescribing record
at every drug round and check that the patient is receiving
oxygen therapy. This is to check that the patient is within the
target saturation and also to check whether weaning and discon-
tinuation should be instituted (grade D).
W2: Most patients are prescribed an oxygen target range. If
patients are on air at the time of the drug round, registered
nurses should sign the drug chart using a code such as ‘A’ for air
and the observation chart should also be ﬁlled in using the code
A for air (see table 5 and ﬁgure 19) (grade D).
W3: All patients should have their oxygen saturation observed
for at least 5 min after starting oxygen therapy or for patients
who require an increased concentration of oxygen and after
oxygen therapy has been decreased or stopped (grade D).
W4: If the oxygen saturation is above the target saturation
range and the patient is stable, the delivery system or oxygen
ﬂow rate should be modiﬁed to return the saturation to within
the target range (grade D).
W5: Patients who have a target saturation of 88–92% should
have their blood gases measured within 30–60 min. This is to
ensure that the carbon dioxide level is not rising. This recom-
mendation also applies to those who are at risk of developing
hypercapnic respiratory failure but who have a normal PCO2 on
the initial blood gas measurement (grade D).
W6: Stable patients whose oxygen saturation is within their
target saturation range of 94–98% do not need repeat blood gas
measurements within 30–60 min if there is no risk of hypercap-
nic respiratory failure and acidosis and may not need any
further blood gas measurements unless there should be further
deterioration including symptoms or signs of possible hypercap-
nia (grade D).
W7: Stable patients on oxygen treatment should have SpO2
and physiological variables (eg, NEWS) measured four times a
day (grade D).
W8: In those who have signs of critical illness (eg, NEWS 7
or above), oxygen saturation should be monitored continuously
and the patient may require level 2 or 3 care on a HDU or crit-
ical care unit (grade D).
W9: If the patient is clinically stable and the oxygen saturation is
within the target range, treatment should be continued (or eventu-
ally lowered) depending on the clinical situation (grade D).
W10: Oxygen therapy should be increased if the saturation is
below the desired range and decreased if the saturation is above
the desired range (and eventually discontinued as the patient
recovers) (grade D).
W11: The new saturation (and the new delivery system) and
ﬂow rate should be recorded on the patient’s observation chart
after 5 min of treatment at the new oxygen concentration. Each
change should be recorded by the clinician trained to administer
oxygen by signing the observation chart (only changes should
be signed for) (grade D).
W12: Repeat blood gas measurements are not required for
stable patients who require a reduced concentration of oxygen
(or cessation of oxygen therapy) to maintain the desired target
saturation (grade D).
W13: Patients with no risk of hypercapnic respiratory failure
do not always need repeat blood gas measurements after an
increase in oxygen concentration. However, the patient requires
clinical review to determine why the oxygen saturation has
fallen (grade D).
W14: Patients at risk of hypercapnic respiratory failure
(usually those with a target range of 88–92%; see table 4)
require repeat blood gas assessment 30–60 min after an increase
in oxygen therapy (to ensure that the carbon dioxide level is not
rising) (grade D).
W15: For patients with no risk of hypercapnic respiratory
failure, monitoring by pulse oximeter is sufﬁcient (repeated
blood gases not required) provided the patient is clinically stable
and the oxygen saturation remains in the desired range, usually
94–98% (grade D).
W16: If a patient’s oxygen saturation is lower than the pre-
scribed target range, ﬁrst check all aspects of the oxygen delivery
system and the oximeter device for faults or errors (grade D).
W17: If a patient’s oxygen saturation is consistently lower
than the prescribed target range, there should be a medical
review and the oxygen therapy should be increased according to
an agreed written protocol (grade D).
W18: If the oxygen saturation fails to rise following 5–10 min
of increased oxygen therapy or if there is clinical concern fol-
lowing medical review, then blood gas measurements should be
repeated (grade D).
X Training in oxygen prescribing and use
X1: All clinicians prescribing oxygen should have appropriate
training and access to written or electronic oxygen prescribing
guidelines based on this national guideline (grade D).
(Training slides for doctors and nurses are available as online
appendices 7 and 8 on the BTS website.)
X2: Every hospital should have a training programme to
ensure that clinical staff are familiar with the hospital’s oxygen
administration policies. In view of the high number of adverse
incidents related to oxygen therapy, it is recommended that all
acute Trusts should include basic training in oxygen use in the
mandatory training programmes for all clinical staff (grade D).
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SECTION 1: INTRODUCTION
1.1 Aim of the guideline
The key aim of this guideline is to make oxygen use in emergency
and healthcare settings safer, simpler and more effective. Oxygen
is probably the commonest drug used in the care of patients who
present with medical emergencies. Prior to the publication of the
ﬁrst BTS guideline for emergency oxygen use in adult patients in
2008,2 ambulance teams and emergency department teams were
likely to give oxygen to virtually all breathless or seriously ill
patients and also to a large number of non-hypoxaemic patients
with conditions such as ischaemic heart disease or stroke based
on custom and practice. About 34% of UK ambulance journeys
in 2007 involved oxygen use.3 This translated to about two
million instances of emergency oxygen use per annum by all UK
ambulance services, with further use in patients’ homes, GP sur-
geries and in hospitals. Audits of oxygen use and oxygen pre-
scription have shown consistently poor performance in many
countries and most clinicians who deal with medical emergencies
have encountered adverse incidents and occasional deaths due to
underuse and overuse of oxygen.4–10
Historically, oxygen has been administered for three main indica-
tions of which only one is evidence-based. First, oxygen is given to
correct hypoxaemia because severe hypoxaemia is clearly harmful
to the human body. Second, oxygen has been administered to ill
patients in case they might become hypoxaemic. Recent evidence
suggests that this practice may actually place patients at increased
risk if impaired gas exchange does actually develop (see section
6.3). Third, a very high proportion of medical oxygen was adminis-
tered because most clinicians believed, prior to 2008, that oxygen
can alleviate breathlessness in most circumstances. However, there
is no good evidence that oxygen relieves breathlessness in non-
hypoxaemic patients. There is evidence of lack of effectiveness or
minimal effectiveness in mildly hypoxaemic breathless patients with
COPD and advanced cancer (see sections 6 and 8.11.4).
Against this background, the Standards of Care Committee of
the BTS established a working party in association with 21
other societies to produce an evidence-based guideline for emer-
gency oxygen use in the UK. This led to the production of the
2008 BTS guideline for emergency oxygen use in adult patients
which was the world’s ﬁrst guideline for emergency oxygen
therapy.2 This guideline has been implemented throughout the
UK and in many other countries leading to over 500 citations in
the medical literature up to the end of 2016.
The purpose of the update to the 2008 guideline is to
strengthen the evidence base of the previous guideline based on
revised methodology (which meets criteria contained in the
AGREE II instrument) and to extend the evidence base to the
end of 2013.11 Additionally, the remit of the 2008 guideline has
been broadened to cover several new aspects of oxygen use and
a broader range of locations where oxygen might be used.
1.2 Intended users of the guideline and target patient
populations
This guideline is mainly intended for use by all healthcare pro-
fessionals who may be involved in emergency oxygen use. This
will include ambulance staff, ﬁrst responders, paramedics,
doctors, nurses, midwives, physiotherapists, pharmacists and all
other healthcare professionals who may deal with ill or breath-
less patients. Advice is also provided for ﬁrst responders belong-
ing to voluntary organisations or other non-National Health
Service (NHS) bodies. Information based on this guideline is
available on the BTS website for use in the following situations:
▸ Hospital use
▸ Primary care use
▸ Ambulance use (supplemented by ambulance service guid-
ance based on this guideline)12
▸ Use by nursing staff and allied health professions.
These abbreviated versions of the guideline contain the key
recommendations and tables and charts that are relevant to the
particular situation. The ‘mini guidelines’ can be downloaded by
healthcare organisations for use on Trust intranets and to
produce paper versions of the guideline for key staff.
1.3 Areas covered by this guideline
The guideline addresses the use of oxygen in three main cat-
egories of adult patients in the prehospital and hospital setting
and in other settings such as palliative care:
▸ Critically ill patients,
▸ Hypoxaemic patients and patients at risk of hypoxaemia,
▸ Non-hypoxaemic patients who may beneﬁt from oxygen (eg,
carbon monoxide poisoning).
1.4 Areas not covered by this guideline
▸ Oxygen use in paediatrics: the present guideline applies only
to patients aged > 16 years.
▸ Oxygen use for high altitude activities.
▸ Oxygen use during air travel.
▸ Underwater diving and diving accidents.
▸ Oxygen use in animal experiments.
▸ Oxygen use in HDUs.
▸ Oxygen use in ICUs.
▸ Interhospital level 3 transfers.
▸ Hyperbaric oxygen.
▸ Respiratory support techniques including tracheal intubation,
invasive ventilation and NIV (CPAP is included).
▸ Self-initiated use of oxygen by patients who have home
oxygen for any reason.
▸ Ongoing care of hypoxaemic patients at home.
1.5 Key changes since the ﬁrst edition of this guideline
published in 2008
Methodology
The evidence review methodology has changed from NICE
methodology to the BTS NICE accredited guideline production
process which is based on the Scottish Intercollegiate Guideline
Network (SIGN) methodology and adheres to AGREE method-
ology (see section 1).
Evidence levels and grade of recommendation
These are now in SIGN format (see section 1 and tables 6 and 7).
Evidence base
The evidence base for the guideline has been updated to August
2013 (and extended to late-2016 for key references). None of the
2008 recommendations have been challenged by new evidence
but many of the existing recommendations are supported by new
information. There have been many observational studies but few
randomised trials directly relevant to the guideline since 2008.
The remit of the guideline has been extended
The new guideline covers not just emergency oxygen use but
most oxygen use in healthcare settings. It also covers short-term
oxygen use by healthcare workers outside of healthcare settings
but domiciliary oxygen use by patients is covered by the BTS
guideline for home oxygen use in adults.13
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The scope of the guideline has been widened
The present guideline includes the following new topics and set-
tings which have been requested by guideline users:
▸ Postoperative and perioperative care including PCA,
▸ Endoscopy and other procedures requiring conscious
sedation,
▸ Palliative care settings including hospices,
▸ Use of helium–oxygen mixtures (Heliox) and nitrous oxide/
oxygen mixtures (Entonox),
▸ Use of CPAP,
▸ Use of oxygen by healthcare professionals in patients’ homes,
▸ Use of oxygen by voluntary rescue organisations and other
non-NHS ﬁrst responders,
▸ High-ﬂow nasal cannulae (HFNC).
The structure and format of the guideline has been changed
since 2008:
The 2008 guideline was published as a supplement in
Thorax.2 Additional educational materials and other resources
including audit tools were made available on the BTS website.
The new guideline exists in two complementary formats.
▸ A concise guideline which contains recommendations and
good practice points is published in BMJ Open Respiratory
Research.
▸ The full guideline including evidence review, physiology
overview, illustrations and references is published in this
edition of Thorax and is available on the BTS website http://
www.brit-thoracic.org.uk.
1.6 Limitations of the guideline
This guideline is based on the best available evidence concerning
oxygen therapy. However, a guideline can never be a substitute
for clinical judgement in individual cases. There may be cases
where it is appropriate for clinicians to act outwith the advice
contained in this guideline because of the needs of individual
patients, especially those with complex or interacting disease
states. Furthermore, the responsibility for the care of individual
patients rests with the clinician in charge of the patient’s care
and the advice offered in this guideline must, of necessity, be of
a general nature and should not be relied on as the only source
of advice in the treatment of individual patients. In particular,
this guideline gives very little advice about the management of
the many medical conditions that may cause hypoxaemia (apart
from the speciﬁc issue of managing the patients’ hypoxaemia).
Readers are referred to other guidelines for advice on the man-
agement of speciﬁc conditions such as COPD, pneumonia, heart
failure, etc. Some of these disease-speciﬁc guidelines may
suggest slightly different approaches to emergency oxygen
therapy whereas the present guideline aims to provide simple
all-embracing advice about oxygen therapy.
SECTION 2: METHODOLOGY OF GUIDELINE PRODUCTION
2.1 Establishment of guideline team
The need for a national guideline for emergency oxygen use was
recognised by the BTS Standards of Care Committee in 2003. A
working party was established with representatives from a wide
range of professions involved in oxygen therapy and a lay repre-
sentative. The original group was expanded in 2006 because it
became clear that the development and implementation of a
national guideline would require input from a very wide range of
professional groups. This group agreed the remit of the 2008
guideline and a series of key questions which were addressed
within the 2008 guideline.2 The group membership was
expanded further and the remit was expanded for the 2016
update of the guideline. A full list of guideline group members is
provided in annex 1. The methodology for the 2016 guideline
adheres to the BTS Guideline Production Manual 2014 which is
aligned to the AGREE criteria for guideline production.11 14
A MEDLINE search for ‘oxygen’ yielded over a quarter of a
million ‘hits’, most of which were not relevant to this guideline.
For this reason, the BTS commissioned the Centre for Reviews
and Dissemination and Centre for Health Economics at the
University of York to undertake bespoke literature searches
based on the literature search strategies employed for the 2008
guideline. The search strategies are shown in detail in online
supplementary appendix 1 on the BTS website (http://www.
brit-thoracic.org.uk).
2.2 Summary of key questions
Key question 1: physiology and pathophysiology of oxygen
▸ What are the dangers of hypoxia/hypoxaemia (ie, what
happens to the human body)?
▸ What level of hypoxaemia is dangerous to all patients (even
healthy adults)?
Table 6 SIGN levels of evidence14
SIGN levels of
evidence
1++ High-quality meta-analyses, systematic reviews of RCTs, or
RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews or RCTs
with a low risk of bias
1 Meta-analyses, systematic reviews, or RCTs with a high
risk of bias
2++ High-quality systematic reviews of case–control or cohort
studies
High-quality case–control or cohort studies with a very
low risk of confounding or bias and a high probability
that the relationship is causal
2+ Well-conducted case–control or cohort studies with a low
risk of confounding or bias and a moderate probability
that the relationship is causal
2− Case–control or cohort studies with a high risk of
confounding or bias and a significant risk that the
relationship is not causal
3 Non-analytic studies, for example, case reports, case series
4 Expert opinion
RCT, randomised controlled trial; SIGN, Scottish Intercollegiate Guideline Network.
Table 7 SIGN grades of recommendation
Grades of recommendations
A At least one meta-analysis, systematic review or RCT rated as 1++, and
directly applicable to the target population; or
A body of evidence consisting principally of studies rated as 1+, directly
applicable to the target population, and demonstrating overall consistency
of results
B A body of evidence including studies rated as 2++, directly applicable to
the target population, and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable to the
target population and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or
Extrapolated evidence from studies rated as 2+
Good practice points
✓ Recommended best practice based on the clinical experience of the
Guideline Development Group
RCT, randomised controlled trial; SIGN, Scottish Intercollegiate Guideline Network.
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▸ What level of hypoxaemia is dangerous to vulnerable groups
(eg, ischaemic heart disease, stroke, elderly)?
▸ Repeat the above searches with additional key words:
elderly, stroke, myocardial infarction, heart failure,
COPD, trauma, renal failure.
▸ Same questions for hypercarbia/hypercapnia:
▸ Search for ‘hypercapnia’ combined with terms implying a
harmful outcome (death/tissue injury/brain damage/coma).
▸ What level of hypercapnia is dangerous to all patients?
▸ What level of hypercapnia is dangerous to vulnerable groups
(as above)?
▸ Same questions for respiratory acidosis:
▸ Search for ‘respiratory acidosis’ combined with terms
implying a harmful outcome (death/tissue injury/brain
damage/coma).
▸ What level of respiratory acidosis is dangerous to all
patients?
▸ What level of respiratory acidosis is dangerous to vulnerable
groups (as above)?
Key question 2: clinical aspects of hypoxaemia and oxygen
therapy for common medical emergencies
▸ How to assess hypoxaemia (clinical, EWS systems, oximetry,
arterial and capillary blood gases).
▸ How to assess hypercarbia/hypercapnia.
▸ Use of oxygen to relieve symptomatic breathlessness.
▸ Use of oxygen in acute COPD.
▸ Use of oxygen in acute asthma.
▸ Use of oxygen in pneumonia.
▸ Use of oxygen for pulmonary embolus.
▸ Use of oxygen in trauma.
▸ Use of oxygen in heart failure.
▸ Use of oxygen in myocardial infarction and unstable coron-
ary artery syndrome.
▸ Use of oxygen in angina.
▸ Use of oxygen for other patients with less common condi-
tions were searched individually (eg, CF, muscular dystrophy,
motor neurone disease, severe kyphoscoliosis, anaphylaxis,
hyperventilation).
Key question 3: oxygen prescription, oxygen delivery systems and
oxygen transport
▸ Oxygen carriage in transport (practical issues; safety issues).
▸ Oxygen delivery systems in ambulances.
▸ Prescription of oxygen.
▸ Local hospital guidelines for oxygen use.
▸ Oxygen delivery systems in hospitals and other healthcare
and emergency settings.
▸ Advantages/disadvantages of each delivery system (Venturi
masks, simple face masks, nasal cannulae, high-ﬂow masks
such as non-rebreathing reservoir masks). Use of oxygen-
driven nebulisers.
▸ Use of CPAP.
▸ Use of ‘alert cards’, alert bracelets or similar hazard warning
systems for patients who are known to be at risk of
hypercapnia.
2.3 How the evidence was assimilated into
the guideline
The search strategy and guideline methodology for the 2008
guideline are described within the original guideline.2 The remit
of the guideline was widened for this update. Signiﬁcant new
areas include the use of oxygen during conscious sedation pro-
cedures, the non-emergency use of oxygen in healthcare settings
and the use of CPAP, Heliox and oxygen–nitrous oxide
mixtures. The methodology used for the current guideline was
based on SIGN methodology as outlined in the BTS Guideline
Production Manual 2014.11 14 15
The 2008 guideline had used NICE levels of evidence so all
searches were rerun in November 2011 and again in August
2013. All abstracts retrieved by the literature search were
screened by pairs of members and reprints of all relevant papers
were obtained. Members of the Guideline Development Group
worked in pairs to assign a SIGN level of evidence to all of the
papers that were judged to be relevant to the guideline (see
tables 6 and 7). Further references were obtained from the
group’s personal literature collections and from the references
contained within the papers which the search yielded and by
focused literature searches by members of the guideline group.
The group continued to monitor the literature up to the end of
2016 for important new publications or very high-quality
abstracts from international meetings that were thought to be
relevant to this guideline.
The group was divided into subgroups to work on each
chapter of the guideline. Contributions by each member of the
group are acknowledged in annex 1. The Guideline
Development Group corresponded by email on a regular basis
to discuss the evidence and to update the guideline and its key
recommendations over the course of 2011–2016. Oxygen
therapy is unusual insofar as there are very few published trials
where different levels of oxygen therapy have been compared in
randomised studies which reported clinically relevant outcomes.
Most advice concerning oxygen therapy is based on expert
opinion guided by extrapolation from non-interventional studies
that do not directly address guideline questions. For this reason,
most of the recommendations in this guideline are at grade D
and it is hoped that the deﬁciency of relevant evidence will
stimulate researchers to conduct randomised trials of oxygen
therapy. However, the fact that a recommendation is graded as
‘grade D’ due to lack of evidence does not imply that the rec-
ommendation is not important of that there is any uncertainty
as to the correct course of action. For example, it would never
be ethical to undertake a randomised controlled trial (RCT) of
oxygen therapy in severe hypoxaemia, so the advice to use
oxygen to correct severe hypoxaemia will always be a grade D
recommendation but it is one of the most important recommen-
dations in this guideline.
Meetings of the full group were held in November 2011 and
September 2012. The updated guideline was reviewed by the
BTS Standards of Care Committee in September 2014, March
2015, September 2015 and June 2016. The guideline was
further reﬁned by email discussion following comments by this
committee. The draft was made available via the BTS website for
6 weeks from 7 December 2015 to 18 January 2016 for public
and stakeholder consultation and comments were invited. The
draft document was sent to two peer reviewers at that time. The
revised document was then submitted to the British Thoracic
Society for ﬁnal approval in October 2016 and endorsement
invited from the other stakeholder societies and colleges.
2.4 Piloting, implementing and auditing the guideline
The principles of the 2008 guideline (target saturation ranges,
etc) were piloted at Salford Royal University Hospital and
Southend University Hospital prior to UK-wide dissemination in
2008. A baseline audit of oxygen use in UK hospitals was under-
taken in 2008 prior to the launch of the guideline and the
process has been audited annually by the BTS each subsequent
year, these audits have monitored implementation of guideline
policies in addition to an audit of process at each hospital.16
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Key features of successful policy implementation were:
▸ Trust-wide introduction of the agreed hospital policy.
▸ Each hospital in the UK has one or more ‘oxygen champions’
to implement and audit the safe use of oxygen locally (see
section 14.6).
▸ Local induction and educational programme for doctors,
nurses and other users of oxygen.
▸ Introduction of prescription charts and patient observation
charts to facilitate the standardisation of oxygen therapy
(ﬁgure 19). Production and implementation of a detailed
hospital oxygen policy based on a model document on the
BTS website (see online supplementary appendix).
▸ Use of standard charts to guide the prescription and adminis-
tration of oxygen (ﬁgure 19).
The educational materials and lecture presentations in web
appendices 7–11 have been used widely in the UK with feed-
back from the oxygen champions in each hospital.
2.5 Planned review and updating of the guideline
The guideline will be reviewed by the British Thoracic Society
within 5 years from publication.
2.6 Declarations of interest
All members of the guideline group made declarations of inter-
est in line with BTS policy and further details can be obtained
on request from BTS.
SECTION 3: NORMAL VALUES AND DEFINITIONS
▸ Normal blood levels of oxygen and carbon dioxide.
▸ Normal oxygen saturation (SaO2) and normal blood pH.
▸ Deﬁnitions of hypoxaemia, hypoxia, hypercapnia, acidosis,
respiratory failure.
Oxygen is transported in the blood in two forms: a small and
negligible amount is dissolved in the plasma and the majority is
bound to haemoglobin and delivered to the tissues. Oxygen
demand and oxygen delivery increase during exercise and
reduce during rest and sleep.
3.1 Blood gas levels of oxygen and carbon dioxide in health
and disease
The human lung delivers oxygen to the blood and removes
carbon dioxide. Several mechanisms exist to regulate breathing
in such a way that both gases are maintained within quite a
narrow range, although carbon dioxide levels are more tightly
regulated than those of oxygen.
3.1.1 Normal ranges for oxygen saturation (SaO2 and SpO2) and
PO2 (PaO2) in the blood at sea level
As there is a ﬁxed amount of haemoglobin circulating in the
blood, the amount of oxygen carried in the blood is often
expressed in terms of how saturated with oxygen the circulating
haemoglobin is. This is what is meant by ‘oxygen saturation
level’. If this is measured directly from an arterial blood sample,
it is termed SaO2. If it is measured from a pulse oximeter it is
termed SpO2. Alternatively, one can measure the PO2 of the
blood (PaO2), known as the ‘partial pressure of oxygen’ in the
blood. This measurement can be expressed in kilopascals (kPa;
normal range 12.0–14.6 kPa) or in millimetres of mercury
(normal range 90–110 mm Hg for young adults).17 The precise
normal ranges for oxygen saturation and PO2 are difﬁcult to
determine accurately due to a lack of data from the ‘normal’
population, that is, non-hospitalised healthy participants.
A US observational study of nearly 900 asymptomatic patients
in the emergency department showed the median SpO2 value to
be 99% with SpO2 values <97% occurring in 5.7% of the
study group.18 However, the study group were young (median
age 38) and predominantly African-American, so these data are
not generalisable to the UK population.
Another North American study measured blood gases and SpO2
at sea level in 96 healthy individuals aged between 18 and 81.17
They found that for adults 2SD range for SaO2 is ∼94–98% at sea
level but this may decline gradually with advancing age (table 8).
A much larger observational study of over 37 000 patients
admitted to four acute medical admissions units across the UK19
found that median SpO2 was 98% for young adults aged 18–
64 years (IQR 97–99%). For adults aged ≥65 years the median
saturation was 96% with IQR 95–98% (table 9). While the
authors of this study recommend setting a normal range of 96–
98%, their study excluded nearly 20% of patients who were
receiving oxygen, many whom were likely to have a SpO2 in the
lower end of the normal range. In further considering these study
results, it is of note that the PaO2 is 0.8 kPa (6 mmHg) lower in
the supine position than in the upright position and most emer-
gency measurements are made in the supine position.20
3.1.2 Oxygen saturation in older adults
The mean SaO2 may be lower in older people than in young
adults. However, it is difﬁcult to dissociate the effects of advan-
cing age from the effects of the diseases that become commoner
in old age. Some papers have reported a fall in the blood PaO2
Table 8 Mean (SD) PaO2 (kPa and mm Hg) and SaO2 (%) values
(with range)
Mean (SD) PaO2 and SaO2 values (with range) in kPa and mm Hg
Age
Mean (SD) PaO2
(kPa and mm Hg)
Range±2SD PaO2
(kPa and mm Hg)
Mean (SD)
SaO2 (%) SaO2±2SD
18–24 13.4 (0.71) 11.98–14.82 96.9 (0.40 96.1–97.7
99.9 (5.3) 89.3–110.5
25–34 13.4 (0.66) 12.08–14.72 96.7 (0.7) 95.3–98.1
99.8 (4.9) 90–109.6
35–44 13.18 (1.02) 11.14–15.22 96.7 (0.6) 95.5–97.9
98.3 (7.6) 83.1–113.5
45–54 13.0 (1.07) 10.86–15.14 96.5 (1) 94.4–98.5
97 (8) 81–113
55–64 12.09 (0.60) 10.89–13.29 95.1 (0.7) 94.5–97.3
90.2 (4.5) 81.2–99.2
>64 11.89 (1.43) 9.02–14.76 95.5 (1.4) 92.7–98.3
88.7 (10.7) 67.3–110.1
Adapted from Crapo et al.17
Values shown for seated healthy men and women non-smoking volunteers at sea
level (adapted from Crapo et al).
PaO2, arterial oxygen tension; SaO2, arterial oxygen saturation.
Table 9 Ranges, mean, SD, median and IQR values for SpO2 (%)
where measurements were made with the patient receiving air for
age ≥18 years (n=37 299) from Smith et al19
Age
(years) n
SpO2
Minimum Maximum Mean SD Median IQR
18–24 1663 80 100 98.0 1.8 98 97–99
25–34 2239 82 100 97.6 1.9 98 97–99
35–44 3412 73 100 97.2 2.1 98 96–99
45–54 4103 76 100 96.8 2.2 97 96–98
55–64 5020 72 100 96.3 2.5 97 95–98
≥65 20 862 70 100 95.8 2.7 96 95–98
SpO2, arterial oxygen saturation measured by pulse oximetry.
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in older participants. Indeed a fall in SpO2 in patients >65 was
demonstrated in Crapo and Smith’s studies, and the former
study shows a decreasing PaO2 with age. However, others have
failed to conﬁrm this observation.21–23 The mean SaO2 in
seated adults aged >64 years in one published study was 95.5%
compared with 96.9% in adults aged 18–24 years, and the SD
was wider in the older age group with a 2SD range of 92.7–
98.3% (tables 8 and 9).17 The mean (SD) SaO2 for recumbent
healthy men aged >70 years in another study was 95.3%
(1.4%) giving a 2SD range of 92.5–98.1% for men of
this age.21 The mean (SD) SaO2 was 94.8% (1.7%) for
recumbent healthy women aged >70 years with a 2SD range of
91.5–98.2%. The authors of this study did not observe any
age-related decline in SaO2 beyond the age of 70 years. The
mean SaO2 in this study of ∼95.0% for recumbent healthy men
and women aged >70 years was below the normal range for
seated healthy young adults. The mean PaO2 in older partici-
pants in this study was 10.3 kPa for men and 9.8 kPa for
women, which is lower than two other studies which reported
mean PaO2 values of 11.2 kPa and 11.1 kPa in healthy older
participants.22 24 Some of these differences are probably due to
participant selection, but there may also be variations in the
results obtained by different blood gas analysers.25
Further data from an unpublished audit of 320 stable hospital
patients in Salford and Southend with no history of lung disease
found a mean (SD) SpO2 of 96.7% (1.77%; 2SD range 95.2–
100%) in patients aged >71 years (R O’Driscoll, A Davison, L
Ward, personal communication). These values were measured
by pulse oximetry in UK hospitals in 2008 and are more likely
to represent the expected normal range of pulse oximetry mea-
surements in the elderly UK population. The variation with age,
sex and posture makes it difﬁcult to give a precise target range
that will apply to all adults who might require oxygen therapy,
but the guideline development committee believe that a target
range of 94–98% will achieve normal or near-normal SpO2/
SaO2 for most adults in the UK and will avoid any risk of clinic-
ally signiﬁcant hypoxaemia.
3.1.3 Oxygen saturation at altitude
While the percentage of oxygen in inspired air is constant at 21%
and does not change with altitude, the fall in atmospheric pres-
sure at higher altitudes decreases the partial pressure of inspired
oxygen. The SaO2 at a given altitude varies with age, sex, ethnic
group and degree of acclimatisation to altitude. For example, a
sample of 3812 people of all ages living in Tibet at an altitude of
about 4000 m had a mean SaO2 of only 88.2%, but people
native to the Andes had an SaO2 about 2.6% higher than
Tibetans living at the same altitude.26 27 However, the physiology
of hypoxaemia at altitude is very different to the physiology of
hypoxaemia at sea level, for example, ventilator changes usually
lead to a marked fall in arterial CO2 level. Millions of people live
at these altitudes with SaO2 values that would cause concern at
sea level. The city of La Paz in Bolivia has a mean altitude of
3600 m and a population of ∼1.5 million people. The SaO2 of
climbers on Mount Everest (8848 m) can fall below 55%.28
Sudden exposure to altitudes above about 4000 m can cause
mountain sickness, high altitude pulmonary oedema and high
altitude cerebral oedema in unacclimatised individuals.
Long-term exposure to high altitude (or to hypoxaemia for any
other reason) can lead to pulmonary hypertension.
3.1.4 Oxygen saturation in acute and chronic diseases
If the blood oxygen level falls to extremely low levels for even a
few minutes (eg, during cardiac arrest), tissue hypoxia and cell
death will occur, especially in the brain. The brain appears to be
the most vulnerable organ during profound hypoxaemia; brain
malfunction is the ﬁrst symptom of hypoxia and brain injury is
the most common long-term complication in survivors of
cardiac arrests and other episodes of profound hypoxaemia.
Sudden exposure to low SaO2 below about 80% can cause
altered consciousness even in healthy participants. It is likely
that other organs in patients with critical illness or chronic
organ damage are vulnerable to the risk of hypoxic tissue injury
at oxygen levels above 80%.
Most experts emphasise the importance of keeping the SaO2
above 90% for most acutely ill patients.29–32 However, the
degree of hypoxia that will cause cellular damage is not well
established and probably is not an absolute value. Healthy older
adults, for instance, have lower SaO2 values at rest than younger
adults. Many patients with chronic lung disease, congenital
cyanotic heart disease or chronic neuromuscular conditions have
oxygen saturations substantially below the normal range, even
when clinically stable.
However, although chronically hypoxaemic patients may tol-
erate an abnormally low SaO2 at rest when in a clinically stable
condition, these resting oxygen levels may not be adequate for
tissue oxygenation during acute illness when the tissue oxygen
demand may increase (eg, sepsis, trauma, pneumonia, head
injury; see section 8).
Acute hypoxaemia with SaO2<90% and sometimes <80% is
seen in many acute illnesses such as pneumonia and heart
failure and it is likely that the clinical manifestations of hypox-
aemia in illness would be similar to those of experimental hyp-
oxaemia in hypobaric chambers (impaired mental function
followed by loss of consciousness). However, the clinical mani-
festations of the illness itself make it difﬁcult to identify which
symptoms and signs are due to hypoxaemia. Pure hypoxaemia,
as seen in hypobaric chambers and at altitude, does not seem to
cause breathlessness in resting participants. Patients with chronic
diseases such as COPD, lung ﬁbrosis, neuromuscular disorders
or congenital heart disease may routinely attend outpatient
clinics with SaO2 levels well below 90% even at a time when
their disease is stable. In an emergency, a clinician who was not
familiar with such a patient (when stable) might interpret the
low saturation as having occurred acutely and aim to achieve an
oxygen saturation that was well above the patient’s usual oxygen
saturation level. Many such patients would qualify for long-term
oxygen therapy. The UK COPD guideline recommends a thresh-
old of 7.3 kPa (55 mm Hg) below which most patients with
COPD will beneﬁt from long-term oxygen therapy (equivalent
to a SaO2 of about 88–89%) and an PaO2 threshold below
8.0 kPa (60 mm Hg) for patients with established cor pulmonale
and some other subgroups.1
3.1.5 Variation in oxygen saturation during sleep
Healthy participants in all age groups have greater variation in
SaO2 when sleeping than while awake. A study of 330 people
referred to a sleep laboratory with normal results of overnight
polysomnography (patients with cranial facial or neurological
abnormalities or previously diagnosed pulmonary disease were
excluded) showed that desaturation routinely occurred with a
mean (SD) minimum SaO2 or ‘nadir’ of 90.4% (3.1%) during
the night (2SD range 84.2–96.6%).33 The mean (SD) overnight
SaO2 ‘nadir’ was 89.3% (2.8%) for participants aged
>60 years.33 In this study, participants aged 20–30 years spent
10% of the night with SaO2 levels below 94.8% and half the
night below 96.3%, and those aged 60 years spent 10% of the
night below 92.8% and half the night below 95.1%.
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Furthermore, the authors of this study excluded obese patients
with any features of sleep apnoea or hypopnoea because these
patients are known to desaturate to very low levels during sleep
(often below 70%). The variation in SaO2 during sleep is exag-
gerated by alcohol and by sedative drugs. This makes it difﬁcult
to evaluate a ‘spot reading’ of SaO2 on a sleeping participant. It
is suggested that SaO2 measurements of sleeping participants
should be interpreted with caution and ideally observed for a
few minutes to see if the participant has got sustained hypox-
aemia or just a transient normal ‘nocturnal dip’.
Oxygen saturation in acute and chronic disease is discussed in
section 3.1.4.
Evidence statements (see recommendations A1–A2):
▸ Normal daytime haemoglobin SaO2 is 96–98% in young
adults in the seated position at sea level but the lower limit
falls slightly with age and is ∼94–98% in adults aged
>70 years (evidence 2+).
▸ All participants have transient dips in oxygen saturation at
night with a mean nadir of 90.4% (2SD range 84.2–96.6%)
in healthy participants in all age groups (evidence level 3).
3.1.6 Normal range for arterial carbon dioxide tension
The reference range for arterial carbon dioxide tension (PaCO2)
is 4.6–6.1 kPa (34–46 mm Hg) for healthy adult men aged 18–
38 years.34 Although this study was undertaken in 1948, it is
consistent with the clinical experience of the guideline group
members and with most modern reference values for PaCO2.
Although different laboratories and textbooks give slightly dif-
ferent reference values, all are within 0.2 kPa of the above refer-
ence range. Any value of PaCO2 of >6.1 kPa (45 mm Hg)
should be considered abnormal, but values up to 6.7 kPa
(50 mm Hg) may be obtained by breath holding.35
3.2 Deﬁnitions of hypoxaemia, hypoxia, type 1 respiratory
failure and hyperoxaemia
Hypoxaemia
Hypoxaemia refers to low PO2 or partial pressure of oxygen
(PaO2) in the blood. For practical reasons, hypoxaemia can also
be measured in relation to oxyhaemoglobin saturation. In adults
the normal range is inﬂuenced by age and comorbidity and the
normal ranges for healthy adults are given in section 3.1.1. The
precise level at which a patient becomes hypoxaemic is debat-
able. One could argue that any saturation below the lower limit
of normal constitutes hypoxaemia. Various authors have deﬁned
hypoxaemia as SaO2 of (1) <94%; (2) <92%; (3) <90%; or
(4) PaO2<60 mm Hg or 8 kPa.
4 36–38 Most authors who have
studied this area have deﬁned hypoxaemia as PaO2<60 mm Hg
(8 kPa) or SaO2<90%.
39 There is no known risk of hypoxic
tissue injury above this level and other guidelines on critical care
set 90% as the minimum below which SaO2 should not be
allowed to fall.31 32
Hypoxia: Hypoxia occurs when oxygen supplies are insufﬁ-
cient to meet oxygen demands in a particular compartment (eg,
alveolar or tissue hypoxia). Tissue hypoxia may be subdivided
into four main causes: hypoxaemic, anaemic, stagnant or histo-
toxic. Oxygen therapy may only correct hypoxia due to hypox-
aemia, other ways to improve oxygen delivery to the tissues
need to be considered.
Hypoxaemic hypoxia: Hypoxaemic hypoxia (sometimes also
referred to as hypoxic hypoxia) is present when the oxygen
content in the blood is low due to reduced partial pressure of
oxygen. This occurs naturally at altitude or occurs secondary to
right-to-left shunts, ventilation–perfusion (V/Q) mismatch,
alveolar hypoventilation or diffusion impairment.
Type 1 respiratory failure, which is deﬁned as PaO2<8 kPa or
60 mm Hg (equivalent to SaO2 of ∼90%) with a normal or low
PaCO2 level is due to hypoxaemic hypoxia.
Anaemic hypoxia: Anaemic hypoxia results from a reduced
level of haemoglobin available for oxygen transport. Although
the patient may not be hypoxaemic (with a normal PaO2 and
SpO2), the reduced oxygen content of the blood may lead to
tissue hypoxia. Carbon monoxide poisoning may also produce
a form of anaemic hypoxia by impairing the ability of haemo-
globin to bind oxygen, thereby reducing oxygen-carrying
capacity.
Stagnant hypoxia: Stagnant hypoxia is a low level of oxygen
in the tissues due to inadequate blood ﬂow (either globally or
regionally). This condition may occur in the extremities if a
person is exposed to cold temperatures for prolonged periods
of time and it is the cause of gangrene in tissue that is deprived
of blood in severe peripheral vascular disease. Stagnant hypoxia
may occur in low cardiac output states.
Histotoxic hypoxia: Histotoxic hypoxia is an inability of the
tissues to use oxygen due to interruption of normal cellular
metabolism. The best known example of this occurs during
cyanide poisoning which impairs cytochrome function. It is
increasingly thought that mitochondrial dysfunction may lead to
decreased oxygen usage in sepsis despite adequate oxygen deliv-
ery. This has also been termed ‘cytopathic dysoxia’.40
Hyperoxia and hyperoxaemia: Hyperoxia and hyperoxaemia
are the counterparts to the above terms and in this guideline
refer to high oxygen content in a compartment and high PO2 in
the blood, respectively. As stated above, for practical purposes
the PO2 in the blood is often measured as oxyhaemoglobin sat-
uration. Furthermore, this guideline is centred on providing
target saturations for various conditions, but it should be noted
that above a PaO2 of ∼16 kPa (120 mm Hg) the oxyhaemoglo-
bin saturation will obviously not change from 100%, yet the
effects of further increases in PaO2 may be important in certain
conditions such as COPD. This is discussed in further detail in
sections 5 and 6.
3.3 Deﬁnition of hypercapnia and type 2 respiratory failure
Hypercapnia is present when the PaCO2 is above the normal
range of 4.6–6.1 kPa (34–46 mm Hg) and patients with hyper-
capnia are said to have type 2 respiratory failure even if the
oxygen saturation is in the normal range. A study of 3524 blood
gas samples in a single hospital found that 27% had type 2
respiratory failure whereas 6% of samples had type 1 respiratory
failure. Forty-one per cent of these samples exhibited hyperoxia
(PaO2>16 kPa).
41 Exclusion of emergency department samples
(many of which were venous) and exclusion of repeat samples
(which are common in patients with COPD) left 8.5% of
samples showing type 1 respiratory failure and 22.7% showing
hypercapnia.42 Hypercapnia was commoner than pure hypox-
aemia on surgical wards and critical care areas as well as on
medical wards.
3.4 Deﬁnition of acidosis (respiratory acidosis and metabolic
acidosis)
Acidosis: Acidity in any ﬂuid is determined by the concentration
of hydrogen ions [H+], and this is normally regulated between
35 and 45 nmol/L. Acidity is more often expressed in terms of
pH where pH=−log10[H+]. The normal pH range of the blood
in humans is between 7.35 and 7.45 units. Acidosis is deﬁned as
a pH<7.35 ([H+]>45 nmol/L) and alkalosis is deﬁned as a
pH>7.45 ([H+]<35 nmol/L). Acidosis can be caused by respira-
tory or metabolic disorders.
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Respiratory acidosis
CO2 þH2O, H2CO3 , Hþ þHCO3
Carbon dioxide (CO2) can combine with water (H2O) to form
carbonic acid (H2CO3) in the blood which, in turn, dissociates
to bicarbonate (HCO3
−) and a hydrogen ion (H+). Acute respira-
tory acidosis occurs if the pH of the blood falls below 7.35
([H+]>45 nmol/L) in the presence of a raised CO2 level. If
respiratory acidosis has been present for more than a few hours,
the kidney retains bicarbonate to buffer the acidity of the blood
and, over hours to days, this may be sufﬁcient to produce a
normal pH. This situation (high PaCO2 with high bicarbonate
and normal pH) is known as ‘compensated respiratory acidosis’.
This situation is common in patients with chronic severe but
stable COPD, but they may have an additional acute rise in
PaCO2 during an acute exacerbation giving rise to ‘acute on
chronic’ respiratory acidosis despite their high bicarbonate level.
This happens because the bicarbonate level was equilibrated
with the previous CO2 level and is insufﬁcient to buffer the
sudden further increase in CO2 level that may occur during an
exacerbation of COPD. Respiratory acidosis is common in clin-
ical practice. Plant et al43 showed that about 20% of patients
with AECOPD requiring hospital admission have respiratory
acidosis.
Metabolic acidosis: This can be caused by failure to excrete
acid produced by the body’s normal metabolic processes (eg,
during renal failure) or by increased production of acid from
abnormal metabolic conditions such as diabetic ketoacidosis.
Alternatively, it may result from direct loss of bicarbonate from
the kidney or gut (eg, during chronic diarrhoea). In all forms of
metabolic acidosis, there is a low blood bicarbonate level, either
due to loss of bicarbonate or due to buffering of excess acid by
bicarbonate which is excreted as CO2. A common cause of
metabolic acidosis is lactic acidosis caused by tissue hypoxia.
This may result from decreased oxygen delivery such as occurs
in hypoxaemia, or low cardiac output states or conditions such
as sepsis where oxygen consumption is impaired in the face of
adequate oxygen delivery. In health, metabolic acidosis will
occur at peak exercise where oxygen delivery is insufﬁcient to
meet demand.
SECTION 4: GENERAL BLOOD GAS PHYSIOLOGY
A full understanding of blood gas physiology in the body
requires a detailed understanding of the anatomy, physiology
and biochemistry of respiration and gas exchange. It is recog-
nised that most readers of this guideline may not have had full
training in all of these specialties, so this physiology section con-
tains a brief overview of basic principles for the non-specialist
reader. The rationale for targeted oxygen therapy is discussed in
detail in section 6.
4.1 Oxygen physiology
Oxygen is transported in the blood in two forms: a small and
negligible amount is dissolved in the plasma and the majority is
bound to the haemoglobin molecule. As there is a ﬁxed amount
of haemoglobin circulating in the blood, the amount of oxygen
carried in the blood is often expressed in terms of how saturated
circulating haemoglobin is with oxygen (SO2).
As discussed in section 3.1 the precise normal SaO2 in
healthy adults at sea level is not known. However, it is within
a narrow range of about 95–98%. This means that almost all
of the oxygen-carrying capacity of haemoglobin in the blood
is used when the SaO2 is in the normal range. Therefore,
giving supplemental oxygen to a healthy young person will
increase the saturation level only slightly from about 97% to
99% or a maximum of 100%, thus producing only a very
small increase in the amount of oxygen made available to the
tissues.
Sudden exposure to low SaO2 levels (below about 80%) can
cause impaired mental functioning even in healthy participants.
The brain is the most sensitive organ to the adverse effects of
hypoxia, but other organs in patients with critical illness may be
vulnerable to the risk of hypoxic tissue injury at oxygen levels
above this range. Most experts emphasise the importance of
keeping the SaO2 above 90% for the majority of acutely ill
patients.29–32 The present guideline suggests a desirable target
saturation range of 94–98%. This range mirrors the normal
range for UK adults with a wide margin of safety above the
90% threshold aforementioned.
Oxygen passes from inspired air in the lungs into the blood-
stream and is delivered to the tissues. If the PaO2 (partial pres-
sure) falls in the blood, this is sensed by receptors in the
carotid body (supplied by the carotid artery in the neck) and
ventilation is stimulated to increase the amount of oxygen
coming into the lung and therefore the blood. The lung has
the ability to divert blood ﬂow away from areas which are
poorly ventilated, so that blood returning from the body can
be efﬁciently replenished with oxygen and also cleared of
carbon dioxide. This occurs through a process called ‘hypoxic
vasoconstriction’ whereby localised low PO2 in the lung air-
spaces cause constriction of feeding blood vessels, therefore
diverting blood to areas of the lung with better ventilation.
This mechanism is unique to the lungs: the circulation of other
organs such as the brain, heart and kidneys will vasodilate in
response to hypoxia to facilitate greater blood ﬂow to areas
starved of oxygen.
If the oxygen-carrying capacity of the blood is low as, for
example, in anaemia, this is detected by the kidneys which
produce a hormone, erythropoietin, to stimulate red blood cell
production; however, this process takes place over a course of
days to weeks. As one of the goals of the circulation is to deliver
oxygen to the tissues of the body, the heart also responds to low
oxygen levels by increasing its output, so increasing ‘oxygen
delivery’. This takes place in seconds.
Hypoxaemia, low PaO2, can be caused by a number of
mechanisms. It occurs naturally at altitude or can occur second-
ary to V/Q mismatch, that is, as a result of poor aeration of
areas of lung or due to abnormalities of gas exchange within the
lung during serious illnesses such as pneumonia, where hypoxic
vasoconstriction may not be able to compensate for this mis-
match. This form of hypoxaemia is the easiest to treat with
oxygen therapy. Oxygen therapy is less effective in other causes
of tissue hypoxia including anaemia where there is a low carry-
ing capacity or where the carrying capacity of haemoglobin has
been reduced by a toxic substance since oxygen availability is
not the limiting feature in these conditions. For example,
carbon monoxide blocks oxygen binding to haemoglobin
despite having a normal level of oxygen in the lungs and in the
blood.
4.2 Carbon dioxide physiology
Carbon dioxide is a product of the body’s metabolism. It is
cleared from the body by being transferred from the blood-
stream into the alveoli in the lungs and then exhaled from the
lungs. It is also excreted via the kidneys where CO2 and water
form carbonic acid which then dissociates into H+ and HCO3
−.
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In a similar way to oxygen, carbon dioxide levels in the blood
are controlled by chemical sensors (in the carotid body and
brainstem).
Carbon dioxide is highly soluble in the blood and is carried in
three forms: bicarbonate (70–85%), dissolved carbon dioxide (5–
10%) and bound to haemoglobin (10–20%), the percentages
varying according to whether it is arterial or venous blood. As
carbon dioxide carriage is not limited by a carrier molecule such as
haemoglobin, it is not expressed as a saturation. Because its carriage
is approximately proportional to the partial pressure (gas tension)
of carbon dioxide in the blood within the physiological range,
carbon dioxide carriage is usually expressed in terms of its partial
pressure. The normal range is 4.6–6.1 kPa or 34–46 mmHg.
Increased levels of carbon dioxide will stimulate ventilation,
thus increasing clearance from the lungs and therefore from the
bloodstream. However, this mechanism is less effective in some
respiratory diseases such as COPD where increased airway
resistance and respiratory muscle weakness can restrict this
response, or where loss of the hypercapnic drive (eg, during
chronic hypercapnia or severe brain injury) also depresses the
ventilatory response. Hypercapnia will occur when there is
decreased effective or ‘alveolar’ ventilation for any reason. Safe
elimination of carbon dioxide is an important physiological
process in the body to maintain pH.
Too little oxygen can give rise to increased respiratory work
to combat the hypoxaemia and, potentially, organ dysfunction
and failure. However, too much oxygen can also be harmful in
some situations especially to some vulnerable patients with
COPD, chest wall deformities or muscle weakness.
Studies have shown that between 20% and 50% of patients
with AECOPD or with obesity-hypoventilation syndrome
(OHS) are at risk of carbon dioxide retention if they are given
an excessively high concentration of oxygen.43–47 If high con-
centrations of oxygen are given to these patients, the oxygen
level in the blood will rise but the level of carbon dioxide will
also rise. This can cause acidosis and, when severe, coma. In the
past it was thought that the main problem was that these
patients were dependent on the stimulus of a low blood oxygen
level—called ‘hypoxic drive’—to stimulate breathing. It was
thought that giving oxygen would cause a rise in the carbon
dioxide level by simply reducing the stimulus to breathe due to
‘lack of hypoxic drive’. However, studies have shown that the
mechanisms for carbon dioxide retention are far more complex
than this simple model suggests.48–50
Oxygen-induced hypercapnia in patients with AECOPD can
be avoided by giving targeted lower concentration oxygen
therapy to vulnerable patients and aiming for a target range of
88–92%51 (see table 3 and recommendation A3).
4.3 Concept of target oxygen saturation (SaO2) ranges
One might ask why one should not aim for a SaO2 of 100%
(hyperoxaemia) in all acutely ill patients. This policy has been
shown to worsen outcomes in vulnerable patients with COPD
and chest wall problems, but there is also a potential for harm
to other patients.
While the administration of oxygen to the hypoxaemic
patient leads to an increase in PaO2 which leads to favourable
physiological effects and ultimately the prevention of cell death,
administering oxygen to the non-hypoxaemic patient has other
physiological effects which are not widely appreciated, although
how important these are clinically is not clear in most cases.
These potentially adverse effects include direct pulmonary tox-
icity, coronary vasoconstriction, decreased cardiac output,
increased free radical generation and the potential to delay the
recognition of physiological deterioration due to the masking of
any desaturation. These risks are discussed in detail in section 6.
For this reason, the guideline group recognises the import-
ance of a physiological target saturation range to guide staff to
administer oxygen in a concentration to treat hypoxaemia
without the risks of hyperoxaemia. As alluded to in section 3,
some patients are chronically hypoxaemic and tolerate lower
than normal saturations. The only RCT of oxygen therapy in
patients with AECOPD randomised patients to receive high-
concentration oxygen therapy versus titrated oxygen to keep
SpO2 88–92% in the prehospital setting.
51 Mortality was signiﬁ-
cantly lower in patients receiving titrated oxygen rather than
high-concentration oxygen. This study highlights the import-
ance of maintaining a target saturation when administering
oxygen to this and other high-risk groups.
Since the purpose of oxygen therapy is to increase oxygen
delivery to tissues, not just to increase oxygen carried by the
blood, it must be remembered that there may be other physio-
logical disturbances that need correcting to increase oxygen
delivery such as low cardiac output and severe anaemia. For
example, improving these factors will improve oxygen delivery
much more than administering oxygen to a patient with a satur-
ation of 90% which, at most, will produce a 10% rise in deliv-
ery. In addition to optimising oxygen delivery from the lungs to
the tissues (DO2), it is important also to treat problems that
might impair delivery of oxygen to the lungs themselves such as
upper airway obstruction, bronchoconstriction and pulmonary
oedema (remember the ‘ABC’ of resuscitation—airway, breath-
ing, circulation).
Since the ﬁrst publication of these guidelines, further studies
have emerged investigating the role of oxygen therapy in dis-
eases other than chronic lung disease. These have demonstrated
the potential risks of hyperoxia and will be discussed in later
sections. Despite these new data, there are still insufﬁcient data
to determine the exact target range in healthy adults. The con-
sensus among the members of the guideline group is that one
should aim for a normal or near-normal SaO2 range of 94–98%
for acutely ill patients except those at risk of hypercapnic
respiratory failure when a target saturation range of 88–92%
should be used (see recommendations A1–A5).
SECTION 5: ADVANCED BLOOD GAS PHYSIOLOGY
This section is a more in-depth description of the physiological
issues surrounding oxygen therapy. Recommendations 1–5 in
section 6 of the guideline will follow logically from this section
and from the brief overview of oxygen physiology in section 4.
5.1 Oxygen delivery
The neurocardiopulmonary axis is designed to optimise global
oxygen delivery and carbon dioxide clearance and the local
tissue vascular beds are responsible for the distribution of blood
ﬂow.
DO2 is expressed by the equation:
DO2 ¼ CaO2 Q
where CaO2 is the oxygen content of the arterial blood and Q
is the cardiac output. CaO2 is the sum of oxygen dissolved in
the blood and the amount of oxygen carried by haemoglobin.
The solubility of oxygen in the blood is very low and therefore
CaO2 is largely determined by the total amount of haemoglobin
and the proportion which is bound to oxygen; which in turn is
dependent on the haemoglobin per cent saturation.
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Figure 3 shows the level of oxygen and carbon dioxide in the
pulmonary artery, in the alveolus and room air and in the pul-
monary venous circulation which leads directly to the arterial
circulation. The PaO2 of mixed systemic venous blood rises
markedly from a low level in the pulmonary artery (about 6 kPa
or 45 mm Hg) to about 16 kPa (120 mm Hg) by the end of the
pulmonary capillary. However, because the lung is not homoge-
neously made up of alveolar capillary units that are matched for
perfusion and ventilation, the PaO2 in the larger pulmonary
veins is lower (13 kPa, 100 mm Hg). This is explained in more
detail below. The gradient of carbon dioxide is much more
gradual, falling from about 7 kPa (52 mm Hg) in the venous
system and pulmonary artery to about 5 kPa (37 mm Hg) in the
pulmonary vein and in the arterial system.
5.1.1 Arterial oxygen tension
V/Q matching
In the upright position, ventilation and perfusion are both
greatest at the bases of the lung. Ventilation is highest at the
bases since the lung is most compressed at the base due to its
weight and the lower intrapleural pressure, such that on inspir-
ation it expands more. Perfusion is also greatest at the base due
to the relatively low perfusion pressure in the pulmonary circu-
lation. In disease, the pulmonary vasculature also maximises
PaO2 by ensuring that the well-ventilated areas of the lung
receive most of the pulmonary blood ﬂow, a process called V/
Q matching. This is largely achieved through a process called
hypoxic pulmonary vasoconstriction (HPV).52 The pulmonary
circulation is unique in this regard compared with all the other
vascular beds in the body which dilate in response to hypoxia
at a threshold of around 8 kPa (60 mm Hg).52 In poorly venti-
lated areas of lung, the precapillary pulmonary arterioles con-
strict in response to sensing low alveolar PO2 (PAO2). This is a
compensating process and, despite it, some deoxygenated
blood may still leave poorly ventilated alveolar capillary units.
Deoxygenated blood leaving poorly ventilated alveolar capil-
lary units cannot be compensated for by mixing with blood
from well-ventilated units as the relationship between PaO2
and CaO2 is not linear. This physiological phenomenon is
often not fully appreciated and therefore is worth a theoretical
worked example (see box).
A much less studied phenomenon that regulates V/Q match-
ing is hypoxic bronchodilation. This effect increases ventilation
to poorly ventilated areas of the lung.53
Ventilatory drive
If PaO2 falls, the peripheral chemoreceptors in the carotid body
drive an increase in ventilation to increase PaO2.
54 This will not
signiﬁcantly increase PO2 in blood leaving already well-
ventilated units, but will increase PO2 leaving less well-ventilated
alveolar units by increasing PAO2 in these units. Although the
ventilatory response to SaO2, and therefore CaO2, is linear
(ﬁgure 4), the carotid body senses PaO2 and not CaO2. This
prevents excessive ventilation in response to anaemia which
would be ineffective in increasing CaO2. The peripheral che-
moreceptors are able to do this because the very high ratio of
DO2 to oxygen consumption of the carotid body means that the
tissue PO2 in the carotid body continues to reﬂect PaO2 and will
not fall even in the presence of anaemic hypoxia.55 56
Example
▸ Before oxygen therapy assume 50% of pulmonary ﬂow is
passing through an area of low V/Q and that the pulmonary
venous oxyhaemoglobin saturation (SpvO2) from this
compartment is 80% (ie, just above mixed venous SO2). The
other 50% is passing through an area of matched V/Q, resulting
in a SpvO2 of 97%. The ﬁnal mixed SpvO2 will be 88.5%.
▸ Following maximal oxygen therapy, assuming no change in
ﬂow as a result of release of HPV, SpvO2 from the low V/Q
compartment rises to 85% and SpvO2 from the matched
compartment rises to a maximum of 100%. The resulting
admixed SpvO2 will now only be 92.5%. This has occurred
because fully saturated blood cannot increase its oxygen
content beyond full saturation despite an increase in PO2,
apart from the minimal contribution from dissolved oxygen;
that is, the relationship between PO2 and oxyhaemoglobin
saturation/blood oxygen content is not linear.
Figure 4 Ventilatory response to hypoxaemia. The relationship is
inversely linear when plotted against oxyhaemoglobin (solid line)
saturation but inversely exponential when plotted against arterial PO2
(dashed line). PO2, oxygen tension.
Figure 3 Regulation of CaO2. Alveolar capillary unit. CaO2, blood
oxygen content; PaCO2, arterial carbon dioxide and oxygen tensions;
PaO2, arterial oxygen tension; PACO2, alveolar carbon dioxide tension;
PAO2, alveolar oxygen tension; PICO2, inspired carbon dioxide tension;
PIO2, inspired oxygen tension; PVCO2, venous carbon dioxide tension;
PVO2, venous oxygen tension.
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5.1.2 Haematocrit
Erythropoiesis is controlled by a negative feedback system
involving erythropoietin. By contrast with the carotid bodies,
the peritubular cells in the kidney are well suited to sensing
oxygen delivery as oxygen extraction is relatively high compared
with oxygen delivery.57 58 Although oxygen delivery to the
kidneys as a whole organ is high due to high renal blood ﬂow,
DO2 is reduced to the renal medulla as oxygen can pass from
arterioles to the postcapillary venous system by shunt diffusion
due to the parallel organisation of arterial and venous systems.42
Consequently, the peritubular cellular PO2 is low. It falls to even
lower levels following reductions in DO2 either as a result of
hypoxaemia or low haematocrit.
5.1.3 The oxyhaemoglobin dissociation curve and the Bohr effect
The oxygen–haemoglobin dissociation curve shows the relation-
ship between haemoglobin SaO2 and PaO2 (ﬁgure 5 and
table 10). The curvilinear shape of the curve has two particular
features that serve to protect from tissue hypoxia. The upper
portion of the curve is ﬂat which means that a marked fall in
PaO2 is still compatible with a nearly complete oxygen satur-
ation. Second, the steep portion of the curve means that despite
rapidly falling oxyhaemoglobin saturation, the PO2 remains rela-
tively well preserved. This property facilitates the continued
delivery of oxygen to the tissues despite progressively lower
levels of saturation.59
The oxygen-carrying capacity of haemoglobin is regulated in
response to other metabolic factors to increase the efﬁciency of
oxygen pick-up and delivery.60 The curve is shifted to the right
because of an increase in temperature, PaCO2 and hydrogen ion
concentration (low pH) or an increase in 2,3-diphosphoglyce-
rate (DPG). This shift to the right enhances release of oxygen to
the tissues and improves oxygen availability, named the Bohr
effect (ﬁgure 5).
The converse holds true for the lungs where lower carbon
dioxide levels favour oxygen loading of haemoglobin.
Consequently, SaO2 cannot accurately predict PaO2 and vice
versa, but table 10 gives approximate equivalents.
Chronic hypoxaemia increases 2,3-DPG in erythrocytes, shift-
ing the dissociation curve to the right and therefore increasing
oxygen delivery to the tissues. Levels of 2,3-DPG are reduced in
stored blood reducing to zero after about 2 weeks. This may
reduce oxygen delivery to the tissues but the magnitude of this
effect is not thought to be clinically signiﬁcant. Once transfused,
levels of 2,3-DPG increase to about 50% normal after about
6 hours and back to normal within 48 hours.
5.1.4 Regulation of DO2
Acutely, the cardiovascular effects of hypoxaemia will tend to
counter the impact of lower CaO2 on DO2 by increasing cardiac
output through increased heart rate and myocardial contractility
and by decreasing afterload by reducing systemic vascular resist-
ance.61 62 Anaemic hypoxia is sensed in the aortic body, pre-
sumably owing to lower perfusion relative to oxygen
consumption. Consequently, the aortic body can act as a sensor
of reduced oxygen delivery as a result of either low PO2 or low
haematocrit (unlike the carotid body).55
At local tissue level, oxygen delivery can be adjusted to
changes in local oxygen consumption. For example, exercising
skeletal muscle receives a greater proportion of total cardiac
output than resting skeletal muscle. This relates in part to hyp-
oxaemia recruiting a larger proportion of the capillary bed by
the relaxation of pericytes, and also through arteriolar
vasodilation.63
5.2 Pathophysiology of hypoxia and hyperoxia
Hypoxia may result from a number of different diseases dis-
cussed in section 8 of this guideline.
5.2.1 Hypoxaemic hypoxia
Hypoxaemic hypoxia in blood leaving an alveolar capillary unit
in the lung may be induced by alveolar hypoxia or incomplete
gas exchange (see deﬁnition in section 3.2). This may be due to
a reduction in inspired oxygen partial pressure, that is, high alti-
tudes, intrapulmonary shunt, V/Q mismatching, alveolar hypo-
ventilation or diffusion impairment.
The alveolar gas equation calculates the oxygen level in the
alveolus using the following formula:
PAO2  PIO2  PACO2=RER
where PAO2 and PACO2 represent alveolar levels of oxygen and
carbon dioxide, RER is the respiratory exchange ratio or the
ratio of carbon dioxide production to oxygen consumption and
inspired PO2 (PIO2)=FiO2×(barometric pressure (100 kPa,
750 mm Hg)—water vapour pressure (∼6 kPa, 45 mm Hg)).
Considering this equation, alveolar hypoxia can be induced
by decreased PIO2 or increased PACO2. If an alveolar capillary
unit is relatively underventilated for its degree of perfusion (low
V/Q ratio), PACO2 will rise due to inadequate clearance and
thus PAO2 will fall. This may happen for a number of reasons
such as increased dead space ventilation during the non-
Figure 5 Oxygen dissociation curve with Bohr effect. 2,3-DPG,
2,3-diphosphoglycerate; PO2, oxygen tension.
Table 10 Approximate relationship between SaO2 and PaO2
Oxygen tension PaO2 (kPa) 4 5 6 7 8 9 10 11 12 13 14 15 16 ≥17
Oxygen tension PaO2 (mm Hg) 30 37.5 45 52.5 60 67.5 75 82.5 90 97.5 104 112.5 120 ≥127.5
Oxygen saturation SaO2 (%) 57.4 71.4 80.7 86.8 90.7 93.2 94.9 96.2 97.0 97.8 98.2 98.6 98.8 ≥99.0
PaO2, arterial oxygen tension; SaO2, arterial oxygen saturation.
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fatiguing pattern of shallow respiration in respiratory failure or
abnormal lung mechanics in advanced COPD. In diseases that
cause global hypoventilation such as respiratory muscle weak-
ness, effectively all areas of lung have low V/Q ratios and this
explains the hypercapnia and hypoxaemia associated with these
conditions.
An extreme form of low V/Q pathophysiology occurs in intra-
pulmonary and extrapulmonary shunt where no gas exchange
occurs at all. An example of intrapulmonary shunt is when the
airway to a lung segment is obstructed by mucus creating an
area of lung tissue that is perfused but not ventilated, thus
acting as a right-to-left shunt. An example of extrapulmonary
shunt is a ventricular septal defect with right-to-left shunting in
Eisenmenger’s syndrome.
In health and at rest, PO2 has equilibrated with the tissue PO2
across the alveolar capillary membrane one-third of the way
along the length of the capillary. With increased thickness of this
membrane, as in ﬁbrotic lung disease, equilibration may take
longer and an oxygen gradient may persist between the alveolus
and blood at the end of the capillary. The overall effect of this
when multiple alveolar capillary units are affected will lead to an
increased alveolar-to-arterial (A–a) gradient. This is exacerbated
during exercise, when capillary transit time decreases.
5.2.2 Other mechanisms of hypoxia
Anaemia and carbon monoxide poisoning may result in ‘anaemic
hypoxia’ by reducing oxygen-carrying capacity (see deﬁnitions in
section 3.2). A low cardiac output state will reduce oxygen deliv-
ery even in the absence of hypoxaemia. Tissue hypoxia may
develop in these circumstances and this is often termed ‘stagnant
hypoxia’. ‘Histotoxic hypoxia’ is due to an inability to metabolise
oxygen at the mitochondrial level and may be due to severe
sepsis or is seen in certain types of poisoning.
5.2.3 Hyperoxia
Hyperoxia can be caused by hyperoxaemia and polycythaemia.
Considering again the alveolar gas equation in the previous
section, hyperoxaemia can only exist in the presence of high
PIO2 or low PACO2 (resulting from hyperventilation). The term
‘hyperoxia’ could technically be used to describe a patient with
polycythaemia without hyperoxaemia, but most clinicians use
the term only to describe situations in which the PaO2 is raised.
5.3 Physiology of carbon dioxide
5.3.1 Normal carbon dioxide homoeostasis
Carbon dioxide is principally carried in the blood in three
forms: carbon dioxide, bicarbonate and as a carbamino com-
pound.64 In the normal physiological range of 4.6–6.1 kPa (34–
46 mm Hg) the relationship between PaCO2 and carbon dioxide
content can be considered linear (ﬁgure 6).
5.3.2 Regulation of carbon dioxide
PaCO2 is sensed at the peripheral
54 and central chemoreceptors
(in the medulla oblongata) by its effect on intracellular pH.65
Consequently, the regulation of PaCO2 is intimately related to
pH homoeostasis (ﬁgure 7).
It is often not appreciated how V/Q matching relates to
PaCO2. As discussed in section 5.2.1, alveolar capillary units
with a low V/Q ratio have increased PACO2. Because of the
high solubility and diffusibility of carbon dioxide, there is little
A–a gradient for carbon dioxide at the end of the capillary, so
blood leaving low V/Q alveolar capillary units has a high PCO2.
As described above, areas of low V/Q are usually minimised
through HPV. It is also thought that a high PCO2 can cause
pulmonary vasoconstriction, adding to the homoeostatic
mechanisms of the lung, matching perfusion to ventilation.66 67
As the relationship between PCO2 and carbon dioxide dissolved
in the blood is approximately linear over the physiological range
(unlike oxygen), blood does not become saturated with carbon
dioxide and therefore a high pulmonary venous PCO2 from low
V/Q areas can be partially balanced by a low pulmonary venous
PCO2 from high V/Q areas. Consequently, by increasing overall
alveolar ventilation, the cardiopulmonary system is able to
prevent hypercapnia despite signiﬁcant V/Q mismatch or shunt,
unless respiratory mechanics are limiting.
As with the carriage of oxygen (Bohr effect), there is a reciprocal
relationship between PO2 and carbon dioxide carriage. This is
known as the Haldane effect.60 Deoxygenated haemoglobin has a
higher carbon dioxide buffering capacity than oxygenated haemo-
globin. This favours carbon dioxide pick-up in the systemic venous
circulation and carbon dioxide ofﬂoading in the lungs.
Acutely, carbon dioxide acts as a sympathomimetic on the
heart: it increases heart rate and stroke volume, increasing
cardiac output. Peripherally it causes vasodilation, reducing sys-
temic vascular resistance. Locally, carbon dioxide acts as a vaso-
dilator, thus diverting blood ﬂow to tissues with high metabolic
demand. The resulting physical signs of hypercapnia are
described in section 7.2.
5.4 Pathophysiology of hypercapnia and hypocapnia
5.4.1 Mechanisms of hypercapnia
The mechanisms of hypercapnia are simpler than hypoxaemia
and there are four possible causes:68
Figure 6 Total carbon dioxide dissociation curve. HbCO2, carbamino
haemoglobin; PCO2 carbon dioxide tension.
Figure 7 Effect of PaCO2 on ventilation with interaction of acidosis
and hypoxaemia. PaCO2, arterial carbon dioxide tension; PCO2 carbon
dioxide tension; PO2, oxygen tension.
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1. Increased concentration of carbon dioxide in the inspired
gas.
2. Increased carbon dioxide production.
3. Hypoventilation or ineffective ventilation.
4. Increased external dead space.
Mechanisms of hypercapnia
The mechanisms of hypercapnia in COPD (and other conditions
predisposing to hypercapnic respiratory failure) are discussed in
section 6.3.1.
Increased concentration of carbon dioxide in the inspired gas
This iatrogenic cause of hypercapnia is uncommon but should
be excluded at the outset in any patient unexpectedly found to
be hypercapnic when breathing from, or being ventilated by,
external equipment. The severity of hypercapnia due to
rebreathing is limited by the rate at which the PCO2 can
increase (no more than 0.4–0.8 kPa/min, 3–6 mm Hg/min).
Increased carbon dioxide production
This is likely only to cause hypercapnia if the minute ventilation
is ﬁxed by artiﬁcial means and if carbon dioxide production is
increased (eg, due to sepsis or increased work of breathing).
Alveolar hypoventilation or ineffective ventilation (deadspace)
Low alveolar minute ventilation is by far the most common
cause of hypercapnia. In clinical practice, COPD is the most
common disease to cause hypercapnia; the problem is secondary
to alveolar hypoventilation rather than a reduced minute venti-
lation per se. Patients adopt a rapid shallow pattern of breathing
during an AECOPD with the result that the ratio of dead space
to tidal volume is increased with more ventilation therefore
being ‘wasted’. A rapid shallow pattern of breathing results in a
bigger proportion of each breath being wasted because of the
need to ventilate the anatomical dead space. Furthermore,
during acute COPD exacerbations, V/Q mismatch may lead to
an increase in physiological dead space, exacerbating the
problem further. It is important to note that this commonly
occurs in the context of an apparent overall increase in minute
ventilation thus hypoventilation being a relative rather than
absolute term. Adequate ventilation cannot be achieved since
the respiratory muscle ‘pump’ is unable to overcome the load as
a result of underlying respiratory mechanics. Alveolar hypoven-
tilation due to a reduction in minute ventilation is seen follow-
ing medullary respiratory centre depression by drugs,
obstruction of a major airway or restriction of the lungs or chest
wall or by respiratory muscle weakness, head injury, intracereb-
ral haemorrhage or opioid narcosis.
Increased external dead space: This would be most common
in patients breathing through artiﬁcial apparatus which has been
incorrectly conﬁgured. Although alveolar hypoventilation is the
most common cause of hypercapnia, it is important to consider
the other potential causes, particularly when patients are receiv-
ing assisted ventilation and an artiﬁcial breathing circuit is used.
5.4.2 Hypoventilation and hyperventilation
Hypoventilation may be physiological—for example, in the face
of a metabolic alkalosis. Pathological hypoventilation will occur
either when the respiratory muscles are unable to ventilate the
lungs sufﬁciently because they are pathologically weak or they
are unable to overcome abnormal lung mechanics such as
during an exacerbation of COPD. Reduced respiratory drive
caused by drugs with sedative properties or by neurological
injury will also produce hypoventilation.
Using the same physiological principles but in reverse, hyper-
ventilation for any reason will produce hypocapnia. This may
occur during pure hyperventilation during an anxiety attack or
during physiological hyperventilation.
5.5 Physiology of oxygen therapy
Oxygen therapy increases PAO2 and is therefore only effective
when alveolar capillary units have some functional ventilation.
Oxygen therapy is ineffective if there is a pure shunt (such as
pulmonary arteriovenous malformations) where mixed venous
blood does not pass through an alveolar capillary unit. There
will only be a small overall increase in PaO2 due to an increase
in dissolved oxygen in the pulmonary venous blood from venti-
lated alveolar capillary units, which is small compared with the
content of oxygen carried by haemoglobin. Despite this, there is
good evidence that breath-hold times can be increased by
breathing oxygen.69–71 One study found that the breath-hold
time of 15 healthy participants increased from 56 s after breath-
ing air to 92 s after breathing 4 L of nasal oxygen for 2 min,
and another study found that 31 healthy volunteers had an
increase in breath-hold time from 32 s breathing air to 61 s after
breathing oxygen whereas the breath-hold time of 29 patients
with chronic pulmonary disease was 9 s compared with 22 s for
a group of 29 similar patients after breathing oxygen. The same
principles are used to preoxygenate patients before intubation
during anaesthesia, allowing a longer safe period of apnoea
between induction of anaesthesia and passage of an endo-
tracheal tube. It is thought that the additional breath-hold time
(and the delay in onset of hypoxaemia following induction of
anaesthesia) is produced not by the marginal increase in blood
oxygen levels but by the increased reservoir of oxygen in the
lungs after breathing oxygen-enriched air.
In poorly ventilated units (ie, low V/Q ratio), PAO2 will be
low. Increasing FiO2 will increase PAO2 and therefore PaO2.
Hypoventilation disorders can be considered as lungs made up
entirely of low V/Q units.
When there is diffusion limitation due to increased alveolar
capillary membrane thickness such as in ﬁbrotic lung disease,
increasing PAO2 will augment the rate of diffusion across the
alveolar capillary membrane by increasing the concentration
gradient.
Increasing dissolved oxygen in plasma by oxygen therapy may
also be used to offset the effects of hypoperfusion to some
extent (stagnant hypoxia) and may well be important in certain
situations (cardiogenic shock), although the effect is only mar-
ginal. Increased inspired oxygen will only marginally mitigate
the effects of anaemic hypoxia but, because the CaO2 in patients
with anaemia is less than that in patients with normal haemoglo-
bin, the effect of additional oxygen carried in solution may
become more important in these situations.
5.6 Strategies for improving oxygenation and delivery
Tissue oxygenation is dependent on optimal or adequate oxygen
delivery to the tissue (DO2). This physiological process is com-
posed of various components that independently and interde-
pendently inﬂuence and determine DO2 and therefore tissue
oxygenation. These components can be considered sequentially.
5.6.1 Optimising PaO2
The physiology of oxygen therapy has already been discussed in
the previous section. However, increasing FiO2 is only one com-
ponent in increasing oxygen uptake in the lungs. Other key
manoeuvres to ensure oxygen delivery to the alveolar capillary
bed include:
O’Driscoll BR, et al. Thorax 2017;72:i1–i90. doi:10.1136/thoraxjnl-2016-209729 i25
BTS guideline
group.bmj.com on April 7, 2018 - Published by http://thorax.bmj.com/Downloaded from 
▸ Maintaining a satisfactory airway.
▸ Ensuring adequate alveolar ventilation.
▸ Reversing any respiratory depressants such as narcotics.
▸ Invasive ventilation or NIV where necessary.
▸ Treating airﬂow obstruction by bronchodilation or sputum
clearance techniques.
▸ Optimising transfer factor (diffusion capacity).
▸ Treatment of pulmonary oedema.
5.6.2 Optimising oxygen carriage
Oxygen is carried in blood mainly by haemoglobin with only a
very small amount of oxygen dissolved in the blood itself.
Adequate haemoglobin is therefore essential for CaO2. The
ideal haemoglobin level for optimal CaO2 and therefore for
optimal DO2 has long been a subject of debate. Previous prac-
tices have favoured haemoglobin levels close to 100 g/L (10 g/
dL), providing adequate CaO2 as well as reducing viscosity of
blood for better perfusion in critically ill patients. However,
studies by Canadian researchers in the late 1990s have shown
that haemoglobin levels of 70 g/L (7 g/dL) were as safe as higher
levels and may produce fewer complications in the critically
ill.72 However, this study was conducted using non-leucocyte
depleted blood and it is possible that some of the infective com-
plications in the group who were given more transfusions might
have been avoided by the use of leucocyte-depleted blood. The
optimal transfusion target for critically ill patients therefore
remains the subject of ongoing discussion among experts in crit-
ical care medicine. Although the issue of optimal haemoglobin
in patients with unstable or symptomatic coronary artery disease
is not settled, haemoglobin levels of 100 g/L (10 g/dL) are
recommended for adequate DO2 (see box).
5.6.3 Optimising delivery
Besides adequate CaO2 and PaO2, delivery of oxygen depends
on adequate ﬂow of oxygenated blood. Cardiac output in turn
depends on adequate blood (circulating) volume, adequate
venous return and adequate and optimal myocardial function.
To avoid tissue hypoxia, attention must therefore be paid to the
volume status of the patient and the adequacy of cardiac func-
tion, as well as initiating oxygen therapy. In severely shocked
patients (eg, cardiogenic shock, septic shock), invasive monitor-
ing and inotropic/vasopressor therapy will usually be indicated
in appropriate higher dependency environments. Some studies
have shown that deliberately increasing oxygen delivery in critic-
ally ill patients as well as high-risk surgical patients reduces
organ failure, reduces length of ICU stay and, most importantly,
improves mortality.73–76 However, there is a substantial body of
evidence showing no favourable effect on morbidity and mortal-
ity by achieving supranormal values for the cardiac index or
normal values for mixed venous oxygen saturation.77–79
SECTION 6: HYPOXIA, HYPOXAEMIA, HYPEROXAEMIA,
HYPERCAPNIA AND THE RATIONALE OF TARGETED
OXYGEN THERAPY
6.1 Effects and risks of hypoxia/hypoxaemia and rationale
for target oxygen saturation range
As this guideline is addressing emergency oxygen therapy and
oxygen therapy in healthcare settings, this section will focus
on the effects and risks of acute hypoxaemia. Section 8 will
discuss the emergency treatment of acute hypoxaemia in
patients with long-term diseases associated with chronic hyp-
oxaemia. The approximate relationship between PaO2 and
SaO2 at normal pH and temperature is shown in table 10 and
ﬁgure 5 (oxygen dissociation curve). The effects and risks of
hypoxaemia are summarised in table 11. Severe hypoxaemia
may lead to brain damage and death. In general, many of the
physiological effects of hypoxaemia are mediated by low
PaO2, irrespective of oxygen content. For example, even
when the total blood oxygen content is normal in the pres-
ence of polycythaemia, hypoxaemia will still exert a physio-
logical effect such as stimulation of ventilation. The risks of
hypoxaemia, however, are usually mediated by low tissue PO2
which may occur as a consequence of a low PaO2 and other
mechanisms such as severe anaemia and low cardiac output
states. These problems can be illustrated in the pathophysi-
ology of myocardial ischaemia which will develop when there
is an imbalance between myocardial DO2 and oxygen con-
sumption (V˙O2). DO2 is not only dependent on PaO2, but
also coronary ﬂow and haematocrit. V˙O2 will also depend
on the stroke work of the heart. Deﬁning a lower limit of
Table 11 Physiological effects of acute hypoxaemia and hyperoxaemia
Hypoxaemia Hyperoxaemia
Effects Risks Effects Risks
Respiratory system Increased ventilation
Pulmonary vasoconstriction
Pulmonary hypertension Decreased ventilation
(minimal)
Worsened ventilation/perfusion
matching
Absorption atelectasis
Cardiovascular
system
Coronary vasodilation
Decreased systemic vascular
resistance (transient)
Increased cardiac output
Tachycardia
Myocardial
Ischaemia/infarction
Ischaemia/infarction of other critically
perfused organs Hypotension
Arrhythmias
Myocardial ischaemia (in context of
decreased haematocrit)
Reduced cardiac output
Reduced coronary blood flow
Increased blood pressure
Increased peripheral resistance
Metabolic system Increased 2,3-DPG
Increased CO2 carriage (Haldane
effect)
Lactic acidosis Decreased 2,3-DPG
Decreased CO2 carriage
(Haldane effect)
Increased reactive oxygen species
Neurological
system
Increased cerebral blood flow due
to vasodilation
Confusion
Delirium
Coma
Decreased cerebral blood
flow
Renal system Renin–angiotensin axis activation
Increased erythropoietin
production
Acute tubular necrosis Reduced renal blood flow
2,3-DFG, 2,3-diphosphoglycerate.
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PaO2 which is considered safe is therefore impossible given
the other variables. Hypoxaemia refers to an abnormally low
PO2 in the blood (see section 3.2). However, it is not possible
to deﬁne a single level of hypoxaemia that is dangerous to all
patients. Some patients with chronic lung disease may be
accustomed to living with SaO2 as low as 80% (PaO2 about
6 kPa or 45 mm Hg) while other patients may be harmed by
modest hypoxaemia. It has been shown that medical patients
with sustained desaturation <90% have impaired medium-
term survival compared with medical patients with saturations
which stay >90%.29
Recent observational data have shown a step-wise increase
in mortality in hypoxaemic acute medical patients breathing
air; the lowest mortality (3.7%) was found in patients with
saturation ≥96% and this increased incrementally to mortality
above 25% among patients with saturation <88%.19
However, much of this survival disadvantage may be due to
the underlying disease which has caused the low oxygen level
(eg, severe COPD or pneumonia) with the degree of hypox-
aemia being a marker of disease severity. Furthermore, the
mean and median oxygen saturation of patients aged >65
and the lower limit of the interquartile range (IQR) was
about 2% lower than the saturation level of young adults so it
is likely that much of the increase in mortality associated with
modest hypoxaemia was related to the age of the patient.
Therefore, the contribution of modest hypoxaemia to mortal-
ity rates is not known.
Mental functioning becomes impaired if the PaO2 falls
rapidly to <6 kPa (45 mm Hg, SaO2<80%) and consciousness
is lost at <4 kPa (30 mm Hg, SaO2<56%) in normal partici-
pants.80–83 Young participants tolerate acute hypoxaemia for
longer than older participants in terms of ‘time of useful con-
sciousness’.83 Safe levels of hypoxaemia in COPD have been dis-
cussed in detail in a review by Murphy et al.84 Many patients
with COPD have a PaO2 of <5 kPa (37.5 mm Hg) correspond-
ing to a SaO2 of <70% during an acute exacerbation.
85
Furthermore, sudden hypoxaemia is more dangerous than hyp-
oxaemia of gradual onset both in health and in disease. For
example, millions of people live at altitudes above 3000 m
despite an average PaO2 of about 7.3 kPa (55 mm Hg, saturation
about 88%) and acclimatised climbers on Mount Everest can
tolerate short-term exposure to an oxygen saturation of 54% or
less with an estimated PaO2 of about 3.3 kPa (25 mm Hg).
26–
28 34 86 Campbell87 summarised this issue eloquently in 1967
when he said “Better a year at a PaO2 of 50 mm Hg (6.7 kPa)
than an hour at a PaO2 of 20 mm Hg (2.7 kPa).”
Urine ﬂow and renal function have been shown to decrease
abruptly when the PaO2 falls below 40 mm Hg (5.3 kPa) which
corresponds to oxygen saturation of ∼74%,88 Hypoxic hepatitis
has been reported in patients with respiratory failure associated
with oxygen levels below 4.5 kPa or 34 mm Hg, whereas
hypoxic hepatitis in patients with cardiac disease is mainly due
to decreased hepatic blood ﬂow (stagnant hypoxia) and occurs
at higher blood oxygen levels.89 90 An in-ﬂight study of patients
with COPD with mean SaO2 of 96% at sea level showed a fall
to 90% in-ﬂight in a commercial airliner and a further fall to a
mean SaO2 of 87% while walking in the aircraft aisles. These
patients had no symptoms during these hypoxaemic episodes.91
A study of 84 healthy airline passengers found that the mean
SaO2 fell from 97% at ground level to 93% (1SD 85–98%) at
cruising altitude.92 A study of healthy airline cabin crew has
shown that the SaO2 of ﬂight attendants falls to a nadir ranging
from 80% to 93% (mean 88.6%) without causing breathlessness
or any other symptoms.93
Without any randomised evidence, the guideline production
team have suggested that the level of saturation which is toler-
ated by healthy people without any symptoms (about 85% sat-
uration) should be regarded as the safe lower limit of
hypoxaemia. However, other comorbidities may need to be
taken into account and expert opinion recommends that the
SaO2 should be maintained above 90% for seriously ill
patients.29–32 For this reason, the present guideline recommends
a target SaO2 (and SpO2) ≥94% for most hypoxaemic patients
to ensure that the actual oxygen level remains above 90% for
most of the time with a 4% margin of safety to allow for vari-
ability in oxygen saturation levels, their recordings and oximeter
error. The accuracy of and pitfalls of oximetry are addressed in
section 7.1.2.
Speciﬁc targets for oxygen therapy in various diseases will
be considered theoretically in this section and practically in
sections 8 and 9. Some patients—especially older people or
those with chronic lung disease—may have an SaO2 below
94% when clinically stable and oxygen should not be given
just to maintain the SaO2 above 94% if the patient is clinically
stable. In assessing an ill patient, the SaO2 level is only one of
several physiological variables that should be monitored. Many
patients with sudden acute illness such as postoperative pul-
monary emboli will have a sudden alteration in physiological
variables as assessed by ‘track and trigger’ systems such as the
modiﬁed Early Warning Scoring (mEWS) systems94 95 or the
UK NEWS.96 Such patients may have only a small fall in SaO2
owing to physiological compensation mechanisms such as
increased ventilation. Healthcare professionals therefore need
to be alert for falls in SaO2 even within the recommended
target ranges. Because of the wide normal range for SaO2 and
the uncertainty concerning the possible physiological conse-
quences of minor hypoxaemia, there was more debate among
the 2008 guideline group about desirable target ranges than
about any other aspect of the guideline. If the SaO2 should fall
slightly below 94%, the key issue is to identify and treat the
cause of the fall (eg, pulmonary embolism) rather than just cor-
recting the hypoxaemia which is not of itself likely to be dan-
gerous at this level. However, there is a danger that healthcare
workers might fail to respond appropriately to abnormal hyp-
oxaemia. After much debate it was concluded that the guide-
line would recommend a target range of 94–98% for all adult
patients. This reﬂects the approximate normal range of SaO2
in healthy adults as discussed in section 3.1. However, a sus-
tained fall in SaO2 of >3%, even within the normal range,
may be an indicator of acute illness and should require clinical
assessment of a patient while a minority of patients (especially
those aged >70 years) may have an SaO2 of <94% even when
clinically stable.
6.1.1 Desirable oxygen saturation ranges in acute illness
▸ Acute hypoxaemia is considered dangerous to healthy partici-
pants below a PaO2 of about 6 kPa (45 mm Hg) or an SaO2
of about 80% due to impaired mentation and risk of tissue
hypoxia, but patients with acute illness or chronic organ
disease or ischaemia are likely to be at risk above this level
and critical care guidelines recommend aiming to achieve sat-
uration >90%.
▸ Changes in physiological ‘track and trigger’ systems such as
the NEWS96 may occur in acute illness with either no
change or only a small change in SaO2 levels.
▸ Critical illness may present initially with only a small fall in
SaO2 level because of compensating mechanisms.
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▸ The upper end of the recommended range in this guideline
(98%) is the upper limit of SaO2 in healthy adults.
▸ The lower end of the suggested target saturation range
(94%) is close to the lower end of the normal range and
ensures that the SaO2 remains above 90% even if it falls
slightly below the target range.
6.2 Potential beneﬁts of hyperoxaemia and supplemental
oxygen therapy in non-hypoxaemic patients
Supplemental oxygen therapy is most commonly given to
correct hypoxaemia as discussed throughout this guideline.
However, there are some circumstances where supplemental
oxygen may be given to non-hypoxaemic patients to achieve
hyperoxaemia. This needs to be distinguished from hyperbaric
oxygen therapy (oxygen therapy delivered above atmospheric
pressure) which is outside the scope of this guideline.
6.2.1 Hyperoxaemia has been shown to be beneﬁcial in the
following clinical situations
▸ Carbon monoxide and cyanide poisoning (see section
8.10.7)
▸ Spontaneous pneumothorax (see section 8.11.6)
▸ Some postoperative complications (see section 8.15.3)
▸ Cluster headache (see section 8.13.7)
6.2.2 Other potential beneﬁts and potential harms of oxygen
therapy in non-hypoxaemic patients
▸ Most guidelines for CPR and the care of patients with critical
illness recommend the use of the highest feasible oxygen con-
centration in the initial stages of resuscitation. Although these
recommendations are not evidence-based, it is unlikely that
controlled trials would ever be undertaken using different
levels of oxygen therapy in these emergencies and it seems
intuitive to maximise oxygen delivery for critically ill patients
with circulatory collapse and respiratory failure. However,
randomised trials have been undertaken of resuscitation of
neonates breathing room air or oxygen and the unexpected
outcome of a Cochrane review was that the survival was
better when room air was used.97 This surprising ﬁnding
cannot be extrapolated to adult patients, but it does emphasise
the need for clinical trials even in areas where one might intui-
tively believe that oxygen would be beneﬁcial. Furthermore,
there is theoretical evidence that patients who have had a res-
toration of spontaneous circulation after cardiac arrest may be
managed more safely with <100% inspired oxygen.98 99
Recent observational studies suggesting possible harmful out-
comes from hyperoxaemia in survivors of cardiopulmonary
resuscitation are discussed in section 8.10.1.
▸ It has been shown that early intervention to increase oxygen
delivery to the tissues in critically ill patients as well as high-
risk surgical patients reduces organ failure, reduces length of
ICU stay and, most importantly, improves survival.73–76
Increased oxygen delivery in part involves oxygen therapy,
but these studies did not show any beneﬁt from aiming at
supraphysiological oxygen delivery. There is some evidence
that hyperoxaemia may be associated with increased mortal-
ity in patients on ICUs, this is discussed in section 8.10.2.
▸ Reported beneﬁts of oxygen therapy in healing of established
wounds and in treatment of wound sepsis are controversial.
Hyperbaric oxygen reduced the risk of amputation in patients
with chronic diabetic foot ulcers and may improve the chance
of healing over 1 year, but the Cochrane reviewers had con-
cerns about the size and quality of existing studies and
recommended further trials.100 It is not known if conven-
tional oxygen therapy has any effect on wound healing.101
▸ The potential beneﬁt of oxygen for prevention of post-
operative wound infection is discussed in section 8.15.3.
▸ Through relief of breathlessness and work of breathing,
oxygen therapy may decrease carbon dioxide production and
consequently offset some of the potential increase in PaO2
that might otherwise occur due to the mechanisms described
in section 6.3.1. However, there are no controlled trials sup-
porting the use of oxygen for this indication.
6.3 Potential adverse physiological effects and clinical risks
of supplemental oxygen therapy and hyperoxaemia
These are summarised in table 11 and in the review by
Downs102 and in other sources.103–107 The following para-
graphs will summarise the physiology and pathophysiology of
supplemental oxygen therapy and hyperoxaemia.
6.3.1 Respiratory system
The most signiﬁcant effect of high-concentration oxygen
therapy on the respiratory system is hypercapnic respiratory
failure in a population of vulnerable patients as described more
fully in section 8.12. This does not occur in the absence of sig-
niﬁcant pulmonary disease or musculoskeletal disease affecting
the thorax, and it can occur while the PaO2 is still within the
normal range or slightly below normal, especially in patients
with exacerbated COPD for whom the baseline oxygen satur-
ation level may be well below the lower limit of normal.
It has been stated for several decades that ‘hyperoxaemia
causes hypercapnic respiratory failure by producing decreased
respiratory drive in patients with intrinsic lung disease, such as
COPD’, and many—if not most—medical textbooks from the
1960s to the present time refer to ‘loss of hypoxic drive’ as the
main cause of hypercapnia and acidosis when high-
concentration oxygen is given to patients with an AECOPD.
This assertion is usually attributed to Campbell who cham-
pioned the concept of controlled oxygen therapy in the 1960s.
However, Campbell87 has been widely misquoted. What he
actually said in 1967 was as follows: “It is usual to attribute the
rise in PaCO2 in these patients to removal of the hypoxic drive
to ventilation but I share the doubts of Pain and co-workers108
that this is the whole story; changes in the pulmonary circula-
tion may also be important.” Most but not all subsequent
studies48 49 108–113 have shown that Campbell was correct in
this assumption as discussed in section 4.2. Another curious
feature of hypercapnia in AECOPD is that it is not universal.87
Some patients with COPD are prone to repeated episodes of
hypercapnic respiratory failure and others may not ever suffer
from this complication. Even among patients with COPD with
chronic hypercapnia, not all will develop an increased carbon
dioxide level (and acidosis) during acute exacerbations. The
theory of ‘loss of hypoxic drive’ as the cause of hypercapnia is
further confounded by the observation that PaCO2 continues to
rise as PaO2 is increased above 13 kPa (100 mm Hg), which has
little impact on decreasing ventilation and most patients with
respiratory acidosis during an exacerbation of COPD have PaO2
above 10 kPa, equivalent to saturation above about 93%.43
Therefore, while a small reduction in ventilation may be a con-
tributing factor to the rise in carbon dioxide levels during
oxygen therapy in COPD, the major factor is the worsening of
V/Q matching. Additional effects of increasing FiO2 will relate
to atelectasis and perhaps worsening airﬂow obstruction due to
increased viscosity. In conditions where there is little intrinsic
lung disease but signiﬁcant respiratory muscle weakness, loss of
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hypoxic respiratory drive will be a greater factor in the develop-
ment of hypercapnia. However, HPV remains a signiﬁcant regu-
lator of V/Q matching even in non-diseased lung.
While the mechanism of oxygen-induced hypercapnia
remains controversial it is likely there are at least six mechan-
isms responsible for this. These are ranked in likely order of
importance below:
▸ V/Q mismatch,
▸ Ventilatory drive,
▸ Haldane effect,
▸ Absorption atelectasis,
▸ Higher density of oxygen compared with air,
▸ Rebreathing can occur if low oxygen ﬂow rates are used
through face masks.
V/Q mismatch
During air breathing, poorly ventilated alveolar capillary units
will be hypoxic and therefore poorly perfused due to HPV. If
high-concentration oxygen is administered, the PAO2 will rise,
thus reversing the HPV and increasing blood ﬂow to that unit.
However, although the oxygen in the unit has increased, it
remains poorly ventilated with a high PACO2 and therefore a
high pulmonary venous PCO2. As more blood is now passing
through these units, the PaCO2 will rise. Normally when there
is no signiﬁcant lung disease or thoracic musculoskeletal disease,
the respiratory system is able to compensate for these changes
by increasing overall ventilation thereby lowering PaCO2.
However, where respiratory mechanics are such that increased
ventilation is limited, PaCO2 will rise. Several authors have
reported that this mechanism is more important than reduction
in ventilatory drive in producing hypercapnia when supplemen-
tary oxygen is administered, but this continues to be a contro-
versial area of respiratory physiology.48 49 108–113
Ventilatory drive
Hypoxaemia drives an increase in ventilation so it follows that
relief of hypoxaemia will cause a decrease in ventilation. The
consequent rise in PaCO2 is inversely proportional to the
decrease in ventilation such that a halving of alveolar ventilation
will lead to a doubling in PaCO2, assuming constant carbon
dioxide production. As shown in ﬁgure 4, any increase in PaO2
above 8 kPa (60 mm Hg) will not signiﬁcantly reduce ventilation
and increases above 13 kPa (100 mm Hg) will have little impact
on ventilation as the carotid sinus discharge is largely attenuated
above 13 kPa. This mechanism is therefore only of importance
in explaining increases in PaCO2 when PaO2 rises to 13 kPa, but
not increases thereafter. This phenomenon is also seen in
normal individuals. Several clinical studies have suggested that
‘hypoxic drive’ makes only a small contribution to the rise in
PaCO2 that is seen clinically when high-concentration oxygen is
given to patients with COPD, but one recent study has sup-
ported this mechanism.48 49 108–113
Haldane effect
The third effect of increasing FiO2 is to decrease the carbon
dioxide buffering capacity of haemoglobin through the Haldane
effect60 (see section 5.3.2).
Absorption atelectasis
The fourth effect, absorption atelectasis, is thought to occur as a
result of absorption of oxygen from alveoli with high PAO2
beyond obstructed airways. This can happen at FiO2 as low as
30–50% and will result in a shunt (increased V/Q mismatch).102
Higher density of oxygen compared with air
Johnson et al114 have shown a reduction in FEV1 in patients
who were breathing pure oxygen compared with breathing air.
They concluded that this effect was probably related to the
slightly increased density and viscosity of oxygen relative to air.
This would increase the work of breathing which could contrib-
ute to hypercapnia in an exhausted patient.
Rebreathing from face masks with low-ﬂow rates
This issue is discussed in section 10 and in a paper by Jensen et al.115
6.3.2 Rebound hypoxaemia following sudden cessation of
supplementary oxygen therapy
Patients who have developed decompensated hypercapnic
respiratory failure following high-concentration oxygen therapy
face a further signiﬁcant danger of rebound hypoxaemia if
oxygen is suddenly withdrawn in an attempt to correct the
effects of excess oxygen therapy.116 117
Rebound hypoxaemia can be explained using the alveolar gas
equation and, given its importance, is best illustrated with a
working example (box). For the purposes of simplicity, this
example makes several assumptions such as a constant respiratory
exchange ratio and A–a gradient between stages 1 and 3. It also
assumes that ventilation remains unchanged. Although when PaO2
falls to 3.4 kPa on removal of oxygen, ventilation will rise, by def-
inition it will not be able to rise sufﬁciently to meet the need to
clear the carbon dioxide stores for the same reason that hypercap-
nic respiratory failure developed in the ﬁrst instance. Rebound
hypoxaemia is a major risk and could cause death. Consequently,
this guideline will recommend that oxygen therapy be stepped
down gradually while monitoring saturation continuously.
Good practice point
✓ Sudden cessation of supplementary oxygen therapy can
cause rebound hypoxaemia with a rapid fall in PO2 to below
the tension that was present prior to the start of supplemen-
tary oxygen therapy.
Example: rebound hypoxaemia
Stage 1: consider a patient with an exacerbation of COPD
whose ABGs are as follows: PaO2 6.5 kPa; PaCO2 7.5 kPa
breathing room air. The PAO2 calculated from the alveolar gas
equation (5.2.1) will be 11.6 assuming a respiratory exchange
ratio of 0.8, giving an A–a gradient of 5.1 kPa.
Stage 2: given maximal oxygen through a reservoir bag mask,
his blood gases become: PaO2 32 kPa; PaCO2 10 kPa. Because
of the high solubility of carbon dioxide, the total body stores of
carbon dioxide will have risen.
Stage 3: If oxygen therapy is suddenly withdrawn, PACO2 and
PaCO2 will remain high initially because of the high carbon
dioxide stores and therefore PAO2 will fall further than it was
initially before oxygen therapy to 8.5 kPa. Assuming the A–a
gradient for oxygen stays at 5.1 kPa for room air breathing, then
calculated PaO2 will become 3.4 kPa.
6.3.3 Cardiovascular and cerebrovascular system
The effects and potential harms of hyperoxaemia on the circula-
tion have been summarised by Thomson et al105 in an editorial
which made a strong case for more trials. Hyperoxaemia causes
coronary and cerebral vasoconstriction and, if the haematocrit is
sufﬁciently low, this may theoretically cause paradoxical tissue
hypoxia because of overall reduction in DO2. There have been
reports of possible harm from the administration of oxygen to
non-hypoxaemic patients with strokes of mild-to-moderate
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severity or to non-hypoxaemic patients with myocardial infarc-
tion as discussed in sections 8.13.1 and 8.13.2. Thomson
et al105 have suggested that oxygen should be ‘prescribed, admi-
nistered and monitored with care’ in order ‘to achieve optimal
tissue oxygenation’, not maximal oxygenation. This view was
proposed by other authors such as Bryan and Jenkinson118 in
the 1980s, but standard medical practice had not taken note of
this advice prior to the publication of the ﬁrst version of this
guideline in 2008. Because there are no published data
suggesting beneﬁt from hyperoxaemia for most medical condi-
tions and because of the theoretical risks, optimal management
should aim for physiological oxygenation. Targets for oxygen
therapy in speciﬁc circumstances, with evidence, are discussed
in section 8.
6.3.4 Reactive oxygen species, tissue toxicity and reports of
increased mortality
Aside from the potentially detrimental physiological effects of
hyperoxaemia, the toxic effects mediated by reactive oxygen
species (ROS) have potential risk.118 Excess ROS are generated in
the presence of high tissue PO2 in the form of hydrogen peroxide
and superoxide, causing oxidative stress and free radical
damage.119 At physiological levels ROS act as signalling mole-
cules, but at higher levels they are cytotoxic, notably being
released by primed neutrophils as a host defence mechanism. It is
thought that ROS are responsible for the development of bronch-
opulmonary dysplasia in ventilated hyperoxygenated premature
infants120 and reperfusion injury postmyocardial infarction.121 It
has been known since the 19th century that prolonged exposure
to high concentrations of oxygen in animal models leads to
diffuse alveolar damage, haemorrhage, alveolar collapse, inﬁltra-
tion of inﬂammatory cells, necrosis, apoptosis and injury to the
endothelium and epithelium in the lungs which causes death in
the rat model after 4 days of exposure to 73% oxygen at one
atmosphere.122 Grifﬁth et al123 demonstrated in 1986 that
normal human lungs are injured by breathing 30–50% oxygen
for 45 hours with leakage of albumin into bronchoalveolar lavage
ﬂuid and other markers of lung injury.123
6.3.5 Delay in recognition of physiological deterioration
It was previously believed that a high FiO2 is protective and
gives patients a margin of safety. However, Downs102 and
Beasley et al106 have argued that unstable patients may actually
be placed at risk by the precautionary use of high-concentration
oxygen therapy.107 124 During physiological deterioration, a
patient given high-concentration oxygen therapy would have a
normal or high pulse oximeter reading masking a progressive
decline in the PaO2/FiO2 ratio and therefore not alerting staff to
impending deterioration requiring mechanical support. A
worked example of this is shown in reference.106 Furthermore,
a patient who deteriorated physiologically while at a low FiO2
would be detected early by pulse oximetry and could have the
FiO2 increased while being transferred to an ICU, whereas a
patient who was already receiving a high FiO2 would desaturate
more slowly but, when the oximeter eventually detected desat-
uration, there would be fewer treatment options because
increasing the FiO2 further would have little effect.
88 92 107
6.3.6 Acute lung injury in patients with acute paraquat poisoning,
bleomycin lung injury and acid aspiration
Oxygen is known to be hazardous to patients with paraquat poi-
soning125 126 and oxygen potentiates bleomycin lung injury and
may potentiate lung injury from aspiration of acids.127–129
Further details concerning these conditions are given in section
8.13.4.
6.3.7 Summary of risks of hyperoxaemia and supplemental
oxygen therapy
Physiological risks
1. Worsened V/Q mismatch.
2. Absorption atelectasis.
3. Coronary and cerebral vasoconstriction.
4. Reduced cardiac output.
5. Damage from oxygen free radicals.
6. Increased systemic vascular resistance.
Clinical risks
1. Worsening of hypercapnic respiratory failure.
2. Delay in recognition of clinical deterioration.
3. Potentially worse outcomes in mild-to-moderate stroke.
4. Speciﬁc risk in patients with previous bleomycin lung
damage or with paraquat poisoning or acid aspiration.
5. Unknown risk–beneﬁt balance in acute coronary artery
disease with normal oxygen saturation.
6. Association with increased risk of death in survivors of
cardiac arrest and among patients on ICUs.
7. Uncontrolled supplemental oxygen therapy can be harmful
to patients who are at risk of hypercapnic respiratory failure,
especially if the PaO2 is raised above 10 kPa.
8. High-concentration oxygen therapy to produce hyperoxae-
mia (above normal oxygen saturation) and has been asso-
ciated with increased risk of death in some patient groups
(eg, patients with mild and moderate strokes, survivors of
cardiac arrests and ICU patients; see section 8).
6.4 Risks of hypercapnia (and respiratory acidosis)
Hypercapnia and respiratory acidosis are inextricably linked
and are best considered together. If hypercapnia develops
slowly (over several days), a patient will have renal compensa-
tion (retention of bicarbonate) and acidosis will not occur in
most such cases. However, acute elevation of the blood
carbon dioxide level produces respiratory acidosis and symp-
toms of hypercapnia. Some of the consequences of an ele-
vated PCO2 are a consequence of the resulting acidosis.
Sometimes the effect of a raised PCO2 on a particular organ
system is opposed by an opposite effect of acidosis. Carbon
dioxide is a vasodilator and patients with hypercapnia may
appear ﬂushed with dilated peripheral veins and a bounding
pulse. Cranial vasodilation may cause headache. Carbon
dioxide in high concentrations has hypnotic effects and
patients with hypercapnia may progress from drowsiness to
confusion to coma.84 130–134 A link has been shown between
inappropriately high blood oxygen levels due to high-
concentration oxygen use and the development of severe
respiratory acidosis in acute COPD with increased risk of
death or requirement for mechanical ventilation.43 46 135
However, the problem of respiratory acidosis is not conﬁned
to patients with COPD. Depressed respiration for any reason
will give rise to hypercapnia. Examples are opioid overdoses,
obesity with hypoventilation and neuromuscular disorders
affecting the muscles of respiration. Recent studies have
shown a rise in the carbon dioxide level in patients with OHS
and also in patients with pneumonia and with acute exacerba-
tions of asthma where the link between hyperoxaemia and
hypercapnia was not previously recognised.47 136 137
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An audit of blood gases from 4866 patients at a university
hospital has shown that hypercapnia was commoner than hyp-
oxaemia in blood gas samples from surgical wards, a surgical
HDU, theatre and the ICU as well as on medical wards and the
medical HDU and many of these hypercapnic patients had
respiratory acidosis.42 Furthermore, a Swiss audit of 530 blood
gas specimens in the emergency department showed that
patients in the lowest pH tertile more often required admission
to ICU (28% vs 12% in the ﬁrst tertile, p<0.001) and had
higher in-hospital mortality (14% vs 5%, p=0.003).138
Hypercapnia on admission was independently associated with
increased risk of ICU admission and increased 30-day mortality
in that study.
6.4.1 Effects of a raised blood carbon dioxide level
Nervous system
Carbon dioxide exerts its effect either directly or as a conse-
quence of acidosis. Hypercapnia increases cerebral blood ﬂow
and thereby may inﬂuence the cerebrospinal ﬂuid pressure. It is
the main factor inﬂuencing the intracellular pH which has an
important effect on cellular metabolism. It exerts an inert gas
narcotic effect similar to that of nitrous oxide. It inﬂuences the
excitability of neurones particularly relevant in the reticular acti-
vating system. Carbon dioxide can induce narcosis when the
PaCO2 rises above 12–16 kPa (90–120 mm Hg).
130
Pulmonary circulation
An elevated PACO2 causes vasoconstriction in the pulmonary
circulation although the effect is less marked than that of hyp-
oxaemia.139 In healthy participants an end expiratory PCO2 of
7 kPa (52 mm Hg) increases pulmonary vascular resistance by
32% which, along with raised cardiac output, increases mean
pulmonary artery pressure by 60%.140 Changes in pH are
thought to be the primary factor responsible for carbon dioxide-
mediated changes in the pulmonary vasculature.141 142
Consequently, as with HPV, changes in PACO2 help to match
perfusion to ventilation.
Respiratory system
As explained in section 5.2.1, a raised carbon dioxide level may
worsen hypoxaemia and its effects because the concentration of
carbon dioxide in the alveolar gas reduces that of oxygen if the
concentration of nitrogen remains constant. Also an increase in
PaCO2 shifts the oxygen dissociation curve to the right.
Cardiovascular system
In general, both hypercapnia and acidosis have direct depres-
sant effects on cardiac myocytes and vascular smooth muscle
cells.143 These effects are normally opposed by the increase in
catecholamines caused by the raised PaCO2. The overall effect
of carbon dioxide on the cardiovascular system is therefore
unpredictable. In artiﬁcially ventilated children a rise in carbon
dioxide increases cardiac output and reduces total peripheral
resistance and blood pressure tends to rise.144 Although an
increase in carbon dioxide depresses heart rate, tachycardia is
more common because of the effects of catecholamine stimula-
tion over-riding the depressant effects on the heart.
Arrhythmias have been reported but are seldom clinically sig-
niﬁcant in normal participants. Carbon dioxide is a systemic
vasodilator.
Kidneys
Renal blood ﬂow and glomerular ﬁltration rate are reduced
abruptly in the presence of levels of PaCO2 above about
65 mm Hg (8.7 kPa).88 145
Blood electrolyte levels
The acidosis that accompanies hypercapnia may cause a rise
in potassium if the acidosis is severe and sustained.
Endocrine system
Hypercapnia increases plasma levels of endogenous adren-
aline and noradrenaline.
6.4.2 Clinical signs
The clinical signs of hypercapnia are produced by the physio-
logical changes described above and are described in detail in
section 7.2.1.
6.5 Risks of acidosis
The major effect of acidosis is depression of the central nervous
system with severe acidosis (pH, 7.0 or [H+] 100 nmol/L)
causing disorientation and later coma. However, as described
above, the effects of pH are inextricably linked with both hyp-
oxaemia and hypercapnia. As a consequence of opposing effects
of acidosis, hypoxaemia and hypercapnia on different target
organs in individual patients together with the fact that derange-
ments of all three components may occur at the same time, it is
very difﬁcult to predict the effects of acidosis per se in an indi-
vidual patient. Furthermore, tissue hypoxia will exacerbate acid-
osis. The consequences will depend on the interplay of the
three variables, complicated by the effects of comorbid disease
states. It is well known that, in patients with COPD, a pH of
<7.30 or [H+] >50 nmol/L during an acute exacerbation is
associated with a much worse prognosis.43
6.6 Rationale of oxygen therapy
Oxygen therapy is usually deﬁned as the administration of
oxygen at concentrations greater than those found in ambient
air. It is usually undertaken to treat or prevent hypoxaemia,
thereby preventing tissue hypoxia which may result in tissue
injury or even cell death. Clinicians must bear in mind that sup-
plemental oxygen is given to improve oxygenation but it does
not treat the underlying causes of hypoxaemia which must be
diagnosed and treated as a matter of urgency.
In some circumstances such as carbon monoxide poisoning or
cyanide poisoning or cluster headache, oxygen therapy is used
to achieve hyperoxaemia. There is evidence from randomised
studies that oxygen does not relieve breathlessness compared
with air in non-hypoxaemic patients with COPD who are
breathless following exertion or in non-hypoxaemic patients
with advanced cancer.146–150 At the tissue level, mitochondrial
activity requires oxygen for aerobic ATP synthesis for cellular
activity. PaO2 of dry air at sea level is 21.2 kPa (159 mm Hg),
but at the mitochondrion, PO2 is in the range of 0.5–3.0 kPa
(4–22 mm Hg) depending on tissue type and local metabolic
activity. This gradient from atmosphere to mitochondrion is
known as the oxygen cascade. There are many factors in this
cascade that affect the ﬁnal mitochondrial PO2 including alveo-
lar gas exchange, oxygen transport in the blood and tissue per-
fusion. Under pathological conditions, any change in one step
in this cascade may result in hypoxia at the mitochondrial level.
Therefore, although not necessarily addressing the underlying
cause of tissue hypoxia, increasing FiO2 with oxygen therapy is
the simplest and quickest way of avoiding hypoxic tissue
damage in patients with hypoxaemia. Besides oxygen therapy,
other steps are usually necessary to improve the delivery of
oxygen to the tissue (see section 5.6).
6.7 Target oxygen saturation in acute illness
Many disease states lead to hypoxaemia and it is standard prac-
tice for breathless patients to be treated with oxygen (see also
section 4.3). However, there have been few controlled trials
comparing different levels of inspired oxygen for patients with
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any of the common diseases that lead to hypoxaemia. It must
also be remembered that oxygen therapy is only one of several
strategies that may be used to increase tissue oxygen delivery for
critically ill patients (see section 5.6). In many clinical situations
oxygen therapy is applied without a speciﬁc end point in mind.
It has been suggested by many studies that hyperoxaemia can
have deleterious physiological and clinical effects (see section
6.3), albeit such effects are not widely reported in conditions
other than COPD. However, potential for harm may well exist
with hyperoxaemia and good medical practice should be fol-
lowed as in all drug prescriptions. This is especially important
in view of recent suggestions by some authors that hyperoxae-
mia may be associated with increased risk in ICU patients and in
survivors of cardiac arrest although this view has been chal-
lenged by other authors.151–156 As the actual PO2 at the mito-
chondrial level is so variable and dependent on many variables
other than PaO2, it is often difﬁcult to set a minimum level of
PaO2 below which deﬁnite cell damage will occur or above
which the host is safe from the effects of hypoxic cell damage.
In addition, it is not possible to monitor mitochondrial PO2
clinically and the only clinically available surrogate of mitochon-
drial hypoxia is lactate production. Although blood lactate levels
are useful and may indicate tissue hypoxaemia, it is a late
marker and therefore is an insensitive tool. Thus, targets set for
‘ideal’ blood gas levels are based on arbitrary goals.
Owing to the natural decline in normal arterial oxygen levels
with age, it has been suggested that the ideal target PaO2 can be
determined by the following equation: ideal PaO2=13.3 kPa
−0.04×age (in years) or 100 mm Hg−0.3×age (in years).157 In
terms of oxygen saturation measured by the bedside, this would
translate into an SaO2 of 94–98% in most situations. This strat-
egy avoids tissue hypoxia in almost all patients and also avoids
potential deleterious effects of hyperoxaemia. Thus, the stand-
ard practice should be to prescribe oxygen to a speciﬁc satur-
ation (or PaO2) rather than in terms of FiO2. Clearly,
consideration will need to be given to patients who have
oxygen-sensitive carbon dioxide retention and targets may well
have to be set lower for these patients (usually 88–92%) to
strike a balance between achieving a desirable and safe SaO2/
PaO2 and carbon dioxide retention. There has been one rando-
mised trial of controlled oxygen therapy with target range 88–
92% in patients with exacerbated COPD.51 This trial is sup-
ported by ﬁve decades of physiological and observational
studies which are reviewed in section 8.12. Speciﬁc disease
states will be addressed in section 8. Patients with
moderate-to-severe hypoxaemia are usually breathless and have
an increased respiratory rate. Apart from causing physical tired-
ness, this also increases work of breathing, therefore increasing
both oxygen consumption and carbon dioxide production. In
these circumstances, oxygen therapy may reduce the work of
breathing and therefore reduce carbon dioxide production.
Therefore, oxygen therapy should theoretically improve breath-
lessness in hypoxaemic patients. However, despite the wide-
spread belief of doctors and patients that oxygen relieves
breathlessness, little evidence of beneﬁt effect has been found in
clinical trials involving patients who were breathless but not
hypoxaemic. For example, one meta-analysis of all published
blinded studies of short burst oxygen therapy for patients with
COPD with breathlessness reported modest and heterogeneous
beneﬁt and another meta-analysis failed to conﬁrm any clinical
beneﬁt.146 158
A 2004 systematic review of oxygen and airﬂow on the relief
of breathlessness at rest in patients with advanced disease of any
cause found only low-grade scientiﬁc evidence that oxygen and
airﬂow improve breathlessness in some patients with advanced
disease at rest, and almost all of these participants were hypox-
aemic and already using oxygen therapy.159 A study published
in 2010 reported no additional symptomatic beneﬁt of oxygen
over air delivered by nasal cannulae for relieving refractory
breathlessness related to life-limiting illness in patients with
PaO2>55 mm Hg (7.3 kPa). Breathlessness decreased in both
study arms, temporally related to provision of medical gas.150
Evidence statements
▸ There have been no randomised trials comparing different
oxygen saturation levels for patients not at risk of hypercap-
nic respiratory failure. Expert opinion (based on physiology
and observational studies) recommends maintaining normal
or near-normal oxygen saturation of 94–98% for these
patients (evidence level 4).
▸ The target saturation in patients with COPD who are at risk
of hypercapnia is 88–92% (evidence level 1+).
▸ The target saturation for patients with other risk factors for
hypercapnia (eg, morbid obesity, chest wall deformities or
neuromuscular disorders) is 88–92% based on expert
opinion which is extrapolated from observational studies
(evidence level 4).
Recommendations for achieving desirable oxygen saturation
ranges in acute illness (see also charts 1–2)
A1: This guideline recommends aiming to achieve a normal
or near-normal oxygen saturation for all acutely ill patients
apart from those at risk of hypercapnic respiratory failure
(grade D).
A2: The recommended target saturation range for acutely ill
patients not at risk of hypercapnic respiratory failure is 94–
98% (grade D).
A3: For most patients with known COPD or other known
risk factors for hypercapnic respiratory failure (eg, morbid
obesity, CF, chest wall deformities or neuromuscular disorders
or ﬁxed airﬂow obstruction associated with bronchiectasis), a
target saturation range of 88–92% is suggested pending the
availability of blood gas results (grade A for COPD, grade D
for other conditions).
A4: Most non-hypoxaemic breathless patients do not beneﬁt
from oxygen therapy, but a sudden reduction of ≥3% in a
patient’s oxygen saturation within the target saturation range
should prompt fuller assessment of the patient (and the oxim-
eter signal) because this may be the ﬁrst evidence of an acute
illness (grade D).
6.8 Effects of body positioning including restraint systems
Appropriate positioning of a patient can maximise V/Q match-
ing. In the healthy self-ventilating adult lung, V/Q matching
improves from non-dependent to dependent areas. In lung
disease, there is a disruption of this pattern and, in these
instances, appropriate positioning may be advantageous in opti-
mising V/Q matching, therefore improving gas exchange, oxy-
genation and carbon dioxide clearance. For these reasons,
breathless patients usually prefer to sit upright or near upright
provided they are able to do so. The relationship between
dependency and V/Q matching is maintained irrespective of the
position of the participant. The physiology is then transferable
into alternate side lying positions; for example, in left side lying
the dependent lung (left) will have the better V/Q matching.
This is important in the presence of asymmetrical lung path-
ology as the ‘good lung down’ principle will maximise V/Q
matching. Many unwell patients are nursed in the semirecum-
bent and supine positions. These positions do not facilitate V/Q
matching as in the upright and full side lying position due to
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the hindrance to expansion of the dependent lung by the dia-
phragm and chest wall. Even in healthy participants the PO2 is
0.7 kPa (5 mm Hg) lower in the supine position than in the
upright position.20 Similarly, 10% of patients with right hemi-
paresis and concomitant chest disease were more hypoxaemic in
the left lateral position.160 Where there is pathological lung
disease and hence already signiﬁcant V/Q mismatch, gas
exchange may be further impaired. This is discussed in a review
of the effects of position on oxygen saturation in acute
stroke.161 Patients with acute stroke without respiratory
comorbidities may be permitted to adopt any body position that
they ﬁnd most comfortable, while those with respiratory com-
promise should be positioned as upright as possible, avoiding
slouched or supine positions to optimise oxygenation.161 The
semirecumbent/supine position is commonly adopted in an
ambulance. In addition, for safety, the patient is strapped into
the stretcher using abdominal and chest restraints with their
arms by their side. While there are a lack of speciﬁc data regard-
ing this, physiological principles suggest that the use of such
positioning and restraints would compromise both respiratory
muscle function and gas exchange. Finally, there are some rare
patients with liver disease, cardiac shunts or lung ﬁbrosis who
have ‘platypnoea and orthodeoxia’ which means that they are
more hypoxic in the upright position.162 Other patients with
scoliosis or with a paralysed hemidiaphragm may feel more
comfortable with the ‘good lung up’. These patients should be
allowed to choose the position in which their breathing is most
comfortable for them.
Evidence statement
▸ Evidence from a number of cohort studies shows that oxygen-
ation is reduced in the supine position, both in healthy partici-
pants and in acute illness but there are no controlled trials
showing beneﬁt from speciﬁc body positions (evidence level 4)
Recommendation
A5: Because oxygenation is reduced in the supine position,
fully conscious hypoxaemic patients should ideally be allowed
to maintain the most upright posture possible (or the most com-
fortable posture for the patient) unless there are good reasons to
immobilise the patient (eg, skeletal or spinal trauma) (grade D).
SECTION 7: CLINICAL AND LABORATORY ASSESSMENT OF
HYPOXAEMIA AND HYPERCAPNIA
7.1 Assessment of hypoxaemia
7.1.1 Clinical assessment of breathless patients and assessment
of cyanosis
Clinicians examining a critically ill patient should remember the
‘ABC’ of emergency medicine. In the case of critically ill patients
it may be necessary to secure the airway and resuscitate a
patient before a detailed history can be obtained and before a
full physical examination can be undertaken. Additionally, it is
important to remember that supplemental oxygen is given to
improve oxygenation but it does not inﬂuence the underlying
cause(s) of hypoxaemia which must be diagnosed and treated as
a matter of urgency.
In assessing an ill patient the SpO2 level is only one of several
physiological variables that should be monitored. Many patients
with sudden acute illness such as postoperative pulmonary
emboli will have a sudden alteration in physiological ‘track and
trigger’ variables as assessed by the mEWS system94 95 163 and
the NEWS developed by the Royal College of Physicians.96
Such patients may have only a small fall in SpO2 due to physio-
logical compensation mechanisms such as increased ventilation.
Clinicians therefore need to be alert for falls in SpO2 even
within the recommended target ranges.
Although the use of ‘track and trigger’ systems are strongly
recommended, the guideline group had some reservations of
their use in patients at risk of hypercapnic respiratory failure,
and in particular, the 2012 version Royal College of Physicians
NEWS as there was no option to set a target range for oxygen
saturations.164 165 Patients at risk of hypercapnic respiratory
failure who are within the target range of 88–92% as recom-
mended in this guideline would score 2–3 EWS points, and may
prompt nursing staff to increase the inspired oxygen level to
achieve ‘normal’ oxygenation (>96%) and put the patient at
risk. The guideline group recommends use of the 2017 update
of the NEWS chart which allows appropriate adjustments to the
scoring for saturation for patients at risk of hypercapnic respira-
tory failure. Patients should score EWS points for saturations
below the target range or if signiﬁcantly above the target range
while breathing oxygen. The 2017 NEWS chart will have a
special oximetry section for patients at risk of hypercapnia.
Evidence statement
▸ There are no controlled trials of different methods of assess-
ment of acutely unwell patients. Advice on clinical assess-
ment is based on expert opinion and retrospective studies of
outcomes (evidence level 4).
Recommendations
B1: Fully trained clinicians should assess all acutely ill
patients by measuring respiratory rate, pulse rate, blood pres-
sure and temperature, and assessing circulating blood volume
and anaemia. Expert assistance from specialists in intensive care
or from other disciplines should be sought at an early stage if
patients are thought to have major life-threatening illnesses and
clinicians should be prepared to call for assistance when neces-
sary including a call for a 999 ambulance in prehospital care or
a call for the resuscitation team or ICU outreach team in hos-
pital care (grade D).
Traditional clinical assessment of hypoxaemia involves clinical
inspection of the skin and buccal mucous membranes to decide
whether central cyanosis is present or absent. This is a difﬁcult
clinical skill, especially in poor lighting conditions. Clinical
assessment of hypoxaemia is made even more unreliable by the
presence of anaemia or polycythaemia. Some patients may have
peripheral cyanosis due to poor peripheral circulation in the
presence of normal SaO2. Several studies have shown that hyp-
oxaemia is often not recognised by emergency medical service
providers, especially if the patient does not complain of respira-
tory distress.166–168 A systematic review of the literature in 2005
reported that most hypoxaemic patients had at least one vital
sign abnormality but skin colour was a poor indicator of hypox-
aemia compared with pulse oximetry.39 For these reasons it is
recommended that clinicians should not rely on visual assess-
ments of ‘cyanosis’ but should instead use pulse oximetry to
obtain an accurate assessment of a patient’s oxygen saturation.
The nature of a patient’s presenting illness may make hypox-
aemia a likely outcome, thus prompting a careful clinical search
for evidence of cyanosis complemented by urgent pulse oxim-
etry. This situation applies to many common acute illnesses such
as heart failure, COPD exacerbation, pneumonia and pulmonary
embolism. A study of 2276 patients with pneumonia showed
that hypoxaemia was independently associated with six risk
factors: age >30 years (OR 3.2), COPD (OR 1.9), congestive
heart failure (OR 1.5), respiratory rate >24/min (OR 2.3),
altered mental status (OR 1.6) and chest radiographic inﬁltrate
involving >1 lobe (OR 2.2).36 Acutely ill patients with signiﬁ-
cant hypoxaemia are likely to have an increased pulse rate or
respiratory rate and, for this reason, usually score several NEWS
points.94 95 163 165 169
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The respiratory rate is the single best predictor of severe
illness.95 However, many patients with marked hypoxaemia may
present with non-speciﬁc ﬁndings such as restlessness and
confusion rather than breathlessness, and oxygen saturation has
been shown to be an independent predictor of mortality in
multivariate analysis of the outcome of emergency
medical admissions.19 170 Furthermore, the work of Thrush
et al171 on normal volunteers has shown that heart rate, blood
pressure and respiratory rate are not reliable indicators of hyp-
oxaemia down to saturation levels as low as 70%. This would
suggest that the changes in vital signs which are seen in most
hypoxic patients are due to the underlying illness rather than
hypoxaemia per se.
Hypoxaemia may be associated with increased or decreased
ventilation. Although some hypoxaemic patients may have
reduced levels of ventilation as a causative factor, the majority
of hypoxaemic patients have increased minute ventilation in an
attempt to increase the blood oxygen level. For example, a
patient with an opioid overdose may have reduced ventilation
causing hypoxaemia despite having structurally normal lungs,
whereas a patient with pneumonia or major pulmonary embol-
ism may have signiﬁcant hypoxaemia due to V/Q mismatch
despite an increased level of ventilation. The ﬁrst patient in this
example may appear peaceful and non-distressed despite signiﬁ-
cant hypoventilation and hypoxaemia, while the second patient
is likely to have increased ventilation and tachycardia. The clin-
ician therefore needs to make separate assessments of a patient’s
oxygen saturation and level of ventilation.
Having completed the history and rapid assessment of the
patient, more detailed physical examination may reveal signs of
an illness such as major pleural effusion, major pneumothorax
or unexpected heart failure that may prompt the clinician to
anticipate the presence of hypoxaemia.
Good practice points for clinical assessment of patients with
suspected hypoxaemia
✓ The medical history should be taken when possible in an
acutely breathless patient and may point to the diagnosis of a
particular acute illness such as pneumonia or pulmonary
embolism or an exacerbation of a chronic condition such as
COPD, asthma or heart failure.
✓ Never discontinue oxygen therapy to obtain an oximetry
measurement on room air in patients who clearly require
oxygen therapy.
✓ Physical examination should be undertaken urgently. This
may provide evidence of a speciﬁc diagnosis such as heart
failure or a large pleural effusion, but it is common for the
cause of breathlessness to remain undiagnosed until the
results of tests such as chest radiographs are available.
✓ Record arterial oxygen saturation measured by pulse oxim-
etry (SpO2) and consider blood gas assessment in patients
with unexplained confusion and agitation as this may be pre-
senting feature of hypoxaemia and/or hypercapnia (cyanosis
is a difﬁcult physical sign to record conﬁdently, especially in
poor light or with an anaemic or plethoric patient).
✓ Carefully measure respiratory rate and heart rate because
tachypnoea and tachycardia are more common than a phys-
ical ﬁnding of cyanosis in hypoxaemic patients.
✓ Appropriate changes should be made to any ‘track and
trigger’ system used to allow for a lower target range in
patients at risk of hypercapnic respiratory failure. These
patients should score no EWS points for saturation if within
their target range and they should score points if the oxygen
saturation falls below the target range or if the saturation rises
above the target range while breathing oxygen. The 2017
update of the NEWS chart has a special section for oximetry
measurements for use with patients who have target range
88–92% and it is recommended that the 2017 NEWS chart
should be used in all hospitals (see recommendation B4).
✓ The presence of a normal SpO2 does not negate the need for
blood gas measurements especially if the patient is on sup-
plemental oxygen therapy. Pulse oximetry will be normal in
a patient with a normal oxygen tension (PO2) but abnormal
carbon dioxide tension (PCO2) or with a low blood oxygen
content due to anaemia. For this reason, blood gases and full
blood count tests are required as early as possible in all situa-
tions where these measurements may affect patient outcomes.
✓ All clinical staff who use oximeters must be trained in their
use and made aware of the limitations of oximetry.
(Oximetry is a valuable clinical tool but subject to artefact
and errors of interpretation).
7.1.2 Value and limitations of pulse oximetry
Clinical assessment of hypoxaemia has been revolutionised by
the advent of pulse oximetry in much the same manner as the
clinical assessment of blood pressure was transformed by the
invention of the sphygmomanometer. However, it was common
in the past to see patients with acute respiratory illness who
have had multiple measurements of their blood pressure but no
record made of their oxygen saturation, peak expiratory ﬂow or
FEV1. In addition to the clinical consequences of underassess-
ment, Howes et al172 and Macnab et al173 have reported that
the availability of a pulse oximeter was highly cost-effective
because the ﬁnding of normal oximetry (>94%) in many
patients allowed paramedics to use oxygen less frequently with a
potential ﬁnancial saving of up to $2324 (∼£1200) per ambu-
lance per annum. The availability now of highly portable,
low-cost pulse oximeters should make the measurement of
oxygen saturations in many clinical scenarios commonplace and
used as the ‘ﬁfth vital sign’. We would encourage all clinical staff
who are involved in the care of acutely ill patients to carry and
use one so that measurement of oxygen saturations is as normal
a part of assessment of a patient as listening to their chest.
Pulse oximetry measures haemoglobin oxygen saturation by
detecting the absorption of light at two speciﬁc wavelengths that
correspond to the absorption peaks of oxygenated and deoxyge-
nated haemoglobin. Oximeters are less reliable at low saturation
such as 80%, but modern oximeters reﬂect the SaO2 accurately
at saturation above about 88%.174–178 In almost all clinical cir-
cumstances covered by this guideline, patients with a saturation
below 88% will be given intensive therapy to bring the satur-
ation up to at least 90%, so the inaccuracy of the instruments at
very low saturation levels should not affect patient management.
In one study of 123 adult patients who had simultaneous mea-
surements of pulse oximetry and SaO2 measured in ABGs, the
95% CI for the median difference ranged from −0.6 to
+0.5%.176It has been estimated that an oxygen saturation of 92%
or above measured by pulse oximetry has a sensitivity of 100%
and speciﬁcity of 86% for excluding hypoxaemia deﬁned as an
arterial oxygen partial pressure below 60 mmHg (8 kPa).179
Oximetry may be less accurate in acutely ill patients on ICUs,
but there are no direct comparisons of the accuracy of pulse
oximetry in critically ill patients compared with stable patients
and healthy individuals. The study of Perkins et al180 showed a
mean SpO2 of 94.6% compared with a mean SaO2 of 95.9%
from 1132 simultaneous oximeter and ABG measurements on
an ICU. Fortunately, this average difference of 1.3% was lower
for pulse oximeter readings, thus allowing a margin of safety in
most cases. This study also showed that ﬂuctuations in oxygen
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saturation measured by oximetry tended to be greater than
changes in SaO2 measured with samples from an indwelling
radial artery catheter.
Although oximetry is widely used, there are few clinical
studies examining its utility. The Cochrane meta-analysis of the
use of oximetry in perioperative monitoring of more than
20 000 patients failed to show any reduction in complications
or deaths where oximetry was used, although oxygen was given
more often to patients who were monitored with pulse oxim-
etry.181 The authors suggested that the correction of modest
hypoxaemia probably does not have much effect on clinical
outcomes.
Pulse oximetry gives no information concerning pH, PCO2 or
haemoglobin level. Blood gases and full blood count tests are
therefore required as early as possible in all situations where
these measurements may affect patient outcomes.
The accuracy of pulse oximetry is diminished in patients with
poor peripheral perfusion which may occur chronically in con-
ditions such as systemic sclerosis or acutely in patients with
hypotension or hypovolaemia. However, it has been suggested
that many types of oximeter may remain accurate at arterial
pressures as low as 20 mm Hg so long as the machine is able to
obtain a reading despite the low pulse pressure.182 Most oxi-
meters give an indication of the pulse signal strength. It is
important to ensure that the oximeter has a good signal if tech-
nically possible, and the probe may need to be tried on different
ﬁngers or toes or on the earlobe to obtain the best available
signal for the individual patient. There are some patients with
poor perfusion for whom pulse oximetry measurements cannot
be made. This includes patients with cold peripheries (eg,
Raynaud’s phenomenon), severe hypotension and peripheral
‘shut down’.
It must be remembered that oximetry gives a normal reading
for oxygen saturation in most patients with anaemia because the
oxygen saturation of the available haemoglobin is normal
although the total amount of haemoglobin available for oxygen
transport is reduced. These patients have normal oxygen satur-
ation levels despite having ‘anaemic hypoxia’ which may cause
considerable reduction in the total oxygen content of the blood.
It is often not recognised that a patient with an SpO2 of 98%
but a haemoglobin of 7 g/dL ((7×0.98×1.34)=9.2 mL O2/dL)
will have a greatly reduced blood oxygen content compared
with a patient with a haemoglobin of 15 g/dL and a saturation
of 85% ((15×0.85×1.34)=17 mL O2/dL; each g/dL haemoglo-
bin when fully saturated carries 1.34 mL oxygen).
The accuracy of oximetry is unreliable in the presence of carbon
monoxide or methaemoglobin. Both of these substances have
similar light absorption characteristics to oxyhaemoglobin so an
apparently normal SpO2 in a patient with carbon monoxide poi-
soning or methaemoglobinaemia may be falsely reassuring.
Carboxyhaemoglobin levels above 2% may cause falsely elevated
SpO2 measurements.
183 Many smokers will have carboxyhaemo-
globin levels above this level shortly after smoking a cigarette, and
the carboxyhaemoglobin level may be elevated to 15% in some
smokers and up to 50% or more in acute carbon monoxide poi-
soning. It is not known if the reduced blood oxygen content in
smokers who develop sudden illness within a few hours of
smoking cigarettes has any effect on clinical outcomes, or if heavy
smokers might beneﬁt from a slightly higher target saturation
range than non-smokers during the ﬁrst few hours of a serious
illness in an effort to maintain a similar blood oxygen content.
Skin pigmentation may also inﬂuence the accuracy of pulse
oximetry readings (usually overestimation but sometimes under-
estimation). In particular, the accuracy of pulse oximetry is
impaired in dark skinned participants at saturation levels below
80–85%.184–186 However, this should rarely be a problem in
clinical practice if the saturation is maintained in the range sug-
gested in the present guideline (94–98% for most patients),
although the work of Jubran and Tobin31 on ventilated partici-
pants suggested that an oxygen saturation of 92% was useful in
predicting a PaO2 above 60 mm Hg (8 kPa) in ventilated white
participants but was less reliable in ventilated black participants
who sometimes had an SpO2 reading that was more than 4%
above the directly measured PaO2. In the case of sickle cell
crisis, pulse oximetry may underestimate the level of oxygen-
ation.187 In these circumstances, under-reading is safer than
over-reading because no truly hypoxaemic patient would be
denied oxygen therapy. In sickle cell patients, one study has
found that pulse oximeters did not misdiagnose either hypox-
aemia or normoxaemia during a sickle cell crisis provided a
good wave signal was present,188 but discrepancy between SpO2
and that measured by co-oximetry (SO2) has been found by
others during a sickle cell crisis189 and stable patients.190 In
these studies, the SpO2 was generally lower than the SaO2, so
pulse oximetry may misdiagnose hypoxaemia in sickle cell
patients when none is present.
Oximeters can be affected by motion of the patient’s hand, but
this is less of a problem with modern oximeters than with older
devices.191 Motion artefact is more of a problem if the patient
also has reduced perfusion of the measuring site.192 A malposi-
tioned oximeter sensor can cause artefact which can overestimate
or underestimate the true oxygen saturation; this can be a par-
ticular problem during repositioning of ill patients.193
The site of oximetry is also important. Finger and earlobe
measurements are more accurate than measurements from a
probe applied to the toe, and ﬁnger probes may be more accur-
ate than ear probes.194 195 Finally, clinical staff need to remem-
ber to remove nail varnish and false nails to avoid artefacts in
oximetry measurements.
Evidence statements
▸ Pulse oximeters are accurate to within 1–2% of directly mea-
sured SaO2 in most participants but the error (usually over-
estimation but sometimes underestimation) is greater in dark
skinned participants, especially with very low saturation
(below 80–85%) (evidence level 2+).
▸ The accuracy of oximeters in shock, sepsis and hypotension
is largely unknown, but most errors are likely to result in
falsely low readings which would result in additional oxygen
being given. Most errors in oximetry are therefore not likely
to place patients at risk, but it is important to ensure that the
oximeter has a good signal and to avoid artefact due to
motion, nail varnish or other potential sources of error (evi-
dence level 3).
▸ It is advised that oximetry measurements on sleeping patients
should be recorded over several minutes to avoid the possi-
bility of being misled by a normal transient nocturnal dip in
oxygen saturation and clinicians should look for evidence of
snoring or sleep apnoea if desaturation is noted during sleep
(evidence level 4).
▸ Pulse oximetry can be misleadingly normal in smokers
because of raised blood carboxyhaemoglobin levels which will
cause a reduced blood oxygen content despite an apparently
normal oxygen saturation and a normal PO2. Patients who
have smoked cigarettes in the previous 10 hours may there-
fore be at increased risk from hypoxaemia (evidence level 3).
▸ There are no controlled trials regarding implementation of
these observational studies and the following recommenda-
tions are based on expert opinion (evidence level 4).
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Recommendations
B2: Oxygen saturation, ‘the ﬁfth vital sign’, should be checked
by trained staff using pulse oximetry in all breathless and acutely
ill patients (supplemented by blood gases when necessary) and
the inspired oxygen device and ﬂow rate should be recorded on
the observation chart with the oximetry result (grade D).
B3: Initial clinical assessment and subsequent monitoring
of acutely unwell patients should include the use of a recog-
nised physiological ‘track and trigger’ system, such as the
NEWS which may trigger clinical review due to hypox-
aemia, need for supplementary oxygen or for other reasons
(grade D). BTS
B4: For patients who are at risk of hypercapnic respiratory
failure, it is recommended that the relevant section of the 2017
NEWS chart should be used. Points are awarded if the oxygen
saturation is below or above the target range (grade D).
7.1.3 Arterial and arterialised blood gases
ABGs are the ‘gold standard test’ for assessing respiratory
failure. However, published studies have shown that arteria-
lised capillary gases from the earlobe (but not from the ﬁnger)
can provide an assessment of pH and PCO2 that is almost iden-
tical to that obtained from an arterial sample (indications for
blood gas sampling are given in section 8.4 and recommenda-
tion 13).196–200 In acute and stable situations the earlobe speci-
men gives a PO2 measurement which is 0.5–1 kPa (3.7–
7.5 mm Hg) lower than the simultaneous arterial measurement
with most of the divergence occurring at PO2 above 8–10 kPa
(60–75 mm Hg).197 200This means that most patients can be
managed safely based on the pH and PCO2 levels measured
from earlobe blood gases supplemented by oxygen saturation
measured by a pulse oximeter.197 200 In critically ill patients,
the initial specimen should be an arterial specimen to guaran-
tee an accurate initial assessment, but capillary gases are espe-
cially valuable for monitoring progress of the blood gases as a
patient stabilises.
Patients who have had simultaneous arterial and earlobe
samples rated the earlobe puncture procedure as being consider-
ably less painful than arterial puncture.201However, the admin-
istration of local anaesthesia before ABG sampling produced a
signiﬁcant reduction in pain.202 203 A recent randomised trial
found that arterial punctures using insulin needles cause less
pain and fewer procedural complications compared with stand-
ard needles.204
The pain score measured on a 100 mm visual analogue scale
mean (±SD) in punctures with the insulin needle was lower
than the standard needle (23±22 vs 39±24 mm; mean differ-
ence=−15 mm; 95% CI −22 mm to −7 mm; p<0.001).
However, due to the higher rate of haemolysis, the authors
recommended that the use of insulin needles should be limited
to conditions that do not require a concurrent potassium value
in the same blood sample.
There is a very small risk of arterial damage from arterial punc-
ture, especially if the radial site is used. Most reports of hand
ischaemia have involved indwelling radial artery cannulae, but
the vessel could also be injured by needle puncture.205 The
guideline therefore recommends that arterialised earlobe speci-
mens should be used more widely than at present as a safer and
less painful alternative to ABG sampling and local anaesthetic
should be used wherever possible for ABG sampling, but this is
often not practical in medical emergencies and blood gas sam-
pling should not be delayed in these circumstances. However, the
accuracy of earlobe samples in shock or hypotension is not
known and it is recommended that ABGs should be used in all
cases of shock or hypotension (systolic blood pressure
<90 mm Hg).
The technique of patient preparation, sample acquisition and
sample processing for arterialised capillary gases is complex and
should only be undertaken by fully trained staff. Capillary gases
are very vulnerable to errors in technique and they should only
be implemented for emergency use in units where staff have
been fully trained in their use. See section 7.2.3 for advice con-
cerning venous blood gases.
Evidence statements for use of arterialised capillary blood gas
measurements
▸ Patients ﬁnd earlobe specimens less painful than arterial
puncture without local anaesthesia (evidence level 2++).
▸ ABG sampling causes pain which can be reduced by
the use of local anaesthetic prior to the test (evidence
level 1+).
▸ Arterialised earlobe blood gases will provide accurate infor-
mation about PaCO2 and pH but do not provide accurate
information concerning PO2 (evidence level 1−).
▸ The earlobe specimen gives a PO2 measurement which is
0.5–1 kPa (4–7.5 mm Hg) lower than the simultaneous arter-
ial measurement with greater divergence at oxygen levels
above 8–10 kPa (60–75 mm Hg) (evidence level 1–).
▸ However, a combination of earlobe gases (to monitor pH and
PCO2) and oximetry (to measure oxygen levels) will allow
safe management of most patients, even in emergency settings.
(The only published evidence is for patients with COPD but
this ﬁnding is likely to be generalisable to most patients other
than those with shock or poor peripheral circulation)
(evidence level 4).
▸ The technique of patient preparation, sample acquisition and
sample processing for arterialised capillary gases is complex
and should only be undertaken by fully trained staff (evidence
level 4).
Recommendations for use of ABGs and arterialised capillary
blood gases
C1: For critically ill patients or those with shock or hypoten-
sion (systolic blood pressure <90 mm Hg), the initial blood gas
measurement should be obtained from an arterial sample. For
most patients who require blood gas sampling, either ABGs or
arterialised earlobe blood gases may be used to obtain an accur-
ate measure of pH and PCO2. However, the PO2 is less accurate
in earlobe blood gas samples (it underestimates the PO2 by 0.5–
1 kPa) so oximetry should be monitored carefully if earlobe
blood gas specimens are used and a repeat arterial specimen
should be taken if there is any concern about the accuracy of a
capillary sample (grade D).
C2: Local anaesthesia should be used for all ABG specimens
except in emergencies (grade A).
7.1.4 Transcutaneous oxygen assessments
Transcutaneous oxygen devices give different information from
pulse oximetry. They are more sensitive to reduced perfusion
and may be used to monitor tissue oxygenation in trauma
patients but their use is beyond the scope of this guideline.206
7.2 Assessment of hypercapnia and acidosis
7.2.1 Clinical assessment
In patients with lung disease, hypercapnia may be accompanied
by visible respiratory distress, but this will be absent when
hypercapnia is a consequence of a reduction in minute ventila-
tion. Patients may have a ﬂushed face, a full and bounding pulse
and muscle twitching together with the characteristic ﬂap of the
outstretched hands. In severe cases, consciousness may be
depressed and convulsions may occur.
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Gross hypercapnia usually occurs with profound hypoxaemia
and it is therefore difﬁcult to disentangle the direct effect of
hypercapnia per se. Coma will usually occur when the PaCO2 is
in the range 12–16 kPa (90–120 mm Hg). Survival has been
seen following a PaCO2 of 67 kPa (500 mm Hg).
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The presence of hypercapnic respiratory failure can be antici-
pated in patients with severe exacerbations of COPD or other
diseases such as severe neuromuscular disorders. Carbon dioxide
is a vasodilator so patients with hypercapnia may develop head-
ache. Carbon dioxide in high concentrations has hypnotic effects
and patients with hypercapnia may progress from drowsiness
with ﬂapping tremor to confusion to coma.84 130–134 A study of
127 episodes of acute respiratory acidosis showed that the best
clinical predictors of respiratory acidosis were drowsiness (OR
7.1), ﬂushing (OR 4.1), the presence of known COPD (OR 3.3)
and the presence of intercostal retraction (OR 2.9).208
Clinical symptoms and signs of carbon dioxide retention
include:
Headache.
Poor appetite.
Vasodilation producing ﬂushing and warm peripheries with
dilated blood vessels (including retinal veins).
Bounding pulse.
Drowsiness.
Flapping tremor.
Confusion.
Coma.
7.2.2 Blood arterial and arteriolar gases
Arterial or arterialised earlobe capillary blood gases will give an
accurate estimation of pH and PaCO2 (see section 7.1.3 for
further details).196–198 The blood gases will need to be repeated
in 30–60 min in patients with signiﬁcant hypercapnia or acidosis
to monitor the response to treatment. Patients with COPD who
remain acidotic despite 30–60 min of standard treatment
(including targeted low-concentration oxygen therapy) are likely
to need NIV.209
7.2.3 Venous PCO2 sampling
It has been suggested that the venous PCO2 level can be used to
screen for hypercapnia in patients with acute respiratory disease.
A study of 196 paired samples of arterial and venous blood
from patients with acute respiratory disease showed that the
PCO2 in the venous sample was an average of 0.77 kPa
(5.8 mm Hg) higher than the simultaneous arterial sample.210 A
venous PCO2 below 6 kPa (45 mm Hg) had 100% sensitivity for
eliminating the risk of hypercapnia (arterial PCO2 above 6 kPa
or 45 mm Hg), although the speciﬁcity was low at 57% and
there was more variation in some studies.211–213 For patients
who are not at risk of metabolic acidosis, the presence of a satis-
factory oxygen saturation measured by pulse oximetry and a
venous PCO2 below 6 kPa (45 mm Hg) can exclude the possibil-
ity of signiﬁcant arterial hypoxia or hypercapnia and may
obviate the need for ABG measurements. This advice is
strengthened by a recent prospective cohort study and a
meta-analysis of ﬁve previous studies.214 215 Although the use of
venous PCO2 is becoming more common, it is still not widely
enough used in clinical practice for the guideline committee to
make a clear recommendation on its use.
7.2.4 Carbon dioxide monitors and non-invasive assessments of
hypercapnia
Waveform capnography to assess end-tidal CO2 is used primar-
ily to conﬁrm tracheal intubation during anaesthesia, intensive
care and for any patients requiring endotracheal intubation.
They are considered the ‘gold standard’ by the Royal College of
Anaesthetists. The absence of any detectable carbon dioxide
output indicates a failed intubation. The management of intu-
bated patients is outside the remit of this guideline.
Waveform capnography monitors are also useful in the man-
agement of cardiac arrest and circulatory collapse. Waveform
capnography during CPR allows: (1) conﬁrmation of correct
tracheal tube placement; (2) monitoring of the respiratory rate;
(3) assessment of CPR quality—improved chest compression
quality results in increased end-tidal CO2 level; (4) indication of
return of spontaneous circulation (ROSC)—a large increase in
end-tidal CO2 during CPR can indicate ROSC; (5) a very low
end-tidal CO2 value during CPR despite high-quality chest com-
pressions is associated with a low probability of ROSC.216–218
These devices are also useful in the care of intubated patients in
the emergency department because, through visualising a typical
‘box wave form’, they can conﬁrm that the tube is in the airway
even in the absence of carbon dioxide production during a
cardiac arrest. A sudden increase in carbon dioxide may be the
ﬁrst sign of spontaneous circulation.219
End-tidal carbon dioxide measurements correlate poorly with
arterial carbon dioxide levels in patients with COPD, but they may
be useful in some research studies of hyperventilation syndromes.
However, these devices are inaccurate in patients with airways
disease and those with a high respiratory rate, so they should not
be used in the management of patients with respiratory failure and
they will not be discussed further in this guideline.
The recent availability of portable devices to measure transcu-
taneous partial pressure of carbon dioxide (PtCO2) at the bedside
provide a promising alternative to an ABG. They function on the
principle that CO2 diffuses extremely well through tissues. A
probe is attached to an area of skin (usually the earlobe) and
warms to 42°C which ‘arterialises’ the underlying capillaries. The
CO2 diffusing through the skin changes the pH of a thin electro-
lyte membrane in the probe and the resulting signal is converted
to an estimate of the PaCO2. As well as measuring PtCO2, the
probe also measure SpO2. Early studies indicate that such devices
can be accurate in normal volunteers. Transcutaneous CO2
devices have provided accurate estimates of PaCO2 in a variety of
clinical scenarios including AECOPD, invasive and NIV in ICUs
and overnight studies of sleep-disordered breathing.220–224
Recently transcutaneous CO2 monitoring has been used in
the emergency department in patients presenting with acute
severe asthma136 and community-acquired pneumonia225 The
PtCO2 accurately assessed PaCO2 as measured by the ‘gold
standard’ ABG.226 A rise in PtCO2 was demonstrated in both
groups of patients on administration of high-ﬂow oxygen for
60 min, the signiﬁcance of this will be discussed further in
section 8.12. These new techniques are not yet recommended
for routine clinical use.
SECTION 8: EMERGENCY OXYGEN USE IN HOSPITAL
SETTINGS
Tables 1–4 are based on section 8, they are shown at the front of
the guideline.
The hospital management of hypoxaemic patients is presented
before the prehospital management. Some readers may prefer to
read section 9 (prehospital care) ﬁrst because most patients
receive prehospital care before hospital care, but the Guideline
Development Group preferred to present the hospital manage-
ment ﬁrst because a wider range of therapeutic options and a
fuller range of investigations such as blood gas results are available
in the hospital environment than in most prehospital settings.
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8.1 Assessment and immediate management of breathless
patients on arrival in hospital
Breathless patients may arrive in hospital directly (without prior
assessment) or in ambulances where they will usually have been
assessed by paramedics who may also have initiated emergency
treatments including oxygen therapy. As discussed in section 7 of
this guideline, assessment, triage and resuscitation of critically ill
patients must be undertaken in parallel with the initiation of
oxygen therapy and speciﬁc treatment must be given for the under-
lying medical condition. All critically ill patients and all patients at
risk of hypercapnic respiratory failure should be triaged as very
urgent and should have blood gases taken on arrival in hospital.
Furthermore, all seriously ill patients should be assessed by senior
clinicians in the emergency department as early as possible. In
many cases, this may involve liaison with intensive care specialists
or with appropriate other specialists who can deal effectively with
the patient’s major medical or surgical problems.
▸ Readers are referred to section 7.1.1 and to disease-speciﬁc
guidelines for advice concerning the immediate assessment
and management of seriously ill patients.
▸ Readers are referred to section 10 for advice concerning
choice of oxygen delivery devices and systems.
▸ Readers are referred to tables 1–4 and charts 1 and 2 in the
introductory section for a summary of the key elements of
oxygen therapy in common medical emergencies.
▸ Remember to ask for senior and specialist advice early in the
care of profoundly ill patients.
▸ Clinicians must bear in mind that supplemental oxygen is
given to improve oxygenation, but it does not treat the
underlying causes of hypoxaemia which must be diagnosed
and treated as a matter of urgency.
8.2 Differences in management in hospital compared with a
prehospital setting
The immediate management of medical emergencies in hospital
settings before blood gas results are available is similar in prin-
ciple to management in the prehospital setting (section 9). The
main priorities are to avoid harmful levels of hypoxaemia for all
patients and to avoid harmful levels of hypercapnia for patients
who are at risk of this complication. However, the amount of
information available to the healthcare professionals increases
rapidly in the hospital environment. The hospital management
is presented before the prehospital management because it
represents the ‘ideal’ management. This may also be achievable
in some prehospital settings such as a well-equipped primary
care centre and in some ambulance settings such as ambulances
with critical care outreach facilities. However, in many prehospi-
tal settings there will usually be less information available con-
cerning a patient’s history and physiology and less equipment
available to assess and treat the patient.
Differences between hospital settings and prehospital settings
include:
• Pulse oximetry is almost always available in hospital at
present. These guidelines also recommend that pulse oxim-
etry must be available in all locations where emergency
oxygen is used (section 9.1).
• Blood gas results can be available within minutes of arrival in
hospital.
• Additional diagnostic information may be available from
history, clinical examination, test results and from the
patient’s hospital records.
• Additional equipment and resources are available.
Because of the universal availability of oximetry in hospitals,
it is rare for the hospital medical team to have to administer
oxygen on the basis that a patient ‘might be hypoxaemic’.
However, initial ‘blind management’ is sometimes necessary for
patients with shock or with very poor peripheral circulation
where a reliable pulse oximetry trace cannot be obtained. ABGs
should be obtained as a matter of urgency in all such cases.
8.3 Which patients need oxygen therapy?
Supplemental oxygen therapy is recommended for all acutely
hypoxaemic patients and for many other patients who are at risk
of hypoxaemia, including patients with major trauma and shock.
Many acutely breathless patients will require supplemental
oxygen therapy, but there are some situations such as acute
hyperventilation or diabetic ketoacidosis where an apparently
breathless patient will not beneﬁt from oxygen therapy. There are
some other clinical situations such as carbon monoxide or
cyanide poisoning where a patient may beneﬁt from oxygen
therapy despite an apparent lack of hypoxaemia or breathlessness
because carbon monoxide binds more avidly than oxygen to the
haemoglobin molecule and cyanide poisoning leads to histotoxic
hypoxia. Carbon monoxide poisoning and cyanide poisoning
often coexist in patients suffering from smoke inhalation.227
Although it is well recognised that profound hypoxaemia can
lead to organ failure and death, it would be unethical to under-
take randomised studies involving the deliberate exposure of
acutely ill patients to severe hypoxaemia so most recommenda-
tions are based on expert opinion unless otherwise stated.
Oxygen saturation should be measured in all breathless and
acutely ill patients as discussed in recommendation 9 and
oxygen therapy should be given to hypoxaemic patients as
described in tables 1–4 and recommendations 1–4. Patients do
not require oxygen therapy if their oxygen saturation is 94% or
above (exceptions are carbon monoxide poisoning, cyanide poi-
soning and pneumothorax; see sections 8.10.7 and 8.11.6).
Patients on oxygen with SpO2>98% (with the above excep-
tions) do not usually require oxygen therapy or may require a
lower concentration. All patients with shock, major trauma,
sepsis or other critical illness should be managed initially with
high-concentration oxygen therapy from a reservoir mask.
Targeted oxygen therapy can be initiated once there is spontan-
eous circulation and oximetry can be measured reliably (see
table 1 and recommendations E1–E2).
8.4 Which patients require blood gas measurements?
Blood gases should be measured as soon as possible in most
emergency situations involving hypoxaemic patients228 and are
essential in patients who may develop hypercapnic respiratory
failure (carbon dioxide retention with risk of respiratory acid-
osis). This includes all patients admitted with an AECOPD, even
in the absence of hypoxaemia.1 Blood gases should also be
checked (and the clinical situation should be reviewed) if the
oxygen saturation should fall by more than three percentage
points, even if the saturation remains within the target range.
For example, a fall from 98% to 94% might be due to a signiﬁ-
cant event such as a pulmonary embolus. In this situation, the
saturation of 94% will not harm the patient but the patient will
remain at serious risk until the pulmonary embolism is diag-
nosed and treated. If oximetry shows a patient to be hypoxae-
mic, the initiation of oxygen therapy should not be delayed
while awaiting the results of blood gas measurements.
Blood gas measurements are not usually required for patients
with no risk factors for hypercapnic respiratory failure and an
oxygen saturation of 94% or above breathing air unless the
patient requires blood gas estimation for other reasons such as
suspected metabolic acidosis or diabetic ketoacidosis. The BTS
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asthma guideline recommends that ABG measurements need not
be undertaken in patients with acute asthma and an oxygen sat-
uration above 92% and no life-threatening features.229 ABG
sampling can be technically difﬁcult, especially for poorly per-
fused patients, and junior staff should ask for assistance from
more senior staff in difﬁcult cases.
Following initial clinical assessment and the availability of a
pulse oximetry measurement, a decision can be made regarding
the need for blood gas estimation within a few minutes of
arrival in the hospital environment or if a previously stable
patient develops breathlessness within a hospital environment.
Oximetry will give no information concerning carbon dioxide
or pH levels and a normal pulse oximetry level may provide
false reassurance in patients on oxygen therapy who may have
unexpected hypercapnia and acidosis. However, careful clinical
assessment supplemented by the use of oximetry will allow the
setting of an appropriate oxygen saturation target for different
groups of patients until blood gas results are available.
If repeated blood gas estimations are required, the timing will
depend on the indication. In general, the oxygen saturation (and
PO2) stabilises at a new higher level within a few minutes of
increasing the concentration of oxygen but the PaCO2 can take
30–60 min to equilibrate. The rise in blood oxygen level can be
monitored with oximetry, so repeat blood gas tests are per-
formed mostly to assess critical illness (immediate sampling
required) or to monitor pH and PCO2 levels (best performed
30–60 min after increasing the concentration of oxygen).
Evidence statement:
▸ The use of blood gases in acute illness is guided by observa-
tional data and expert opinion (evidence level 4).
Recommendation
C3: Blood gases should be checked in the following
situations
• All critically ill patients (grade D).
• Unexpected or inappropriate fall in SpO2 below 94% in
patients breathing air or oxygen or any patient requiring
oxygen to achieve the above target range (grade D).
(Allowance should be made for transient dips in saturation to
90% or less in normal participants during sleep.)
• Deteriorating oxygen saturation (fall of ≥3%) or increasing
breathlessness in a patient with previously stable chronic hyp-
oxaemia (eg, severe COPD) (grade D).
• Most previously stable patients who deteriorate clinically and
require increased FiO2 to maintain a constant oxygen satur-
ation (grade D).
• Any patient with risk factors for hypercapnic respiratory
failure who develops acute breathlessness, deteriorating
oxygen saturation, drowsiness or other features of carbon
dioxide retention (grade D).
• Patients with breathlessness who are thought to be at risk of
metabolic conditions such as diabetic ketoacidosis or meta-
bolic acidosis due to renal failure (grade D).
• Any other evidence from the patient’s medical condition that
would indicate that blood gas results would be useful in the
patient’s management (eg, an unexpected change in ‘track
and trigger’ systems such as a sudden rise of several units in
the NEWS or an unexpected fall in oxygen saturation of 3%
or more, even if within the target range) (grade D).
8.5 Can arterialised earlobe capillary gases be used as a
substitute for ABGs?
Readers are referred to section 7.1.3 for advice concerning
when to use ABGs and when to use arterialised capillary blood
gases.
8.6 Should oxygen be prescribed at a ﬁxed concentration or
to achieve a target saturation?
In the past, oxygen was prescribed at a ﬁxed FiO2 or at a
ﬁxed ﬂow rate via nasal cannulae or variable performance
face masks. However, several audits have shown that many
(or most) patients did not receive the prescribed concentration
of oxygen when this methodology was used.4–10 Furthermore,
a patient’s oxygen requirement may vary over time so the pre-
scribed oxygen concentration may be too high or too low
even a short time after the prescription was written. For this
reason, it is recommended that oxygen should be prescribed
to a target saturation range rather than prescribing a ﬁxed
concentration of oxygen or FiO2. This is analogous to an
insulin ‘sliding scale’ where the prescriber speciﬁes a variable
dose of insulin to achieve a target blood glucose range rather
than prescribing a ﬁxed dose of insulin. This will allow the
appropriate healthcare professional—usually a doctor, regis-
tered nurse or physiotherapist—to adjust each patient’s con-
centration of oxygen to achieve the safest oxygen saturation
range for each patient.
The prescriber may indicate a starting concentration, device
or ﬂow rate, but there needs to be an agreed system for adjust-
ing the oxygen concentration upwards or downwards according
to a patient’s needs (see charts 1 and 2; sections 11.3.6 and
11.3.7 and ﬁgure 19). As a patient improves, he or she is likely
to require a lower FiO2 over a time period that will vary
between patients. Most recovering patients will eventually
require no supplemental oxygen. On the other hand, a deterior-
ating patient may need an increased concentration of oxygen.
This increase can be initiated by registered nursing staff or
physiotherapists.
Good practice points
✓ The requirement for an increased concentration of oxygen is
an indication for urgent clinical reassessment of the patient
(and repeat blood gas measurements in most instances). See
recommendations W13 and W15 for exceptions.
✓ Oxygen should be prescribed to a target saturation range
rather than prescribing a ﬁxed concentration of oxygen or
FiO2 (see recommendations A1, A2, A4 and A5).
It is recommended that all patients admitted to hospital
should have a prescription for an oxygen target range set at the
time of admission, ideally as part of an ‘admission bundle’
which may include other key elements such as thromboprophy-
laxis and MRSA prevention. This will ensure that the correct
amount of oxygen will be administered while awaiting full
medical assessment if the patient should deteriorate unexpect-
edly at any time during the hospital admission.
8.7 What should be the target oxygen saturation range for
patients receiving supplementary oxygen?
8.7.1 Oxygen saturation target range for most patients
As discussed in sections 4–6 of this guideline, there is no evi-
dence of beneﬁt from above normal oxygen saturation in most
clinical situations and there is evidence that excessive concen-
trations of oxygen can have adverse effects, even in some
patients who are not at risk of hypercapnic respiratory failure.
A target oxygen saturation range of 94–98% will achieve
normal or near-normal oxygen saturation for most patients
who are not at risk of hypercapnic respiratory failure.
Furthermore, the suggested lower limit of 94% allows a wide
margin of error in the oximeter measurement, thus minimising
the risk of any patient being allowed to desaturate below 90%
due to inaccurate oximetry.
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8.7.2 Oxygen requirements for speciﬁc groups of patients
• Patients with critical illness requiring high-concentration
oxygen therapy are discussed in section 8.10.
• Patients with medical emergencies which frequently cause
breathlessness and hypoxaemia are discussed in section 8.11.
• Patients with COPD and other conditions that may predis-
pose to hypercapnic respiratory failure are discussed in
section 8.12.
• Medical emergencies for which oxygen was commonly given
in the past but is not actually indicated unless the patient is
hypoxaemic are discussed in section 8.13.
8.8 Importance of blood gas measurements in guiding
oxygen therapy
As soon as blood gas measurements are available, a patient’s
further treatment can be guided by the results of this test. For
patients with a normal or low PCO2 and no risk factors for
hypercapnic respiratory failure, it is safe to aim at an oxygen sat-
uration in the normal range (94–98%). For patients with a
raised PCO2, a lower oxygen saturation is indicated (88–92%),
especially if the patient is acidotic. NIV is recommended for
patients with COPD who have hypercapnia and a pH<7.35
([H+] >45 nmol/L) despite 1 hour of standard medical treat-
ment including controlled oxygen therapy.1 209
8.9 What should be the initial choice of oxygen delivery
system in hospital settings?
The technical and practical aspects of different oxygen delivery
systems are discussed in section 10. For major trauma cases and
for severely hypoxaemic patients without risk factors for hyper-
capnic respiratory failure, a non-rebreathing mask (reservoir
mask) at 15 L/min is the suggested ﬁrst choice. The delivery
system and FiO2 may be adjusted later to a lower concentration
of oxygen as a patient improves or towards supported ventila-
tion if the patient deteriorates. The majority of patients with
modest hypoxaemia can be treated with nasal cannulae or a
simple face mask at a ﬂow rate which is adjusted to maintain the
oxygen saturation in the target range for their speciﬁc clinical
presentation. Chart 2 shows a suggested scheme that allows the
oxygen level to be adjusted upwards or downwards in gradual
increments depending on a patient’s clinical progress (see also
sections 11.3.6 and 11.3.7). Venturi masks were previously
recommended for low-concentration oxygen therapy because
they deliver a more reliable oxygen concentration than nasal
cannulae or variable ﬂow masks.230 They can also be combined
with a humidiﬁer system when necessary (see section 10.2.3).
The mask and/or ﬂow should be rapidly changed if the initial
choice does not achieve the target saturation. However, the only
randomised study of targeted oxygen therapy in AECOPD used
nasal cannulae which have the advantage of being adjustable (by
variation in ﬂow rate) without having to change the device
itself.51
8.9.1 Devices used in emergency oxygen therapy in hospitals
(see section 10 for further details)
• High-concentration oxygen from reservoir mask (15 L/min)
or when using a bag mask or advanced airways (supraglottic
airway or tracheal tube) for assisted ventilation during
respiratory arrest or during CPR.
• Nasal cannulae (2–6 L/min) or simple face masks (5–10 L/
min) for medium-concentration oxygen therapy (and HFNC
using specialised equipment for high-concentration oxygen
therapy, often as an alternative to a reservoir mask).
• Twenty-four per cent Venturi mask at 2 L/min or 28%
Venturi masks at 4 L/min for patients at risk of hypercapnic
respiratory failure (alternatively use nasal cannulae at 1–2 L/
min, especially when the patient has stabilised).
• Tracheostomy masks for patients with a functioning tracheos-
tomy (adjust ﬂow to achieve desired saturation).
8.10 Recommended oxygen therapy for major medical
emergencies and critical illness (see also table 1 and
recommendations E1-E6)
There are a number of major medical emergencies where
patients are very likely to suffer from hypoxaemia. High-
concentration oxygen therapy from a reservoir mask at 15 L/min
is recommended in the initial management of all such patients
prior to stabilisation and the availability of a reliable oximetry
reading. Once this is achieved, the concentration of oxygen can
be titrated downwards to maintain a target saturation of
94–98%. It is recommended that patients with COPD or other
risk factors for hypercapnia who develop a critical illness should
be treated by emergency services in the same manner as other
critically ill patients until urgent blood gas results become avail-
able because the primary issue is the critical illness. Critically ill
patients with hypercapnia, hypoxaemia and acidosis will require
immediate assessment by intensive care teams and will usually
require tracheal intubation and mechanical ventilation.
Evidence statement
▸ The use of oxygen in major medical emergencies is guided
by observational data and expert opinion (evidence level 4).
8.10.1 Cardiac arrest and other conditions requiring CPR
The 2015 guideline for Adult Advanced Life Support issued by
Resuscitation Council UK recommends the use of the highest
possible inspired oxygen level for ventilation during CPR; that
guideline also makes recommendations regarding choice of
airway and ventilation technique in these circumstances.231 The
present guideline endorses these proposals during the period of
resuscitation. Subsequent management will depend on the
underlying condition and the patient’s degree of recovery. There
is theoretical evidence that patients with a ROSC may be
managed more safely with a lower initial inspired oxygen than
with 100% oxygen.98 99 Recently, in an observational study,
Kilgannon et al151 152 reported increased mortality among sur-
vivors of cardiac arrest who had been exposed to very high
levels of oxygen (PaO2>300 mm Hg or 40 kPa) in the ﬁrst
24 hours on the ICU. Bellomo et al154 also found an excess of
deaths in this group of patients but argued that the risk was no
longer statistically signiﬁcant after multivariate analysis. Elmer
et al232 reported a small single-centre study in 2015 in which
severe hyperoxaemia (PaO2>300 mm Hg or 40 kPa) was asso-
ciated with increased hospital mortality but moderate hyperox-
aemia (101–299 mm Hg) was not associated with decreased
survival.
A systematic review and meta-analysis by Wang et al233 con-
cluded that hyperoxaemia appears to be correlated with
increased in-hospital mortality in survivors of adult cardiac
arrest but the result should be interpreted cautiously because of
the signiﬁcant heterogeneity and the limited number of studies
that were analysed.
Based on the above evidence, current UK and European
Resuscitation guidelines recommend a target oxygen saturation
of 94–98% once spontaneous circulation had been restored.231
This guideline endorses these recommendations.
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Evidence statement
▸ The use of oxygen during and after CPR is based on expert
opinion and extrapolation from observational data (evidence
level 4).
Recommendation
E1: Use the highest feasible inspired oxygen for ventilation
during CPR (see table 1 and section 8.10). Once spontaneous cir-
culation has returned and arterial blood oxygen saturation can be
monitored reliably, aim for a target saturation range of 94–98%
and take an ABG sample to guide ongoing oxygen therapy. If the
blood gas shows hypercapnic respiratory failure, reset the target
range to 88–92% or consider mechanical ventilation (grade D).
8.10.2 Critically ill patients including major trauma, shock and
major sepsis
There is evidence that early intervention to normalise oxygen
delivery to the tissues using volume expansion and vasoactive
agents is beneﬁcial in the management of critically ill patients
with shock or sepsis, but there is no evidence of beneﬁt from
attempts to achieve supranormal oxygen delivery.73–75 234–238 In
fact, there is evidence that hyperoxia can cause a paradoxical
decrease in whole body oxygen consumption in critically ill
patients,239 and it has been demonstrated that hyperoxia can
impair oxygen delivery in septic patients.240 A study using a rat
model of progressive haemorrhage found that both hypoxaemia
and hyperoxaemia compromised haemodynamics. There was a
paradoxical fall in tissue PO2 in hyperoxaemic animals despite
the high PaO2.
241 These factors may account for the observation
by deJonge (but disputed by Eastwood) that mortality was ele-
vated among intensive care patients who were hyperoxaemic
during the ﬁrst day on the ICU.153 155 In de Jonge’s study of
36 307 patients on ICUs in the Netherlands, the adjusted OR
for death was lowest in a PO2 range of 8.9–10.6 kPa (equivalent
to saturation about 93–96% at normal pH). Two recent system-
atic reviews with meta-analysis have addressed this subject. Both
studies concluded that hyperoxaemia was associated with
increased hospital mortality but caution is required in interpret-
ing the results because of heterogeneity in the included studies,
including different deﬁnitions of hyperoxaemia.242 243 A rando-
mised trial published in 2016 reported ICU mortality of 11.6%
in 216 patients randomised to a target saturation range of 94–
98% (median PaO2 11.6 kPa) compared with 20.2% mortality
among 218 patients randomised to conventional therapy
(median PaO2 13.6 kPa).
244 The absolute risk reduction was
8.6% (risk reduction 0.086; 95% CI 0.017 to 0.150; p=0.01)
and hospital mortality was 24.2% vs 33.9% (absolute risk
reduction 0.099; 95% CI 0.013 to 0.182; p=0.03). However,
the trial was prematurely terminated due to difﬁculty with
recruitment, and the authors advise caution in interpreting the
results for this reason.
Most critically ill patients are at risk of multiorgan failure and
therefore require intensive care assessment as a matter of urgency.
Critical care consensus guidelines set 90% saturation as the
minimum level below which oxygen saturation should not be
allowed to fall.31 32 245 The 2012 Surviving Sepsis Campaign guide-
line is mainly based on mixed venous oxygen saturation or central
venous saturation but also recommends a target SaO2 of 88–95%
for patients with sepsis.31 32 245 However, these recommendations
are based on directly measured SaO2 in critical care settings with
intensive levels of nursing and monitoring. The present guideline
recommends a slightly higher target saturation range prior to the
transfer of these seriously ill patients to critical care facilities.
For most critically ill or severely hypoxaemic patients, initial
oxygen therapy should involve the use of a reservoir mask,
aiming at an oxygen saturation of 94–98%. If the patient has
concomitant COPD or other risk factors for hypercapnic
respiratory failure, the initial saturation target should also be
94–98% pending the results of blood gas estimations and assess-
ment by intensive care specialists. If critically ill patients with
COPD have hypercapnia and acidosis, the correction of hypox-
aemia must be balanced against the risks of respiratory acidosis
and ventilatory support using NIV or invasive ventilation should
be considered.
It is also recognised that many patients with long bone frac-
tures may develop hypoxaemia even in the absence of injury to
the airway or chest (possibly due to opioid treatment and fat
embolism) and they should be monitored with oximetry and
given oxygen if necessary.38 246–248 These patients, if not critic-
ally ill, should have a target oxygen saturation of 94–98% or
88–92% if they have coexisting COPD or other risk factors for
hypercapnic respiratory failure.
Evidence statement
▸ The use of oxygen in critical illness is based on expert
opinion guided by physiology and observational data (evi-
dence level 4).
Recommendation
E2: In critical illness, including major trauma, sepsis, shock
and anaphylaxis, initiate treatment with a reservoir mask at
15 L/min and aim at a saturation range of 94–98%. This advice
also applies to patients with critical illness who have risk
factors for hypercapnia pending the results of blood gas mea-
surements and expert assessment. In patients with spontaneous
circulation and a reliable oximetry reading, it may be possible
to maintain a saturation of 94–98% using lower concentrations
of oxygen (grade D).
8.10.3 Drowning
Survivors of drowning may have suffered inhalation of fresh or
sea water into the lungs and may become hypoxaemic.
Supplemental oxygen should be given to all patients with satur-
ation below 94%, aiming at a target saturation of 94–98%.249
Evidence statement
▸ The use of oxygen in drowning is based on expert opinion
(evidence level 4).
Recommendation
E3: In cases of drowning, aim at an oxygen saturation of
94–98% once adequate circulation is restored (grade D).
8.10.4 Anaphylaxis (see recommendation E2)
Patients with anaphylaxis are likely to suffer from tissue hypoxia
due to a combination of upper and/or lower airway obstruction
together with hypotension. In addition to speciﬁc treatment of
these problems, the Resuscitation Council UK recommends
initial high-concentration oxygen (10–15 L/min, by reservoir
mask) for patients with anaphylaxis.231 250 The present guide-
line would endorse this practice in the immediate management
of anaphylaxis followed by a target saturation of 94–98% once
the patient’s oxygen saturation can be measured reliably.
Evidence statement
▸ The use of oxygen in anaphylaxis is based on expert opinion
(evidence level 4).
8.10.5 Major pulmonary haemorrhage or massive haemoptysis
Major pulmonary haemorrhage and massive haemoptysis can
occur for a large number of reasons ranging from acute pulmon-
ary vasculitis to erosion of a blood vessel by a lung tumour. In
addition to speciﬁc treatment of the causative condition, most
such patients require supplemental oxygen treatment (also see
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table 1). A target saturation range of 94–98% is recommended.
Treatment should be initiated with high-concentration oxygen
via a reservoir mask and subsequently adjusted according to
chart 2 to maintain a saturation of 94–98% pending the results
of blood gas measurements.
Evidence statement
▸ The use of oxygen in pulmonary haemorrhage is based on
expert opinion (evidence level 4).
8.10.6 Epileptic ﬁts
As this is a life-threatening condition where a patient may suffer
from cerebral hypoxia (and oximetry may not be possible),
patients with status epilepticus should be treated in accordance
with table 1 (reservoir mask until clinically stabilised).
Evidence statement
▸ There have been no clinical trials of oxygen use during epi-
leptic ﬁts and it may be impossible to obtain an oximetry
signal in these circumstances. Expert opinion advises the
administration of high-concentration oxygen until oximetry
measurements can be obtained (evidence level 4).
Recommendation
E4: In patients with acute seizures due to epilepsy or other
causes, high-concentration oxygen should be administered until
a satisfactory oximetry measurement can be obtained and clini-
cians should then aim for an oxygen saturation of 94–98% or
88–92% if the patient is at risk of hypercapnic respiratory
failure (grade D).
8.10.7 Major head injury
Patients with major head injury are at risk of hypoxaemia and
hypercapnia. They require urgent assessment and maintenance
of airway patency, either through positioning, simple adjuncts
or early tracheal intubation and ventilation to avoid further
brain injury due to brain oedema which may be aggravated by
hypoxaemia and/or hypercapnia. These patients should be
triaged directly where possible to a major trauma centre. Initial
treatment should include high-concentration oxygen via a reser-
voir mask pending availability of satisfactory blood gas measure-
ments or until the airway is secured by intubation which will
also protect against the risk of aspiration due to reduced con-
sciousness. Although hypoxaemia is common in patients with
head injury (and associated with poorer outcomes), the relative
contribution of hypoxaemia to outcome is not yet estab-
lished.37 251–255 All authors agree that hypoxaemia should be
corrected, but a review of the literature concluded that there is
no evidence of clinical beneﬁt from hyperoxia in brain injured
patients and a subsequent clinical study showed that normobaric
hyperoxia did not improve brain metabolism in ﬁve patients
with acute severe brain injury.256 257 There are no UK guidelines
for oxygen therapy in the immediate phase after head injury, but
US guidelines recommend maintaining an oxygen saturation
above 90% for patients with acute brain injury.30 An American
study published in 2009 describes a cohort of 3420 patients and
the authors reported worse outcomes in patients with severe
traumatic brain injury associated with hypoxaemia and extreme
hyperoxaemia. Outcomes were optimal in the PaO2 range of
110–487 mm Hg (14.6–65 kPa).258 Other observational studies
have suggested that hyperoxaemia may be associated with
improved outcomes. Asher et al259 recently reported the out-
comes for 193 adult patients with severe traumatic brain injury
who had overall survival of 57%. They reported that a PaO2
threshold between 250 and 486 mm Hg (33–65 kPa) during the
ﬁrst 72 hours after injury was associated with improved all-cause
survival, independent of hypocarbia or hypercarbia. Two recent
observational studies have provided further evidence that hyper-
oxaemia may be associated with increased mortality in traumatic
brain injury.260 261 The present guideline advises giving supple-
mentary oxygen if required to maintain an oxygen saturation in
the range of 94–98% pending the publication of randomised
studies comparing normoxaemia with normobaric
hyperoxaemia.
Evidence statement
▸ The use of oxygen in cases of major head injury is based on
expert opinion and extrapolation from observational studies
(evidence level 4).
Recommendation
E5: In cases of major head injury, aim at an oxygen satur-
ation of 94–98%. Initial treatment should involve high-
concentration oxygen from a reservoir mask at 15 L/min
pending availability of satisfactory blood gas measurements or
until the airway is secured by intubation (grade D).
8.10.8 Carbon monoxide poisoning
Patients with carbon monoxide poisoning may have a normal
level of PaO2 but a greatly reduced level of oxygen bound to
haemoglobin because this has been displaced by carbon monox-
ide.262 Standard pulse oximetry cannot screen for carbon mon-
oxide exposure as it does not differentiate carboxyhaemoglobin
from oxyhaemoglobin and blood gas measurements will show a
normal PaO2 in these patients. Some newer co-oximeters can
measure carboxyhaemoglobin levels as well as SpO2.The blood
carboxyhaemoglobin level must be measured to assess the
degree of carbon monoxide poisoning. The half-life of carboxy-
haemoglobin in a patient breathing air is ∼300 min; this
decreases to 90 min with high-concentration oxygen via a reser-
voir mask. The most important treatment for a patient with
carbon monoxide poisoning is therefore to give high-
concentration oxygen via a reservoir mask. Comatose patients
or those with severe mental impairment should be intubated
and ventilated with 100% oxygen. The role of hyperbaric
oxygen remains controversial. A 2011 Cochrane review con-
cluded that existing randomised trials did not establish whether
the administration of hyperbaric oxygen to patients with carbon
monoxide poisoning reduced the incidence of adverse neuro-
logical outcomes.263 However, a randomised trial published in
2007 has suggested that patients with loss of consciousness or
high carboxyhaemoglobin levels may have less cognitive seque-
lae if given hyperbaric oxygen.264
Evidence statement
▸ The use of oxygen in carbon monoxide poisoning is based
on expert opinion and extrapolation from observational
studies (evidence level 4).
Recommendation
E6: In cases of carbon monoxide poisoning, an apparently
‘normal’ oximetry reading may be produced by carboxyhaemo-
globin, so aim at an oxygen saturation of 100% and use a reser-
voir mask at 15 L/min irrespective of the oximeter reading and
PaO2 (grade D).
8.11 Serious illnesses requiring moderate levels of
supplemental oxygen if the patient is hypoxaemic (see table 2)
Patients who present with acute medical emergencies who are
not critically ill and who have saturation >85% can be treated
with medium-concentration oxygen therapy from nasal cannulae
or a simple face mask with a target saturation range of 94–98%.
Some of these patients (eg, patients with pneumonia) may subse-
quently deteriorate, requiring high-concentration oxygen from a
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reservoir mask or requiring respiratory support such as invasive
ventilation. Others may turn out to have an additional diagnosis
of COPD or neuromuscular disease with a risk of hypercapnic
respiratory failure and they should be managed with a 24%
Venturi mask at 2–3 L/min or 28% Venturi mask at 4 L/min or
1–2 L of oxygen via nasal cannulae, aiming at a target saturation
of 88–92%. There are no published trials supporting the use of
oxygen to relieve breathlessness in non-hypoxaemic patients,
and there is evidence from randomised studies that oxygen does
not relieve breathlessness compared with air in non-hypoxaemic
patients with COPD who are breathless following exertion or
breathless palliative care patients with PO2>7.3 kPa or
55 mm Hg (saturation above about 88%).146 150
8.11.1 Patients with acute onset of hypoxaemia of unknown
cause with no pre-existing respiratory disorders or risk factors
It is common for breathless and hypoxaemic patients to have no
ﬁrm diagnosis at the time of presentation. For most acutely
hypoxaemic patients whose medical problem is not yet diagnosed,
an oxygen saturation range of 94–98% will avoid the potential
hazards associated with hypoxaemia or hyperoxaemia (see sec-
tions 4–6 and tables 1–2). Aiming for an oxygen saturation in the
normal range (rather than an abnormally high oxygen level) will
also have the effect of allowing the lowest effective FiO2 to be
used, thus avoiding risks such as absorption atelectasis and V/Q
mismatch that may be associated with the use of very high
fractions of inspired oxygen (see sections 5 and 6). The priority
for such patients is to make a speciﬁc diagnosis as early as possible
and to institute speciﬁc treatment for the underlying condition.
Early blood gas measurement is mandatory in the management of
patients with sudden unexplained hypoxaemia.
Evidence statement
▸ The use of oxygen in most instances of acute hypoxaemia is
guided by expert opinion based on physiology and observa-
tional studies except where indicated otherwise in the sec-
tions that follow (evidence level 4).
Recommendations
D1: For acutely breathless patients not at risk of hypercapnic
respiratory failure who have saturations below 85%, treatment
should be started with a reservoir mask at 15 L/min in the ﬁrst
instance (see ﬁgures 1–2 (charts 1–2) and table 2 and sections
8.10 and 10).* The oxygen concentration can be adjusted
downwards (using nasal cannulae at 1–6 L/min or a simple face
mask at 5–10 L/min) to maintain a target saturation of 94–98%
once the patient has stabilised (grade D).
D2: In other cases of acute hypoxaemia without critical
illness or risk factors for hypercapnic respiratory failure, treat-
ment should be started with nasal cannulae (or a simple face
mask if cannulae are not tolerated or not effective) with the
ﬂow rate adjusted to achieve a saturation of 94–98% (grade D).
D3: If medium-concentration therapy with nasal cannulae or a
simple face mask does not achieve the desired saturation, change
to a reservoir mask and seek senior or specialist advice (grade D).
Good practice point
✓ High-ﬂow nasal oxygen using specialised equipment should
be considered as an alternative to reservoir mask treatment in
patients with acute respiratory failure without hypercapnia.
*For initial management of patients at risk of hypercapnic
respiratory failure, see recommendations G1 and G2.
8.11.2 Acute asthma
The BTS/SIGN guideline for the management of acute asthma
recommends that the oxygen saturation should be maintained
between 94% and 98%.229 Although there is no danger of
tissue hypoxia at any saturation above 90%, a drop of oxygen
saturation below 94% may indicate deterioration and should
prompt a further assessment. Supplemental oxygen should be
started using nasal cannulae at 2–4 L/min or a simple face mask
at 5 L/min or 35–40% Venturi mask and adjusted as necessary
to maintain a saturation of 94–98%.265
A study which was published in 2003 showed that the adminis-
tration of 100% oxygen to patients with acute severe asthma pro-
duced an increased PaCO2 and a decreased peak expiratory ﬂow
compared with patients treated with 28% oxygen.266 The
authors of that study recommended the use of targeted oxygen
therapy rather than giving high-concentration oxygen to all
patients with acute severe asthma. This advice has been rein-
forced by the randomised study of Perrin et al136 who found a
signiﬁcant increase in transcutaneous PCO2 when oxygen was
given at 8 L per minute via simple face mask. Of 106 patients
randomised to high-concentration oxygen or targeted oxygen
therapy (target 93–95%), all 10 instances of hypercapnia
occurred in patients given high-concentration oxygen therapy.
Hypercapnia in acute asthma indicates a near-fatal attack and
indicates the need for consideration of intensive care admission
and ventilation.229 The trial of Perrin et al suggests that many
cases of hypercapnic respiratory failure in acute asthma may be
due to excessive oxygen therapy. It remains appropriate to give
oxygen to patients with acute severe asthma in the absence of
oximetry or blood gas results, but there is no evidence of beneﬁt
from giving oxygen to patients who are not hypoxaemic and the
above study suggests that unnecessary oxygen administration may
cause harm. Oxygen should not be withheld from hypoxaemic
patients with severe asthma because of concerns about possible
hypercapnia, but oxygen therapy should be conﬁned to what is
necessary to achieve a saturation range of 94–98%.266 267
Evidence statements
▸ Patients with acute asthma should not be given high-
concentration oxygen therapy in the absence of severe hypox-
aemia (evidence level 4).
▸ The suggested target saturation range of 94–98% in acute
asthma is based on expert opinion in the absence of rando-
mised trials (evidence level 4).
Recommendation
F1: In acute asthma, aim at an oxygen saturation of 94–98%
(see tables 2 and 3 and sections 8.11 and 8.13) (grade D).
8.11.3 Pneumonia
The BTS guideline for pneumonia recommends aiming at an
oxygen saturation target range of 94–98% in uncomplicated
pneumonia with appropriate adjustments for patients with
COPD, guided by blood gas measurements.268 The present
guideline endorses these principles. It has recently been demon-
strated that high-concentration oxygen therapy can increase
transcutaneous CO2 level in patients presenting with suspected
community-acquired pneumonia.137
Evidence statement
▸ The use of oxygen in pneumonia is based on expert opinion
(evidence level 4).
Recommendation
F2: In cases of pneumonia who are not at risk of hypercapnic
respiratory failure, aim at an oxygen saturation of 94–98%
(grade D).
8.11.4 Lung cancer and other cancers with pulmonary
involvement
Most patients with cancer who present with acute breathlessness
have a speciﬁc causative factor such as a pleural effusion,
O’Driscoll BR, et al. Thorax 2017;72:i1–i90. doi:10.1136/thoraxjnl-2016-209729 i43
BTS guideline
group.bmj.com on April 7, 2018 - Published by http://thorax.bmj.com/Downloaded from 
pneumonia, COPD, anaemia or collapse of a lobe or collapse of
a whole lung.269 270 Relief of breathlessness may be achieved by
treating these causative factors or by the use of opioid medicines
but there is increasing evidence that supplemental oxygen does
not relieve breathlessness for non-hypoxaemic patients with
cancer, as discussed in section 8.17. However, it is likely that
patients with cancer with signiﬁcant hypoxaemia may have
some relief from breathlessness if given oxygen.
Evidence statement
▸ The use of oxygen in the acute management of lung cancer
is based on expert opinion and extrapolation from observa-
tional studies (see separate advice on palliative care in section
8.17; evidence level 4).
Recommendation
F3: In acute breathlessness due to lung cancer, aim at an
oxygen saturation of 94–98% unless there is coexisting COPD.
See also ‘Oxygen use in palliative care’ section 8.17 (grade D).
8.11.5 Deterioration of ﬁbrotic lung conditions and other
conditions involving parenchymal lung disease or alveolitis
It is recognised that patients with ﬁbrosing lung conditions such as
idiopathic pulmonary ﬁbrosis may have acute deteriorations or
exacerbations, often during intercurrent chest infections. Other
patients may present acutely with breathlessness due to extrinsic
allergic alveolitis, sarcoidosis or other types of parenchymal lung
disorders. These patients often have a high degree of V/Q mis-
match and a requirement for high oxygen concentrations to
achieve satisfactory blood gases and they are not at risk of hyper-
capnia. The oxygen level should be adjusted to maintain an oxygen
saturation in the range of 94–98%, but this level may not be achiev-
able or only achievable with a reservoir mask. Patients with severe
idiopathic pulmonary ﬁbrosis are rarely suitable for invasive venti-
lation or NIV because of the progressive nature of the condition.
Evidence statement
▸ The use of oxygen in deteriorating pulmonary ﬁbrosis is
based on expert opinion (evidence level 4).
Recommendation
F4: In acute deterioration of pulmonary ﬁbrosis or other
interstitial lung diseases, aim at an oxygen saturation of 94–
98% or the highest possible if these targets cannot be achieved
(grade D).
8.11.6 Pneumothorax
As with pleural effusions, patients with a large pneumothorax
may be breathless and hypoxaemic and may require supplemen-
tal oxygen for symptom relief pending deﬁnitive treatment by
aspiration or drainage. However, high-concentration inhaled
oxygen can also increase the rate of reabsorption of air from a
pneumothorax up to fourfold.271 A 2012 study using rabbits
with traumatic pneumothorax conﬁrmed that resolution time
was signiﬁcantly faster with high FiO2 but there was evidence of
lung toxicity above 60% oxygen.272 The BTS guideline on the
management of pneumothorax recommends the use of high-
concentration oxygen (reservoir mask) in all patients without
COPD who require hospital admission for observation due to a
moderate-sized pneumothorax that does not require drain-
age.273 Once a pneumothorax is drained or aspirated success-
fully, the patient should not require oxygen therapy unless there
is additional pathology such as pneumonia, asthma or COPD
requiring speciﬁc treatment.
Evidence statement
▸ The use of oxygen in pneumothorax is based on expert
opinion and extrapolation from observational studies (evi-
dence level 4).
Recommendations
F5: In most cases of pneumothorax, aim at an oxygen satur-
ation of 94–98% if the patient is not at risk of hypercapnic
respiratory failure (grade D).
F6: In patients with pneumothorax having hospital observa-
tion without drainage, the use of high-concentration oxygen
(15 L/min ﬂow rate via reservoir mask) is recommended unless
the patient is at risk of hypercapnic respiratory failure (grade D).
8.11.7 Pleural effusion
If a pleural effusion is causing signiﬁcant breathlessness, the
most effective treatment is to drain the effusion. Hypoxaemic
patients with pleural effusions are likely to beneﬁt from supple-
mentary oxygen therapy. The BTS guidelines for management
of pleural effusions do not give any speciﬁc advice concerning
oxygen therapy, but it seems reasonable to give supplementary
oxygen to hypoxaemic patients to maintain a saturation of 94–
98%.
Evidence statement
▸ The use of oxygen in pleural effusion is based on expert
opinion (evidence level 4).
Recommendation
F7: In pleural effusion, aim at an oxygen saturation of 94–
98% (or 88–92% if the patient is at risk of hypercapnic respira-
tory failure) (grade D).
8.11.8 Pulmonary embolism
Most patients with suspected pulmonary embolism have normal
oxygen saturation and the main focus of treatment is to reach a
speciﬁc diagnosis and to start anticoagulant treatment. These
patients do not require oxygen therapy unless there is hypox-
aemia. In these cases, the lowest concentration of oxygen that
will achieve a target saturation of 94–98% is recommended.
However, patients with massive or multiple pulmonary embol-
ism may be profoundly hypoxaemic and should initially be
given high-concentration oxygen via a reservoir mask to achieve
an oxygen saturation of 94–98% pending deﬁnitive treatment
such as thrombolysis. It has been suggested that the blood
oxygen saturation may underestimate the severity of pulmonary
artery obstruction in acute pulmonary embolism if shock is
present.274
Evidence statement
▸ The use of oxygen in pulmonary embolism is based on
expert opinion (evidence level 4).
Recommendation
F8: In pulmonary embolism, aim at an oxygen saturation of
94–98% (or 88–92% if the patient is at risk of hypercapnic
respiratory failure) (grade D).
8.11.9 Acute heart failure
Most patients with acute heart failure are breathless, usually due
to pulmonary oedema or low cardiac output, especially if car-
diogenic shock is present. The pathophysiology of oxygen trans-
port in cardiogenic shock has been discussed in detail by
Creamer et al.275 It has been shown in an animal model that the
ventilatory failure of cardiogenic shock may be due to an
impairment of the contractile process of the respiratory
muscles.276 Miñana et al277 did not ﬁnd increased mortality in
Spanish patients with acute heart failure who had hypoxaemia
deﬁned as PaO2<60 mm Hg (8 kPa) which would correspond
to saturation below about 91% at normal pH. In addition to
speciﬁc treatment for heart failure, patients should be given sup-
plemental oxygen to maintain a saturation of 94–98%. This is
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consistent with the European Society of Cardiology Task Force
and European Society of Intensive Care recommendation that
patients with acute heart failure should receive oxygen to main-
tain SpO2 of >90%.
278 Patients with marked hypoxaemia (sat-
uration <85%) should be treated with a reservoir mask initially
and patients with coexisting COPD will require a lower target
saturation of 88–92% pending the availability of blood gas
results.
Evidence statements
▸ The use of oxygen in acute heart failure is based on expert and
extrapolation from observational studies (evidence level 4).
▸ In hospital settings, patients with acute pulmonary oedema
may beneﬁt from CPAP and from non-invasive ventilatory
support (evidence level 1+, see evidence statement in section
8.19.2).
Recommendations
F9: In acute heart failure, aim at an oxygen saturation of 94–
98% (or 88–92% if the patient is at risk of hypercapnic respira-
tory failure) (grade D).
F10: CPAP with entrained oxygen or high-ﬂow humidiﬁed
nasal oxygen to maintain saturation 94–98% (or 88–92% if at
risk of hypercapnia) should be considered as an adjunctive treat-
ment to improve gas exchange in patients with cardiogenic pul-
monary oedema who are not responding to standard treatment
(or NIV if there is coexistent hypercapnia and acidosis) (grade B).
8.11.10 Breathlessness due to severe anaemia
▸ If breathlessness is due to severe anaemia, the speciﬁc treat-
ment is blood transfusion. Studies by Canadian researchers
in the late 1990s have shown that haemoglobin levels of
70 g/L (7 g/dL) were as safe as transfusion to higher levels
and may produce fewer complications in the critically ill.72
However, this study was conducted using
non-leucocyte-depleted blood and it is possible that some of
the complications in the group who were given more transfu-
sions might have been avoided by the use of leucocyte-
depleted blood. The optimal transfusion target for critically
ill patients therefore remains the subject of ongoing discus-
sion among experts in critical care medicine and readers are
referred to national guidelines for blood transfusion.279
Giving oxygen to increase an already normal oxygen satur-
ation will have very little effect on the oxygen-carrying
power of the blood, but it is reasonable to administer supple-
mental oxygen to maintain a saturation of 94–98% if the sat-
uration is below these levels breathing air or if breathlessness
is a very prominent symptom.
Evidence statement
▸ The use of oxygen in anaemia is based on expert opinion
based on blood gas physiology (evidence level 4).
Recommendations
F11: In anaemia, aim at an oxygen saturation of 94–98% or
88–92% if the patient is at risk of hypercapnic respiratory
failure (grade D).
Good practice point
✓ Correction of anaemia by blood transfusion should be based
on national guidelines.
8.11.11 Sickle cell crisis
Patients with sickle cell disease frequently present with an acute
painful crisis and less frequently with an ‘acute chest syndrome’
comprising breathlessness, chest pain and fever with pulmonary
inﬁltrates on the chest radiograph. The exact causes and
mechanisms are not well understood, but oxygen should be
given to all hypoxaemic patients with sickle cell crisis to avoid
further intravascular sickling. There are no randomised studies
of oxygen therapy in acute chest syndrome and no randomised
studies of acute painful crisis in adults, but two small rando-
mised trials showed no clinical beneﬁt in non-hypoxaemic chil-
dren with acute painful crisis.280 281 Patients with sickle cell
disease may have a reduced oxygen saturation even when clinic-
ally stable. Homi et al282 reported a mean saturation of only
92.5% (95% CI 92.0% to 93.0%) in a group of children and
young adults (age 9–18 years) with stable sickle cell disease com-
pared with an average saturation of 97.1% (95% CI 98.8% to
97.3%) in a local control group. The British Committee for
Standards in Haematology recommended in 2003 that oxygen
should be given if the oxygen saturation falls below what is
normal for the individual patient or a default target of 95% if
the usual saturation is unknown.283 The 2012 NICE guideline
reinforced this advice.284 This is consistent with the advice in
the present guideline to aim at a normal or near-normal oxygen
saturation for non-hypoxaemic patients with a target saturation
of 94–98%. Readers are referred to the guideline on sickle cell
disease for disease-speciﬁc management of this condition.283
Evidence statement
▸ During an acute sickle cell crisis, low SaO2 as assessed by pulse
oximetry is common. Research suggests that this usually indi-
cates a low PaO2 although during an acute painful crisis pulse
oximetry may underestimate the true SaO2. Desaturations
during an acute sickle cell crisis should be treated with oxygen
to reduce further sickling and progression of the crisis with
further vaso-occlusive events (evidence level 1−).
Recommendation
F12: In sickle cell crisis and acute chest syndrome, aim for an
oxygen saturation of 94–98% or aim at the saturation level that
is usual for the individual patient (grade D).
Good practice point regarding sickle cell crisis
✓ Arterial or arterialised capillary blood gases should be
sampled if there is any doubt about the reliability of oximetry
during a sickle cell crisis.
8.12 Recommended oxygen therapy for patients who may
be vulnerable to medium or high concentration of oxygen
Tables 1–4 are based on section 8, they are shown at the front of
the document (see also table 3).
COPD is the best known condition that can predispose to
hypercapnic (type 2) respiratory failure with acidosis, especially
if the blood oxygen level is increased above 10 kPa (75 mm
Hg).43 45 However, there are a number of other conditions
which can render patients vulnerable to hypercapnic respiratory
failure. The emphasis for such patients is to avoid clinically
harmful levels of hypoxaemia or hypercapnia by giving carefully
titrated oxygen therapy or, if necessary, by supporting the
patient with the use of non-invasive or invasive mechanical
ventilation.
Patients without COPD at risk of hypercapnic respiratory
failure include the following:
• CF.
• Non-CF bronchiectasis (often in association with COPD or
severe asthma).
• Severe kyphoscoliosis or severe ankylosing spondylitis.
• Severe lung scarring from old tuberculosis (especially with
thoracoplasty).
• Morbid obesity (BMI>40 kg/m2).
• Musculoskeletal disorders with respiratory muscle weakness,
especially if on home ventilation.
• Overdose of opioids, benzodiazepines or other respiratory
depressant drugs.
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8.12.1 COPD exacerbations
There is an extensive literature documenting the effects of high-
concentration oxygen therapy in acute COPD.43–
45 48 85 87 103 114 117 130 285–298 These reports show that the
administration of supplemental oxygen to patients with exacer-
bated COPD (or with severe but stable COPD) often causes a
rise in PaCO2 with subsequent respiratory acidosis for reasons
summarised in section 5.3. The literature up to 2001 is sum-
marised in detail in the review by Murphy et al.84 Some patients
with COPD are prone to repeated episodes of hypercapnic
respiratory failure in response to oxygen therapy and others may
not ever suffer from this complication. Apart from patients with
recurrent hypercapnic respiratory failure, it is not possible to
predict if individual patients with COPD will develop hypercap-
nia during an acute exacerbation, so all patients with moderate or
severe COPD should be considered to be at risk of this complica-
tion until the results of blood gas measurements are available. It
is therefore important that patients who are at risk of having
COPD should be diagnosed accurately, and this can only be done
by measurement of spirometry.1 The advice given for patients
with COPD also applies to other forms of ﬁxed airﬂow obstruc-
tion such as patients with chronic irreversible asthma or ﬁxed
airﬂow obstruction associated with bronchiectasis.
Some patients with acute severe exacerbations of COPD may
be too breathless to undertake spirometry on arrival in hospital,
but NICE guidance is that all patients should have the test per-
formed before discharge from hospital to conﬁrm the diagnosis
of COPD and to assess the severity of the condition.1 There is
very little literature describing the effects of oxygen therapy in
the other conditions listed above, but patients with these condi-
tions are recognised to be at risk of hypercapnic respiratory
failure and should be treated in a manner analogous to patients
with COPD.
It has been shown that patients with COPD with a pH
reading <7.35 ([H+]>45 nmol/L) despite controlled oxygen
therapy are more likely to die and more likely to meet criteria
for intubation and ventilation.43 285 289 One of these reports
also showed that patients with a high PaO2 on arrival in hospital
(>10.0 kPa or 75 mm Hg) were more likely to meet criteria for
ventilation and the severity of acidosis was related to high PaO2
values.43 Based on these results, Plant et al43 recommended an
upper limit of about 92% saturation for patients with exacerba-
tions of COPD to prevent the PaO2 rising above 10 kPa. This
report was supported by the work of Joosten et al45 which
showed that a PaO2 of >74.5 mm Hg (10 kPa) in acute COPD
was associated with an increased likelihood of admission to a
HDU, increased need for NIV and a longer stay in hospital.
Roberts et al46 reported outcomes among 5052 patients with
exacerbated COPD where oxygen therapy in the ambulance was
documented. They found that the mortality was 7.2% in
patients who were managed with <35% oxygen but mortality
was 11.1% in those given ≥35% oxygen and the need for NIV
increased from 9% to 22% when high-ﬂow oxygen was given.
Based on the above literature, this guideline recommends a
maximum saturation of 92% while awaiting blood gas results in
AECOPD and other conditions that may predispose to hyper-
capnic respiratory failure. Although the rise in PaCO2 (and fall
in pH) is greatest in patients who are given sufﬁcient oxygen
therapy to elevate the PaO2 above 10 kPa, it is important to
note that hypercapnia can occur in acute COPD even if the
oxygen saturation is <88%.296 The best management strategy
for patients with persistently acidotic COPD is a trial of NIV
with supplemental oxygen therapy, if required to maintain
oxygen saturations 88–92%.43 209 299
Some patients with previous hypercapnic respiratory failure
will have alert cards or an entry in their electronic record to
alert the emergency team to the optimal concentration of
oxygen required during the patient’s previous hospital admis-
sions (see section 9.7). In the absence of such information, it is
suggested that a target of 88–92% should be set initially for
patients with a history of previous NIV or invasive ventilation
and, if necessary, modiﬁed later based on blood gas results.
These patients should be categorised as very urgent by ambu-
lance teams and emergency services, requiring immediate blood
gas measurement and senior assessment on arrival at the hos-
pital emergency department. Against this background, the study
of Austin et al51 has strengthened the advice given in this guide-
line. These authors randomised 405 patients with presumed
exacerbation of COPD to high-concentration oxygen (8–10 L/
min via reservoir mask) or to titrated oxygen treatment with
target range 88–92% using nasal cannulae (with nebulised bron-
chodilator therapy driven by compressed air). Mortality was 9%
among those given high-concentration oxygen and 4% among
those randomised to targeted oxygen therapy. For patients with
spirometrically conﬁrmed COPD, mortality was 9% vs 2%,
respectively. Further support for targeted oxygen therapy was
supplied in the 2012 study of Cameron et al.135 They under-
took retrospective review of the records of 254 COPD admis-
sions to one hospital and they found that both hypoxaemia
(PaO2<60 mm Hg or 6 kPa) and hyperoxaemia
(PaO2>100 mm Hg or 13.3 kPa) were associated with increased
risk of serious adverse outcome, deﬁned as a composite of
hypercapnic respiratory failure, assisted ventilation or inpatient
death. Twenty-four per cent of patients were hyperoxaemic and
these patients had OR of 9.2 for serious adverse outcome com-
pared with normoxaemia. Hypoxaemia occurred in 33% of
patients and was associated with an OR of 2.2 for serious
adverse outcome. Expressed in terms of the BTS guideline
target range, the OR for serious adverse outcome was 2.0 for
those with saturation below 88% compared with 88–92%.
There was no increase in risk in the range of 93–96% but the
OR for serious adverse outcome was 2.4 if the saturation was
above 96%. The evidence for targeted oxygen therapy in exa-
cerbated COPD is now so strong that it is unlikely that ethical
approval would be granted for any further trials that rando-
mised patients to high-concentration oxygen. However, it is not
known if 88–92% is necessarily the ideal saturation range and it
would be ethical to randomise patients with COPD to targeted
oxygen with a target range slightly above or below or slightly
wider or narrower than 88–92%.
Unfortunately, clinical studies have shown that patients with
COPD are frequently given very high concentrations of oxygen,
either because of misdiagnosis or because the risks of hyperoxia
in patients with COPD have been overlooked.43–45 285 Many
patients with COPD are unaware of the diagnosis or are mis-
labelled as having asthma (see section 9.5). The diagnosis of
COPD should be communicated clearly to the patient because
ambulance teams have difﬁculty differentiating asthma and
COPD in the prehospital setting. In a recent Australian study,
only 57% of 1048 patients recorded as COPD by ambulance
teams had an emergency department discharge diagnosis of
COPD.300
The consensus from the literature in the past was that patients
with AECOPD should be treated with Venturi masks to minim-
ise the risks of hypercapnic respiratory failure.84 However, with
the availability of continuous oximetry during medical emergen-
cies, it is now possible to titrate the ﬂow of oxygen from nasal
cannulae to achieve the desired target range and nasal cannulae
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were used in the only randomised trial of targeted oxygen
therapy for patients with COPD.51 If Venturi masks are used, it
is not yet known if it is better to start with a 28% Venturi mask
or a 24% Venturi mask. Initial management with a 28% Venturi
mask appears to be safe.301 The current guideline recommends
starting with either a 28% Venturi mask of 1–2 L of nasal
oxygen in cases of COPD with no known history of hypercapnic
respiratory failure, with downward adjustment to a 24% mask
(in hospital) if the saturation rises above 92%. In cases of prior
hypercapnic failure who do not have an oxygen alert card, it is
recommended that prehospital treatment should be started using
a 28% Venturi mask at 4 L/min or a 24% Venturi mask in hospi-
tals (and prehospital if available) with a target saturation of 88–
92%. Observational studies in the 1960s suggested that a PaO2
of 50 mm Hg or 6.7 kPa (saturation about 84%) will prevent
death from hypoxaemia in acute COPD exacerbations.290 291 If
the saturation should fall below 88% despite treatment with a
24% or 28% Venturi mask, the patient should be treated with
nasal cannulae or a simple face mask with the ﬂow adjusted to
maintain a saturation of 88–92% pending the availability of
blood gas results. This small subgroup of patients is at very high
risk of death and should be treated as a high priority on arrival
in emergency departments, requiring immediate senior assess-
ment and ABG measurements.
Evidence statements
▸ The target saturation in patients with COPD who are at
risk of hypercapnia is 88–92% (evidence level 1+).
▸ The target saturation for patients with other risk factors for
hypercapnia (eg, morbid obesity, chest wall deformities or
neuromuscular disorders or ﬁxed airﬂow obstruction associated
with bronchiectasis) is 88–92% based on expert opinion which
is extrapolated from observational studies (evidence level 4).
Recommendations
G1 (also A3): For most patients with known COPD or other
known risk factors for hypercapnic respiratory failure (eg,
morbid obesity, CF, chest wall deformities or neuromuscular
disorders or ﬁxed airﬂow obstruction associated with bronchi-
ectasis), a target saturation range of 88–92% is suggested
pending the availability of blood gas results (grade A for
COPD, grade D for other conditions).
G2: Some patients with COPD and other conditions are vul-
nerable to repeated episodes of hypercapnic respiratory failure.
In these cases, it is recommended that treatment should be
based on the results of previous blood gas estimations during
acute exacerbations. For patients with prior hypercapnic
failure (requiring NIV or intermittent positive pressure ventila-
tion) who do not have an alert card, it is recommended that
low-concentration oxygen treatment should be started using a
24% Venturi mask at 2–3 L/min (or a 28% Venturi mask at
4 L/min or nasal cannulae at 1–2 L/min if a 24% mask is not
available) with an initial target saturation of 88–92% pending
urgent blood gas results. these patients should be treated as a
high priority by emergency services and the oxygen concentra-
tion should be reduced if the saturation exceeds 92% but
increased if it falls below 88% (grade D).
Good practice points for COPD and other conditions that
may cause hypercapnic respiratory failure
Diagnosis of COPD or suspected exacerbation of COPD:
✓ If the diagnosis is unknown, patients over 50 years of age
who are long-term smokers with a history of chronic breath-
lessness on minor exertion such as walking on level ground
and no other known cause of breathlessness should be
treated as having suspected COPD for the purposes of this
guideline.
✓ Spirometry should be measured at least once during hospital
admissions for suspected COPD (as per NICE COPD guide-
line1). Measurement of spirometry may conﬁrm (or exclude)
a diagnosis of airﬂow obstruction and the FEV1 level is a
useful indicator of disease severity in COPD.
Immediate management of patients with known or suspected
COPD:
✓ If the saturation remains below 88% in prehospital care
despite a 28% Venturi mask, change to nasal cannulae at 2–
6 L/min or a simple face mask at 5 L/min with target satur-
ation of 88–92% and alert the emergency department that
the patient is to be treated as a high priority.
✓ Patients with a respiratory rate >30 breaths/min should have
the ﬂow rate from Venturi masks set above the minimum
ﬂow rate speciﬁed for the Venturi mask packaging to com-
pensate for the patient’s increased inspiratory ﬂow (see
ﬁgure 11B). Increasing the oxygen ﬂow rate into a Venturi
mask does not increase the concentration of oxygen which is
delivered.
✓ Patients with a signiﬁcant likelihood of severe COPD or
other illness that may cause hypercapnic respiratory failure
should be triaged as very urgent on arrival in hospital emer-
gency departments and blood gases should be measured on
arrival in hospital.
✓ Prior to availability of blood gas measurements, use a 24%
Venturi mask at 2–3 L/min or nasal cannulae at 1–2 L/min or
28% Venturi mask at 4 L/min and aim for an oxygen satur-
ation of 88–92%
Initial hospital management of patients with exacerbation of
COPD:
✓ Patients with exacerbations of COPD need careful
monitoring for hypercapnic (type 2) respiratory failure with
respiratory acidosis which may develop in the course of a
hospital admission even if the initial blood gases were
satisfactory.
✓ Avoid excessive oxygen use in patients with COPD. The risk
of respiratory acidosis in patients with hypercapnic respira-
tory failure is increased if the PaO2 is above 10.0 kPa due to
previous excessive oxygen use.
✓ If following blood gas measurements the pH and PCO2 are
normal, aim for an oxygen saturation of 94–98% unless
there is a history of previous hypercapnic respiratory failure
requiring NIV or intermittent positive pressure ventilation or
if the patient’s usual oxygen saturation when clinically stable
is below 94% (these patients should have a target range of
88–92%). Blood gases should be repeated at 30–60 min to
check for rising PCO2 or falling pH.
✓ Recheck blood gases after 30–60 min (or if there is evidence
of clinical deterioration) for all patients with COPD or other
risk factors for hypercapnic respiratory failure even if the
initial PCO2 measurement was normal.
✓ If the PCO2 is raised but pH is ≥7.35 ([H+]≤45 nmol/L) and/
or a high bicarbonate level (>28 mmol/L), the patient has
probably got long-standing hypercapnia; maintain target range
of 88–92% for these patients. Blood gases should be repeated
at 30–60 min to check for rising PCO2 or falling pH.
✓ If the patient is hypercapnic (PCO2>6 kPa or 45 mm Hg)
and acidotic (pH<7.35 or [H+]>45 nmol/L), start NIV with
targeted oxygen therapy if respiratory acidosis persists for
more than 30 min after initiation of standard medical
management.
✓ For patients using Venturi masks, consider changing from
Venturi mask to nasal cannulae once the patient has
stabilised.
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✓ For patients who use LTOT for severe COPD, a senior clin-
ician should consider setting a patient-speciﬁc target range if
the standard range of 88–92% would require inappropriate
adjustment of the patient’s usual oxygen therapy while the
patient is in hospital.
Management of hypercapnia or respiratory acidosis due to
excessive oxygen therapy—avoidance of life-threatening rebound
hypoxaemia (see section 6.3.2)
✓ If a patient is suspected to have hypercapnic respiratory
failure due to excessive oxygen therapy, the oxygen therapy
must be stepped down to the lowest level required to main-
tain a saturation range of 88–92%. This may be achieved
using 28% or 24% oxygen from a Venturi mask or 1–2 L/
min via nasal cannulae depending on oxygen saturation and
subsequent blood gas measurements.
✓ Sudden cessation of supplementary oxygen therapy can
cause life-threatening rebound hypoxaemia with a rapid fall
in oxygen saturations below the starting oxygen saturation
prior to the start of supplementary oxygen therapy.
8.12.2 Exacerbation of CF
Patients with breathlessness due to CF should be managed in a
Cystic Fibrosis Centre unless this is not possible for geographical
reasons. If not possible, all cases should be discussed with the
Cystic Fibrosis Centre or managed according to a protocol that
has been agreed with the regional centre. Patients with advanced
CF may suffer from exacerbations which are similar to exacerba-
tions of advanced COPD with associated hypoxaemia and
hypercapnia. The principles of management are similar to those
in AECOPD, including a need to maintain adequate oxygen sat-
uration and avoiding excessive hypercapnia and acidosis. As in
COPD, NIV may be of value in severe cases.302 NIV in CF may
also be helpful to reduce symptoms (eg, work of breathing and
breathlessness) and assist in airway clearance.
It is recommended that patients with acute exacerbations of
CF should be managed on similar lines to patients with AECOPD
with a target oxygen saturation of 88–92% for most patients, but
recognition that individual patients may need to be managed dif-
ferently on the basis of previous and current blood gas measure-
ments. One study has shown that patients with a respiratory rate
above 30 breaths/min often have an inspiratory ﬂow rate above
the minimum ﬂow rate speciﬁed on the mask packaging and may
therefore beneﬁt from a doubling of this ﬂow rate.303 However,
there is no direct experimental evidence of the clinical effective-
ness of increased ﬂow rates from Venturi devices. It is possible
that patients with very high inspiratory ﬂow rates might beneﬁt
from a 28% Venturi mask with the ﬂow rate set at 6–8 L/min to
minimise the risk of the inspiratory ﬂow rate exceeding the gas
ﬂow rate (see section 10.2.3). Patients with CF who have had pre-
vious episodes of hypercapnic respiratory failure should be
issued with an oxygen alert card with recommendations based on
previous blood gas measurements.
Evidence statement
▸ The optimal oxygen saturation level for patients with acute
exacerbations of CF has not yet been investigated in clinical
trials. Expert opinion advises treating these patients in a similar
manner to patients with AECOPD who are at risk of hypercap-
nic respiratory failure (evidence level 4).
Recommendation
G3: Initial oxygen treatment of CF exacerbations should be
similar to the initial oxygen treatment of COPD exacerbations
with target saturation 88–92% (see sections 8.12.1–8.12.2)
(grade D).
8.12.3 Chronic musculoskeletal and neurological disorders
Hypoxaemia due to musculoskeletal and neurological disorders
may be associated with acute illness (such as a chest infection)
superimposed on a chronic neuromuscular condition. However,
muscle weakness can be acute, subacute (eg, Guillain-Barre’ syn-
drome) or chronic (see section 8.13.6). For most patients with
inadequate ventilation due to neuromuscular weakness, non-
invasive or invasive ventilatory support is more useful than sup-
plementary oxygen and these patients are at risk of hypercapnic
respiratory failure which may be aggravated by high concentra-
tions of oxygen. For this reason, it is recommended that spirom-
etry should be monitored carefully and blood gases should be
obtained as early as possible in all such cases. Pending the avail-
ability of blood gas results, a saturation target of 88–92% will
avoid the risks of severe hypoxaemia or severe hypercapnia. The
NICE guidance on NIV in motor neurone disease is also applic-
able to other neuromuscular conditions causing respiratory
failure.304
▸ Evidence statement
The optimal oxygen saturation level for patients with muscu-
loskeletal and neurological disorders has not yet been investi-
gated in clinical trials. Expert opinion advises urgent blood gas
assessment and early consideration of NIV with a target satur-
ation of 88–92% while blood gas results are awaited (evidence
level 4).
Recommendation
G4: In the initial management of musculoskeletal and neuro-
logical disorders with acute respiratory failure or
acute-on-chronic respiratory failure, aim at an oxygen satur-
ation of 88–92% and measure blood gases to determine if NIV
will be required (grade D).
Good practice point regarding patients with neurological
disorders
✓ Patients with respiratory failure due to neurological disor-
ders or muscle disease are at high risk of dying and require
urgent assessment to determine if they are likely to require
non-invasive or invasive ventilator support rather than
oxygen therapy. Monitor these patients with blood gases
and regular spirometry (forced vital capacity). Patient’s
wishes regarding this form of treatment should be estab-
lished as early as possible in the course of the illness,
ideally before an acute episode has developed.
8.12.4 Obesity-hypoventilation syndrome
Patients with the OHS are chronically hypercapnic unless
treated with NIV and may decompensate acutely resulting in
hypercapnic respiratory failure with acidosis.305 One study has
found the incidence of hypoventilation to be as high as 31% in
a cohort of obese hospitalised patients.306 Wijesinghe et al47
have demonstrated in 2011 that breathing 100% oxygen causes
worsening hypercapnia in stable patients with obesity-associated
hypoventilation. For purposes of oxygen therapy, patients with
morbid obesity should be treated in a similar manner to patients
with an AECOPD. The target saturation will usually be 88–92%
but, as with COPD, a lower target range may be appropriate for
individual patients based on blood gas measurements during a
previous exacerbation or due to acute acidosis. Assessment of
patients with increasing shortness of breath or worsening
oxygen saturation must include blood gases. As in COPD,
patients with respiratory acidosis may beneﬁt from NIV.
Evidence statement
▸ Patients with OHS are at risk of worsening hypercapnia
when administered high-ﬂow oxygen (evidence level 1+).
i48 O’Driscoll BR, et al. Thorax 2017;72:i1–i90. doi:10.1136/thoraxjnl-2016-209729
BTS guideline
group.bmj.com on April 7, 2018 - Published by http://thorax.bmj.com/Downloaded from 
▸ However, the optimal oxygen saturation level for patients
with OHS has not yet been investigated in clinical trials.
Expert opinion advises treating these patients in a similar
manner to patients with AECOPD who are at risk of hyper-
capnic respiratory failure (evidence level 4).
Recommendations
G5: Morbidly obese patients (BMI>40 kg/m2), even without
evidence of coexistent OSA are at risk of hypoventilation and
should be given titrated oxygen to maintain a target saturation
of 88–92% (grade D).
G6: NIV should be considered for hypercapnic patients with
COPD, CF, neuromuscular disorders or morbid obesity who are
at risk of hypercapnic respiratory failure if the pH is <7.35 or
[H+]>45 nmol/L (grade D). See BTS/ICS Guideline for the
ventilatory management of acute hypercapnic respiratory failure
(ref 299).
8.13 Common medical emergencies for which oxygen
therapy is indicated only if hypoxaemia is present (see also
table 4)
There are a number of conditions such as myocardial infarc-
tion, angina and stroke for which oxygen was traditionally
given to all patients in an attempt to increase oxygen delivery
to the heart or brain. However, the administration of supple-
mental oxygen to normoxaemic patients has very little effect
on blood oxygen content but may reduce myocardial and cere-
bral blood ﬂow due to vasoconstriction which is a physio-
logical response to hypoxia in most vital organs. There is no
evidence of beneﬁt from the administration of supplemental
oxygen to non-hypoxaemic patients with these conditions and
there is some evidence of possible harm, especially when used
at high-ﬂow rates, so it is recommended that oxygen should
only be given to patients with these conditions if hypoxaemia
is present, usually due to complications such as heart failure or
pneumonia. There are no published trials supporting the use
of oxygen to relieve breathlessness in non-hypoxaemic
patients, and there is evidence from randomised studies that
oxygen does not relieve breathlessness compared with air in
non-hypoxaemic patients with COPD who are breathless fol-
lowing exertion.146
8.13.1 Acute myocardial infarction, suspected myocardial
infarction and acute coronary syndromes
Some patients with acute myocardial infarction have heart
failure and should be treated accordingly (see section 8.11.9).
Most patients with suspected or conﬁrmed myocardial infarc-
tion are not hypoxaemic and most are not breathless. In the
case of non-hypoxaemic patients, it is not known if supplemen-
tary oxygen may be beneﬁcial by increasing the amount of
oxygen delivered to the hypoxaemic area of myocardium or
whether it may actually cause vasoconstriction with increased
systemic vascular resistance and reduced myocardial oxygen
supply with worsened systolic myocardial performance.307–315
A study of patients having coronary arteriography found that
breathing 100% oxygen reduced coronary blood ﬂow velocity
by 20% and increased coronary resistance by 23%.316 A study
of 16 healthy individuals using MRI found that coronary artery
oxygen delivery fell by 11% due to decreased cardiac output
and decreased left ventricular perfusion while breathing oxygen
at 8 L/min via a mask despite the increased blood oxygen
content.317 However, Ranchord et al318 found that high-
concentration oxygen increased the time to onset of
exercise-induced myocardial ischaemia in patients with stable
ischaemic heart disease, suggesting that the physiology of
oxygen delivery to the heart may be different during exercise in
ischaemic heart disease. Reduced myocardial oxygen consump-
tion might also be associated with reduced contractility.
There is a theoretical possibility that high oxygen levels might
exacerbate reperfusion injury to the heart.314 Despite a multi-
tude of large studies of intervention in myocardial infarction,
there had been only three published randomised studies of
oxygen therapy prior to 2015. A randomised trial in 1976 did
not identify any beneﬁt from such therapy but found some evi-
dence of potential harm.319 This trial reported a signiﬁcantly
greater rise in aspartate aminotransferase and heart rate which
could suggest increased infarct size in the oxygen treated group.
There was a difference in mortality between the two groups that
did not reach statistical signiﬁcance (3 deaths in 77 patients
treated with air vs 9 deaths in 80 patients given oxygen at 6 L/
min via a simple face mask for 24 hours). This study was under-
taken at a time before angiographic interventions were possible
for myocardial infarction.
Ranchord et al320 randomised 136 patients with ST-elevation
myocardial infarction to 6 L of oxygen via simple face mask or
titrated oxygen to achieve saturation of 93–96% for 6 hours after
randomisation in a hospital setting. The trial was conducted
between 2007 and 2009 and most patients had angiographic inter-
ventions. There was no difference in troponin T level between the
groups and the number of deaths was too low (3) to permit mean-
ingful analysis. Eighty-ﬁve per cent of patients in both groups had
received oxygen in the ambulance and/or emergency department
for a mean of 62 min prior to randomisation and almost all
patients received thrombolysis or percutaneous coronary interven-
tion within 4 hours of onset of chest pain. Therefore, this study
really evaluated the effect of stopping oxygen therapy prior to
therapeutic intervention in a group of patients of whom most had
already received oxygen for more than 1 hour.
The third study was an open-label randomised study con-
ducted in Russia which was reported with limited methodo-
logical details.321 Twenty-eight patients received oxygen in
addition to standard therapy for 30 min prior to myocardial
revascularisation and for 3 hours after the intervention, 30
patients received oxygen for 3 hours after the intervention and
79 patients received ‘standard therapy’. Details of oxygen
therapy prior to randomisation were not given. This study
reported one death among 58 patients randomised to oxygen
therapy and no deaths among 79 patients randomised to stand-
ard therapy but the authors reported fewer complications
among those randomised to oxygen.
A systematic review and a historical review of oxygen
therapy in acute myocardial ischaemia have both concluded
that there was no evidence to support this practice in non-
hypoxaemic patients and some evidence of possible
harm.322 323 Further systematic reviews and meta-analysis in
2011 and 2012 concluded that the existing studies lacked
power, no clear conclusions can be drawn and further studies
are needed.324 325 One study from 1969 showed that hypox-
aemia did not affect the availability of oxygen for myocardial
metabolism in normal participants until the oxygen saturation
fell to about 50%, but evidence of myocardial ischaemia was
seen at saturations of 70–85% in participants with coronary
artery disease.326 In these circumstances, it is advised that
patients with myocardial infarction or chest pain suspicious of
myocardial infarction should be given supplementary oxygen if
required to maintain a saturation of 94–98%.
The study by Wilson and Channer4 in 1997 showed that
desaturation below 90% was common in patients with myocar-
dial infarction within the ﬁrst 24 hours of admission to a
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coronary care unit, but these authors may not have been aware
that nocturnal desaturation to this level is very common in
healthy individuals.33 Wilson and Channer4 did not demonstrate
any correlation between hypoxaemic events and adverse cardiac
events. They did, however, show that monitoring by oximetry
was inadequate in UK coronary care units in the mid-1990s.
The 2010 NICE Guideline for Chest Pain of recent onset
recommends setting an oxygen target saturation range of 94–
98% based on the arguments discussed above and the advice
given in the 2008 BTS Emergency Oxygen Guideline.327 The
2012 guidelines for acute myocardial infarction of the European
Society for Cardiology recommends the following: “Oxygen (by
mask or nasal prongs) should be administered to those who are
breathless, hypoxic (SaO2<95%), or who have heart failure.”
328
The 2011 American College of Cardiology/American Heart
Association guideline for Management of Patients With Unstable
Angina/Non-ST-Elevation Myocardial Infarction gives the fol-
lowing advice:329 “Supplemental oxygen should be administered
to patients with UA/NSTEMI with an arterial saturation <90%,
respiratory distress, or other high-risk features for hypoxemia.”
This is followed by the following unreferenced advice: “It is rea-
sonable to administer supplemental oxygen to all patients with
UA/NSTEMI during the ﬁrst 6 h after presentation.” The
limited available evidence supports the suggestion that clinicians
should aim at normal or near-normal oxygen saturation in
patients with myocardial infarction, acute coronary syndrome
and chest pain suspicious of coronary artery disease. A target
saturation range of 94–98% will meet all of these goals, and
further research of this topic should be prioritised because this
is such a common medical problem and there is so little existing
evidence.
Fortunately, there is one recent published study and other
forthcoming studies of oxygen use for myocardial infarction in
ambulances. The AVOID study in Australia was study was
designed to determine whether withholding routine supplemen-
tal oxygen therapy in patients with acute ST-elevation myocar-
dial infarction but without hypoxaemia prior to reperfusion
decreases myocardial infarct size.330–332 The results have sug-
gested that cardiac enzyme levels were higher and infarct size at
6 months was 55% bigger as determined by cardiac MR scan
when oxygen was administered. Mean peak troponin was
similar in the oxygen and no oxygen groups (57.4 vs 48.0 μg/L;
ratio 1.20; 95% CI 0.92 to 1.56; p=0.18). There was a signiﬁ-
cant increase in mean peak creatine kinase in the oxygen group
compared with the no oxygen group (1948 vs 1543 U/L; means
ratio 1.27; 95% CI 1.04 to 1.52; p=0.01). There was an
increase in the rate of recurrent myocardial infarction in the
oxygen group compared with the no oxygen group (5.5% vs
0.9%; p=0.006) and an increase in frequency of cardiac
arrhythmia (40.4% vs 31.4%; p=0.05). At 6 months, the
oxygen group had an increase in myocardial infarct size on
cardiac MR (n=139; 20.3 vs 13.1 g; p=0.04).331 A subsequent
publication by these authors showed that there was a signiﬁcant
increase in troponin and creatine kinase levels which was
dependent on the total dose of supplemental oxygen (litres of
supplemental oxygen received) and a typical patient receiving
supplemental oxygen in the ﬁrst 12 hours after ST-elevation
myocardial infarction would experience an ∼20% increase in
myocardial infarct size.332
The DETO2X-AMI trial is a further randomised trial of
oxygen versus air in the management of suspected myocardial
infarction and was started in Sweden and will hopefully provide
more useful information concerning the management of this
common medical emergency.333
In the past, most emergency calls to ambulance services
because of chest pain were treated with high-concentration
oxygen in accordance with the Joint Royal Colleges Ambulance
Liaison Committee ( JRCALC) older guidance.334 However, this
guidance was updated in 2009 to reﬂect the advice given in the
2008 BTS Emergency Oxygen Guideline with a target saturation
range of 94–98% for most patients with chest pain.12 Most
such patients have a ﬁnal diagnosis of undifferentiated chest
pain rather than acute coronary artery syndrome and most
patients with undifferentiated chest pain are normoxaemic. The
clinical management of a very large number of patients was
therefore changed following the introduction of the 2008 BTS
guideline and subsequent publications have tended to support
the concept of aiming for normoxaemia in patients with sus-
pected myocardial infarction.
Evidence statements
▸ The optimal oxygen saturation level for patients with myocar-
dial infarction and acute coronary syndromes has not yet been
investigated in clinical trials. Expert opinion advises maintain-
ing normal or near-normal saturation unless the patient is at
risk of hypercapnic respiratory failure (evidence level 4).
▸ There is evidence from two randomised studies that the
administration of oxygen to non-hypoxaemic patients in the
immediate management of myocardial infarction may be
associated with increased infarct size (evidence level 1+).
Recommendation
F13: In myocardial infarction and acute coronary syndromes,
aim at an oxygen saturation of 94–98% or 88–92% if the
patient is at risk of hypercapnic respiratory failure (grade D).
8.13.2 Stroke
In the past, it was customary to give supplemental oxygen to all
patients with stroke to try to improve cerebral oxygenation.
There are four published randomised trials of oxygen therapy in
patients with stroke with normal oxygen saturation, none of
which have shown beneﬁts. A study of supplemental oxygen (2
or 3 L/min dependent on baseline oxygen saturation) for
24 hours (n=550) found no difference in 1-year survival for the
entire cohort of patients with stroke and no difference in sur-
vival for patients with more severe strokes. However, a post hoc
subgroup analysis found that for patients with minor strokes,
1-year mortality was 18% in the group given oxygen and 9% in
the group given air (OR 0.45; 95% CI 0.23 to 0.90;
p=0.02).335 A pilot study of oxygen supplementation at a rate
of 2 or 3 L/min, dependent on baseline oxygen saturation for
72 hours in the UK (n=300) suggested better neurological
recovery at 1 week, but showed no difference in survival and
recovery at 6 months.336 337 The study did not ﬁnd an excess
risk for minor strokes in patients given oxygen. A much larger
study (n=8003) using the same dose and duration of oxygen
treatment has just closed and is only available in abstract format
so far, but conﬁrms that routine oxygen treatment does not
reduce mortality or improve recovery.338
A small randomised trial of high-concentration oxygen
therapy (10 L/min) in non-hypoxaemic patients (n=40) showed
no clinical beneﬁt339 and a study of very high-ﬂow oxygen
(45 L/min) was terminated in 2009 after enrolling 85 patients
because of excess mortality in the hyperoxaemia group (40% vs
17%), the full report had not yet been published when this
guideline was prepared.340 Finally, an observational study
reported increased mortality associated with hyperoxaemia in
ventilated patients with stroke on ICUs.341
Post-stroke hypoxaemia is common and associated with worse
outcome in some small studies.342 343 The risk of hypoxaemia is
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particularly high at night, during interward transfers and in the
CT scanner.342 344 Regular monitoring of oxygen saturation and
treatment of all episodes of hypoxaemia has been shown to
improve outcome in an observational study.343 It is therefore
recommended to monitor oxygen saturation regularly (at least
every 4 hours, including the night) during the acute phase of
stroke and to treat every episode of hypoxaemia.
The most common causes of hypoxaemia after stroke are
obstruction of airﬂow by secretions in the upper airway or com-
plications of the stroke such as pneumonia, pulmonary embol-
ism or heart failure. These must be addressed in every patient
who develops hypoxaemia post-stroke.
It is recommended that patients with stroke should receive
supplemental oxygen only after the airway has been cleared and
if this treatment is required to achieve an oxygen saturation of
94–98% (88–92% for patients with coexisting risk of COPD or
other risk of respiratory acidosis). High concentrations of
oxygen should be avoided unless required to correct hypox-
aemia. As patients with stroke tolerate nasal cannulae better
than oxygen masks, oxygen should be given via nasal cannulae
unless a strictly controlled oxygen concentration is
indicated.345 346
There has also been some discussion concerning the optimal
body position for the management of patients with stroke and
potential hypoxaemia. A systematic review of clinical studies in
conscious patients concluded that there was limited evidence
that sitting in a chair had a beneﬁcial effect and lying positions
had a deleterious effect on oxygen saturation in patients with
acute stroke with respiratory comorbidities, but patients with
acute stroke without respiratory comorbidities can adopt any
body position.161 The authors of this review recommended that
people with acute stroke and respiratory comorbidities should
be positioned as upright as possible as discussed in section 6
and recommendation A5. No trials have expressly addressed the
best position in unconscious and semiconscious patients with
stroke. As in other patient groups with a reduced level of con-
sciousness the recovery position is recommended to safeguard
the airway.
Evidence statements
▸ High concentrations of oxygen in normoxaemic patients
with stroke may be associated with increased mortality (evi-
dence level 1−).
▸ Routine oxygen for non-hypoxic patients with stroke does
not improve recovery or reduce disability (evidence level 1−).
▸ Patient positioning has not been shown to affect SaO2 as
measured by pulse oximetry in patients without cardio-
respiratory comorbidities, but sitting out in a chair improves
oxygenation in patients with pre-existing cardiorespiratory
disease (evidence level 1−).
Recommendation
F14: High concentrations of oxygen should be avoided in
patients with stroke, unless required to maintain normal oxygen
saturation. Aim at an oxygen saturation of 94–98% or 88–92% if
the patient is at risk of hypercapnic respiratory failure (grade D).
Good practice points regarding stroke management
✓ Oxygen saturation should be monitored at least every
4 hours throughout the day and night in patients with acute
stroke and all episodes of hypoxaemia treated.
✓ Patients with hypoxaemia post-stroke require medical review
to establish and treat the cause.
✓ Oxygen should only be given once the airway has been
cleared and at the lowest concentration necessary to achieve
an oxygen saturation of 94–98% or 88–92% if the patient is
at risk of hypercapnic respiratory failure.
✓ Oxygen should be given via nasal cannulae, unless there are
clear indications for a different oxygen delivery system.
✓ Patients with stroke and cardiorespiratory comorbidities
should be positioned as upright as possible, in a chair if pos-
sible (see recommendation A5).
✓ Patients with a reduced level of consciousness after stroke
should be nursed in the recovery position with the paralysed
side lowest.
8.13.3 Anxiety and hyperventilation or dysfunctional breathing
Many patients who present to hospital with breathlessness are
found to have no cardiopulmonary problems and many such
patients have a speciﬁc diagnosis of hyperventilation, dysfunc-
tional breathing, vocal cord dysfunction or panic attacks, some-
times in addition to asthma or some other underlying
respiratory disorder.347 Many such patients will have an abnor-
mally high oxygen saturation of 99% or 100% and clearly do
not require supplemental oxygen therapy but some patients
with vocal cord dysfunction may develop respiratory failure due
to upper airway obstruction. Many other non-hypoxaemic
patients will present to hospital with acute breathlessness of
unknown cause, and the majority of patients with an elevated
respiratory rate are likely to have an organic illness. In some
cases, simple investigations will reveal a speciﬁc diagnosis such
as pneumothorax or pneumonia or pulmonary embolism, but
many cases remain undiagnosed. A policy of giving supplemen-
tal oxygen if the saturation falls below 94% will avoid exposing
patients with undiagnosed medical illnesses to the risk of hypox-
aemia while avoiding the unnecessary use of oxygen in patients
with behavioural or dysfunctional breathlessness.
Studies in normal volunteers have demonstrated that compen-
satory desaturation may occur shortly after voluntary hyperven-
tilation.348 The mean PaO2 of 10 male volunteers increased
from 13.7 kPa (103 mm Hg) to 18.6 kPa (140 mm Hg) during
hyperventilation but fell to a nadir of 7.8 kPa (58 mm Hg)
about 7 min after cessation of hyperventilation and did not nor-
malise until after a total of 17 min of observation. It is not
known whether or not this occurs after pathological hyperventi-
lation, but this phenomenon could cause considerable confusion
if it should occur in an emergency department.
A traditional treatment for hyperventilation was to ask the
participant to rebreathe from a paper bag to allow the carbon
dioxide level in the blood to normalise. However, it has been
shown that this practice can cause hypoxaemia with potentially
fatal consequences.349 The average fall in PO2 during rebreath-
ing was 26 mm Hg (3.5 kPa) and the maximum fall was
42 mm Hg (5.6 kPa). This guideline does not recommend
rebreathing from a paper bag in cases of hyperventilation.
Good practice points regarding patients with suspected
hyperventilation
✓ Organic illness must be excluded before making a diagnosis
of hyperventilation.
✓ Patients with a deﬁnite diagnosis of hyperventilation should
have their oxygen saturation monitored. Those with normal
or high SpO2 do not require oxygen therapy.
✓ Rebreathing from a paper bag can be dangerous and is NOT
advised as a treatment for hyperventilation.
8.13.4 Poisoning with substances other than carbon monoxide or
cyanide
Many poisons and drugs can cause respiratory or cardiac depres-
sion or direct toxic effects on the lungs. The treatment of indi-
vidual toxic agents is beyond the scope of this guideline.
Speciﬁc antidotes such as naloxone for opioids or ﬂumazenil for
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benzodiazepines should be given if available and oxygen satur-
ation should be monitored closely. Supplemental oxygen should
be given to achieve a target saturation of 94–98% pending the
results of blood gas analysis (88–92% if at risk of hypercapnic
respiratory failure, including patients with overdoses of narcotic
agents). All potentially serious cases of poisoning should be
monitored in a level 2 or 3 environment (HDU or ICU).
Three speciﬁc types of lung injury deserve special mention.
Oxygen is known to be hazardous to patients with paraquat poi-
soning,125 126 and oxygen potentiates bleomycin lung injury.
Because of these risks, oxygen should be given to patients with
these conditions only if the oxygen saturation falls below 85%.
Some authors have suggested the use of hypoxic ventilation
with 14% oxygen as a speciﬁc treatment for paraquat poison-
ing.350 Bleomycin lung injury can be potentiated by high-
concentration oxygen therapy, even if given several years after
the initial lung injury.127 It is therefore recommended that high
concentrations of oxygen should be avoided in patients with
possible bleomycin-induced lung injury and a lower oxygen sat-
uration target range should be accepted (eg, 88–92%).
There is evidence from animal experiments that oxygen may
potentiate lung injury from aspiration of acids.128 129 The effect
in humans is not known so patients with acid inhalation should
have the usual adult target saturation range of 94–98%, but it
would appear prudent to aim in the lower half of the target
range for these patients and clinical trials in humans are clearly
required.
Evidence statement
▸ For most types of poisoning, the optimal oxygen saturation
level has not yet been investigated in clinical trials. Expert
opinion advises maintaining normal or near-normal satur-
ation unless the patient is at risk of hypercapnic respiratory
failure or unless they require high oxygen levels (carbon
monoxide or cyanide poisoning) or have ingested a poison
such as paraquat or bleomycin where supplemental oxygen
may aggravate tissue damage (evidence level 4).
Recommendations
F15: In most poisonings, aim at an oxygen saturation of 94–
98% unless the patient is at risk of hypercapnic respiratory
failure (grade D).
F16: In poisoning by paraquat and poisoning by bleomycin,
give oxygen only if the saturation falls below 85% and reduce or
stop oxygen therapy if the saturation rises above 88% (grade D).
8.13.5 Metabolic, endocrine and renal disorders
Many metabolic and renal disorders can cause metabolic acid-
osis which increases respiratory drive as the body tries to correct
the acidosis by increased excretion of carbon dioxide via the
lungs. Although these patients have tachypnoea, they do not
usually complain of breathlessness and most have high oxygen
saturation (unless there is a coexisting pulmonary or cardiac
problem). Supplementary oxygen is not required for such
patients unless the oxygen saturation is reduced. In such cases,
oxygen should be given to maintain a saturation of 94–98%.
Evidence statement
▸ The optimal oxygen saturation level for patients with most
metabolic, endocrine and renal disorders has not yet been
investigated in clinical trials. Expert opinion advises main-
taining normal or near-normal saturation unless the patient is
at risk of hypercapnic respiratory failure (evidence level 4).
Recommendation
F17: In most metabolic and renal disorders, aim at an
oxygen saturation of 94–98% unless the patient is at risk of
hypercapnic respiratory failure (grade D).
8.13.6 Acute and subacute neuromuscular disorders producing
respiratory muscle weakness
Patients with acute or subacute conditions affecting the respira-
tory muscles (often superimposed on chronic conditions) are at
risk of sudden onset of respiratory failure with hypoxaemia and
hypercapnia and may require non-invasive or invasive ventila-
tory support. This applies especially to patients with
Guillain-Barre’ syndrome for whom spirometry (forced vital
capacity) should be monitored carefully as this should detect the
onset of severe respiratory failure prior to the development of
hypoxaemia. If the oxygen level falls below the target satur-
ation, urgent blood gas measurements should be undertaken
and the patient is likely to need ventilatory support.
Good practice point
✓ Patients with respiratory failure due to neurological disorders
or muscle disease are at high risk of dying and require
urgent assessment to determine if they are likely to require
non-invasive or invasive ventilator support rather than
oxygen therapy. Monitor these patients with blood gases and
regular spirometry (forced vital capacity). Patient’s wishes
regarding this form of treatment should be established as
early as possible in the course of the illness, ideally before an
acute episode has developed.
8.13.7 Cluster headache
Relief from cluster headache has been reported in 56–85% of
cases.351–354 Beneﬁt has recently been reported for other types
of headache.355 Although this could be considered as a form of
emergency oxygen therapy, these patients are not breathless or
hypoxaemic. Cluster headache is one of the most severe pain
disorders known to humans. Patients can attend emergency
departments in an acute cluster attack but because of the rela-
tively short duration and frequency of the episodes, home treat-
ment of the acute cluster attack is most often undertaken. For
patients with cluster headache arrangements for home and
ambulatory oxygen is recommended for treatment of the acute
cluster headache bout. Oxygen at a ﬂow rate of at least 12 L/
min from a reservoir mask is recommended.353 Patients who
have episodic cluster headache may not need oxygen on a
longer term basis and once they have been cluster headache free
for over 4 weeks the oxygen supply can be uplifted. However,
because of the recurrent nature of the condition, emergency
supply of oxygen should be made available for cluster headache
sufferers. In a study comparing the use of oxygen with air, 78%
patients given oxygen at 12 L/min via reservoir mask for 15 min
had a reduction in pain at 15 min as compared with 20% for
those breathing air at 12 L/min (p<0.001).354 In a further
study, there was a complete or substantial reduction in pain at
30 min in 56% of patients (nine participants) in 80% or more
of their cluster headaches when given oxygen at 6 L/min for up
to 15 min from a reservoir mask compared with 7% on air.352
Evidence statement
▸ Oxygen therapy can provide relief from cluster headache
(evidence level 1−).
Recommendation
F18: For patients with cluster headaches, oxygen should be
administered using a ﬂow of at least 12 L/min from a reservoir
mask and home oxygen should be provided (grade D).
8.14 Obstetric emergencies and labour
The use of oxygen has been recommended during many obstetric
emergencies and, in particular, for collapse related to haemor-
rhage, pulmonary embolism, eclampsia or amniotic ﬂuid
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embolism. Severe pre-eclampsia and eclampsia may occasionally
present with pulmonary oedema and this can occur in the ante-
natal or postnatal periods. Medical problems such as pneumonia
or acute exacerbations of asthma are not uncommon during preg-
nancy. Peripartum cardiomyopathy is rare but may present with
heart failure in the postnatal period. Major trauma is increasingly
common, particularly related to road trafﬁc accidents.
The use of oxygen during pregnancy should follow the same
general principles as the use of oxygen for other patients. Pregnant
women suffering major trauma or severe hypoxaemia should be
started on high-concentration oxygen via a non-rebreathing reser-
voir mask and those with milder hypoxaemia can use nasal cannu-
lae or a simple face mask or Venturi mask to achieve an oxygen
saturation of 94–98% in most cases. Risk factors for hypercapnia
are uncommon among women of child-bearing age but morbid
obesity is an increasing problem in the UK population and is asso-
ciated with risk of hypercapnia (see section 8.12.4). Morbidly
obese pregnant women with hypoxaemia are at risk of hypercap-
nia and should have a target range of 88–92% pending availability
of blood gas results. Pregnant women who are fully conscious
with no cardiovascular compromise may be managed in the sitting
position or if lying down should use the full left lateral position. If
an undelivered woman is hypoxaemic with reduced consciousness
level or needing respiratory or cardiovascular support or CPR, she
should be managed with left lateral tilt applied. This will improve
cardiac output and may also facilitate breathing for mechanical
reasons. As an alternative, the patient can be left lying relatively
ﬂat and the uterus can be displaced manually (preferably to the
left) in order to relieve aortocaval compression. This will usually
require additional help and is uncomfortable.
Oxygen was commonly given as part of the treatment for
many obstetric emergencies. However, it is recommended that,
when oxygen is administered during pregnancy or labour, clini-
cians should aim to achieve normoxaemia (saturation 94–98%).
There is no randomised trial evidence to suggest that maternal
‘hyperoxaemia’ is beneﬁcial to mother or fetus. A 2008 review
of the use of oxygen during intrauterine resuscitation concluded
as follows: “Caution should be exercised when considering
maternal oxygen administration as a ﬁrst-line intrauterine resus-
citation measure until more data are available, reserving its use
after other measures have been unsuccessful in resolving the
non-reassuring fetal heart rate pattern.”356
Oxygen is often given for short periods when acute fetal
compromise is suspected in labour in the hope of increasing
oxygen delivery to the fetus. A Cochrane review found no trials
addressing the use of oxygen for fetal compromise but the
authors identiﬁed two trials of prophylactic oxygen in labour
which reported a statistically signiﬁcant increase in the incidence
of cord blood acidosis (pH<7.20 or [H+]>63 nmol/L) in the
oxygenation group (relative risk (RR) 3.5, 95% CI 1.34 to
9.19).357 A small (n=56) randomised trial in Washington, USA
reported in 2012 that the delivery room resuscitation rate was
20% for infants of mothers randomised to 2 L of nasal oxygen
for at least 30 min before delivery compared with 0% in those
receiving air from a nasal cannula (p=0.03).358 This study
reported cord blood acidosis in just one participant in each
group. When this study is added to the Cochrane review, the
reported prevalence of cord blood acidosis in three published
studies was 18/151 (12%) in those randomised to oxygen
therapy and 6/140 (4%) when air was used throughout labour.
A recent clinical opinion paper included a review of the two
randomised trials assessing use of maternal oxygen supplemen-
tation in labour.359 These authors also noted an absence of data
conﬁrming fetal beneﬁt and the possibility that increased free
radical activity may be harmful. The authors of this 2014 paper
conclude that appropriately powered randomised trials are still
required. Until then, oxygen supplementation should be
reserved for conﬁrmed maternal hypoxaemia in labour, and
should not be considered an appropriate intervention for non-
reassuring fetal status.
This ﬁts with the recommendation that pregnant women with
evidence of hypoxaemia should have their blood oxygen satur-
ation maintained in the normal range (94–98%) using supple-
mental oxygen only when required to achieve this effect. This
applies before or during labour as well as in the immediate post-
natal period. The causes of maternal hypoxaemia may include
trauma, pre-existing or new medical conditions as well as
pregnancy-speciﬁc complications. In all of these situations the
aim should be normoxaemia (saturation 94–98%).
A Cochrane review of the use of supplemental oxygen for
caesarean section during regional analgesia concluded as
follows: “Current evidence suggests that supplementary oxygen
given to healthy term pregnant women during elective caesarean
section under regional anaesthesia is associated with higher
maternal and neonatal oxygen levels (maternal SpO2, PaO2,
UaPO2 and UvPO2) and higher levels of oxygen free radicals.
However, the intervention was neither beneﬁcial nor harmful to
the neonate’s short-term clinical outcome as assessed by Apgar
scores.”360
A randomised trial of postpartum oxygen inhalation con-
cluded that this practice is not beneﬁcial for reducing vaginal
blood loss during the third and fourth stages of labour.361
Evidence statements
▸ There have been no trials comparing different oxygen regi-
mens in acutely unwell pregnant women so management
should be based on the oxygen levels that are believed to be
optimal in other groups of acutely unwell adults (evidence
level 4).
▸ When women in late pregnancy (ie, above 20 weeks) lie ﬂat
on their backs, aortocaval compression by the gravid uterus
reduces maternal cardiac output. This is improved by using
left lateral tilt or manual displacement of the uterus. Placing
the patient in the full left lateral position is another alterna-
tive (evidence level 3).
▸ Although maternal oxygen therapy can increase fetal oxygen
levels, there are limited data regarding its risks or possible
beneﬁts to the mother, fetus and newborn (evidence level 4)
Recommendations
H1: Women who suffer from major trauma, sepsis or acute
illness during pregnancy should receive the same oxygen
therapy as any other seriously ill patients, with a target oxygen
saturation of 94–98%. The same target range should be applied
to women with hypoxaemia due to acute complications of preg-
nancy (eg, collapse related to amniotic ﬂuid embolus, eclampsia
or antepartum or postpartum haemorrhage) (grade D).
H2: Women with underlying hypoxaemic conditions (eg,
heart failure) should be given supplemental oxygen during
labour to achieve an oxygen saturation of 94–98% unless they
are at risk of hypercapnic respiratory failure (target range 88–
92%) (grade D).
H3: Pregnant women who are fully conscious with no cardio-
vascular compromise may be managed in the sitting position or
if lying down should use the full left lateral position (grade D).
H4: Pregnant women above 20 weeks gestation (uterine
fundus at or above the level of the umbilicus) who are at risk
of developing associated cardiovascular compromise (eg,
trauma, vaginal bleeding, etc) should be positioned to avoid
aortocaval compression by using left lateral tilt, manual uterine
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displacement or by placing them in a full left lateral position
(grade D).
H5: Women who are more than 20 weeks pregnant with evi-
dence of hypoxaemia associated with reduced consciousness or
those requiring respiratory or cardiovascular support or CPR
should be managed with left lateral tilt or manual uterine dis-
placement (ideally to the left) to improve cardiac output and
oxygen delivery (grade D).
H6: The use of oxygen supplementation during intrauterine
fetal resuscitation during labour was widespread in the past but
there is no evidence of beneﬁt. There is weak evidence of harm
to the fetus if supplemental oxygen is given for long periods
during uncomplicated labour. Overall, the use of oxygen during
labour is only required when there is evidence of maternal hyp-
oxaemia (oxygen saturation <94%) (grade D).
8.15 Use of oxygen in postoperative and perioperative care,
including PCA device use
8.15.1 Oxygen use, pulse oximetry and the incidence of
hypoxaemia in the postoperative period
Postoperative breathlessness and hypoxaemia can develop due to
a variety of complications including atelectasis, pneumonia and
pulmonary embolism. The use of opioid analgesia commonly
used for moderate-to-severe pain can lead to and exacerbate
respiratory failure, which can potentially be life-threatening.
Historically, it has been common practice for postoperative
patients to receive routine supplemental oxygen for a period
ranging from hours to days after surgery to prevent hypox-
aemia, particularly those receiving opioid analgesia. High-risk
patients undergoing major surgery are best managed in an ICU
and HDU settings which facilitate the continuous monitoring of
SpO2 and usually end tidal CO2 (this is standard in ventilated
patients). Regular ABG analysis using arterial lines is also avail-
able in ICU and HDU settings. This allows oxygen therapy to
be administered in a dose sufﬁcient to relieve hypoxaemia
without causing hyperoxia.
However, the majority of postoperative patients are managed
on general surgical wards where continuous monitoring is not
possible. The question of whether all postoperative patients
should receive supplemental oxygen routinely is debatable and
there is lack of robust evidence from RCTs to either support or
refute its use.
A number of observational studies have documented a high
incidence of postoperative hypoxaemia.182 362–364 A Cochrane
review of 22 992 patients reported on the incidence of hypox-
aemia in the perioperative and postoperative period.181
Unsurprisingly, it is difﬁcult to draw any conclusions on the
overall incidence of hypoxaemia due to the variation in popula-
tion groups, operative procedure and anaesthetic modality.
This same Cochrane review included data from ﬁve trials in
which patients were randomised to pulse oximetry monitoring
or no pulse oximetry during and after surgery.181 The review
showed that pulse oximetry leads to a 1.5-fold to 3-fold reduc-
tion in perioperative hypoxaemia. However, while pulse oxim-
etry led to the detection of hypoxaemia and interventions to
correct it, there was no difference in complication rates between
the two groups. Additionally postoperative cognitive function,
length of hospital stay and mortality was the same in both
groups. The authors suggested that correcting modest hypox-
aemia, by increasing the blood oxygen saturation from marginal
to satisfactory may confer no beneﬁt to the patient. However,
only small numbers of studies were included and further work
is required for clariﬁcation.
The incidence of postoperative hypoxaemia demonstrated in
randomised trials is again, variable. Gift et al366 found no clinic-
ally signiﬁcant difference in SpO2 in nearly 300 postoperative
patients randomised to four different treatments including
oxygen 4 L/min via nasal cannulae, 40% oxygen via mask,
nurse-led hyperinﬂation and no treatment.365 Canet et al365
found that the incidence of hypoxaemia was higher after breath-
ing air compared with 35% oxygen and the incidence increased
if the patients were older or if they received general
anaesthesia.366
Given the potential to develop hypoxaemia and the inability
to continuously monitor oxygenation in most postoperative
patients, is it safer to routinely administer supplemental oxygen
to all patients to prevent hypoxaemia? The major disadvantage
to this approach is that while supplemental oxygen will correct
hypoxaemia it can mask the ability to detect hypoventilation.228
Additionally, recently, Niesters et al107 have shown that hyper-
oxia has an additive effect on opioid-induced respiratory depres-
sion. Furthermore, there is a large body of evidence showing
hyperoxia is associated with haemodynamic alterations which
may increase myocardial ischaemia and impair cardiac perform-
ance (see section 8.13.1). A recent randomised trial of 340
patients postcardiac surgery administering nasal high-ﬂow
oxygen compared with usual care (oxygen to keep SpO2>93%)
showed no improvement in postoperative oxygenation.367
However, patients in the high-ﬂow group were less likely to
require escalation of respiratory support at any time during the
study (47 patients in the high-ﬂow group (27.8%) compared
with 77 patients (45%) in the standard care group (OR 0.47,
95% CI 0.29 to 0.7, p<0.001). The authors hypothesised that
the low-level airway pressure support provided by the nasal
high-ﬂow system may have inﬂuenced this outcome.
In a recent editorial, Martin and Grocott368 highlight the
need to re-evaluate the unrestricted use of oxygen by anaesthe-
tists. They discuss the relationship between oxygen therapy in
perioperative care, critical care and resuscitation, highlighting
the lack of clinical beneﬁt from hyperoxaemia and the potential
to lead to poor outcomes. They propose a strategy of ‘precise
control of arterial oxygenation’ in which oxygen is administered
to a deﬁned target, for example, PaO2 of 8–10 kPa or SaO2 88–
92% thus avoiding potential harm from hypoxaemia and hyper-
oxaemia and improving clinical outcomes. These recommenda-
tions are in keeping with this present guideline.
The ‘routine’ use of supplemental oxygen postoperatively,
therefore remains controversial.76 181 369–372 More evidence
from RCTs is required. Regular, but not necessarily, continuous
oxygen saturation monitoring is mandatory. In keeping with the
2004 SIGN guideline on postoperative care which recommends
maintaining an oxygen saturation above 92% for postoperative
patients, this present guideline recommends administering
oxygen to maintain a target saturation of 94–98% for most
patients, and a target saturation of 88–92% in those patients at
risk of hypercapnic respiratory failure.370
Evidence statement
▸ Pulse oximetry in the perioperative period leads to a signiﬁ-
cant reduction in perioperative hypoxaemia. However, iden-
tiﬁcation and correction of mild or moderate hypoxaemia
with pulse oximetry does not lead to a reduction in compli-
cation rates, length of stay or mortality (evidence level 1+).
Good practice points
✓ A target saturation of 94–98% is recommended for most sur-
gical patients except those at risk of hypercapnic respiratory
failure when a range of 88–92% should be achieved.
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✓ Pulse oximetry monitoring is recommended for post-
operative patients despite the lack of evidence from rando-
mised studies.
8.15.2 Patient-controlled analgesia
One of the commonest indications for anaesthetists to prescribe
supplemental postoperative oxygen therapy is to help prevent
hypoxaemia when PCA is used. In two reviews, the incidence of
postoperative hypoxaemia in patients receiving PCA was found
to be 11.5% and 15.2%.373 374
However, Cashman and Dolin’s373 systematic review compar-
ing the effects of acute postoperative pain management on
respiratory function found PCA did not lead to more respiratory
events when compared with intramuscular analgesia and epi-
dural anaesthesia. They reviewed 165 studies used a variety of
indicators for respiratory depression including hypoventilation,
hypercarbia, oxygen desaturation and requirement for naloxone.
When using respiratory rate as a measure of respiratory depres-
sion, there was no difference between all three modalities of
analgesia. However, when oxygen desaturation was used as an
indicator for respiratory depression the incidence of desatur-
ation in the intravenous PCA group was signiﬁcantly lower
(mean 11.5% (95% CI 5.6% to 22%)) compared with epidural
analgesia (mean 15.1% (95% CI 5.6% to 22%)) and intramus-
cular analgesia (mean 37% (95% CI 22.6% to 45.9%)). This is
perhaps surprising when PCA use is the commonest indication
for supplemental oxygen.
Importantly, while administering supplemental oxygen cor-
rects hypoxaemia, it has the ability to mask respiratory depres-
sion by delaying the onset of desaturation.102 107 A study using
transcutaneous carbon dioxide monitoring via ear lobe probe
(TOSCA) compared postoperative patients using epidural anal-
gesia and patients using morphine via PCA infusion pump.375
All patients received oxygen 4 L/min in the postoperative
period. Signiﬁcant desaturations were not observed in either
group. However, the PCA group had a higher median PtCO2,
lower respiratory rate and longer hypercarbia time as detected
by the TOSCA. This study demonstrates that transcutaneous
carbon dioxide monitoring is useful in detecting opioid-induced
respiratory depression. It also shows that hypoventilation is
common when PCA analgesia is administered. However, outside
the operating theatre and intensive care where only pulse oxim-
etry is available, the use of supplemental oxygen may mask
hypoventilation. For this reason, oxygen should be administered
to correct hypoxaemia rather than prevent it. A target saturation
of 94–98% is recommended in most patients except those at
risk of hypercapnic respiratory failure when a range of 88–92%
should be achieved.
Niesters et al107 have recently demonstrated in a
proof-of-concept study that hyperoxaemia has an additive effect
on opioid-induced respiratory depression. In a study of 20
healthy volunteers, there was steep reduction in minute ventila-
tion and increase in end-tidal CO2 when breathing 50% oxygen
compared with breathing air while receiving a remifentanyl infu-
sion. Additionally apnoeic episodes were signiﬁcantly higher
while breathing oxygen. An audit of blood gases from 4866
patients at a university hospital has shown that hypercapnia was
commoner than hypoxaemia in blood gas samples from surgical
wards, a surgical HDU, theatre and the ICU as well as on
medical wards and many of these hypercapnic patients had
respiratory acidosis.42
In the absence of large RCTs investigating the effects of PCA
and the effects of hyperoxaemia, oxygen should be administered
to correct hypoxaemia rather than prevent it. A target saturation
of 94–98% is recommended in most patients except those at
risk of hypercapnic respiratory failure when a range of 88–92%
should be achieved.
Good practice points
✓ Patients using PCA should have two-hourly oximetry obser-
vations because of the risk of hypoxaemia. Oxygen should
be administered to keep patients within the appropriate
target saturation range.
✓ A target saturation of 94–98% is advised in most patients
having PCA except those at risk of hypercapnic respiratory
failure when a range of 88–92% should be achieved.
8.15.3 The role of hyperoxaemia in reducing postoperative
complications
High levels of inspired oxygen (eg, 80%) in the perioperative
and postoperative periods have in the past, been proposed to
improve clinical outcomes including a reduction in the incidence
of surgical site infection. The rationale for its use being that
increased tissue PO2 within surgical wounds might enhance neu-
trophil killing capacity resulting in reduced rates of infection.
Earlier meta-analysis supported this hypothesis;376 377 however,
three RCTs have been published subsequently and do not
concur with these ﬁndings.378–380
Two recent meta-analysis again show conﬂicting results:
Togioka et al381 included seven randomised trials and found no
overall beneﬁt of hyperoxia in reducing surgical site infection.
However, a statistically signiﬁcant beneﬁt was demonstrated in
subgroups undergoing general anaesthesia and colorectal
surgery. Hovaguimian et al382 included nine randomised trials
in their meta-analysis and concluded that high perioperative
oxygen did reduce the risk of perioperative surgical site infec-
tion. Both these meta-analyses included the largest RCT in this
area (the PROXI trial), including 1400 patients, which showed
no beneﬁt in the administration of 80% oxygen compared with
30% oxygen in the risk of developing surgical site infection
after abdominal surgery.379 Long-term follow-up of patients
with cancer within the PROXI study revealed a 45% increase in
long-term mortality in the high FiO2 group (HR was 1.45; 95%
CI 1.10 to 1.90; p=0.009).383 Kurz et al384 reported in 2015
that supplemental oxygen did not reduce surgical site infection
risk among patients having colorectal resections.
Hyperoxia has also been proposed to reduce the incidence of
postoperative nausea and vomiting via a number of mechanisms
including the prevention of subtle intestinal ischaemia reducing
serotonin release and the reduction of dopamine release in the
carotid bodies. This has been extensively investigated with con-
ﬂicting evidence from RCTs. Two recent systematic reviews and
meta-analyses show differing results.382 385 Orhan-Sungur
et al385 included data from 10 studies and showed no overall
beneﬁt in hyperoxaemia reducing the risks of postoperative
nausea and vomiting. Hovaguimian et al382 included data from
11 studies and showed high concentrations of oxygen provided
a signiﬁcant protective effect in a subgroup of patients who
received inhalation anaesthetics without prophylactic antie-
metics. However, overall there was no beneﬁt in the composite
end point postoperative nausea and vomiting.
Experimental data have shown hyperbaric oxygen improves
anastomotic integrity in animal models.386 387 Recently, 72
patients who underwent elective open infraperitoneal anasto-
mosis for rectal cancer were randomised to 30% or 80%
oxygen at induction and for 6 hours postoperatively.388 The risk
of anastomotic leak was 46% lower in the 80% FiO2 group (RR
0.63; 95% CI 0.42 to 0.98) versus the 30% FiO2 group. The
same group has shown similar results in patients with
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oesophagojejunal anastomosis when the risk of anastomotic leak
was 49% lower in the 80% FiO2 group (RR 0.61; 95% CI 0.40
to 0.95) versus the 30% FiO2 group.
389 However, the numbers
of patients in both studies in each treatment arm were small and
further work is required from other investigators to validate this
ﬁnding, especially in view of the concerns of Meyhoff et al383
that high-concentration oxygen may increase medium-term mor-
tality in patients having cancer surgery.
Evidence statements
▸ The possible effects of hyperoxaemia in the perioperative and
postoperative period remain controversial and may or may
not reduce overall surgical site infection. However, there may
be beneﬁt in subgroups of patients undergoing general anaes-
thesia and colorectal surgery for non-malignant disease (evi-
dence level 1−).
▸ Hyperoxaemia in the perioperative and postoperative period
does not substantially reduce the incidence of postoperative
nausea and vomiting but meta-analyses have come to conﬂict-
ing conclusions (evidence level 1−).
▸ Hyperoxaemia in the perioperative and postoperative period
has been shown to improve anastomotic integrity in patients
undergoing gastric and colorectal surgery (evidence level 1−).
Recommendation
J1: Hyperoxaemia is not recommended routinely in the peri-
operative and postoperative period to reduce the incidence of
postoperative nausea and vomiting (grade D).
Good practice point
✓ There is conﬂicting evidence concerning the balance of
potential beneﬁts and risks of perioperative hyperoxaemia to
reduce the risk of surgical site infection in elective surgery
and there is no evidence for this practice in patients having
emergency surgical procedures. More trials are required for
speciﬁc procedures and more information is required con-
cerning long-term mortality risks to patients with cancer. In
the meantime, oxygen should not be used for this indication
outside of clinical trials.
8.16 Use of oxygen during endoscopy and other procedures
involving conscious sedation
Conscious sedation may be deﬁned as “a technique in which the
use of a drug or drugs produces a state of depression of the
central nervous system enabling treatment to be carried out, but
during which verbal contact with the patient is maintained
throughout the period of sedation. The drugs and techniques
used to provide conscious sedation should carry a margin of
safety wide enough to render loss of consciousness unlikely.”390
Conscious sedation is a common hospital procedure in a variety
of settings from the endoscopy suite to the emergency depart-
ment. It is performed by anaesthetists, physicians, trained nurses
and operating department practitioners. The most commonly
used sedative agents are those belonging to the benzodiazepine
and opioid classes and increasingly, propofol.
During ﬁbre-optic bronchoscopy reduction in SaO2 is a
common occurrence391–393 independent of whether a transnasal
or transoral approach is selected.394 There are several contributing
factors including the effect of central respiratory depressant drugs,
partial physical occlusion of the airway by the bronchoscope, pro-
longed use of airway suction, as well as V/Q mismatch produced
by instillation of anaesthetic solution and lavage ﬂuids in the
airways.395–397 One small non-blinded randomised study showed
no signiﬁcant inﬂuence of patient positioning (supine vs semire-
cumbent) on the desaturation observed during ﬁbre-optic bron-
choscopy,393 although a further study has shown a higher rate of
desaturation in the sitting as opposed to supine position.398
Milman et al391 demonstrated that following benzodiazepine
sedation, without supplemental oxygen, 38% of patients desat-
urate (SpO2<90%) before bronchoscopy, 80% during and 60%
following the procedure. Thus, all patients undergoing
ﬁbre-optic bronchoscopy should be routinely monitored using
transcutaneous pulse oximetry which provides an accurate non-
invasive method for assessing hypoxaemia during the sedation,
procedure and recovery stages.
There are variable data available on the effect of hypoxaemia
on the incidence of signiﬁcant complications including cardiac
arrhythmia during ﬁbre-optic bronchoscopy. In an early pro-
spective study minor rhythm abnormalities were frequently
noted, with more major rhythm abnormalities more commonly
seen in patients who developed hypoxaemia following the pro-
cedure.399 All arrhythmias were self-limiting and did not lead to
haemodynamic compromise. This ﬁnding was reiterated in a
further study which again showed a noted association between
hypoxaemia and the development of cardiac arrhythmia.392 In
contrast, Lundgren et al395 in a small study of 10 patients with
restrictive lung disease secondary to pulmonary ﬁbrosis demon-
strated that although prolonged airway suctioning lead to a
reduction in PaO2 there was no signiﬁcant associated increased
incidence of cardiac arrhythmia. Further studies have shown no
increase in arrhythmias during ﬁbre-optic bronchoscopy, with
similar rates of minor arrhythmias to that seen during lung func-
tion testing.391 394
The degree and duration of hypoxaemia may be ameliorated
by oxygen supplementation provided via a nasal or pharyngeal
catheter.391 393 In a large 6-year retrospective study (n=1051) it
was demonstrated that routine use of oxygen on a prophylactic
basis was not required during ﬁbre-optic bronchoscopy even
when conscious sedation is performed, as most desaturations
observed were transient and thus not requiring speciﬁc interven-
tion.400 The requirement for supplemental oxygen is, however,
known to increase in relation to falling FEV1 or PEF. Jones and
O’Driscoll400 showed that 35% of those with an FEV1<1 L
required administration of oxygen, 14% with an FEV1 of 1.0–
1.5 L and 7% with an FEV1>1.5 L. However, requirement for
supplemental oxygen remains variable, ranging from 5% to
32% and thus needs to be assessed on an individual basis.400 401
Oxygen supplementation should thus be used when desatur-
ation is signiﬁcant (SpO2<90%, change of SpO2>4%) and pro-
longed (>1 min) to reduce the risk of hypoxaemia-associated
complications.391 392 399 400 402 The arterial oxygenation target
should be dependent on the individual patient, a SpO2 of 94–
98% being suitable for the majority of patients, except those at
risk of hypercapnic respiratory failure where an appropriate
target is a SpO2 88–92%.
Reduction in transcutaneous SaO2 has also been reported
during and following both upper403–409 and lower408–410 GI
endoscopy, particularly during more complicated therapeutic
procedures such as endoscopic retrograde cholangiopancreato-
graphy.409 411 412 A small observational study showed more
marked desaturation in those patients with a pre-existing
requirement for long-term oxygen therapy.412 Hypoxaemia is
likely to be multifactorial, as is the case with bronchoscopic pro-
cedures, a consequence of sedation and the physical distortion
of the airway produced by passage of the endoscope. Thus, as
with ﬁbre-optic bronchoscopy it is essential to ensure adequate
facilities for monitoring of transcutaneous oxygen saturations at
all stages throughout the procedure.
Hypoxaemia during GI endoscopy may be more frequently
observed in individuals with pre-existing cardiorespiratory
disease or those undergoing complicated therapeutic
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procedures, especially if heavily sedated.292 293 295 296 300 301
Although the use of oxygen therapy on a prophylactic basis is
suggested in all those patients receiving conscious sedation in
the current guidelines of the British Society of
Gastroenterology,301 there are, however, no recognised studies
analysing whether routine use of prophylactic oxygen
decreases or increases the risks of GI endoscopy even in at-risk
patients. There is a risk that routine oxygen use might actually
mask the development of respiratory failure in such patients
because the patient could develop hypercapnia and carbon
dioxide narcosis despite having satisfactory oxygen saturation
measurements. Such patients require careful continuous
oxygen saturation monitoring and clinical observation
throughout, and facilities for oxygen administration should be
readily available in the event of signiﬁcant desaturation as dis-
cussed in section 7.
Limited data are available on the use of oxygen during other
procedures involving conscious sedation. Invasive cardiac proce-
dures such as cardiac catheterisation and angioplasty have been
associated with arterial oxygen desaturation in a signiﬁcant pro-
portion of patients, particularly those with recognised cardio-
respiratory disease, and can be corrected by supplemental
oxygen administration.413 In an emergency department setting,
procedures requiring conscious sedation may also be associated
with hypoxaemia; however, use of oxygen in a prophylactic
manner has not been demonstrated to reduce the incidence of
hypoxaemic events, although these studies were small and likely
to be underpowered to this end.414 415
SaO2 monitoring is indicated during the administration of
sedation, procedure and recovery period in all procedures
involving conscious sedation. Signiﬁcant caution should be
taken with both the administration of sedation and supplemen-
tal oxygen in patients with known resting hypercapnia or signiﬁ-
cant lung disease who are at risk of hypercapnic respiratory
failure. It is crucial to ensure sufﬁcient clinical assessment of
patients at all times. Monitoring of transcutaneous carbon
dioxide levels and capnography in additional to standard moni-
toring may be of use, particularly in high-risk patients and those
receiving moderate or deep sedation to identify early signs of
respiratory depression.416 417
Evidence statements
▸ Hypoxaemia is a common observation during ﬁbre-optic
bronchoscopy related to use of central depressant drugs,
partial airway occlusion, use of airway suction, patient posi-
tioning and instillation of ﬂuid into the airways. There is a
noted relationship between reduced FEV1 and PEF and
increased occurrence of hypoxaemia (evidence level 4).
▸ Hypoxaemia is also noted during both upper and lower GI
endoscopy and other procedures involving conscious sedation
(evidence level 2+).
▸ The use of supplemental oxygen via nasal or pharyngeal cath-
eter can ameliorate hypoxaemia (evidence level 2+).
▸ Oxygen supplementation should be provided to patients with
persistent reduction in SaO2 (SpO2<90% or change >4%,
for >1 min) (evidence level 4).
Recommendations
J2: All procedures involving conscious sedation warrant
routine continuous monitoring of oxygen saturation via pulse
oximetry prior to and during the procedure, and in the recovery
period, particularly ﬁbre-optic bronchoscopy and upper GI
endoscopy where a reduction in SaO2 is common, particularly
with concurrent use of sedation (grade C).
J3: Signiﬁcant arterial oxygen desaturation (SpO2<90% or
fall of 4% or more that is prolonged (>1 min during endoscopy
procedures)) should be corrected by supplemental oxygen with
the aim of achieving target oxygen saturations of 94–98%, or
88–92% in those at risk of hypercapnic respiratory failure
(grade D).
J4: Complicated upper GI endoscopy or procedures in
patients with cardiorespiratory comorbidity are especially likely
to lead to hypoxaemia and may also lead to hypercapnia, espe-
cially if the patient is heavily sedated. It is recommended that
blood gases should be measured if such patients should require
prolonged oxygen administration. The routine administration of
oxygen is not recommended as it may delay the recognition of
respiratory failure (grade D).
J5: Constant clinical assessment of the patient is crucial at all
stages of conscious sedation procedures and monitoring of cap-
nography or transcutaneous carbon dioxide levels may be a
useful adjunct to identify early respiratory depression (grade D).
J6: During the recovery period after procedures requiring con-
scious sedation, supplemental oxygen should be titrated to achieve
target saturations of 94–98% in most patients and 88–92% in
those at risk of hypercapnic respiratory failure (see section 10.5.1)
(grade D).
8.17 Use of oxygen in palliative care settings
In 2004, a working party of the Association of Palliative
Medicine Scientiﬁc Committee set out to examine the evidence
concerning the use of oxygen for the palliation of breathlessness
in COPD, advanced cancer and chronic heart failure.418 They
found that there was evidence that oxygen may have a useful
role in the palliation of breathlessness.419 420 However, the con-
clusion of most subsequent studies147 148 150 421 and systematic
reviews159 422–424 is that there is no difference between oxygen
or air in relief of breathlessness, although the intervention with
either seems to induce some sense of relief of symptoms. There
is general consensus that facial cooling (eg, by hand-held fan) of
second and third branches of trigeminal/vagal nerve reduces the
sensation of breathlessness.425 These mechanisms are believed
to be the reasons why both air and oxygen seem to work
equally.
In addition, there is also the question of the relationship of
hypoxaemia to the sensation of breathlessness. There does not
seem to be a clear relationship between the two as it has been
shown that occurrence of hypoxaemia (or absence of hypox-
aemia) has no relationship to relief of breathlessness in palliative
care patients.426
Breathlessness in terminally ill patients is a complex multifa-
ceted problem. The relief of this distressing symptom should be
individualised in each patient. The evidence of beneﬁt from
opioids and non-pharmacological treatments is stronger than
the evidence of beneﬁt from oxygen, especially for non-
hypoxaemic patients426 427 (evidence level 2+). Simple devices
like hand-held fans may be tried before more complex methods
(eg, oxygen and its attached equipment) are tried. There is
concern in the clinical community that dying patients may
become psychologically dependent on oxygen and become
afraid to let go of the equipment even when clearly dying. Face
masks can be intrusive and may be perceived as a barrier by the
family members between them and the patient. Campbell and
colleagues have shown that, when death is imminent, in the
absence of respiratory distress, oxygen should not be routinely
given even when severe hypoxaemia is present. Among those
already receiving oxygen, it was possible to discontinue it in
90% without causing distress.428
Previous clinical recommendations for the use of oxygen in
palliative care were based on the recommendations from the
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working party of the Association of Palliative Medicine Science
Committee in 2004418 but most publications since that date
have cast doubt on the value of oxygen therapy for patients
with advanced cancer or heart failure unless the patient is
hypoxaemic. For some conditions such as advanced pulmonary
ﬁbrosis requiring palliative care, the potential beneﬁts of oxygen
for non-hypoxaemic patients at rest have not been addressed in
clinical trials although many patients with this condition desat-
urate on exertion and beneﬁt from ambulatory oxygen therapy.
Readers should refer to the BTS Home Oxygen guideline for
guidance about the medium-term use of oxygen by palliative
care patients in the home setting.13
Evidence statements
▸ Breathlessness is a common symptom among palliative care
patients but there is little evidence that the degree of breath-
lessness is related to the oxygen saturation (evidence level 2
+).
▸ Most recent studies have shown that there is no difference
between oxygen and air in the relief of breathlessness in non-
hypoxaemic palliative care patients (evidence level 1+).
▸ There is contradictory evidence concerning the possible bene-
ﬁts of oxygen in hypoxaemic palliative care patients, most
studies were negative (evidence level 2+).
▸ Recent studies suggest that alternative treatments such as opioids
or non-pharmacological therapy such as a hand-held fan or treat-
ment of anxiety may be more beneﬁcial (evidence level 2+).
Recommendations
K1: Oxygen use in palliative care patients should be restricted
to patients with SpO2 consistently <90% or patients who
report signiﬁcant relief of breathlessness from oxygen. In non-
hypoxaemic patients, opioids and non-pharmacological mea-
sures should be tried before oxygen (grade B).
K2: In general, there is no role for the monitoring of oxygen
saturation or PO2 in comfort-focused care in the last few days
of life. If the patient appears comfortable, oxygen levels are
irrelevant and should not inﬂuence care (grade D).
Good practice points related to oxygen use in palliative care
Oxygen therapy for the symptomatic relief of breathlessness
in palliative care patients is more complex than the simple cor-
rection of hypoxaemia. Consider the following issues:
✓ Consider early involvement of palliative care specialists and
physiotherapists.
✓ As breathlessness is a multifactorial sensation, a comprehen-
sive assessment of contributing factors (such as anxiety)
should be carried out.
✓ Low-dose opioids should be considered because they are
effective for the relief of breathlessness in palliative care
patients.
✓ A trial of a hand-held fan to help relieve breathlessness is
recommended prior to trial of oxygen.
✓ Oxygen use has to be tailored to the individual and a formal
assessment made of its efﬁcacy for reducing breathlessness
and improving quality of life for that person.
✓ Oxygen therapy should not be continued in the absence of
patient beneﬁt or where its disadvantages (eg, discomfort of
masks or nasal cannulae, drying of mucous membranes) out-
weigh any likely symptomatic beneﬁt.
8.18 Use of helium–oxygen mixtures (Heliox)
Helium is an inert gas which is lighter and less dense than
oxygen and nitrogen which comprise over 99% the air that we
breathe. Helium has been mixed with oxygen (Heliox), usually
in a ratio of 80:20 or 70:30 to treat adults and children with
upper and lower airway disease as the reduced gas density can
decrease resistance to airﬂow and therefore the work of breath-
ing in narrowed airways. A 4-year study in a critical care unit
reported 92 instances of use (73% paediatric) with an ∼50/50
ratio of upper and lower airway disorders treated by Heliox.429
The use of Heliox for upper airway obstruction in adults has
not been the subject of formal clinical trials because presenta-
tions are rare, the site and nature of airﬂow obstruction is vari-
able and patients tend to present as acute emergencies where
randomisation would be difﬁcult. However, there are case
reports of beneﬁt where Heliox has been used with apparent
beneﬁt to patients (and no side effects other than temporary
alteration in the voice).
Heliox has been used in asthma and COPD, both as an
inhaled gas and as the driving gas for nebulised treatments.
There is a great deal of uncertainty about possible beneﬁts,
partly because the gas itself can affect the calibration and func-
tioning of equipment and this can inﬂuence measures of airﬂow
such as peak expiratory ﬂow and FEV1. A systematic review in
2003 concluded that the existing evidence did not provide
support for the administration of helium–oxygen mixtures to
emergency department patients with moderate-to-severe acute
asthma with the caveat that the conclusions were based on
between-group comparisons and small studies and the results
should be interpreted with caution.430 A later review in 2007
and a small randomised trial published in 2011 noted a slight
improvement in airﬂow measures but the clinical signiﬁcance
could not be determined.431 432
The use of Heliox in COPD has been less studied than its use
in asthma. A retrospective study of 81 patients with AECOPD
and respiratory acidosis reported a signiﬁcant decrease in intub-
ation and mortality in the Heliox group and shorter ICU stay
and hospital stay in survivors.433 The authors advised (in 2001)
that prospective randomised studies were needed and a later
meta-analysis (in 2004) concluded that deﬁnitive evidence of
beneﬁt was lacking.434 Heliox has been used with reported
beneﬁt in conjunction with non-invasive positive pressure venti-
lation but that is outside the scope of this guideline.
The use of Heliox as a driving gas for nebulisers is also con-
troversial, partly due to the complex interactions between the
driving gas and the inhaled medication and measures of airﬂow.
A systematic review in 2007 concluded that the use of Heliox to
drive nebulisers in patients with acute asthma slightly improved
airﬂow measures but it was not possible to determine whether
this improved recovery.431
Evidence statements
▸ There is little evidence overall to suggest that Heliox has any
beneﬁt over air–oxygen mixtures in asthma or COPD and it is
more expensive than oxygen–air mixtures (evidence level 1−).
▸ There is weak evidence from case reports and clinical practice
that a therapeutic trial of Heliox may be reasonable in
patients with mechanical upper airway obstruction or post-
operative stridor (evidence level 3).
Recommendations
L1: There is insufﬁcient evidence to support the use of
Heliox either as an inhaled gas or as the driving gas for nebu-
liser therapy in adult patients with acute exacerbations of
asthma or AECOPD except as part of randomised clinical trials
or in exceptional circumstances (grade D).
L2: A therapeutic trial of Heliox is reasonable in patients
with mechanical upper airway obstruction or postoperative
stridor (grade D).
L3: Heliox use for patients with asthma or COPD should be
considered only in clinical trials or in specialist hands for severe
exacerbations that are not responding to standard treatment
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(and in patients with COPD where there are contraindications
to intubation) (grade D).
8.19 Use of CPAP
The principles and indications for use of CPAP outside of
urgent care are beyond the scope of this guideline as are the
technical details of CPAP use. Acute CPAP therapy is used com-
monly in the management of acute pulmonary oedema and
many patients who are overweight or long-term users of home
CPAP require hospital admission for the management of
medical and surgical conditions. Most of these patients should
continue to use their own CPAP device during their hospital
admission (usually overnight) and some may need to entrain
oxygen to maintain their target oxygen saturation range. The
use of CPAP in patients in the preoperative and postoperative
period to treat or prevent hypoxaemia in patients with sleep-
disordered breathing and the use of CPAP to treat pulmonary
oedema warrant special consideration.
8.19.1 Use of CPAP in perioperative care
Obesity has reached epidemic proportions with more than one
billion overweight adults worldwide, of whom at least 300
million are obese (see also section 8.15). Obesity predisposes to
OSA and OHS. CPAP is the mainstay of medical treatment for
patients with OSA. It has been shown to reduce apnoeas and
daytime sleepiness as well as reducing sequelae of untreated
OSA such as impaired cognition, hypertension, coronary artery
disease and cerebrovascular accident.435 The incidence of post-
operative desaturation and respiratory failure is unsurprisingly
high in patients with OSA.436 Residual anaesthetic drugs have
the potential to weaken the muscles of the upper airway and
depress the respiratory drive, thus amplifying the disease. CPAP
in the postoperative period has been shown to reduce reintuba-
tion and severe respiratory complications after major abdominal
surgery in patients without sleep-disordered breathing.437 An
observational study of 16 patients with OSA reported a reduc-
tion in postoperative complications in patients who used CPAP
preoperatively, on extubation and continuously for 24–48 hours
after surgery.438 The British Obesity and Metabolic Surgery
Society (BOMSS) recommend patients with diagnosed sleep-
disordered breathing established on CPAP or bi-level positive
airway pressure ventilation (BiPAP) who are undergoing surgery,
to bring their machines with them and use them in the pre-
operative and postoperative period.439 Patients with OSA or
OHS with evidence of desaturation <88% in the postoperative
period should be started on CPAP or BiPAP rather than supple-
mental oxygen alone. Supplemental oxygen can be entrained if
necessary to maintain the target saturation range, usually 88–
92%.
Caution should be exercised when administering oxygen to
all morbidly obese patients even those without a diagnosis of
sleep-disordered breathing. One study of 40 morbidly obese
patients undergoing laparoscopic bariatric surgery showed the
incidence of postoperative hypoxaemia was as high in patients
without OSA compared with those with a diagnosis of OSA and
supplemental oxygen did not reduce the frequency of oxygen
desaturations.440
Evidence statements
▸ OSA is associated with increased incidence of desaturation,
respiratory failure, cardiac events and ICU admission (evi-
dence level 1+).
▸ CPAP therapy used in the preoperative and postoperative
period reduces complications in patients with OSA after
surgery (evidence level 2+).
Recommendation
N1: Patients with diagnosed sleep-disordered breathing estab-
lished on CPAP undergoing surgery should bring their machines
with them and use them in the preoperative and postoperative
period. If adequate saturations are not achieved despite CPAP
therapy then assess for worsening ventilation with blood gases
and oxygen should be entrained to achieve a saturation of
88–92% (grade D).
8.19.2 Use of CPAP in acute pulmonary oedema
Two meta-analysis studies and one large RCT (Gray et al443)
have provided evidence that CPAP administered with supple-
mental oxygen has deﬁnite measurable physiological and short-
term clinical beneﬁts in pulmonary oedema.441 442 The longer
term beneﬁts are less clear, in particular any reduction in mor-
tality. The meta-analysis and a prehospital RCT looking at use
of CPAP suggest reduced mortality and/or intubation
rates.441 442 444 However, this mortality beneﬁt was not found
in the largest and best constructed RCT.443 In addition, this
study did not report a reduction in the number of intubations.
Evidence statements
▸ Patients with cardiogenic pulmonary oedema, treated with
CPAP and O2 show early improvement in gas exchange when
compared with standard treatment (evidence level 1+).
▸ Reports that short-term mortality and intubation rates are
decreased were not conﬁrmed in the largest RCT (evidence
level 1+).
▸ The use of CPAP therapy in the prehospital environment may
be beneﬁcial to patients with acute pulmonary oedema as it
can potentially decrease the need for endotracheal intubation,
improve vital signs during transport to hospital and improve
short-term mortality (evidence level 1+).
Recommendation
N2: CPAP with entrained oxygen to maintain saturation 94–
98% should be considered as an adjunctive treatment to
improve gas exchange in patients with cardiogenic pulmonary
oedema who are not responding to standard treatment in hos-
pital care or in prehospital care (grade B).
SECTION 9: EMERGENCY USE OF OXYGEN IN
AMBULANCES, COMMUNITY AND PREHOSPITAL SETTINGS
This section applies to a range of clinical settings to include
emergency oxygen use in patients’ homes, GP practices or
health centres and within an ambulance care setting.
Management in some prehospital settings such as a primary care
centre or in a paramedic ambulance may be almost identical to
hospital management. Readers are referred to section 10 for
advice concerning choice of oxygen delivery devices and
systems.
Readers are referred to tables 1–4 and charts 1 and 2 for a
summary of the key elements of oxygen therapy in common
medical emergencies. A brief summary of this section can be
downloaded from www.brit-thoracic.org.uk.
Ongoing care at home of chronically hypoxaemic patients is
not covered by this guideline. There is little literature on which
to base any recommendations when such patients have an acute
exacerbation of their condition, but patient safety should be the
priority. The NICE guidelines on COPD recommend that
patients receiving long-term oxygen and those with an PaO2 of
<7 kPa should be considered for treatment in hospital during
exacerbations.1
Good practice point
✓ Chronically hypoxaemic patients with a clinical exacerbation
associated with a 3% or greater fall in oxygen saturation on
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their usual oxygen therapy should usually be assessed in hos-
pital with blood gas estimations. PaO2 of <7 kPa equates to
SpO2 below ∼85%.
9.1 Pulse oximetry and availability of oxygen
It is essential to provide optimal oxygen therapy at the earliest
possible opportunity while the acutely breathless patient is being
assessed and treated in the community and during transfer to
hospital. For most such patients the main concern is to give suf-
ﬁcient oxygen to support their needs. Hypoxaemia can lead to
cardiac arrhythmias, renal damage and, ultimately, cerebral
damage. However, excessive oxygen therapy can also be danger-
ous for some patients, especially those with advanced COPD.
Target saturation should be used; pulse oximetry is necessary to
achieve this. Section 10.4.2 provides advice concerning the
choice of oxygen cylinders in primary care practices.
Emergency ambulances and emergency/fast response type
vehicles and ambulance service motorbikes and cycles should be
equipped with oxygen and oximeters appropriate to the mode
of transport. Thus, fast response cars/motorbikes and cycles will
require hand-held ﬁnger oximeter-type devices and staff initiat-
ing oxygen in the home will need a portable or ﬁnger oximeter.
Pulse oximetry devices used by Community First Responder
(CFR) schemes should wherever possible reﬂect that of the
ambulance service to which they are afﬁliated. Likewise
Voluntary Aid Societies (VAS) medical directors are encouraged
to discuss the purchase and use of pulse oximeters.
There are many cheap, small, ﬁnger oximeters available on
the internet, but there has been no thorough evaluation of the
accuracy and reliability of these devices. However, they are now
being widely used by medical staff in many settings, and by
patients on oxygen therapy at home. In the future, having a
small oximeter may be as ubiquitous as a stethoscope, reinfor-
cing that oxygen saturations should be the ‘ﬁfth vital sign’.
Within hospital medicine, the oximeter reading is now estab-
lished as an essential part of the NEWS.96
Evidence statement
▸ The use of oximeters in acute care is based on physiological
data and expert opinion in the absence of randomised trials
(evidence level 4).
Recommendations
T1: Pulse oximetry must be available in all locations where
emergency oxygen is being used by healthcare professionals
(see also the limitations of using pulse oximetry section 7.1.2)
(grade D).
V1: Emergency oxygen should be available in primary care
medical centres, preferably using oxygen cylinders with inte-
gral high-ﬂow regulators. Alternatively, oxygen cylinders ﬁtted
with high-ﬂow regulators (delivering up to 15 L/min) must be
used to allow use with reservoir masks (grade D).
V2: Healthcare organisations should take measures to elimin-
ate the risk of oxygen tubing being connected to the incorrect
wall oxygen outlet or to outlets that deliver compressed air or
other gases instead of oxygen. Air ﬂow meters should be
removed from the wall sockets or covered with a designated
air outlet cover when not in use. Special care should be taken
if twin oxygen outlets are in use (grade D).
9.2 Clinical assessment by ﬁrst responder(s) (GP, nurse or
ambulance staff )
It is suggested that the ﬁrst healthcare professional(s) to encounter
an acutely breathless patient should perform an initial ‘ABC’
assessment, followed by obtaining a quick history from the patient
and/or family or friends. Immediate assessment should include
recording of pulse rate, respiratory rate and pulse oximetry.
• Clinical assessment of a breathless patient starts with ‘ABC’
(see recommendation B1).
• A brief history should be taken from the patient or other
informant.
• Initial assessment should include pulse and respiratory rate in
all cases (see recommendation B1).
• Pulse oximetry should always be measured in patients with
breathlessness or suspected hypoxaemia (see recommendation
B2).
• Disease-speciﬁc measurements should also be recorded (eg,
peak expiratory ﬂow in asthma, blood pressure in cardiac
disease).
9.3 Immediate management of hypoxaemic patients
Having ascertained that the airway is clear, the ﬁrst responders
should start oxygen treatment if the oxygen saturation is below
the target. The initial oxygen therapy should follow the general
principles given in tables 1–4 and charts 1 and 2. There is some
evidence that bronchodilator therapy, however given, can cause
increased V/Q mismatch and reduced blood oxygen levels in
acutely ill patients shortly after treatment (see section 10.8.1).
Good practice points
✓ The initial oxygen therapy to be used in the various clinical
situations is given in tables 1–4.
✓ If there is a clear history of asthma or heart failure or other
treatable illness, appropriate treatment should be instituted
in accordance with guidelines or standard management plans
for each disease.
✓ The oxygen saturation should be monitored continuously
until the patient is stable or arrives at hospital for a full
assessment. The oxygen concentration should be adjusted
upwards or downwards to maintain the target saturation
range.
✓ In most emergency situations, oxygen is given to patients
immediately without a formal prescription or drug order.
The lack of a prescription should never preclude oxygen
being given when needed in an emergency situation.
However, a subsequent written record must be made of what
oxygen therapy has been given to every patient (in a similar
manner to the recording of all other emergency treatment).
9.4 Patients with known COPD
A proportion of breathless patients will have COPD. A 2006
Cochrane review of oxygen therapy for COPD in the prehospi-
tal setting found no relevant randomised studies but the paper
by Austin et al51 in 2010 has shown a reduced mortality in
patients with COPD in prehospital care who were managed
with titrated oxygen to achieve a target saturation of 88–92%
compared with high-concentration oxygen therapy (RR
0.22).445
Audits of emergency admissions in UK hospitals have shown
that at least 5% of all medical admissions and 25% of breathless
or hypoxaemic medical patients who require hospital admission
have COPD or other conditions that may place them at risk of
hypercapnia.165 UK government data list over 100 000 hospital
admissions due to COPD each year which constitutes 2% of all
emergency admissions to hospitals in England and Wales.446
Many of these patients will require carefully titrated oxygen
therapy because they are at risk of carbon dioxide retention or
respiratory acidosis. In a large UK study, 47% of patients with
exacerbated COPD had PaCO2>6.0 kPa (45 mm Hg), 20% had
respiratory acidosis (pH<7.35 or [H+]>45 nmol/L) and 4.6%
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had severe acidosis (pH<7.25 or [H+]>56 nmol/L).43 Acidosis
was more common if the blood oxygen was >10 kPa
(75 mmHg). Plant et al43 recommended that patients with acute
COPD should be maintained within a PaO2 range of 7.3–10 kPa
(55–75 mmHg) to avoid the dangers of hypoxaemia and acidosis.
Good practice points (section 8.12 and table 3)
✓ Patients with COPD should initially be given oxygen via a
Venturi 24% mask at 2–3 L/min or Venturi 28% mask at a
ﬂow rate of 4–6 L/min or nasal cannulae at a ﬂow rate of 1–
2 L/min.
✓ Some patients may beneﬁt from higher ﬂow rates via the
Venturi mask (see section 10.2.3). The target oxygen satur-
ation should be 88–92% in most cases or an individualised
saturation range based on the patient’s blood gas measure-
ments during previous exacerbations.
9.5 Patients who should be assumed to have COPD
One of the challenges faced by the initial clinical response staff
is that the diagnosis may be unclear and the patient’s medical
records or detailed history may not be available. It has been
shown that ambulance teams may be aware of a diagnosis of
COPD in only 58% of cases.447
The Guideline Group consider that an initial diagnosis of
COPD should be assumed if there is no clear history of asthma
and the patient is >50 years of age and a long-term smoker or
ex-smoker with a history of longstanding breathlessness on
minor exertion. The diagnosis should be reassessed on arrival at
hospital where more information will probably become avail-
able, and the FEV1 should be measured unless the patient is too
breathless to undertake spirometry.
Good practice point
✓ If the diagnosis is unknown, patients >50 years of age, who
are long-term smokers with a history of chronic breathless-
ness on minor exertion such as walking on level ground, and
no other known cause of breathlessness, should be treated as
having suspected COPD for the purposes of this guideline.
Patients with COPD may also use terms such as chronic
bronchitis and emphysema to describe their condition but
may sometimes mistakenly use ‘asthma’ (see table 3).
9.6 Other patients at risk of hypercapnic respiratory failure
with respiratory acidosis
• Patients who are already on long-term oxygen therapy most
of whom will have COPD.
• Patients with ﬁxed airﬂow obstruction associated with
bronchiectasis.
• Any patient with severe kyphoscoliosis or severe ankylosing
spondylitis.
• Severe lung scarring from old tuberculosis (especially with
thoracoplasty).
• Morbid obesity (BMI>40 kg/m2).
• Patients with neuromuscular disorders (especially if muscle
weakness has led to wheelchair use).
• Any patient on home mechanical ventilation.
• Overdose of opioids, benzodiazepines or other drugs causing
respiratory depression.
9.7 Oxygen alert cards and 24% or 28% Venturi masks in
patients with COPD (and others at risk of respiratory
acidosis) who have had an episode of hypercapnic
respiratory failure
The administration of high oxygen concentrations in acute
COPD and other conditions (see section 8.12) leads to worsen-
ing of hypercapnic respiratory failure and respiratory acidosis.43
Patients with COPD on oxygen therapy with a PO2>10 kPa
(75 mm Hg) are at risk of CO2 retention may be assumed to
have excessive oxygen therapy. This is a very common problem,
data from the 2008 national COPD audit indicate that 30% of
patients with COPD had received >35% oxygen in the ambu-
lance prior to admission and 35% were still receiving high-
concentration oxygen when blood gases were taken in
hospital.46
If a patient is found to have respiratory acidosis due to exces-
sive oxygen therapy, the oxygen therapy should not be discon-
tinued immediately because the oxygen level will fall
signiﬁcantly over 1–2 min by virtue of the alveolar gas equation
(see section 5.2.1), whereas the carbon dioxide level will take
much longer to correct itself (see section 5.3.2). In this situ-
ation, the oxygen treatment should be stepped down to 28% or
35% oxygen from a Venturi mask, or oxygen at 1–2 L/min from
nasal cannulae depending on oxygen saturation and blood gas
results. A saturation target of 88–92% is recommended for acid-
otic patients in hypercapnic respiratory failure and NIV is
required if the acidosis does not resolve quickly.1 43 This avoid-
able problem has occurred historically during the transfer to
hospital, prior to measurement of ABGs or before a deﬁnitive
diagnosis is known. Furthermore, ambulance staff are often not
informed at present of a diagnosis of COPD and may not be
aware of the presence of other high-risk conditions such as
kyphoscoliosis or respiratory failure due to neuromuscular con-
ditions.447 These patients should be issued with an oxygen alert
card (example shown in ﬁgure 8) and a 24% or 28% Venturi
mask based on previous blood gas results. The recommended
oxygen saturation will be based on the clinical scenario for each
individual patient but will usually be 88–92%, occasionally 85–
88% or 85–90% based on previous blood gas results. Patients
should be instructed to show this card to the ambulance crew
and emergency department staff in order to avoid the use of
high oxygen concentrations. This scheme can be successful.448
The ambulance service should be informed about which patients
are issued with oxygen alert cards. The Association of
Ambulance Chief Executives (AACE) JRCALC UK Ambulance
Services Clinical Practice Guidelines 2016: (London, AACE,
2016) reﬂect this 2017 BTS Guideline for the use of oxygen in
COPD.12
Good practice points (see also section 8.12)
✓ Patients with COPD (and other at-risk conditions) who have
had an episode of hypercapnic respiratory failure should be
issued with an oxygen alert card and with a 24% or 28%
Venturi mask. They should be instructed to show the card to
the ambulance crew and emergency department staff in the
event of an exacerbation.
✓ The content of the alert card should be speciﬁed by the
physician in charge of the patient’s care, based on previous
blood gas results.
✓ If a patient has an oxygen alert card, initial oxygen therapy
should be based on the guidance on the card until the results
of blood gases are available.
✓ Oxygen alert cards with agreed content can be obtained via
the BTS website.
✓ The primary care team and ambulance service should also
be informed by the responsible clinician that the patient
has had an episode of hypercapnic respiratory failure and
carries an oxygen alert card. The home address and ideal
oxygen concentration or target saturation ranges of these
patients can be ﬂagged in the ambulance control systems
and information disseminated to ambulance crews when
required.
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✓ Out-of-hours services providing emergency primary care ser-
vices should be informed by a responsible clinician that the
patient has had an episode of hypercapnic respiratory failure
and carries an oxygen alert card. Use of oxygen in these
patients will be guided by the instructions on the alert card or
by a patient-speciﬁc protocol which can be shared by hospital
teams, the ambulance service and the primary care team.
✓ During treatment by ambulance staff, oxygen-driven nebuli-
sers should be used for patients with asthma and may be
used for patients with COPD in the absence of an air-driven
compressor system. If oxygen is used for patients with
known COPD, its use should be limited to 6 min. This will
deliver most of the nebulised drug dose but limit the risk of
hypercapnic respiratory failure (section 10.8.2). Ambulance
services are encouraged to explore the feasibility of introdu-
cing battery-powered, air-driven nebulisers or portable ultra-
sonic nebulisers.
✓ If a patient is suspected to have hypercapnia or respiratory
acidosis due to excessive oxygen therapy, the oxygen therapy
should not be discontinued but should be stepped down to
the lowest level required to maintain a saturation range of
88–92%. This may be achieved using 28% or 24% oxygen
from a Venturi mask or 1–2 L/min via nasal cannulae
depending on oxygen saturation and subsequent blood gas
results.
9.8 Choice of devices in prehospital care
The range of oxygen delivery devices is very wide as discussed
in section 10. However, most patients can be managed with one
of ﬁve types of oxygen delivery device.
Good practice points
It is recommended that the following delivery devices should
be available in prehospital settings where oxygen is administered
(see section 10):
✓ High-concentration reservoir mask (non-rebreathe mask) for
high-concentration oxygen therapy;
✓ Nasal cannulae (preferably) or a simple face mask for
medium-concentration oxygen therapy;
✓ Twenty-eight per cent Venturi mask for patients with deﬁnite
or likely COPD (patients who have an oxygen alert card
may have their own 24% or 28% Venturi mask);
✓ Tracheostomy masks for patients with tracheostomy or previ-
ous laryngectomy.
9.9 Emergency use of oxygen in patient’s home
The emergency use of oxygen in the patient’s home will be
determined by what is available in the patient’s home (see
section 10.4) or what is carried by the ﬁrst responder. GPs are
probably unlikely to carry an emergency oxygen supply such as
a portable cylinder unless they work in remote or rural areas. If
oxygen is available in the patient’s home by either oxygen con-
centrator or short burst oxygen by cylinder, the ﬂow rate should
be guided by the use of pulse oximetry if available. Otherwise,
the need for oxygen may need to be determined by the presence
of central cyanosis which can be very difﬁcult in poor light.
Enough oxygen should be given to achieve 88−92% if the
patient is known to be at risk of hypercapnia, or the target sat-
uration as stated on their oxygen alert card. Otherwise ﬂow rate
should be titrated to achieve saturations of 94–98% or correc-
tion of cyanosis if no pulse oximeter is available. It is not
recommended that patients adjust their own ﬂow rate of an
existing oxygen supply based on saturations or increase in
breathlessness unless it is part of an agreed escalation plan.
Good practice points
✓ GPs or ﬁrst responders visiting a patient’s home should carry
a portable pulse oximeter to assess hypoxaemia and guide
use of oxygen if available and should call emergency services
if hypoxaemia or other serious illness is suspected.
✓ Those attending patients as an emergency in rural or remote
areas should consider carrying a portable oxygen cylinder as
part of their emergency equipment.
9.10 Use of oxygen by rescue services and other non-NHS
ﬁrst responders
The BTS Guideline was written for use by healthcare profes-
sionals, mostly operating within the NHS and emphasises the
strategy of titrating supplemental oxygen to target levels of
oxygen saturation, facilitated by the use of pulse oximeters.2
However, it is recognised that emergency oxygen is used in
many other circumstances, especially by volunteers involved in
Mountain Rescue, Lifeboat Rescue, Cave Rescue and similar ser-
vices. In these circumstances, training of volunteers is the
responsibility of the individual organisation and it is recognised
that oximeters may not be available in all circumstances where
oxygen is used by such teams. Furthermore, there are many cir-
cumstances such as hypothermia and shock where oximetry
readings may be unreliable and these circumstances are more
likely to be present during call-outs by the above services than
during general ambulance operations in the UK. The AACE
JRCALC UK Ambulance Services Clinical Practice Guidelines
2016: London, AACE, 2016 contains succinct guidance for
ambulance staff in the UK based on the BTS Guideline.12 It is
recommended that other ﬁrst responder organisations may wish
to base their oxygen strategies on the principles of the BTS
guideline and the succinct practical advice, tables and ﬂowchart
contained in the JRCALC drugs section, accepting the limita-
tions previously listed and the challenging environment in
which these teams may operate. It is appreciated that oxygen
Figure 8 Example of oxygen alert
card.
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may be used on a more pragmatic basis if it is not possible to
obtain a reliable oximetry reading due to conditions such as
shock or hypothermia or if oximetry is not available.
Organisations are advised to prepare guidance for situations
when oximetry is unreliable or unavailable for the above
reasons. Organisational guidance should reﬂect the general
principles of the BTS and JRCALC guidelines but BTS cannot
endorse the speciﬁc recommendations of other bodies, espe-
cially if oxygen is given without monitoring by pulse oximetry.
It is recognised that voluntary organisations may have difﬁculty
in providing training (and regular refresher training) in the use
of oxygen and oximeters to large numbers of volunteers.
However, BTS regards the use of oximetry to guide oxygen
therapy as best practice. Organisations should give very careful
consideration to any decision resulting in a pulse oximetry not
being used at the casualty site and/or in transport of seriously
ill patients based on purely ﬁnancial reasons.
9.11 Use of nitrous oxide/oxygen mixtures (eg, Entonox)
Entonox is a 50:50 mixture of oxygen and nitrous oxide that
has been widely used as an inhalational analgesic agent for
many years. However, a Danish review in 1994 reported as
follows: “There are no controlled studies concerning the effect
of pain treatment in the pre-hospital phase. The few available
controlled studies conducted inside the hospital have not shown
signiﬁcant pain-relieving effects of nitrous oxide for patients suf-
fering from pain of acute medical or surgical origin when com-
pared to other methods of pain treatment.”449 Su et al450
reported better pain control and a lower caesarean section rate
when 50% nitrous oxide was given to 658 women in labour
compared with 642 women given 50% oxygen. The commonest
side effect was dizziness which affected 39% of those given
nitrous oxide and none of the control participants. Because of
its rapid onset of action and lack of serious side effects, it has
been widely used in providing analgesia during childbirth and in
trauma patients, in the emergency department and in the ambu-
lance or scene of an accident. The gas mixture is usually self-
administered using a facemask with a demand valve that the
patient holds to their face. The demand valve opens to allow
gas to ﬂow when it detects an inspiration. The analgesic onset is
rapid, occurring within a few breaths. The main side effect is
drowsiness and if the patient takes too much, because they are
holding the mask to their face, the mask will slip off and the
patient returns to breathing ambient air again. The rapid
washout of nitrous oxide means that the patient regains con-
sciousness very quickly. The mixture is less dense than air and
may expand in air ﬁlled cavities, and as such, is contraindicated
in patients with known emphysema.451
There is a concern of course that if Entonox is used in
patients who are at risk of hypercapnic respiratory failure, the
high concentration of oxygen may precipitate hypercapnia.
Again, if the patient does become drowsy because of hypercap-
nia or the sedating effect of Entonox, they may release the mask
and return to breathing air again. Unfortunately, if the patient
has a cause for hypoxaemia, this will result in swinging from
hyperoxaemia to hypoxaemia. Thus for this reason, the guide-
line group advise that Entonox is best avoided in patients who
are at risk of hypercapnia or hypoxaemia.
Evidence statement
▸ The use of Entonox gas mixture is based on expert opinion
in the absence of randomised trials to study the effects on
oxygen physiology. The value of Entonox as an analgesic
agent is outside the scope of this guideline (evidence level 4).
Recommendation
M1: The use of Entonox gas mixture for analgesia should be
avoided if possible in patients at risk of hypercapnic respiratory
failure (grade D).
9.12 Use of oxygen in prehospital care for pregnant women
The use of oxygen in the management of pregnant women in
prehospital care should follow the same principles as in hospital
care (section 8.14). All healthcare professionals caring for
women in pregnancy should be aware of the importance of left
lateral tilt or manual displacement of the uterus in circumstances
of trauma, collapse, etc. This applies at gestations above
20 weeks (ie, when the fundus of the uterus reaches the level of
the umbilicus). This will potentially improve maternal cardiac
output and improve the mechanics of breathing. Pregnant
women suffering major trauma or severe hypoxaemia should be
started on high-concentration oxygen via a non-rebreathing res-
ervoir mask and those with milder hypoxaemia can use nasal
cannulae or a simple face mask or Venturi mask to achieve an
oxygen saturation of 94–98% in most cases.
If mild/moderate analgesia is required during transportation,
‘Entonox’ may be administered—see previous section 9.11.
Recommendations for oxygen use in pregnancy are given in
section 8.14.
SECTION 10: PRACTICAL ASPECTS OF OXYGEN THERAPY
Oxygen delivery systems can be considered as two components:
the method of storage and provision of oxygen (eg, cylinders);
the method of delivery to the patient (eg, Venturi mask). The
options available for both will depend on the environment in
which it is being used and the needs of the patient.
10.1 Oxygen storage and provision and safety
10.1.1 Cylinders (compressed gas)
Cylinders contain compressed gas held under a very high pres-
sure. They come in an array of sizes and hence capacity, ranging
from small portable cylinders for individual patient use to large
cylinders suitable for hospital use (table 12). These can be used
for bedside administration where piped oxygen is not available
or can be the supply for a piped system.
With recent changes in technology, high-pressure cylinders
are now available (ie, ﬁlled to 200 bar rather than 137 bar
which can contain 54% more gas for the same size cylinder). It
is important for all users of oxygen to be aware that most
oxygen cylinders are colour-coded (black cylinder with white
shoulder) but some high-pressure oxygen cylinders are all white.
Small lightweight cylinders are also available for ambulatory use
(eg, some weigh 3.2 kg when full). All systems containing com-
pressed gases in the UK are subject to the Pressure Systems
Safety Regulations 2000 (SI 2000 No 128). These regulations
are intended to prevent the risk of injury from pressurised
systems. Oxygen supports combustion and there is a risk of ﬁre
if oxygen is used close to combustible materials and a source of
ignition. There is one case report of a serious ﬁre caused by
spontaneous sparking in the outﬂow system of an oxygen cylin-
der.452 Although oxygen is not an explosive gas, it is possible
Table 12 Examples of oxygen cylinder sizes and capacities
Size C CD D E F G HX J
Height 36 49 46 79 86 124 94 145
Capacity (L) 170 460 340 680 1360 3400 2300 6800
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for oxygen cylinders to explode if heated during a ﬁre, and
deaths have been recorded in these circumstances.453 454
Healthcare organisations must ensure that they have a policy
in place which ensures the safety of patients, staff and contrac-
tors in the provision, storage, use and maintenance of com-
pressed gas systems as required by the Health and Safety at
Work Act 1974.
Clinicians using oxygen cylinders should check the labelling
of the cylinder to ensure that it is an oxygen cylinder and
checks should be made to ensure that the cylinder is not empty
or near empty.
10.1.2 Liquid oxygen
Liquid oxygen is contained in pressure tanks and is obtained
from atmospheric oxygen by fractional distillation. It has to be
evaporated into a gas before use. Large tanks are often used by
hospitals and small tanks can be used domestically. Portable
liquid oxygen is also available in small portable containers
which can be ﬁlled from the larger tanks.
10.1.3 Oxygen concentrators
Oxygen concentrators are largely used in the domiciliary setting
for the provision of long-term oxygen therapy and are therefore
not used in the acute setting so will not be covered further.
10.2 Patient delivery methods/interfaces
10.2.1 High-concentration reservoir mask (non-rebreathing mask)
This type of mask delivers oxygen at concentrations between
60% and 90% when used at a ﬂow rate of 15 L/min
(ﬁgure 9).455 The delivered oxygen concentration is variable and
will depend on the mask ﬁt and the patient’s breathing pattern.
These masks are most suitable for trauma and emergency use in
patients in whom carbon dioxide retention is unlikely.
10.2.2 Simple face mask
This type of mask delivers oxygen concentrations between 40%
and 60% (ﬁgure 10). It is sometimes referred to as an MC Mask,
Medium Concentration Mask, Mary Catterall Mask or as a
‘Hudson Mask’, but the latter description is discouraged because
the Hudson Company make many types of mask (including high-
concentration reservoir masks). The guideline group favours the
term ‘simple face mask’. The oxygen supplied to the patient will
be of variable concentration depending on the ﬂow of oxygen and
the patient’s breathing pattern. The concentration can be
changed by increasing or decreasing the oxygen ﬂows between
5 and 10 L/min. However, different brands of simple face mask
can deliver a different oxygen concentration at a given ﬂow
rate. Flows of <5 L/min can cause increased resistance to
breathing, and there is a possibility of a build-up of carbon
dioxide within the mask and rebreathing may occur.115
This mask is suitable for patients with respiratory failure
without hypercapnia (type 1 respiratory failure) but is not suit-
able for patients with hypercapnic (type 2) respiratory failure.
The mask may deliver a high concentration of oxygen (>50%)
and is therefore not recommended for patients who require low-
concentration oxygen therapy because of the risk of carbon
dioxide retention. Patients using a simple face mask may have
an inspiratory ﬂow rate greater than the gas ﬂow rate from the
mask, so the simple face mask should not be used at ﬂow rates
below 5 L/min.115 Several publications have shown that patients
who require medium-concentration oxygen therapy tend to
prefer nasal cannulae to simple face masks and the cannulae are
more likely to be left in position by the patient and less likely to
fall off.456–459
10.2.3 Venturi mask
AVenturi mask will give an accurate concentration of oxygen to
the patient regardless of oxygen ﬂow rate (the minimum sug-
gested ﬂow rate is written on each Venturi device and the avail-
able options are shown in table 13; ﬁgure 11A,B). The oxygen
concentration remains constant because of the Venturi principle.
The gas ﬂow into the mask is diluted with air which is entrained
via the cage on the Venturi adaptor. The amount of air suckedFigure 9 High-concentration reservoir mask (non-rebreathing mask).
Figure 10 Simple face mask.
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into the cage is related to the ﬂow of oxygen into the Venturi
system. The higher the ﬂow the more air is sucked in. The pro-
portions remain the same and therefore the Venturi mask deli-
vers the same concentration of oxygen as the ﬂow rate is
increased.
Venturi masks are available in the following concentrations:
24%, 28%, 31%, 35%, 40% and 60%. They are suitable for all
patients needing a known concentration of oxygen, but 24%
and 28% Venturi masks are particularly suited to those at risk of
carbon dioxide retention. A further beneﬁt of Venturi masks is
that the ﬂow rate of gas from the mask will usually exceed the
inspiratory ﬂow rate of the patient. One study has shown that
patients with a respiratory rate >30 breaths/min often have an
inspiratory ﬂow rate above the minimum ﬂow rate speciﬁed on
the mask packaging.303 Therefore, for patients with a high
respiratory rate, it is suggested that the ﬂow rate for Venturi
masks should be set above the minimum ﬂow rate listed on the
packaging (increasing the oxygen ﬂow rate into a Venturi mask
does not increase the concentration of oxygen which is deliv-
ered). The accuracy of oxygen delivery from a Venturi mask is
greatly reduced if the mask is not accurately placed on the
patient’s face.460
Patients with a respiratory rate >30 breaths/min often have a
ﬂow rate which is above the minimum delivered by the Venturi
system as speciﬁed by the ﬂow rate recommended for the mask.
The ﬂow may be increased as shown in ﬁgure 11B.
Venturi masks deliver a constant percentage of oxygen but the
effect on the patient will depend on the condition being treated
and on the breathing pattern and baseline oxygen saturation of
the patient. As might be expected from the oxygen dissociation
curve, patients with an oxygen saturation that is already in the
normal range will have a very small rise in oxygen saturation
(although the PaO2 is likely to rise substantially). However,
patients with very low oxygen saturation will have a marked rise
if given even a small concentration of oxygen. This is because
the oxygen dissociation curve is actually a ‘rapid escalator’
rather than a ‘slippery slope’.102 106 This is illustrated in
ﬁgure 12 which demonstrates that a small increase in inspired
oxygen concentration can make a big difference when the
Table 13 Total gas flow rate from Venturi masks at different
oxygen flow rates
Oxygen flow L/min
Venturi values
24 28 31 35 40 60
20 84 40
15 84 82 30
12 67 50 24
10 78 56 41
8 89 63 46
6 67 47
4 102 44
2 51
Total flow—L/min.
Figure 11 (A) (a) Venturi mask, (b) range of concentrations available, (c) operation of Venturi valve. For 24% Venturi mask the typical oxygen
ﬂow of 2 L/min gives a total gas ﬂow of 51 L/min. For 28% Venturi mask, 4 L/min oxygen ﬂow gives total gas ﬂow of 44 L/min (table 13). (B)
Suggested ﬂow rates for Venturi masks and adjustment for high respiratory rate. RM, reservoir mask; RR, relative risk.
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saturation is below 80% but the response to oxygen is much less
if the saturation is close to or above 90%.
10.2.4 Nasal cannulae
Nasal cannulae can be used to deliver low-concentration and
medium-concentration oxygen concentrations (ﬁgure 13).
However, there is wide variation in patients’ breathing patterns so
the same ﬂow rate of nasal oxygen may have widely different
effects on the blood oxygen and carbon dioxide levels of different
patients. Nasal cannulae at 1–4 L/min can have effects on oxygen
saturation approximately equivalent to those seen with 24–40%
oxygen from Venturi masks.230 463 The actual concentration of
oxygen delivered (FiO2) cannot be predicted and so cannot be
used if a calculation of A–a gradient is required. The oxygen con-
centration continues to rise up to ﬂows above 6 L/min. Some
patients may experience discomfort and nasal dryness at ﬂows
above 4 L/min, but they can be well tolerated (see section
10.2.5).230 464 Although one might expect mouth breathing to
reduce the efﬁciency of nasal cannulae, the majority of studies
have shown that mouth breathing results in either the same
inspired oxygen concentration or a higher concentration, espe-
cially when the respiratory rate is increased.464 This is important
because patients with acute breathlessness are likely to breathe
quickly and via the mouth rather than the nose. As there is marked
individual variation in breathing pattern, the ﬂow rate must be
adjusted based on oximetry measurements and, where necessary,
blood gas measurements. A cross-over comparison of nasal cannu-
lae versus a Venturi mask (both adjusted to give satisfactory initial
oxygen saturation) showed that the oxygen saturation of patients
with exacerbated COPD fell below 90% for 5.4 hours/day during
treatment with nasal cannulae compared with 3.7 hours/day
during treatment with a Venturi mask.465 However, that study was
published in 1999 before oximetery was widely used to monitor
oxygen saturation.
The upper range of oxygen delivery from nasal cannulae is a
little lower than the output of a simple face mask, but the lower
range goes a lot lower than a simple face mask which should
not be used below a ﬂow rate of 5 L/min (about 40%
oxygen).115 The performance and variation of nasal cannulae
for medium-concentration oxygen therapy is broadly similar to
that of the simple face mask, both in laboratory experi-
ments230 464 and in clinical practice.457–459 466 467 One study
suggested that the saturation was lower with nasal cannulae than
with simple face masks in a subgroup of men following abdom-
inal surgery.467 However, the use of target ranges would resolve
this issue. Three patient preference studies comparing nasal can-
nulae with simple face masks in postoperative care found that
patient preference was strongly in favour of nasal cannulae with
up to 88% of patients preferring cannulae to masks.457–459
Another advantage of cannulae over simple face masks is that
they are less likely to be removed accidentally and they allow
the patient to speak and eat.458 468 There are no comparisons of
these devices in acute care, but there is no reason to believe that
the results would be any different for patients requiring
medium-concentration oxygen therapy. Nasal cannula (not
Venturi masks) were used in the Austin et al’s51 study which
showed improved survival from controlled oxygen therapy in
AECOPD.
Advantages of nasal cannulae compared with simple face masks
for medium-concentration oxygen therapy
• Comfort (but a minority of patients dislike the ﬂow of
oxygen into the nose, especially above 4 L/min).
• Adjustable ﬂow gives wide oxygen concentration range (ﬂow
rate of 1–6 L/min gives FiO2 from ∼24% to ∼50%), suitable
for variable oxygen therapy and concentration titration.
• Patient preference.
• No claustrophobic sensation.
• Not taken off to eat or speak and less likely to fall off.
• Less affected by movement of face.
• Less inspiratory resistance than simple face masks.
• No risk of rebreathing of carbon dioxide.
• Cheaper.
Figure 12 Oxygen saturation response to treatment with 24%, 28% and 35% oxygen in hypoxaemic patients with COPD. This illustration shows
actual oxygen saturations from Warrel et al85 and King et al293 together with calculated saturations from DeGaute et al,461 Schiff and Massaro292
and Bone et al462 (two different groups of patients). COPD, chronic obstructive pulmonary disease.
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Disadvantages of nasal cannulae
• May cause nasal irritation or soreness.
• May not work if nose is severely congested or blocked.
• Actual concentration of oxygen (FiO2) cannot be predicted
10.2.5 High-ﬂow humidiﬁed oxygen via nasal cannulae
There is increasing use of HFNC as an alternative delivery
device for adults requiring medium-concentration and high-
concentration oxygen therapy (ﬁgure 14). There is currently a
small body of evidence to support its use as well as growing
interest from positive clinical observations. The therapeutic
effects are thought to be multifactorial and include delivery of
increased FiO2, a CPAP effect and greater comfort for the
patient when compared with face masks. To deliver HFNC,
three elements are required: a patient interface, a gas delivery
device and a humidiﬁer. However, speciﬁc research on the effect
of humidiﬁcation and high-ﬂow oxygen therapy is lacking (see
section 10.6.1). A ﬂow of at least 60 L/min can be accommo-
dated via standard dimension prongs on adult nasal cannula.
Several manufacturers provide these, speciﬁcally designed for
high-ﬂow application. Ritchie et al469 reported a positive airway
pressure of about 7 cm H2O in normal volunteers at a ﬂow of
50 L/min. Trials to date are few and small; however, Tiruvoipati
et al470 performed a prospective randomised trial of 50 patients
postextubation, who required high-ﬂow oxygen therapy. This
study showed HFNC to be as effective as high-ﬂow face mask in
delivering oxygen to extubated patients as well as a signiﬁcant
difference in tolerance of HFNC and a trend towards improved
comfort in this group. A recent study by Hernández et al471 ran-
domised 527 mechanically ventilated patients at low risk of rein-
tubation to either high-ﬂow nasal oxygen or conventional
oxygen for 24 hours after extubation.
They reported that the use of HFNC oxygen compared with
conventional oxygen therapy reduced the risk of reintubation
within 72 hours (4.9% vs 12.2%; p=0.04). A prospective
sequential comparison trial by Roca et al472 examined 20
patients with acute hypoxaemic respiratory failure and com-
pared HFNC with conventional oxygen therapy. HFNC was
better tolerated and more comfortable than face mask. HFNC
was associated with better oxygenation and lower respiratory
rate. Cuquemelle et al473 also reported greater patient comfort
using this system. In further support a study by Parke et al,474
60 patients with mild-to-moderate hypoxemic respiratory failure
were randomised to receive HFNC or high-ﬂow face mask and
they analysed the success of allocated therapy, NIV rate and oxy-
genation. Signiﬁcantly, more HFNC patients succeeded with
their allocated therapy and the rate of NIV in this group was
10%, compared with 30% in the high-ﬂow face mask group.
The HFNC patients also had signiﬁcantly fewer desaturations.
Frat et al475 randomised 310 patients with acute hypoxaemic
respiratory failure (without hypercapnia) to treatment with
HFNC, reservoir mask or NIV and they found that HFNC
increased the number of ventilator-free days and reduced
90-day mortality but did not signiﬁcantly reduce the intubation
rate which was the primary end point of the study.
Figure 13 Nasal cannulae.
Figure 14 High-ﬂow humidiﬁed nasal cannulae, ﬂow generator and
humidiﬁer system.
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Larger and more comprehensive studies are still awaited but
research to date is encouraging, indicating that HFNC may have
an important role to play in the delivery of high-ﬂow oxygen
both in terms of physiological advantages and the tolerance and
comfort of the individual patients who are not at risk of hyper-
capnia (evidence level 2− to 1−).
Good practice point
✓ High-ﬂow nasal oxygen should be considered as an alterna-
tive to reservoir mask treatment in patients with acute
respiratory failure without hypercapnia.
10.2.6 Tracheostomy mask
These devices are designed to allow oxygen to be given via a
tracheostomy tube or to patients with previous laryngectomy
(ie, neck breathing patients; ﬁgure 15). The oxygen ﬂow rate
should be adjusted to achieve saturation in accordance with
tables 1–4 and chart 1 (ﬁgure 1). Oxygen given in this way for
prolonged periods needs constant humidiﬁcation and patients
may need suction to remove mucus from the airway.
10.2.7 Non-invasive ventilation
This treatment option is beyond the scope of the present guide-
line. Readers are referred to the BTS guideline concerning the
use of NIV in patients with exacerbations of COPD.209 299
10.3 Oxygen carriage and delivery during patient transport
in ambulances
Transport of oxygen cylinders in vehicles comes under the
Transport of Dangerous Substances Act or the Carriage
Regulations only if 1000 L or more (measured by the water cap-
acity of the cylinder) is carried at any one time. Ambulances are
therefore exempt from this. Normal health and safety require-
ments will still apply.476 477
10.3.1 Health and Safety Executive guidance for safe use of
oxygen cylinders476 477
• All cylinders must be secured appropriately so they cannot
move in transit (includes portable cylinders).
• No smoking in the vicinity of cylinders.
• Cylinders must be checked regularly for obvious signs of
leakage.
• Cylinders must be kept out of direct sunlight.
• Green warning triangle ‘compressed gas’ should be displayed
on the vehicle.
• Cylinders should never be lifted by the neck.
• They should only be changed by suitably trained personnel.
• Apart from portable cylinders, all cylinders should be moved
using a cylinder trolley.
• Cylinders must be turned off/fully closed when not in use
• Cylinders must be in date. Staff should check the expiry date
prior to use.
10.3.2 Oxygen use by UK ambulance services
Currently, within the UK, the ambulance service—whether NHS
or private—has a range of vehicles and oxygen delivery systems
at their disposal. There is an increasing use of cycle response
units which tend to use the lightweight AZ or C sized cylinder
with a capacity of 170 L. Motorcycle response units are gener-
ally equipped with the same AZ or C sized cylinders. Fast
response units based on cars tend to be equipped with at least
two of the lightweight CD sized cylinders which hold 460 L.
The CD cylinder is also the size favoured by mountain, cave
and mines rescue teams.
Front-line ambulances are usually equipped with piped
oxygen ﬁttings (Schraeder type) and supplied from two HX
sized (2300 L) cylinders, as well as carrying at least two CD
sized cylinders to power a portable oxygen-powered resuscitator.
The piped supply has several outlet points placed in strategic
positions to which are attached standard Schrader ﬂow meters
(0–15 L/min). This enables oxygen to be given throughout the
patient’s journey. The ambulance is also equipped with a port-
able supply which can be used at the site of an accident, taken
into a patient’s home or can be used when transferring a
patient. They carry a range of patient interfaces for delivering
the oxygen under the different circumstances encountered.
Portable resuscitators are always capable of supplying free-
ﬂow oxygen therapy as well as their resuscitator facility. Again,
there are a variety of portable oxygen-powered resuscitators and
it is beyond the scope of these guidelines to describe each one
available for use in prehospital care. It is strongly suggested that
those practitioners who need to work closely with the ambu-
lance service should become familiar with the equipment used
by their local ambulance service provider. With the possible
exception of the cycle response units, all types of ambulance
service response will have portable resuscitators, bag-valve mask
devices and hand-operated suction as a minimum. Front-line
emergency ambulances will also have rechargeable battery-
powered suction available.
Patient transport service ambulances are equipped with an
oxygen supply, normally an HX cylinder (2300 L) delivering the
oxygen via a ﬂow meter attached directly to the cylinder. Such
vehicles also tend to carry basic hand-held suction devices. A
range of oxygen masks are usually available for the different
types of patients carried on such vehicles. Vehicles that are
equipped with an oxygen supply should also carry oximeters to
ensure appropriate use of oxygen (see section 9.8 for advice on
which oxygen delivery devices should be carried in ambulances).
10.4 Oxygen carriage in other vehicles and in primary care
settings and patients’ homes
10.4.1 Oxygen carriage in private cars (Health and Safety
Executive guidance)
When travelling by car, patients have the freedom to carry their
own portable oxygen cylinder.476 477 Some GPs in rural areas
also carry oxygen in their cars. However, it is advised that
certain safety precautions should be followed:
• Patients are allowed to carry oxygen cylinders for their own
use without putting any labels or signs on their vehicle. This
includes public transport such as buses or taxis. It is an
offence to display a hazard diamond if oxygen is not being
transported in a vehicle so it is preferable not to use a hazard
triangle on private vehicles.Figure 15 Tracheostomy mask.
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• The cylinder should be secure within the car and cannot
move during transport or in the event of an accident. The
authors of this guideline are aware of one fatality caused by a
patient smoking in a vehicle where an unsecured liquid
oxygen cylinder spilt into the ﬂoor-well during sudden
braking.
• Patients should inform their car insurance company if oxygen
is carried in the car.
10.4.2 Medical centres and primary care practices
The majority of medical centres and practices should have a
supply of oxygen for emergency use. Generally, cylinders with
integral high-ﬂow regulators should be ordered. Otherwise, the
cylinder must be ﬁtted with a high-ﬂow regulator capable of
delivering a ﬂow of up to 15 L/min in order to deliver medium-
concentration and high-concentration oxygen therapy. A recom-
mended list of oxygen delivery devices for use in prehospital
care is given in section 9.8.
Emergency oxygen should be available in primary care medical
centres, preferably using oxygen cylinders with integral high-ﬂow
regulators. Alternatively, oxygen cylinders ﬁtted with high-ﬂow
regulators (delivering up to 15 L/min) must be used to allow use
with reservoir masks (see recommendation V1).
10.4.3 Emergency use of oxygen in the patient’s home
In patients’ homes, oxygen is usually provided for long-term
therapy with an oxygen concentrator and an ambulatory supply
with lightweight cylinders (or a portable liquid oxygen system).
Long-term oxygen therapy is covered in other guidelines. In
some circumstances, there may be a supply of cylinders for
short-term/short-burst therapy or palliative use. The existing
home oxygen supply may be used by a patient or GP in an
emergency situation before the arrival of an ambulance using
the patient’s existing interface. If a GP is attending a patient at
home with oxygen, ideally, the use of oxygen should be guided
by pulse oximetry. The existence of any oxygen alert card
should be asked for so that the emergency services attending
can be aware of the target saturation and oxygen supply titrated
accordingly.
The patient/carers should be made aware of the following
Health and Safety recommendations:476 477
• All cylinders should be stored on a cylinder trolley or suitably
secured so they cannot be knocked over.
• There should be no trailing oxygen tubing.
• A green warning triangle for ‘compressed gas’ should be dis-
played by the front door (warns emergency services in the
event of a ﬁre).
• The minimum number of cylinders should be stored in the
house.
• There should be no smoking in the vicinity of oxygen
cylinders.
• Cylinders must be checked regularly for obvious signs of
leakage.
• Cylinders must be kept out of direct sunlight.
• Oxygen must not be used near a naked ﬂame or source of
heat.
10.5 Oxygen delivery systems in hospitals
Most hospitals have piped oxygen systems as described previ-
ously, although some wards can still be found where piped
oxygen is not available and large compressed gas cylinders are
used to supply the oxygen. Acute hospitals can spend up to
£100 000 per annum on liquid oxygen, so any device that uses
lower oxygen ﬂow rates could have signiﬁcant economic savings
for hospitals (eg, nasal cannulae instead of a simple face mask
for medium-concentration oxygen).
10.5.1 Perioperative and postoperative care
Medium-concentration masks and nasal cannulae are usually
sufﬁcient (target saturation 94–98%) except for patients with
known signiﬁcant COPD who should receive oxygen from a
24% or 28% Venturi mask or 1–2 L/min from nasal cannulae
aiming at a saturation range of 88–92%.
10.5.2 Emergency departments
Medium-concentration or high-concentration oxygen is nor-
mally used (via nasal cannulae, simple face mask or reservoir
mask), but particular attention should be given to patients who
have hypercapnic respiratory failure when a 24% or 28%
Venturi mask or nasal cannulae at a ﬂow rate of 1–2 L/min
would be appropriate.
10.5.3 General wards and respiratory wards
The method of oxygen delivery will depend on the following
circumstances:
• Expected duration of treatment.
• Type of respiratory illness.
• Pattern of breathing (high or low respiratory rate and drive).
• Need for humidiﬁcation.
• Risk of carbon dioxide retention.
• Presence of confusion and its effect on potential compliance.
Nasal cannulae, simple face masks, reservoir masks and
Venturi masks should be used where appropriate (see tables 1–4
and charts 1 and 2 in the main guideline). Nasal cannulae at
ﬂow rates or 0.5–1.0 L/min are sometimes used as a substitute
for Venturi masks in acute or postacute patients with COPD on
respiratory wards (adjusting ﬂow as necessary to achieve the
desired ABG tensions). This practice requires the use of paediat-
ric ﬂow meters to ensure consistent and ﬁnely calibrated oxygen
delivery and is not recommended outside specialist units.
10.5.4 Devices used in emergency oxygen therapy
Based on the advantages of each delivery system discussed
above, the following recommendations are made for delivery of
oxygen in medical emergencies. It is likely that additional equip-
ment will be maintained in specialist units, but specialist treat-
ment is outside the scope of the present guideline.
Good practice points (see tables 1–4)
✓ Most hospital patients can be managed with the same deliv-
ery device, as in good practice points which follow section
9.8, but a 24% Venturi mask should also be available.
• The high-concentration reservoir mask at 15 L/min is
the preferred means for delivering high-concentration
oxygen to critically ill patients until reliable pulse oxim-
etry monitoring has been established.
• Nasal cannulae should be used rather than simple face
masks in most situations requiring medium-
concentration oxygen therapy. Nasal cannulae are pre-
ferred by patients for reasons of comfort and they are
less likely to be removed during meals. There is also a
cost-saving.
• The ﬂow rate from nasal cannulae for medium-
concentration oxygen therapy should be adjusted between
2 and 6 L/min to achieve the desired target saturation.
• Venturi masks are recommended for patients requiring
precise control of FiO2. Venturi masks can deliver a con-
stant FiO2 of 24%, 28%, 31%, 35%, 40% and 60%
oxygen with a greater gas ﬂow than a simple face mask.
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In those at risk of developing hypercapnic respiratory
failure with oxygen therapy, the use of Venturi masks
may reduce this risk. Furthermore, there is less likeli-
hood of dilution of the oxygen stream by room air if
the patient’s inspiratory ﬂow rate exceeds the ﬂow rate
delivered by the face mask.
✓ For many patients, 24–28% Venturi masks can be substituted
with nasal cannulae at low-ﬂow rates (1–2 L/min) to achieve
the same target range.
✓ The ﬂow rate from simple face masks should be adjusted
between 5 and 10 L/min to achieve the desired target satur-
ation. Flow rates below 5 L/min may cause carbon dioxide
rebreathing and increased resistance to inspiration.
✓ Patients with COPD with a respiratory rate of >30 breaths/
min should have the ﬂow rate set to above the minimum
ﬂow rate speciﬁed for the Venturi mask and/or packaging
(see ﬁgure 11B) (increasing the oxygen ﬂow rate into a
Venturi mask increases the total gas ﬂow from the mask but
does not increase the concentration of oxygen which is
delivered).
✓ HFNC are well tolerated and may be used as an alternative
in hypoxic adult patients requiring medium-concentration to
high-concentration oxygen therapy and who are not at risk
of hypercapnia.
10.5.5 Flow meters
All oxygen delivery systems must have a method of taking the
high pressure/ﬂow of gas and reducing it so it can be adminis-
tered to the patient at a speciﬁc ﬂow depending on the indivi-
dual’s needs and mask being used. Piped oxygen points have
Schrader ﬂow meters and cylinders have pressure and ﬂow regu-
lators. Most oxygen ﬂow meters use a ﬂoating ball to indicate
the ﬂow rate. The centre of the ball should be aligned with the
appropriate ﬂow rate marking. The example shown in ﬁgure 16
indicates the correct setting to deliver 2 L/min.
10.5.6 Oxygen tubing and oxygen wall outlets
Oxygen tubing is needed to connect ﬂow meters and regulators
to the patient delivery device. It is important to ensure that all
tubing is connected correctly at both ends. The National Patient
Safety Agency has reported frequent adverse events related to
oxygen use, including four reports of instances where an
oxygen mask was connected in error to a compressed air outlet
instead of an oxygen outlet. Compressed air outlets are often
used to drive nebulisers in hospitals because they are quieter
than electrical compressors. However, the ﬂow meter looks very
similar to an oxygen ﬂow meter and is often mounted beside an
oxygen ﬂow meter so it is very important to ensure that air ﬂow
meters are clearly labelled. There is a similar risk with other
piped gas outlets such as those delivering nitrous oxide in some
hospitals. Air ﬂow meters are never required in an emergency
and should be removed from wall sockets or covered by a desig-
nated ‘hood’ when not in use, an example is shown in ﬁgure 17.
The guideline authors are also aware of some cases where
twin oxygen outlets were in use and the wrong one had been
turned on or off. For example, one patient tried to turn off the
oxygen ﬂow after ﬁnishing a nebulised treatment but acciden-
tally turned off the oxygen ﬂow to a neighbouring patient with
serious consequences. It is recommended that patients should
not be allowed to adjust oxygen ﬂow, especially if there are dual
outlets.
Healthcare organisations should take measures to eliminate
the risk of oxygen tubing being connected to the incorrect
wall oxygen outlet or to outlets that deliver compressed air or
other gases instead of oxygen. Air ﬂow meters should be
removed from the wall sockets or covered with a designated
air outlet cover when not in use. Special care should be taken
if twin oxygen outlets are in use (see recommendation V2).
Evidence statement
▸ Matters related to oxygen tubing and equipment and wall
outlets are based on expert opinion and manufacturers’
advice (evidence level 4).
Recommendation
V2: Healthcare organisations should take measures to elimin-
ate the risk of oxygen tubing being connected to the incorrect
wall oxygen outlet or to outlets that deliver compressed air or
other gases instead of oxygen. Air ﬂow meters should be
removed from the wall sockets or covered with a designated air
outlet cover when not in use. Special care should be taken if
twin oxygen outlets are in use (grade D).
10.6 Use of humidiﬁed oxygen
10.6.1 Rationale for use of humidiﬁed oxygen
The upper airway normally warms, moistens and ﬁlters inspired
gases. When these functions are impaired by a pathological
process or when they are bypassed by an artiﬁcial airway, it is
common practice to provide humidiﬁcation. The main reason
for using humidiﬁcation, especially with high-ﬂow oxygen, is
Figure 16 Flow meter showing correct setting to deliver oxygen at a rate of 2 L/min.
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that it may reduce the sensation of dryness in the upper airways
that oxygen can cause. However, in the non-intubated popula-
tion, there appears to be little scientiﬁc evidence of any beneﬁt
from humidiﬁed oxygen except that single doses of nebulised
isotonic saline have been shown to assist sputum clearance and
reduce breathlessness in patients with COPD.478 479 There is
also evidence that humidiﬁcation, when combined with physio-
therapy, can increase sputum clearance in bronchiectasis.480
RCTs of the effects of humidiﬁed high-ﬂow oxygen on patient
comfort are required. Use of low-ﬂow oxygen through nasal
cannulae is well tolerated without the need for humidiﬁca-
tion.481 HFNC require warmed and humidiﬁed oxygen.
Evidence statement
▸ The use of humidiﬁed oxygen in acute care is based on
expert opinion (evidence level 4).
Recommendations
Q1: Humidiﬁcation is not required for the delivery of
low-ﬂow oxygen (mask or nasal cannulae) or for the short-term
use of high-ﬂow oxygen. It is not therefore required in prehospi-
tal care. Pending the results of clinical trials, it is reasonable to
use humidiﬁed oxygen for patients who require high-ﬂow
oxygen systems for more than 24 hours or who report upper
airway discomfort due to dryness (grade D).
Q2: In the emergency situation, humidiﬁed oxygen use can
be conﬁned to patients with tracheostomy or an artiﬁcial airway
although these patients can be managed without humidiﬁcation
for short periods of time (eg, ambulance journeys) (grade D).
Q3: Humidiﬁcation may also be of beneﬁt to patients with
viscous secretions causing difﬁculty with expectoration. This
beneﬁt can be achieved using nebulised normal saline (grade D).
10.6.2 Use of bubble humidiﬁcation systems
Humidiﬁed oxygen is widely administered in hospitals across
the UK and this is presumed to alleviate nasal and oral discom-
fort in the non-intubated patient. Humidiﬁcation of supplemen-
tal oxygen was commonly delivered by bubbling oxygen
through either cold or warm sterile water before it reached the
patient. However, the effect on patient comfort is negli-
gible.481 482 Bubble humidiﬁers may, however, represent an
infection hazard and should not be used.483 There is no evi-
dence of a clinically signiﬁcant beneﬁt from ‘bubble bottle’
systems but there is an infection risk.
Evidence statement
▸ The advice not to use bubble bottles is based on expert
opinion (evidence level 4).
Recommendation
Q4: Bubble bottles which allow a stream of oxygen to
bubble through a container of water should not be used
because there is no evidence of a clinically signiﬁcant beneﬁt
but there is a risk of infection (grade D).
10.6.3 Large volume nebulisation-based humidiﬁers
If humidiﬁcation is required, it should ideally deliver the
inspired gas at a temperature of 32–36° C. Cold water humidi-
ﬁers are simple and inexpensive but less efﬁcient than a warm
water systems (about 50% relative humidity at ambient tempera-
tures). The warm water option is more effective, targeting a
relative humidity of 100%, but both systems are thought to be a
potential infection control risk. Warm water humidiﬁers are
expensive and mostly conﬁned to ICUs and HDUs and thus
outside the scope of this guideline.
Newer humidifying systems are really ‘giant nebulisers’
with a 1 L reservoir of saline or sterile water and an adjust-
able Venturi device (ﬁgure 18). These systems are attached
directly to the oxygen ﬂow meter and connected to an
aerosol mask via Flex tube. They allow delivery of precise
oxygen concentrations of 28%, 35%, 40% and 60% oxygen
via their Venturi device. This requires a speciﬁc oxygen ﬂow
rate as well as adjusting the Venturi nozzle on the device. It
is possible to deliver 24% oxygen using a special adaptor.
These large volume humidiﬁers have a high humidiﬁcation
output. The main indication for use is to assist with expec-
toration of viscous sputum. There are no published rando-
mised studies involving these devices, but it has been shown
that single doses of nebulised saline can assist sputum pro-
duction and relieve breathlessness in patients with
COPD.478 479
Good practice points related to humidiﬁed oxygen therapy
✓ Consider use of a large volume oxygen humidiﬁer device for
patients requiring high-ﬂow rates or longer term oxygen,
especially if sputum retention is a clinical problem.
✓ In the absence of an artiﬁcial airway, the decision to humid-
ify supplemental oxygen needs to be made on an individual
basis but this practice is not evidence-based.
10.7 Use of oxygen in patients with tracheostomy or
laryngectomy
The number of patients with a tracheostomy being cared for in
a ward setting is increasing as critical care personnel use this as
a method of facilitating weaning from mechanical ventilation. In
the absence of a pressurised circuit, oxygen is predominantly
delivered via tracheostomy mask. This is a variable performance
device and delivers concentrations up to 60–70%. If the patient
deteriorates and requires an increased oxygen concentration
exceeding the concentration that a variable performance inter-
face can deliver (60–70%), it will be necessary to seek an alter-
native delivery system, usually a T-piece device ﬁtted directly to
the tracheostomy tube.
With a mask system, the interface will be connected to a
humidiﬁcation system via elephant tubing. As inserting a trache-
ostomy tube bypasses the patient’s natural mechanisms to warm
and moisturise inspired gases, it is essential to humidify any sup-
plemental oxygen being delivered to the tracheotomised patient.
This will help maintain a patent tracheostomy tube, reducing
the build-up of secretions within the inner tube or the tracheos-
tomy itself and minimising any subjective discomfort that the
patient may experience.
Evidence statement
▸ The use of tracheostomy masks is based on expert opinion
and clinical experience (evidence level 4).
Figure 17 Air outlet cover.
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Recommendation
P1: When oxygen is required by patients with prior tracheos-
tomy or laryngectomy, a tracheostomy mask (varying the ﬂow
as necessary) should achieve the desired oxygen saturation
(tables 1–4). An alternative delivery device, usually a T-piece
device ﬁtted directly to the tracheostomy tube, may be necessary
if the patient deteriorates (grade D).
10.8 Delivering oxygen to patients who require nebulised
bronchodilator therapy
10.8.1 Nebulised bronchodilator therapy in asthma
In patients with acute severe asthma, oxygen should be used as
the driving gas for the nebulised bronchodilators whenever pos-
sible at a gas ﬂow rate of 6–8 L/min because these patients are at
risk of hypoxaemia. If the available cylinders in general practice
do not produce this ﬂow rate, an air-driven nebuliser (with elec-
trical compressor) should be used with supplemental oxygen by
nasal cannulae at 2–6 L/min to maintain an appropriate oxygen
saturation level. There is some evidence that bronchodilator
therapy (whether delivered by nebuliser or by metered dose
inhaler) may cause pulmonary vasodilation leading to increased
V/Q mismatch and reduced blood oxygen levels in acutely ill
patients and in patients with stable COPD and asthma.484–486
The lowest oxygen saturation occurs not during bronchodilator
therapy but about 25 min later.486 One group reported a rise in
oxygen saturation during bronchodilator therapy.487
There is some evidence that bronchodilator therapy, however
given, can cause increased V/Q mismatch and reduced blood
oxygen levels in acutely ill patients shortly after treatment.
10.8.2 Nebulised bronchodilator therapy for patients with COPD
and other risk factors for hypercapnic respiratory failure
When an oxygen-driven nebuliser is given to patients with
COPD there is a risk of hypercapnia and acidosis due to the high
FiO2 which is delivered. In AECOPD the carbon dioxide level
can rise substantially within 15 min of starting high-
concentration oxygen therapy.48 Edwards et al488 have conﬁrmed
that oxygen-driven nebulisers cause elevation of the blood CO2
level in patients with COPD. The Austin et al’s51 study which
demonstrated improved mortality with targeted oxygen therapy
in patients with AECOPD used air-driven nebulisers to ensure
that the target saturation was maintained. When nebulised
bronchodilators are given to hypercapnic patients, they should
ideally be given using an electrical compressor or ultrasonic
nebuliser and, if necessary, supplementary oxygen should be
given concurrently by using nasal cannulae at 1–4 L/min to main-
tain an oxygen saturation of 88–92%. For hypercapnic patients
or those with a history of hypercapnia, oxygen saturation should
be monitored continuously during nebulised treatments. If an
electrical compressor or ultrasonic nebuliser is not available,
compressed air can be used to drive the nebuliser but care should
be taken to ensure that the nebuliser is not attached to an oxygen
outlet (see section 10.8). Once the nebulised treatment is com-
pleted, targeted oxygen therapy should be reinstituted.
Compressed air is not routinely available for treatment by
ambulance staff. In this situation, oxygen-driven nebulisers may
be used but should be limited to 6 min for patients with known
COPD because the nebuliser mask delivers a high concentration
of oxygen (about 60%). Since most of the effective dose from a
nebuliser chamber is delivered within 6 min, limiting oxygen-
driven nebulisers to 6 min will minimise the risk of hypercapnic
respiratory failure while delivering most of the nebulised drug
dose. It must be recognised that patients with COPD may
develop hypercapnia and respiratory acidosis if they are left on
high-ﬂow oxygen via a nebuliser mask system long after the neb-
ulisation process has ﬁnished.
Evidence statement
▸ High-concentration oxygen therapy can cause hypercapnia
within 15 min in acute COPD (evidence level 4).
▸ The use of oxygen to drive nebulisers is based on expert
opinion and extrapolation from observational studies (evi-
dence level 4).
Recommendations
R1: For patients with asthma, nebulisers should be driven by
piped oxygen or from an oxygen cylinder ﬁtted with a high-
ﬂow regulator capable of delivering a ﬂow rate of >6 L/min.
The patient should be changed back to his/her usual oxygen
mask or cannulae when nebuliser therapy is complete. If the
cylinder does not produce this ﬂow rate, an air-driven nebuliser
(with electrical compressor) should be used with supplemental
oxygen by nasal cannulae at 2–6 L/min to maintain an appro-
priate oxygen saturation level (grade D).
R2: When nebulised bronchodilators are given to patients
with hypercapnic acidosis, they should be given using an ultra-
sonic nebuliser or else a jet nebuliser driven by compressed air
and, if necessary, supplementary oxygen should be given con-
currently by nasal cannulae to maintain an oxygen saturation of
88–92%. The same precautions should be applied to patients
who are at risk of hypercapnic respiratory failure prior to the
availability of blood gas results and the oxygen saturation
should be monitored continuously during treatment. Once the
nebulised treatment is completed for patients at risk of hyper-
capnic respiratory failure, their previous targeted oxygen
therapy should be reinstituted (grade D).
Good practice points
Do not allow hypoxaemia to occur while administering nebu-
lised treatments:
✓ For hypoxaemic patients, oxygen therapy should continue
during nebulised treatments.Figure 18 Large volume nebulisation-based humidiﬁer.
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Driving gas for nebulised treatment in ambulances:
✓ During treatment by ambulance staff oxygen-driven nebuli-
sers should be used for patients with asthma and may be
used for patients with COPD in the absence of an air-driven
compressor system. If oxygen is used for patients with
known COPD, its use should be limited to 6 min. This will
deliver most of the nebulised drug dose but limit the risk of
hypercapnic respiratory failure (section 10.4). Ambulance
services are encouraged to explore the feasibility of introdu-
cing battery-powered, air-driven nebulisers or portable ultra-
sonic nebulisers.
10.9 Delivery of helium–oxygen mixtures (Heliox)
The use of helium–oxygen mixtures is discussed in section 8.18.
The evidence base for the use of this gas mixture is weak and
the use of Heliox as an inspired gas or as the driving gas for
nebuliser therapy is not recommended outside of randomised
clinical trials. The use of Heliox affects the delivery of aerosol-
ised treatment in complex ways so the choice of nebuliser
systems for the use of Heliox as a driving gas in clinical trials is
outside the scope of this guideline. The most likely use for
Heliox in clinical practice is for patients with mechanical upper
airway obstruction or postoperative stridor. It has been shown
that Heliox administration via a standard high-concentration
reservoir mask leads to signiﬁcant dilution by room air.489 For
this reason, Heliox should be administered via a system that
achieves a gas tight seal, with no leaks between the delivery
device and the surroundings.
Heliox 80:20 mixture has a similar oxygen content to air
(nitrogen:oxygen 79:21). Heliox 70:30 delivers a higher FiO2
but is more dense than Heliox 80:20 because it contains more
oxygen which is denser than helium. The overall balance
between oxygen content and gas density has not been addressed
in clinical trials but it is recommended that clinicians should aim
to keep the saturation in the appropriate target range for the
individual patient, usually 94–98% for patients with asthma or
upper airway obstruction and 88–92% for patients with severe
COPD.
10.10 Delivery of nitrous oxide/oxygen mixtures (eg,
Entonox)
The use of nitrous oxide/oxygen mixtures (Entonox, a 50:50
mix) is discussed in section 8.18. The gas is supplied in a range
of cylinder sizes ranging from small portable cylinders for
ambulances to much larger ones that can allow the gas to be
piped to various outlets around a labour ward. The gas mixture
is usually self-administered using a facemask with a demand
valve that the patient holds to their face. The demand valve
opens to allow gas to ﬂow when it detects an inspiration. Like
oxygen, Entonox is classiﬁed as a medical gas, and although it is
recommended that it is prescribed, it is not a prescription-only
medicine. The manufacturers recommend that it should only be
prescribed and administered by suitably trained personnel
within established clinical guidelines or protocols.
10.11 Delivery of oxygen during procedures that may
partially occlude the airway (eg, bronchoscopy)
Reduction in oxygen saturation is common during endoscopic
procedures that may partially occlude the airway such as bron-
choscopy and upper GI endoscopy, and supplemental oxygen is
recommended in some guidelines for all patients given sedation
and selected patients without sedation.402 490 491 This guideline
emphasises the importance of monitoring oxygenation during
the procedure by use of continuous pulse oximetry (see section
8.16).
All guidelines stress caution with the use of sedation and sup-
plemental oxygen in those at risk of hypercapnia. The BSG
guidelines recommend preoxygenation at 2 L/min to prevent
hypoxaemia, claiming that this is safe even in patients with
COPD.491 However, the authors of this guideline recommend
that oxygen should be administered only to correct hypoxaemia.
Particular caution is advised in patients who may be prone to
carbon dioxide retention and the use of transcutaneous CO2
monitoring in these patients has been suggested.492
Generally, oxygen is delivered at a ﬂow rate of at least 2 L/
min via nasal cannulae through one or both nostrils to maintain
oxygen saturations above 90% or to correct falls in saturation of
>4% as discussed in section 8.16. Patient positioning (supine or
semirecumbent) had no signiﬁcant effect on oxygen saturations
during bronchoscopy in a study of 38 patients.393
Evidence statement
▸ The use of oxygen during endoscopic procedures is based on
expert opinion and extrapolation from observational studies
(evidence level 4).
Recommendations J2–J6
J2: All procedures involving conscious sedation warrant
routine continuous monitoring of oxygen saturation via pulse
oximetry prior to and during the procedure, and in the recovery
period, particularly ﬁbre-optic bronchoscopy and upper GI
endoscopy where a reduction in SaO2 is common, particularly
with concurrent use of sedation.
J3: Signiﬁcant arterial oxygen desaturation (SpO2<90% or
fall of 4% or more that is prolonged (>1 min during endoscopy
procedures)) should be corrected by supplemental oxygen with
the aim of achieving target oxygen saturations of 94–98%, or
88–92% in those at risk of hypercapnic respiratory failure.
J4: Complicated upper GI endoscopy or procedures in
patients with cardiorespiratory comorbidity are especially likely
to lead to hypoxaemia and may also lead to hypercapnia, espe-
cially if the patient is heavily sedated. It is recommended that
blood gases should be measured if such patients should require
prolonged oxygen administration. The routine administration of
oxygen is not recommended as it may delay the recognition of
respiratory failure.
J5: Constant clinical assessment of the patient is crucial at all
stages of conscious sedation procedures and monitoring of cap-
nography or transcutaneous carbon dioxide levels may be a
useful adjunct to identify early respiratory depression.
J6: During the recovery period after procedures requiring
conscious sedation, supplemental oxygen should be titrated to
achieve target saturations of 94–98% in most patients and 88–
92% in those at risk of hypercapnic respiratory failure (see
section 10.5.1).
10.12 CPAP devices and indications
CPAP is a form of non-invasive ventilatory support that may be
used when high inspired oxygen concentrations (>60%) are not
sufﬁcient to maintain adequate oxygenation in patients with
respiratory failure without hypercapnia. CPAP maintains a fairly
constant positive pressure throughout inspiration and expir-
ation, and the positive pressure applied is thought to improve
lung expansion, recruit atelectactic areas and offset intrinsic
PEEP, reducing work of breathing. Conditions in which CPAP
has been used successfully in the management of acute respira-
tory failure include heart failure, pneumonia, ARDS, chest wall
trauma and pulmonary ﬁbrosis avoiding intubation and mechan-
ical ventilation.
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The indications, use and equipment required for CPAP are
more fully described in the BTS guideline for NIV.209 Generally,
a gas ﬂow generator is required, usually powered by the wall air
and oxygen supplies or oxygen cylinder, and delivered by a
tightly ﬁtting facial or nasal mask, or hood. The level of positive
pressure can be adjusted by the use of different sized valves
ﬁtted to the mask, or by a single variable valve. Domiciliary
CPAP machines used for the treatment of OSA are not suitable
for the management of respiratory failure as they may not be
able to maintain pressure in patients with rapid respiratory rates
and high minute ventilation. Non-invasive ventilators that are
designed to deliver BiPAP can be used to deliver CPAP by
setting the same inspiratory and expiratory pressure.
SECTION 11: PRESCRIPTION, ADMINISTRATION AND
MONITORING OF OXYGEN THERAPY
11.1 Safe prescription and administration of oxygen
11.1.1 Legal status of medical oxygen: Does it need a
prescription?
Medical oxygen is a drug. However, the legal status of oxygen
in the UK is that of a medicinal product on the General Sales
List (Medicines and Healthcare Products Regulatory Agency,
personal communication). This means that the sale or dispensa-
tion of oxygen does not technically require a prescription
because it is not a ‘prescription-only medicine’. This status was
conferred for practical reasons to facilitate the use of oxygen in
the domiciliary setting where the distribution system no longer
involves pharmacies. However, the use of oxygen by parame-
dics, registered nurses, doctors, physiotherapists and others in
emergency situations is similar to the use of all other medicinal
products by these people. Clinical governance requires that the
intentions of the clinician who initiates oxygen therapy should
be communicated clearly to the person who actually administers
oxygen to the patient and an accurate record must be kept of
exactly what has been given to the patient. In this respect,
oxygen is in the same category as paracetamol, aspirin, ibupro-
fen, antihistamines, antiemetics and many other medicines that
do not require a prescription if purchased by a patient for his/
her own use but do require accurate documentation if adminis-
tered by a health professional to a patient. In healthcare settings,
all of these medicines are conventionally recorded on a ‘pre-
scription chart’ or ‘drug kardex’ alongside drugs in the
‘prescription-only’ category such as antibiotics.
A hospital ‘prescription chart’ is a document in which doctors
and other prescribing clinicians make a list of all drugs and
medicinal products required by a patient and where registered
nurses and other clinicians make a record of all drugs that have
been administered to the patient. In many hospitals, the pre-
scription and documentation of administration are recorded dir-
ectly into the Electronic Patient Record. These documents are
also used by hospital pharmacies to dispense medicines but, for
technical reasons, these hospital documents (or the equivalent
documents in primary care settings or the Patient Report Form
(PRF) or electronic PRF used by the ambulance services) do not
have the same legal status as a prescription that is given to a
patient to take to a community pharmacist for the purposes of
dispensing a medicine. The ‘prescription’ of oxygen in acute
healthcare settings is therefore not technically a prescription for
two reasons: (1) oxygen is not a prescription-only medicine;
and (2) a hospital drug chart is not truly a prescription. The
second issue applies to all medicines used in healthcare settings,
not just to oxygen. However, the words ‘prescription’ or ‘pre-
scription chart’ are widely used to describe the documents
which record the use of medicines in UK hospitals and other
healthcare settings. For this reason, the present guideline will
use the term ‘prescribe’ and ‘prescription chart’ for all orders
for oxygen use. The important issue is that there must be a clear
written record of all medicinal products, including oxygen,
which are given to a patient by healthcare professionals. Ideally,
this document should be prepared at the time when oxygen
therapy is started. In emergencies, however, clinicians will treat
the patient ﬁrst and subsequently make written records of all
treatments given, including oxygen therapy.
11.1.2 Reasons to prescribe oxygen therapy
Oxygen is prescribed for hypoxaemic patients to increase PO2
and decrease the work of breathing necessary to maintain a
given PaO2 (see section 6). The concentration of oxygen
required depends on the condition being treated; an inappropri-
ate concentration may have serious or even lethal effects.
Appropriate target saturation ranges for common medical emer-
gencies are given in section 8 of this guideline and in tables 1–4.
Each hospital should have an agreed policy and protocol for
oxygen prescribing to allow staff to adjust oxygen delivery
devices and to give oxygen in emergency situations prior to the
availability of a prescription. The use of a patient group direc-
tion (PGD) may be appropriate if other solutions have not
worked in the clinical setting. Please see details at: https://www.
nice.org.uk/guidance/MPG2 and http://www.medicinesresources.
nhs.uk/en/Communities/NHS/PGDs/.
Although a PGD is not strictly required for medical gases
(because they are not a prescription-only medicine) it is import-
ant for every organisation to have a written policy to regulate
oxygen use up to time when a prescription is written, for
example, for patients arriving by ambulance in the emergency
department with oxygen use already initiated by the ambulance
service. For some organisations, a PGD may be considered as the
best way to address this important issue. BTS audits up to 2015
have shown that only 57% of patients using supplemental oxygen
in UK hospitals had a valid prescription or written order. This is
a situation that would not be tolerated for any other drug.
11.1.3 Implementing an oxygen prescription policy
Oxygen prescriptions may include initial mode of delivery and
ﬂow rate (eg, 4 L/min via nasal cannulae). But the most import-
ant aspect of the prescription is to give a target range. The clini-
cians who administer oxygen (usually registered nurses,
midwives or physiotherapists) should be trained and empowered
to adjust the oxygen concentration upwards and downwards as
necessary to maintain the patient in the target saturation range
(including adjustments made during nebulised therapy driven by
oxygen or nebulised therapy driven by air with simultaneous
administration of oxygen by nasal cannulae). This will require
all hospitals to have an agreed oxygen administration pro-
gramme with universal access to educational materials about
oxygen administration. The clinicians who monitor the oxygen
saturation (often healthcare assistants) should be trained to
inform those who have been trained to administer oxygen if the
oxygen saturations fall above or below the target saturations.
Those doing the monitoring should also understand the import-
ance for the patient of keeping in the target range.
Implementing this policy will require all organisations to have
agreed procedures (which may include PGDs up to the time
when a prescription is written) and training programmes for all
clinical staff and regular training programmes in the safe use of
oxygen and audit of outcomes.
Many hospitals have developed an ‘admission bundle’ for all
patients admitted to hospital. This bundle may include checking
i74 O’Driscoll BR, et al. Thorax 2017;72:i1–i90. doi:10.1136/thoraxjnl-2016-209729
BTS guideline
group.bmj.com on April 7, 2018 - Published by http://thorax.bmj.com/Downloaded from 
for hospital-associated thrombosis risk, checking MRSA risk and
the prescription of antithrombotic agents and anti-MRSA agents
if appropriate. As part of this process, many hospitals now
specify that an oxygen saturation target must be set for all
patients on admission to hospital so that the nursing team will
know the correct starting target range if oxygen therapy should
suddenly become necessary (as well as making a callout to the
medical team to assess the patient). Furthermore, this allows
nurses making bedside observations to know if the oxygen satur-
ation is appropriate for each patient whether or not the patient
is receiving oxygen at the time when the observation is made.
Some older people without respiratory problems may have
oxygen saturation below 94% and the target range for such
patients should be adjusted accordingly. It was reported in the
2011 BTS national emergency oxygen audit that almost half of
UK hospitals now have a policy of setting a target saturation
range for all patients at the time of admission to hospital.
Policies of this sort will become even more important when the
EWS system takes oxygen saturation (above or below target
range) into account.16
11.1.4 Administration and monitoring of oxygen therapy
The appropriate device should be used to provide the prescribed
oxygen and the effects should be monitored using pulse oxim-
etry, monitoring of respiratory rate and close observation of the
patient. Arterial or capillary blood gas analysis should be
repeated if clinical progress is not satisfactory and in all cases of
hypercapnia and acidosis.
11.1.5 Education of health professionals
The clinician or registered healthcare professional administering
the oxygen therapy should be aware of the hazards of hypox-
aemia and hyperoxaemia and the signs and symptoms of inad-
equate or excessive oxygen delivery.
11.1.6 How to prescribe oxygen effectively
In the past, oxygen was often not prescribed at all or prescribed
on a standard hospital drug chart as ‘oxygen’. It was unusual for
the prescription to include full details of what device to use,
what ﬂow rate(s) to administer and whether the prescription
was for a ﬁxed concentration of oxygen or to aim at a speciﬁc
oxygen saturation target.4–10
It has been shown that a purpose-designed oxygen prescrip-
tion sheet can improve oxygen prescribing in the short term,
but experience has shown that free-standing oxygen prescription
charts are often forgotten and unused.7 Recent audit studies by
members of the guideline group (part of annual BTS hospital
oxygen audits) have shown improved standards of prescribing
with the use of a preprinted section for oxygen use in all hos-
pital drug charts and with prompted electronic prescribing of
oxygen for all hospital patients. This system was further
enhanced by setting a desired saturation range for each patient.
Suggested target saturations for common medical conditions are
given in sections 8 and 9 of this guideline. It is important that
healthcare professionals where oxygen is administered are famil-
iar with the optimal saturation ranges for common conditions
(see online appendix 3), and it is also important that those deli-
vering the oxygen are familiar with the equipment in use and
the best types of device to deliver low-concentration, medium-
concentration and high-concentration oxygen therapy. Figure 19
shows a working example of a preprinted oxygen section for a
hospital prescription chart, and ﬁgures 1 and 2 (charts 1 and 2)
give advice to prescribers and advice to those delivering oxygen
onwards.
The safe use of oxygen includes careful consideration of the
appropriate delivery device (mask, cannulae, etc) together with an
appropriate source of oxygen and an appropriate oxygen ﬂow rate.
An oxygen target range should be prescribed for all hospital
patients. The method and rate of oxygen delivery should be
altered by registered nurses or other registered healthcare profes-
sionals in order to achieve the prescribed target saturation as per
the hospital policy. For most conditions, oxygen should be pre-
scribed to achieve a target saturation of 94–98% (or 88–92% for
those at risk of hypercapnic respiratory failure). The nurse should
sign this prescription chart or the electronic equivalent on every
drug round. This signature on the drug chart conﬁrms that the
patient is either receiving appropriate oxygen therapy (the delivery
device and ﬂow rate should be documented alongside the SpO2 on
the bedside observations chart or electronic observations system)
or else has SpO2 within the target range on air at the most recent
observation round. It is not necessary to measure oximetry during
drug rounds but action may be required if the patient was docu-
mented to be outside of their target range at the most recent obser-
vations round and if no action has yet taken place.
Evidence statement
▸ Prescription of oxygen in acute illness is based on expert
opinion (evidence level 4).
Recommendations for safe prescribing and safe administration of
oxygen
S1: Every healthcare facility should have a standard oxygen
prescription document or, preferably, a designated oxygen
section on all drug-prescribing cards or guided prescription of
oxygen in electronic prescribing systems (grade D).
S2: A prescription for oxygen should always be provided,
except in sudden illness when it must be started immediately
and documented retrospectively (grade D).
S3: Doctors and other prescribers should prescribe oxygen
using a target saturation range (sections 8, 9 and 11) and sign
the drug chart or electronic prescribing order (grade D).
S4: An oxygen target saturation range should be prescribed
for all patients who are admitted to hospital. This will ensure
that every patient will receive appropriate oxygen therapy if it
should be required. It will also ensure that all clinicians are
aware of the appropriate oxygen target range for every patient
under their care (grade D).
Good practice points related to prescribing and administering
oxygen therapy to patients
✓ Oxygen should be prescribed on the drug chart or electronic
prescribing system using a target saturation range.
✓ Oxygen should be prescribed to a target saturation range
rather than prescribing a ﬁxed concentration of oxygen or
FiO2 (see recommendations A1, A2, A4 and A5).
✓ For hypoxaemic patients, oxygen therapy should continue
during other treatments such as nebulised therapy. Clinicians
should assess the clinical status of the patient prior to pre-
scribing oxygen and the patient’s condition should be reas-
sessed frequently during oxygen use (see recommendations
B1–B3).
✓ In most emergency situations, oxygen is given to patients
immediately without a formal prescription. The lack of a
prescription should never preclude oxygen being given when
needed in an emergency situation. However, a subsequent
written record must be made of what oxygen therapy has
been given to every patient in a similar manner to the
recording of all other emergency treatment.
✓ If a patient has an oxygen alert card, initial oxygen therapy
should be based on the guidance on the card until the results
of blood gases are available.
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Monitoring and adjusting therapy (see sections 9–11)
T1: Pulse oximetry must be available in all locations where emer-
gency oxygen is being used by healthcare professionals (see also the
limitations of using pulse oximetry section 7.1.2) (grade D).
T2: All documents which record oximetry measurements or
blood gas results should state whether the patient is breathing
air or a speciﬁed oxygen delivery device and ﬂow rate using the
abbreviations shown in table 5 (grade D).
T3: In all situations where repeated blood gas measurements
are required, they should be measured as soon as possible,
usually within 30 min of any treatment change, to determine if
the proposed target saturations are appropriate. Consider the
use of an indwelling arterial catheter if multiple samples are
likely to be required (grade D).
T4: Adjustments should only be made by registered staff who
have been trained to administer oxygen. If the oxygen satur-
ation falls below the prespeciﬁed range, the concentration of
oxygen should be increased; if the saturation rises above this
range, the oxygen concentration should be reduced. If the moni-
toring of oxygen saturation is performed by unregistered staff
(eg, healthcare assistants), there must be a clear protocol in
place which requires that they should inform staff who are
trained to administer oxygen if the oxygen saturation is above
or below the target saturation (grade D).
Good practice points related to administration of oxygen therapy
✓ For hypoxaemic patients, oxygen therapy should continue
during other treatments such as nebulised therapy. Clinicians
should assess the clinical status of the patient prior to pre-
scribing oxygen and the patient’s condition should be reas-
sessed frequently during oxygen use (see recommendations
B1–B3).
✓ The administering healthcare professional should note the
oxygen saturation before stating oxygen therapy whenever
possible but never discontinue or delay oxygen therapy for
seriously ill patients (see recommendation B2).
✓ The healthcare professional should start oxygen therapy
using an appropriate delivery system and ﬂow rate as speci-
ﬁed in sections 8– 10 of this guideline. The target oxygen
saturation should be documented on the respiratory section
of the observation chart.
✓ Whenever possible, patients should be given an oxygen
information sheet (example in web appendix 6 of this guide-
line on the BTS website).
✓ Staff should check the oxygen supply and connections on a
regular basis because there have been serious incidents due
to disconnection or misconnection of oxygen supplies.
✓ Staff must ensure that adequate oxygen is provided during
transfers and while patients are in diagnostic departments.
Additionally, oxygen saturation should be monitored
continuously for seriously ill patients who require escorted
transfers. This is because there have been serious incidents
involving accidental discontinuation of oxygen or cylinders
running out during interward transfers or transfers to other
departments such as for x-rays.
Practical aspects of oxygen dispensing, documentation and
monitoring
W1: Registered nurses and others who dispense drugs in hos-
pitals should sign the drug chart or electronic prescribing record
at every drug round and check that the patient is receiving
oxygen therapy. This is to check that the patient is within the
target saturation and also to check whether weaning and dis-
continuation should be instituted (grade D).
W2: Most patients are prescribed an oxygen target range. If
patients are on air at the time of the drug round, registered
nurses should sign the drug chart using a code such as ‘A’ for
air and the observation chart should also be ﬁlled in using the
code A for air (see table 5 and ﬁgure 19; grade D).
W3: All patients should have their oxygen saturation
observed for at least 5 min after starting oxygen therapy or for
patients who require an increased concentration of oxygen and
after oxygen therapy has been decreased or stopped (grade D).
W4: If the oxygen saturation is above the target saturation
range and the patient is stable, the delivery system or oxygen
ﬂow rate should be modiﬁed to return the saturation to within
the target range (grade D).
W5: Patients who have a target saturation of 88–92% should
have their blood gases measured within 30–60 min. This is to
ensure that the carbon dioxide level is not rising. This recom-
mendation also applies to those who are at risk of developing
hypercapnic respiratory failure but who have a normal PCO2
on the initial blood gas measurement (grade D).
W6: Stable patients whose oxygen saturation is within their
target saturation range of 94–98% do not need repeat blood
gas measurements within 30–60 min if there is no risk of hyper-
capnic respiratory failure and acidosis and may not need any
further blood gas measurements unless there should be further
deterioration including symptoms or signs of possible hypercap-
nia (grade D).
W7: Stable patients on oxygen treatment should have SpO2
and physiological variables (eg, NEWS) measured four times a
day (grade D).
W8: In those who have signs of critical illness (eg, NEWS 7
or above), oxygen saturation should be monitored continuously
and the patient may require level 2 or 3 care on a HDU or crit-
ical care unit (grade D).
W9: If the patient is clinically stable and the oxygen saturation
is within the target range, treatment should be continued (or even-
tually lowered) depending on the clinical situation (grade D).
Figure 19 Working example of
oxygen section for hospital prescription
charts. *Saturation is indicated in
almost all cases except for terminal
palliative care.
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W10: Oxygen therapy should be increased if the saturation is
below the desired range and decreased if the saturation is above
the desired range (and eventually discontinued as the patient
recovers) (grade D).
W11: The new saturation (and the new delivery system) and
ﬂow rate should be recorded on the patient’s observation chart
after 5 min of treatment at the new oxygen concentration. Each
change should be recorded by the clinician trained to administer
oxygen by signing the observation chart (only changes should
be signed for) (grade D).
W12: Repeat blood gas measurements are not required for
stable patients who require a reduced concentration of oxygen
(or cessation of oxygen therapy) to maintain the desired target
saturation (grade D).
W13: Patients with no risk of hypercapnic respiratory failure
do not always need repeat blood gas measurements after an
increase in oxygen concentration. However, the patient requires
clinical review to determine why the oxygen saturation has
fallen (grade D).
W14: Patients at risk of hypercapnic respiratory failure
(usually those with a target range of 88–92%; see table 4)
require repeat blood gas assessment 30–60 min after an increase
in oxygen therapy (to ensure that the carbon dioxide level is not
rising) (grade D).
W15: For patients with no risk of hypercapnic respiratory
failure, monitoring by pulse oximeter is sufﬁcient (repeated
blood gases not required) provided the patient is clinically
stable and the oxygen saturation remains in the desired range,
usually 94–98% (grade D).
W16: If a patient’s oxygen saturation is lower than the pre-
scribed target range, ﬁrst check all aspects of the oxygen delivery
system and the oximeter device for faults or errors (grade D).
W17: If a patient’s oxygen saturation is consistently lower
than the prescribed target range, there should be a medical
review and the oxygen therapy should be increased according to
an agreed written protocol (grade D).
W18: If the oxygen saturation fails to rise following 5–
10 min of increased oxygen therapy or if there is clinical
concern following medical review, then blood gas measurements
should be repeated (grade D).
Training in oxygen prescribing and use
X1: All clinicians prescribing oxygen should have appropriate
training and access to written or electronic oxygen prescribing
guidelines based on this national guideline (grade D).
(Training slides for doctors and nurses are available as online
supplementary appendices 7 and 8 on the BTS website.)
X2: Every hospital should have a training programme to
ensure that clinical staff are familiar with the hospital’s oxygen
administration policies. In view of the high number of adverse
incidents related to oxygen therapy, it is recommended that all
acute Trusts should include basic training in oxygen use in the
mandatory training programmes for all clinical staff (grade D).
11.2 Starting oxygen therapy
Safe prescribing and safe administration of oxygen are closely
linked. In emergencies, oxygen therapy should be started imme-
diately and documented as soon as possible. In all other situa-
tions, oxygen should be prescribed in accordance with the
standards described in section 11.1 before administration is
started. The healthcare professional who administers the oxygen
therapy (usually a nurse or physiotherapist) should be fully
trained and should follow local or national protocols as
described in section 11.1.
Good practice points
✓ The administering healthcare professional should note the
oxygen saturation before starting oxygen therapy (see recom-
mendation B2).
✓ The healthcare professional should start oxygen therapy
using an appropriate delivery system and ﬂow rate as speci-
ﬁed in sections 8 –10 of this guideline. The target oxygen
saturation should be documented on the respiratory section
of the observation chart.
✓ Whenever possible, patients should be given an oxygen
information sheet (example in web appendix 6 of this guide-
line on the BTS website).
11.3 Monitoring oxygen therapy
11.3.1 Pulse oximeters
Pulse oximetry should be available to all healthcare staff man-
aging patients receiving oxygen therapy and they should be
trained in their use (see section 7 for technical and practical
information regarding oximeter use). Clinicians should be aware
that pulse oximetry gives no information about the PCO2 or pH
and most pulse oximeters are unreliable when a patient’s SpO2
falls below about 85%. Pulse oximetry is dependent on pulsatile
ﬂow, and it may not be possible to achieve a satisfactory oxim-
eter reading in patients with cold hands, especially those with
severe Raynaud’s phenomenon due to collagen vascular diseases
(which may also cause hypoxic lung disease). The readings may
also be affected by shock, skin pigmentation, nail varnish, etc
(see section 7). It is essential to record the oxygen delivery
system alongside the oximetry result.
All measurements of oxygen saturation should be recorded in
the observation chart along with the code for the oxygen delivery
system that is being used. If the patient is breathing air at the time
of the observation, this should also be recorded in the chart (see
recommendation B2 and ﬁgure 19).
11.3.2 Arterial or arterialised capillary blood gases
• Arterial or arterialised capillary blood gases should be mea-
sured and the oxygen device and ﬂow rate should be noted
on arrival at hospital (or at the time when oxygen therapy
becomes necessary) for most patients requiring emergency
oxygen therapy (see recommendations C1–C3).
• Blood gas measurements should be repeated in all critically
ill patients and in many other cases according to the response
to treatment (see recommendations C1–C3).
11.3.3 Physiological monitoring: ‘track and trigger’ systems
• EWS systems such as the NEWS are useful for monitoring
patients.
• Tachypnoea is a sensitive indicator of deteriorating respira-
tory function.
• All acutely ill patients should have physiological monitoring
using EWS or a similar physiological assessment system in
addition to pulse oximetry (see recommendation B3).
• The original 2012 version of the NEWS allocated inappro-
priate points for hypoxaemia to patients with target ranges
below 94–98% who were within their target range. It was
necessary to correct for this when using such charts.165
This is recognised in the 2017 update of the NEWS chart
which makes special provision for patients at risk of hyper-
capnia. Patients at risk of hypercapnia should score no
NEWS points for saturation if within their target range and
they should score points if the oxygen saturation falls below
the target range or if the saturation rises above the target
range while breathing oxygen.
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11.3.4 Monitoring during the ﬁrst hour of oxygen therapy
Evidence statement
▸ Monitoring of oxygen therapy is based on expert opinion.
▸ All patients should have their oxygen saturation observed for at
least 5 min after starting oxygen therapy or for patients who
require an increased concentration of oxygen and after oxygen
therapy has been decreased or stopped (see recommendation
W3) (evidence level 4).
11.3.5 Subsequent monitoring
The exact requirements for monitoring will depend on the clin-
ical condition of each patient. Saturations are usually measured
after 1 hour of oxygen therapy and then four-hourly. Stable
patients should be monitored four times a day. However, critic-
ally ill patients will require continuous monitoring of oxygen
saturation and other physiological measurements.
11.3.6 When to increase oxygen therapy
In most instances, failure to achieve the desired oxygen saturation
is due to the severity of the patient’s illness, but it is important to
check that the oximeter is correctly placed and functioning nor-
mally as well as checking that the oxygen delivery device and the
oxygen ﬂow rate are correct. If the oxygen is being delivered
from a cylinder, clinicians should check the labelling of the cylin-
der to ensure that it is an oxygen cylinder and checks should be
made to ensure that the cylinder is not empty or near empty.
11.3.7 When to lower oxygen therapy
Most conditions which require supplemental oxygen therapy
will improve with treatment and it will then be possible to
reduce the amount of oxygen administered to the patient.
Improvement will usually be conﬁrmed by observing an improv-
ing oxygen saturation and a reduction in the physiological score
on the NEWS observation chart as discussed in section 7.
Evidence statement
▸ Adjustment of oxygen therapy is based on expert opinion
(evidence level 4).
Recommendations
U1: Lower the oxygen concentration if the patient is clinically
stable and the oxygen saturation is above the target range or if
it has been in the upper zone of the target range for some time
(usually 4–8 hours) (grade D).
U2: If the target saturation is maintained, the new delivery
system and ﬂow should be continued. Repeat blood gas mea-
surements are not required. If the patient is stable, the process
can be repeated and the patient can eventually be weaned off
oxygen (see section 12) (grade D).
SECTION 12: WEANING AND DISCONTINUATION OF
OXYGEN THERAPY
In most acute illnesses, oxygen therapy will be reduced grad-
ually as the patient recovers and oxygen therapy can be discon-
tinued once the patient can maintain a saturation of 94–98%
while breathing air (or the patient’s baseline oxygen saturation
level if known). Some patients may have episodic hypoxaemia
during recovery from acute illness (eg, patients with COPD with
intermittent mucus plugging) and some convalescent patients
may be comfortable at rest with a satisfactory oxygen saturation
but may desaturate and become breathless when they start to
mobilise. The ongoing prescription of a target saturation range
will cover both of these types of occurrence.
Some patients with chronic lung diseases will already be
established on long-term oxygen therapy and should be tapered
slowly to their usual maintenance oxygen delivery device and
ﬂow rate.
A small number of patients who have suffered major respira-
tory or cardiac injury may require a prescription for home
oxygen to permit safe discharge from hospital. However, many
patients with COPD exacerbations may have a low PO2 on dis-
charge from hospital but a reasonable PO2 at a subsequent clinic
visit, so decisions about long-term oxygen should not be made
on the basis of blood gas measurements made during AECOPD
(see BTS guideline for home oxygen in adults).13
12.1 How to discontinue oxygen therapy for stable patients
Evidence statement
▸ Reduce oxygen therapy gradually for stable patients
(see section 11.3.7). Weaning and discontinuation of oxygen
therapy is based on expert opinion in the absence of rando-
mised trials (evidence level 4).
Recommendations
U3: Most stable convalescent patients will eventually be
stepped down to 2 L/min via nasal cannulae prior to cessation
of oxygen therapy. Patients at risk of hypercapnic respiratory
failure may be stepped down to 1 L/min (or occasionally 0.5 L/
min) via nasal cannulae or a 24% Venturi mask at 2 L/min as
the lowest oxygen concentration prior to cessation of oxygen
therapy (grade D).
U4: Oxygen therapy should be stopped once a patient is clin-
ically stable on low-concentration oxygen and the oxygen satur-
ation is within the desired range on two consecutive
observations (but the prescription for a target saturation range
should remain active in case of future deterioration). It may be
appropriate to alter the target range following senior review in
patients with chronic cardiopulmonary disease who either have
saturations <94% when stable or in whom it is deemed sens-
ible to discharge from hospital with saturations <94% pending
an outpatient oxygen assessment. Oxygen should also be
stopped if the patient has come to the end of a written protocol
of timed oxygen (eg, postoperatively) (grade D).
U5: Oxygen saturation on air should be monitored for 5 min
after stopping oxygen therapy. If it remains in the desired range
it should be rechecked at 1 hour (grade D).
U6: If the oxygen saturation and physiological ‘track and
trigger’ score (eg, NEWS) is satisfactory at 1 hour, the patient
has safely discontinued oxygen therapy. However, saturation
and physiology should continue to be monitored on a regular
basis according to the patient’s underlying clinical condition
(grade D).
U7: If the saturation falls below the patient’s target range on
stopping oxygen therapy, restart the lowest concentration that
maintained the patient in the target range and monitor for
5 min. If this restores the saturation into the target range, con-
tinue oxygen therapy at this level and attempt discontinuation
of oxygen therapy again at a later date provided the patient
remains clinically stable (grade D).
U8: If a patient requires oxygen therapy to be restarted at a
higher concentration than before to maintain the same target
saturation range, the patient should have a clinical review to
establish the cause for this deterioration (grade D).
U9: Some patients may have episodic hypoxaemia (eg, after
minor exertion or due to mucus plugging) after they have safely
discontinued oxygen therapy. An ongoing prescription for a
target saturation range will allow these patients to receive
oxygen as the need arises but transient asymptomatic desatur-
ation does not require correction (grade D).
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SECTION 13: OUTCOMES AND AUDIT
13.1 Audit
Audits of oxygen prescription and use have been carried by
the BTS in 2008 prior to the launch of the ﬁrst edition of this
guideline and most years since then.16 About 14% of UK hos-
pital patients receive supplemental oxygen therapy on any
given day but only one-third of these patients had any type of
prescription or written order for oxygen in 2008, this had
risen slowly to only 57% by the time of the 2015
audit.493 494 Audit of oxygen use within individual healthcare
organisations is strongly encouraged and the oxygen cham-
pion at each Trust can compare their results with the average
for all other units.
13.2 Audit of compliance with guideline
It is recommended that all users of oxygen will audit their own
practice against the suggested optimal practice suggested in this
guideline. This applies especially to high-frequency users such as
ambulance services, emergency departments and medical wards.
On the job audit
Regular reviews of the drug card and observation chart on
medical rounds at the pilot sites have been very important in
the successful introduction of this policy. This has provided
instant feedback for doctors, nurses and healthcare assistants
and has produced successful change.
Whole hospital and ward audits
An audit tool is available on the BTS audit website (https://
audits.brit-thoracic.org.uk/). This has been successfully used UK
wide and since 2008 with annual nationwide audits and the
facility for individual units to use the audit tool for a local audit
at any time. The audit tool allows healthcare organisations to
monitor how many patients are receiving oxygen therapy,
whether there is a valid prescription and the proportion of
patients within the target range. Healthcare organisations can
also audit the documentation of oxygen saturation on observa-
tion rounds and whether oxygen has been signed for on drug
rounds. Organisational issues can also be audited such as the
following:
• Does the Trust have an oxygen prescribing policy based on
this guideline?
• Is there a standard prompted oxygen in the prescription
document or electronic record?
• Is training implemented for nursing staff?
• Is training implemented for medical staff?
SECTION 14: DISSEMINATION AND IMPLEMENTATION OF
THE GUIDELINE AND EDUCATION OF HEALTHCARE
PROFESSIONALS
These matters are covered in more detail in online appendix 11.
14.1 Dissemination
Dissemination of this guideline will be encouraged and sup-
ported strongly by the societies involved in the production of
the guideline.
14.2 Local guidelines
It is recognised that many healthcare organisations tend to
modify national guidelines for local use. Summaries of the
guideline for acute hospitals, ambulance services and general
practice are shown in online supplementary appendices 3 and 5
on the BTS website (www.brit-thoracic.org.uk). Educational
materials are available on the BTS website (appendices 7 and 8).
It is hoped that the shortened version of this guideline (or a
customised local version) will be made available on the website
of every NHS Trust.
14.3 Local oxygen policy
It is usual for a new policy to be presented to the local policy
committee. A specimen example of a local policy is available in
web appendix 4 to help with the production of this policy in
individual healthcare organisations.
14.4 Oxygen prescription chart
Implementation of the guideline requires an ‘oxygen section’ in
the prescription chart or in the electronic prescribing record in
all hospitals. A specimen example is available in ﬁgure 19. From
experience, it is recommended that oxygen should be placed at
the start of the prescription chart because all hospital patients
need a speciﬁed target saturation range. The oxygen prescrip-
tion may be missed if it is placed in another part of the drug
chart.
14.5 Staff education
Medical staff education is fundamental to the success of this
guideline. Teaching slides are available on the BTS website. It is
thought that these are suitable for FY1, FY2 and specialty trai-
nees. They are also suitable for undergraduate medical educa-
tion. Nursing staff and nursing students also require education
as do physiotherapists, pharmacists, midwives and other clini-
cians including healthcare assistants and other unregistered staff
who may assist in the care of patients who are using supplemen-
tal oxygen. Slide sets have also have also been produced for this
purpose and are available on the BTS website. It is suggested
that small groups of 5–10 nurses from wards are taught in ses-
sions lasting 30 min each day before the introduction of the
guideline locally. This has been found to be more successful
than relying on training days as this would take too long to
train enough staff adequately.
14.6 Local champions
Local champions exist in hospitals, local champions in hospi-
tals, PCT providers and ambulance services who have helped
to introduce these guidelines. The Guideline Development
Group are very grateful to the local oxygen champions for
organising the introduction of local oxygen policies in 89% of
UK acute hospital Trusts by 2011. In most instances, the
oxygen champions have introduced a new prescription chart
and helped to organise staff education. Clinical governance
leads will also need to become committed to the implementa-
tion of the Emergency Oxygen Guideline and audit of this
process.
14.7 Beneﬁts of nationwide implementation
One major beneﬁt of nationwide implementation is that, when
staff transfer between organisations, they will be familiar with
the oxygen prescription and administration system.
SECTION 15: AREAS REQUIRING FURTHER RESEARCH
Because of the life and death nature of many conditions for
which emergency oxygen therapy is used, it seems that clinicians
have been wary of conducting controlled trials of oxygen
therapy for most of the commoner indications. Additionally, it
can be difﬁcult to obtain ethical approval for such studies
because seriously ill patients are usually not able to provide
informed consent.
Further research is required in many areas including:
Basic physiological studies
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• Effect of cigarette smoking on blood levels of oxygen and
carbon dioxide in acute illness.
Clinical trials
• Randomised trial of ‘precautionary use’ of oxygen in critical
illness compared with a conservative policy of monitoring
carefully and giving titrated oxygen therapy oxygen only if
the saturation falls below the target range (and trials to deter-
mine the best target range to aim for).
• RCTs of nasal high-ﬂow humidiﬁed oxygen compared with
NIVor high-concentration oxygen in critical illness.
• The optimal oxygen target values and their feasibility during
CPR and immediately after a restoration of spontaneous cir-
culation in order to improve survival and neurological
outcome.
• Prospective studies of the effect of oxygen in non-
hypoxaemic patients with major trauma and head injury.
• Use of oxygen in myocardial infarction (at date of guideline
publication, AVOID study is published in 2016 and
DETO2X-AMI trial is ongoing).330–333
• Use of oxygen in unstable coronary syndromes or type 2
myocardial infarction.
• Use of oxygen in chest pain of presumed cardiac origin.
• Studies to determine if different types of oxygen mask can
affect clinical outcomes.
• Use of oxygen in obstetric emergencies.
• Prospective studies to determine the optimal target saturation
range for patients not at risk of hypercapnia, for example,
target range 92–96% vs 94–98%.
• Use of nasal cannulae to deliver low-dose oxygen therapy
(eg, nasal cannulae at 0.5–1.0 L/min compared with 24%
and 28% face masks).
• Prospective studies to establish the ideal target saturation
range in patients with exacerbated COPD; for example,
should the target range be 88–92% or slightly lower or
slightly higher for optimal outcome?
• RCTs of nasal high-ﬂow (but low concentration) humidiﬁed
oxygen compared with NIV in patients exacerbated COPD
with hypercapnic respiratory failure and pH 7.30–7.35 fol-
lowing initial optimisation of treatment.
• RCTs of titrated oxygen therapy in acute presentations of
patients with conditions associated with chronic respiratory
failure (eg, neuromuscular disease or obesity-associated
hypoventilation).
• RCTs of titrated oxygen therapy in patients presenting
acutely with non-hypercapnic respiratory failure (eg, heart
failure, pneumonia).
• Randomised trials to determine if nitrous oxide is an effect-
ive analgesic agent and if the oxygen component affects clin-
ical outcomes.
• Randomised trials to determine if clinical outcomes can be
improved by the use of Heliox mixtures and, if so, which
conditions are likely to beneﬁt.
• Use of oxygen as required for relief or breathlessness in non-
hypoxaemic patients with acute illness.
• Effects of humidiﬁed high-ﬂow oxygen on patient comfort.
• Effects of increased ﬂow rates from Venturi masks on patient
comfort and oxygen saturation.
• Further comparisons of high-ﬂow nasal oxygen with reservoir
masks and high-concentration Venturi masks.
Implementation studies
• Beneﬁts of alert cards and personalised oxygen masks for
patients with prior hypercapnic respiratory failure.
• Further studies of clinical outcomes of patients exposed to
hyperoxia.
• Relationship between oxygen levels and outcomes in a wide
range of conditions.
• Studies to determine if implementation of this guideline
improves patient outcomes.
• Studies to determine the best way to help clinicians to
comply with guideline recommendations.
Systematic reviews
• Outcomes from different levels of oxygen supplementation
in AECOPD.
• Updated review of oxygen therapy in myocardial infarction.
• Review of oxygen therapy in stroke.
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